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CHAPTER 1
Drug Design Based on the 2-Arylethyl Amine 
Moiety: the Monoamine-Neurotransmitter
Core
Abstract
In this chapter, the importance of medicinal chemistry in the area of drug discovery 
is emphasized. Combinatorial chemistry, a powerful technology that helps 
pharmaceutical companies to find new drugs, is described.
The process of how information is delivered within the nervous system (the 
synapse) and the compounds responsible for this delivery (the neurotransmitters) are 
also described.
Finally, the biological importance of the 2-arylethyl amine moiety is presented.
Chapter 1
1.1 Introduction
Medicinal chemistry1 is a chemistry-based discipline, which also involves aspects of 
biological, medical, and pharmaceutical sciences. It is concerned with the invention, 
discovery, design, identification, and preparation of biologically active compounds, the 
study of their metabolism, the interpretation of their mode of action at the molecular 
level, and the construction of structure-activity relationships (SAR).2
1.2 Drug Discovery
In medicine and pharmacology, drug discovery is the process that involves the 
identification of a target (e.g., a protein) and the discovery of some suitable drug 
candidates that can inhibit or stimulate the target; in a nutshell, the development of 
new chemicals that might have a desired specific biologic activity. This process is 
multidisciplinary; it combines many fields of science, such as organic chemistry, 
biology, computational chemistry, pharmacology, pharmacokinetics, toxicology, and 
clinical trials.
Drug discovery and development is a long and expensive process. The average total 
cost per drug is around one billion euros (year 2000) and the development time is 10­
15 years.3
The phases of drug discovery and development process with the approximate costs 
and time frame are shown in Scheme 1.1.
Scheme 1.1 Drug Discovery and Development Process.
Clinical development phase Approval phase 
------------------------------------------------- II--------------------1
research and 
discovery 
2-5 _
( Preclinical Í Phase I 
studies in 20-80 healthy 
animal models individuals
\  years \
( Phase II f  Phase III 
100-300 1000-3000 
patients patients 
1-2  years 2-3 years
/ _
review and 
approval 
1-2  years
approval
V  V
% Compounds advanced at each stage
( 5% Í 2 % ( 20% D
Cost
( €364 million ( €508 million ( €103 million £
Two major phases are involved in creating a new drug:
• The discovery phase: Firstly, a biochemical pathway that is operative in a targeted 
pathological process is defined. This pathway is analyzed by determining those 
enzymes or receptors (the target protein) that, if modulated, could inhibit the 
pathological process.
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Secondly, new active compounds that show binding toward the target, called hits, 
and modulate the target in a desirable fashion are searched for. These hits are typically 
found by screening many compounds for the desired biological properties. They can 
come from natural (plants, animals, and fungi) or synthetic sources (historical 
compound collections and combinatorial chemistry). Nowadays, the screening process is 
automated and a company can assay over 100,000 individual compounds a day, using 
a method called high-throughput screening (HTS), before moving onto the optimization 
step.
Thirdly, some of these hits are then promoted to lead compounds by a second 
screening; now focused on selectivity for the target, biophysical and absorption, 
distribution, metabolism, excretion, and toxicity (ADME-Tox) properties. Finally, a 
chemical modification of the lead compounds, process called lead optimization, is 
accomplished in an attempt to augment their beneficial activity and achieve more 
favorable interactions and fewer side effects. The modified molecule that exhibits the 
best selectivity and pharmacokinetic parameters may ultimately be formulated as a 
drug for the treatment of the targeted pathological process.
• The development phase: Modern drug development conducts extensive and 
expensive testing to allow safety and efficacy data to be collected for potential new 
drugs. These clinical trials are required in order to obtain the necessary approvals from 
the health authorities.
Computational chemistry has an important role in drug discovery nowadays. 
Computational methods (e.g., molecular docking, quantitative structure-activity 
relationships [QSAR], pharmacophore mapping) can be used to predict properties, 
cluster hits, design focused libraries, and search for analogues to explore the potential 
of hit series. In addition, the interactions between a particular compound and a given 
protein target can be simulated by these methods. Finally, drug candidates can be 
refined and modified with the aid of computational methods.
1.2.1 Combinatorial Chemistry4
As mentioned above, natural products have historically been the main source of 
biologically active compounds used in drug discovery. This concept, however, began 
to change at the end of last century when, thanks to the development of combinatorial 
chemistry, the time and costs associated with producing effective and competitive new 
drugs were dramatically reduced.5
3
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Traditionally, organic synthesis and medicinal chemistry involved the construction 
of one organic molecule at a time. During the last decade of the twentieth century, 
combinatorial chemistry or combinatorial synthesis was developed. Combinatorial 
synthesis is a means of producing, simultaneously, a large number of compounds 
(called library) in a short time period. Combinatorial synthesis may be practiced either 
in solution or on solid support; in the latter case the process can be automated or semi­
automated. Combinatorial synthesis can be performed to produce mixtures of 
compounds in each reaction vessel or to obtain a single product in each different flask, 
a process known as parallel synthesis.
1.2.1.1 Solid-Phase Combinatorial Chemistry
Solid-phase synthesis has changed radically since Merrifield's pioneering work back 
in 1963,6 which earned him a Nobel Prize in 1984. Solid-phase synthesis was first 
developed for biopolymers (first peptides, then oligonucleotides) and then spread to 
every field that involves organic synthesis. The general sequence of steps in solid­
phase combinatorial chemistry is depicted in Scheme 1.2. Firstly, the substrate A is 
attached to a polymeric solid support (bead) through a linker. Then, the transformation 
takes place and thanks to the immobilization, a simple filtration is enough for the 
separation of intermediates from reagents and soluble by-products after every step. 
One important issue for the success of this principle is that the support and the linker 
should be unreactive under the reaction conditions. Finally, the product is selectively 
cleaved from the solid support, under mild conditions, to obtain product B after a 
simple filtration.
Scheme 1.2 Solid-Phase Chemistry.
/ ' “ v  ,____ , im m o b iliza tio n  / ' - x  ,____ , tra n s fo rm a tio n  / - n  ,____ , c le a va g e
+ A -------------------- ► Q - C Z h A  --------------------► Q - C Z h B  --------- B
Several different support materials have been developed for solid-phase synthesis. 
The proper type of support has to be selected for every transformation due to 
incompatibilities with some solvents and reagents.
The most common solid supports in solid-phase synthesis are hydrophobic 
polystyrene resin beads. They consist of polystyrene cross-linked with 1-2% 
divinylbenzene. The reactivity of the bead sites strongly depends on the solvation of 
these resins.
4
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1.2.1.2 Solution-Phase Combinatorial Chemistry
As stated above, the benefit of preparing libraries on solid supports is based on the 
rapid purification by a simple filtration, especially when there is a need to separate 
excess reagents from the reaction products. It should be noted that solid-phase 
chemistry also has some disadvantages and limitations. There is a narrower scope in 
the choice of reagents (they should not react with the support or the linker), solvents (a 
good swelling is needed), temperature (very low and high temperatures should not be 
used), concentrations (concentrated solutions are usually required), and catalysts 
(heterogeneous catalysts cannot be used) than in solution-phase chemistry where the 
reactions can be performed under any conditions. In addition, it is difficult to monitor 
the progress of the reactions using solid supports; the range of chemistry available, the 
knowledge in the literature, and the availability of the equipment on solid phase is not 
as vast as in solution. Another advantage of solution-phase combinatorial chemistry is 
the absence of additional steps (immobilization and cleavage).
A schematic comparison between orthodox and parallel syntheses applied to drug 
discovery is depicted in Scheme 1.3.7
Scheme 1.3 Orthodox versus Parallel Synthesis.
R1
R2.
Next Purify x  A R3^C . )
^  I n w - t h r m  i n h n i  it c r - m o n i n n
B
C
Dcompound V J  Characterize
Lo -t roug put scree i g ^  Next Rn \ lC-MS
library  ^ N ) HPLC
High-throughput screening
Orthodox Synthesis Parallel Synthesis
Orthodox synthesis generates new compounds, which are purified and fully 
characterized, through a multistep transformation (e.g., from A to the final product C). 
Based on the screening results and the biological activity of these compounds, new 
analogues are designed, prepared, and then screened. This process is repeated to 
optimize both activity and selectivity of the drug candidates.
In contrast, parallel synthesis produces a compound library of n individual products 
(B, C, D ... N) at the same time by reaction of a substrate A with multiple reactants (R1, 
R2, R3... Rn). As in the case of orthodox synthesis, the library is screened, but in this 
case with minor purification and with only minimal characterization of the individual 
compounds, using a rapid-throughput screening technique. This process is also 
repeated to optimize the activity and the selectivity of the drug, but it works n times 
faster than orthodox synthesis.
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1.3 Synapse and Neurotransmitters8
The nervous system is a very intricately organized structure presenting a network of 
specialized cells that communicate information about an animal's surroundings and 
itself. It also functions throughout the body to coordinate the activities of the other 
body systems. The nervous system is composed of neurons and glial cells, which aid in 
the function of the neurons. The nerve cells are able to receive, conduct, and store 
information. Thanks to the neurons' ability of information transmission with network 
behavior, the nervous system can store experiences (memory) and establish responses 
on the basis of prior experiences (learning).
Neurons are electrically isolated from one another by an intercellular gap, about 20 
nm wide, called the synaptic cleft (with the exception of the sites of electrical synapses). 
The signal transmission between neurons is known as synapse. Synapses are functional 
connections between neurons or between neurons and other types of cells. Signal 
transmission between chemical synapses is carried out by neurotransmitters, molecules 
which are released from the presynaptic neuron into the synaptic cleft and bind to the 
receptors in the membrane of the postsynaptic neuron (Figure 1.1). The release of 
neurotransmitters is most commonly driven by arrival of an action potential at the 
synapse, but may also be driven by graded electrical potentials.
Figure 1.1 Synapse.
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Based on their chemical nature, neurotransmitters can be divided into two major 
groups: biogenic amines and amino acids (Figure 1.2).
Neurotransmitters
Amino Acids 
(GABA, glutamate, aspartate, glycine)
Figure 1.2 Classification o f Neurotransmitters Based on Their Chemical Nature.
The action of a neurotransmitter is to activate a receptor. The information delivered 
by the neurotransmitter depends on the structure of both the receptor and the 
neurotransmitter. When there is a dysfunction in the neurotransmitter system (e.g., 
there is shortage or excess of any neurotransmitter) a disease or a disorder arises. For 
example, a shortage of dopamine is one of the causes of Parkinson's disease9 and low 
levels of noradrenaline and serotonin are associated with depression.10
1.4 The 2-Arylethyl Amine Moiety
The structure of the monoamine neurotransmitters and some of the actions they are 
responsible for are depicted in Figure 1.3. All the monoamine neurotransmitters 
possess a common core structure (highlighted): an aryl group (phenyl, indolyl, or 
imidazolyl), then a two-carbon spacer, and an amine.
ho^ ^ ^ V x  N H2
H O ^ ^
dopamine 
(movement, pleasure)
*N
H
serotonin 
(appetite, mood)
OH
H O ^ ^ x k ^  NHMe
H O ^ ^ ^
adrenaline 
(short-term stress, 
bronchodilator)
OH
H O ^
noradrenaline 
(attention, mood)
l = \
-----------------
histamine 
(awake state)
Figure 1.3 Structure and Actions o f the Monoamine Neurotransmitters.
2
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Due to their similarity to the monoamine neurotransmitters, there is a plethora of 
compounds containing the 2-arylethyl amine scaffold (including phenethylamine itself) 
that are involved in the monoamine-neurotransmitter systems, or are active in the 
nervous system, and/or are pharmacologically active drugs. The 2-arylethyl amines 
are a broad and diverse class of compounds that include neurotransmitters, hormones, 
stimulants, hallucinogens, entactogens, anorectics, bronchodilators, and 
antidepressants. The 2-arylethyl amines and their salts are also chemical intermediates 
of commercial significance; they are used in the preparation of pharmacologically 
active compounds.11 Figure 1.4 depicts some drugs (active in the nervous system, 
which contain a 2-arylethyl amine scaffold); including venlafaxine12 and salmeterol,13 
two of the ten best-selling prescription drugs in 2006;14 and their actions.
NMe2 
OH
MeO
venlafaxine
(antidepressant)
NH2
O '*
phentermine
(anorectic)
f  H 
' . Ä
salmeterol
(bronchodilator)
mirtazapine
(antidepressant)
Figure 1.4 Drugs Presenting the 2-Arylethyl Am ine Scaffold.
o
• A NH2
tranylcypromine
(antidepressant)
H
NH2
phenelzine
(antidepressant)
As shown in Figure 1.5, this feature is also present in many hallucinogenic drugs, 
such as LSD, MDMA (ecstasy), mescaline, and psilocybin (magic mushrooms).15
O
Et2N" .„.MeNJÙH
y SS x , il f  ^""N
H
LSD
MeO.
< x n "
NHMe
MeOX T '
OMe
ecstasy mescaline
Figure 1.5 Hallucinogenic Drugs with the 2-Arylethyl Am ine Scaffold.
NH2
O
.P-- HO / O 
HO
-Me
psilocybi
1.4.1 Synthesis of 2-Arylethyl Amines
The development of practical and efficient procedures for the preparation of 2- 
arylethyl amines has been the focus of several studies, aside from the many random 
examples that can be found in the literature.
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One of the most common syntheses of 2-arylethyl amines is the N-alkylation 
reactions of amines with the corresponding activated alcohols16 or halides.17 Within this 
concept, Maynard et al. reported on the synthesis of a series of compounds with 
antihistaminic activity; one of the examples is depicted in Scheme 1.4.
Scheme 1.4 N-Alkylation Reaction o f a Phenethyl Bromide.
-Br O
r ç
r u-S k^NH NaOH, Et3(Bn)NBr \ _/
CH2Cl2/H20, A ‘\ ííí'í''''f
74%
Another common method for the synthesis of 2-arylethyl amines is the reductive 
amination reaction of 2-arylacetaldehydes.18 Hatzenbuhler et al. investigated 3- 
aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter 
affinity using this methodology (Scheme 1.5).19
Scheme 1.5 Reductive Amination Reaction o f a 2-Arylacetaldehyde.
CONH'2
AcOH, MeOH
F
2
F
Another general method developed by Hartwig et al. is the regioselective 
hydroamination of styrene derivatives (Scheme 1.6).20
Scheme 1.6 Hydroamination Reaction o f a Styrene Derivative.
M e O v ^ ^ , , ^ ^
The class of 2-arylethyl amines can also be prepared by the addition of benzylzinc 
compounds to iminium salts (Scheme 1.7).21
5 mol% Ru(cod)(2-methylallyl)2 i^^O  
7 mol% DPPPent/10 mol% CF3S03H Me0 ^ ^ ^ \ ^ \ ^ .N _^
HN'—^  dioxane, 100 °C, 24 h
91%
+
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Scheme 1.7 Aminomethylation Reaction o f Benzylzinc Compounds.
c x (H C H 0 )n, NMP 
60 °C, 10 h
•HCl
N
n
CH2
BrZn
CN
THF, 21 °C, 10 min CN
73%
N
Hydroxyimination of aromatic ketones, followed by reduction, was used by Cannon 
et al. to synthesize conformationally restricted derivatives of dopamine (Scheme 1.8).22
Scheme 1.8 Synthesis o f a Conformationally Restricted Derivative o f Dopamine.
0  O
M e ^ ^ ^ x  J  BuONO, HCl M e 0 ^ ^ ^ ^ (  1. H2, Pd(C), AcOH
Y Y \  — 1 I  ) = n  — — -----------► II J  V l
M e ^  M e0H  '  M e O ^ ^ ^ H  21 °C  77% "  h ^ ^ ^ ^ NH2
M e 0  40 °C, 30 min 2. 48% HBr, A, 3 h, 74%
92%
It is known that the difference in activity and receptor selectivity of drugs might be 
explained by the conformation of the contained privileged structure. Generation of 
semi-rigid drugs facilitates the study of their interactions with the receptors, may lead 
to more selective interactions with fewer side effects, and permits the rational design of 
more potent and selective drugs in the future.
Probably, one of the best ways to synthesize conformationally restricted 2-arylethyl 
amines is by a 1,3-dipolar cycloaddition reaction using azomethine ylides and vinyl 
arenes. Damour et al. used this methodology for the construction of conformationally 
restricted mimetics of tryptophan (Scheme 1.9a),23 and GlaxoSmithKline used this 
cycloaddition approach for the synthesis of compounds that potentiate the glutamate 
receptor for use against schizophrenia (Scheme 1.9b).24
Scheme 1.9 1,3-Dipolar Cycloaddition Reaction with Azomethine Ylides 
a)
MeO"
COoMe 
i 2 
"N C 02MeI 2
C02Et
+
"N" 
S 02Me
TiC l4, Et3N
CH2C l2, 1.5 h, A 
99%
-C 0 2Et
C 02Me 
CO2Me
Ni
SO2Me
-Boc
Co 2h
^ N ' Boc
'' c o 2h
10
Drug Design Based on the 2-Arylethyl A m ine Moiety: the M onoamine-Neurotransmitter Core
In our group, the Diels-Alder cycloaddition reaction has been used for the synthesis 
of conformationally restricted 2-arylethyl amines. Thus, epibatidine analogues were 
synthesized by the cycloaddition of methyl pyrrole-1-carboxylate with phenyl vinyl 
sulfone, followed by removal of the sulfonyl group, and reductive Heck coupling with 
aryl halides (Scheme 1.10).25
Scheme 1.10 Synthesis o f Epibatidine Derivatives via a Diels-Alder Reaction.
O ^C02Me H.S 0 2Ph 1. MeCN________  N 1. ArX, P d (0A c )2, Bu4NCl Ar N
N II  1.2 GPa, 50 °C ^  ^ 7  K 0 2CH, DMF, 60 °C V  " 7
C 02Me ¿P-— /  ¿ -^— /
2 2. 6%  Na(Hg) 2. TM SI, C H C l3
Nitro and cyano styrene derivatives have been used in our group as building blocks 
for the synthesis of a large array of 2-arylethyl and 3-arylpropyl amines, respectively.26 
The general procedure involved a Diels-Alder reaction followed by reduction (Scheme 
1.11), giving rise to products that can be further functionalized.
Scheme 1.11 General Procedure for the Synthesis o f 2-Arylethyl and 3-Arylpropyl Amines.
cycloaddition
As an ilustration of this procedure, Aben et al. reported the preparation of paroxetine 
precursors from a cycloaddition reaction between 3-aryl-2-cyanoacrylates and ethyl 
vinyl ether (Scheme 1.12).27
Scheme 1.12 Synthesis o f Paroxetine Precursors.
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In addition, inspired by methodology developed by Denmark and others,28 Kuster et 
al. used nitro alkenes for the synthesis of 3-arylpyrrolidines from a (4+2)/ (3+2) 
cycloaddition reaction (Scheme 1.13).26b
Scheme 1.13 Synthesis o f a 3-Phenylpyrrolidine.
PMB0^ | + f N° 2 + [j"Ph CH2Cl2, 1.5 G P a ^  PMB^ a ^ ^ Ph CH2CI 2, MeOH ^  ^  Ph
+
P ^  11 21 °C, 18 h ' Y "  '  50 atm, 21 °C, 24 h
76%  Ph 96%  Ph
1.5 Purpose and Outline of the Investigation
This thesis deals with the design and synthesis of skeleton-diversified libraries of 
compounds whose core structure is based on the 2-arylethyl amine moiety: the 
common feature of the monoamine neurotransmitters. As mentioned above, one 
approach to increase the biological activity of small molecules is to minimize the 
flexibility of the potential drug through the use of conformationally restricted 
analogues.29 Thus, the compounds herewith presented are based on a 3-arylpyrrolidine 
scaffold, where the spatial arrangement of the 2-arylethyl amine moiety is restricted to 
anticlinal and antiperiplanar conformations.
The synthetic content of this thesis is divided in two parts:
• The first part, Chapters 2 and 3, deals with the development of the methodology 
for synthesizing the main scaffolds that contain the conformationally restricted 2- 
arylethyl amine moiety, being 3-(aminomethyl)-4-arylpyrrolidine-3-carboxylates 
(Chapter 2) and 3-amino-4-arylpyrrolidine-3-carboxylates (Chapter 3).
In Chapter 2, different techniques for parallel functionalization are explored, such as 
solid-phase chemistry and solution-phase parallel synthesis. The main scaffolds were 
successfully synthesized in solution from methyl 2-cyanoacetate by a Knoevenagel 
condensation reaction with an array of aromatic aldehydes, followed by a 1,3-dipolar 
cycloaddition reaction with an azomethine ylide, and finally the reduction of the nitrile 
to obtain the aminomethyl group.
Chapter 3 describes the same methodology utilized in Chapter 2, but the synthesis 
starts with methyl 2-nitroacetate to form scaffolds with one carbon atom fewer, that is, 
an amino group, which is obtained by reduction of the nitro group.
12
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• The second part; Chapters 4, 5, and 6; deals with the parallel derivatization of the 
scaffolds from the previous work, rendering them more rigid, restricting the 
conformations of the 2-arylethyl amine even further, and combining them with other 
privileged structures. It is known that the combination of privileged structures can lead 
to new chemical entities that may have pharmacological relevance30 and increase the 
structural diversity.
In Chapter 4 the solution-phase parallel synthesis of a 144-compound library of 
(thio)hydantoins spiro-fused to pyrrolidines is described. These products combine the 
2-arylethyl amine moiety and a (thio)hydantoin ring.
Chapter 5 describes the parallel synthesis of dihydrouracils spiro-fused to 
pyrrolidines, as well as the parallel synthesis of a-ureidomethyl acids by hydrolysis of 
the spiro dihydrouracils. This chapter includes some exploration reactions to 
synthesize other new scaffolds, such as dihydrothiouracils and ß-lactams spiro-fused to 
pyrrolidines and tetrahydromethanobenzazepines.
In the last chapter of this thesis, the Pictet-Spengler cyclization reaction of the 
scaffolds synthesized in Chapters 2 and 3 to form tri- and tetracyclic compounds, 
combining the 2-arylethyl amine moiety and a tetrahydro(hetero)areno[c]pyridine or a 
tetrahydro(hetero)areno[c]azepine, is described. The pyridine-based products are 
further derivatized in a parallel fashion to make two libraries of potentially 
pharmacologically important compounds.
Parts of this dissertation have been published31 or will be published in the near 
future.
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CHAPTER 2
Synthesis of 3-(Aminomethyl)-4- 
arylpyrrolidine-3-carboxylates
A bstract
A  general three-step synthesis of frans-4-aryl-substituted 3-(am inom ethyl)- 
pyrrolidine-3-carboxylates from  m eth yl 2-cyanoacetate is reported. The first step  
u tilizes a K noevenagel condensation  reaction w ith  different arom atic a ld eh yd es to 
form  (E)-2-cyanoacrylates. The second  step g ives rise to the pyrrolid ine-core structures 
o f the title com p ou n d s by  a 1,3-dipolar cycloadd ition  reaction u sin g  an azom eth ine  
ylide. The last step consists of the reduction  of the cyano group to y ie ld  the 
am inom ethyl group of the m eth yl pyrrolidinecarboxylates.
Chapter 2
2.1 In troduction
The com p ou n d s described in  this chapter contain  the p riv ileged  2 - a r y l e t h y l  (Chapter 
1) and 3 - a r y l p r o p y l  a m in e  scaffolds. The latter is also an im portant priv ileged  structure 
active in the central nervou s system . Som e k ey  exam ples contain ing this structure are 
dep icted  in Figure 2.1: the antidepressants paroxetine 1,1 d u loxetine 2,2 and the fam ous  
fluoxetine 3 (Prozac®),3 w h ich  w a s the third m ost-prescribed  antidepressant in U nited  
States in  2007;4 risperidone 4,5 u sed  for the treatm ent of schizophrenia and w a s the 
tenth b est-se llin g  drug w o r ld w id e  in 2006;6 and m ethadone 5, u sed  m edically  as a 
m aintenance anti-addictive for u se  in patients on  op io id s.7
O
F
JO.
p - N
O
NMe2
Figure 2.1 C o m p o u n d s  P re se n tin g  the 3 - A r y lp r o p y l  A m in e  M o ie ty .
3
1 2 3
N
F
4 5
In this chapter, w e  present our research tow ards the d evelop m en t of a synthetic  
m eth od  for the title com pounds. B esides the fact that they cou ld  be im portant in their 
o w n  right, th ey  are in ten ded  for further funtionalization  as scaffolds for library 
syntheses (Chapter 5) and as substrates for the form ation of n ew  scaffolds (Chapter 6). 
D ifferent techniques for parallel functionalization  w ere therefore explored, such  as 
so lid -phase chem istry and so lution-phase parallel synthesis.
2.2 R esu lts  and  D iscu ss io n
W e en v ision ed  that a suitable strategy to syn th esize the title com p ou n d s m ay  
proceed  as sh o w n  retrosynthetically in Schem e 2.1. The am inom ethyl group of 
com p ou n d s 6 A -C  cou ld  be derived  from  a m asked  am ino function, such as a cyano  
group, by reduction. C om p ou nd s 7 A -C  p o ssess tw o  electron-w ithdraw ing groups at 
the carbon in the 3-position  of the pyrrolidine, rendering it a perfect pattern for 
preparation by  a 1,3-cycloaddition  reaction b etw een  an azom eth ine y lid e  and an  
electron-deficient alkene. This w o u ld  leave the 3-aryl-2-cyanoacrylates 8 A -C  as 
starting m aterials, w h ich  cou ld  be m ad e b y  a K noevenagel condensation  reaction  
b etw een  the organyl 2-cyanoacetates 9 A -C  and an arom atic aldehyde.
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Scheme 2.1 R e tr o sy n th e tic  A n a ly s is  f o r  the S y n th e s is  o f  O r g a n y l 3 - (A m in o m e th y l) -4 -a r y lp y r ro lid in e -3 -  
c a rb o x y la tes  6 A - C .
CO2R c0 2R nc  ^ ^co2r
MeN
m  m  NC  /CO2R
|^ | , „ / NH2 M e ^ " CN l = >  X  l = >  N^ Cp2R
'''Ar ''Ar Ar
6A-C 7A-C 8A-C 9A-C
R = Wang resin A, pMB B, Me C
2.2.1 K n o ev en a g el C o n d en sation  R eaction
A s outlined  in Schem e 2.1, the K noevenagel reaction w a s  perform ed w ith  three  
different a-cyano  esters: (1) the "W ang resinyl" 9A  (ester attached to a so lid  support), 
(2) the 4 -m eth oxybenzyl ester 9B, and (3) the m eth y l ester 9C. "W ang resinyl" 2- 
cyanoacetate 9A  w a s syn th esized  w ith  the initial id ea  to d evelop  a  so lid -p h ase m ethod  
for the five-step-library syn th esis w ith  tw o  /  three sites of d iversification  (see Chapters 
5 and 6), thereby taking advantage of the tim esav in g  purification m eth ods of so lid ­
p hase synthesis (see Chapter 1). M odel com pou n ds based  on  4-m eth oxybenzyl 2- 
cyanoacetate 9B w ere syn th esized  in order to obtain IR spectroscopic data that cou ld  
be com pared  w ith  the esters attached to the so lid  support. IR is one of the few  
techniques u sed  for m onitoring so lid -phase transform ations. This also a llow ed  for the  
optim ization  o f the reaction cond itions to be u sed  on  the so lid  phase. Finally, the 
com m ercially available m eth yl 2-cyanoacetate 9C w a s u sed  once it w a s d ecid ed  to 
syn th esize the scaffolds and prepare libraries in  solution  phase.
The research com m enced  w ith  the synthesis of com pou n ds 9A  and 9B, w h ich  are not 
com m ercially  available (Schem e 2.2). Thus, 2-cyanoacetic acid 10 w a s separately  
cou p led  w ith  the com m ercially  available W ang resin  11 and w ith  4-m eth oxybenzyl 
alcohol 12 u s in g  com m on ly  u sed  cou p lin g  cond itions (DIC, HOBT, THF)8 to afford  
com p ou n d s 9A  and 9B, respectively. Both com p ou n d s presented  approxim ately the 
sam e IR stretching vibrations for C = N  and C=O  (2262 and 1750 cm -1, respectively).
Scheme 2.2 S y n th e s is  o f  the O r g a n y l 2 -C y a n o a c e ta te s  9 A  a n d  9B .
O ^  DIC, hobt
NC
HOBT 0
HO< ) ----------------------- ► N C ^ A X JV_y THF. 0 ^  21 20 h ON C ^ H  H0^ , °C, ' ■ ^ '^ O -
10 11 9A
O
O H O ^ ^ ,  DIC, HOBT NC.
OH ^"^O M e THF, 0 °C, 2 h
10 12 98% 9B ^  'OMe
+
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The K noevenagel condensation  reaction b etw een  th ese a -cyano  esters and aromatic 
aldehyd es w a s then studied. The reaction cond itions for this condensation  are critically  
d ep en d en t on  the electron-w ithdraw ing groups boun d  to the activated m eth ylene9 and  
need to be op tim ized  in every case. In our group, condensations w ith  2-cyanoacetates 
h ave p rev iou sly  been  perform ed u sin g  N H 4O A c in THF under m icrow ave  
irradiation.10 Thus, the arom atic a ldehyd es 1 3 a -e  w ere reacted w ith  4-m eth oxybenzyl 
2-cyanoacetate 9B under the stated cond itions to afford the 2-cyanoacrylates 8B a-e, 
h ow ever, the reaction d id  n o t go to com pletion  in any case. Inversely, u sin g  catalytic 
piperid ine in EtOH at room  tem perature the reaction d id  go to com pletion  (Table 2.1).11 
The products 8B a-e  are on ly  sparingly  solub le in EtOH so cou ld  be easily  collected  by  
filtration. These products w ere recrystallized  from  EtOH y ie ld in g  crystals of >99.5% 
purity. U nfortunately, the ethyl esters 8 D a -e  w ere also form ed by a transesterification  
process w ith  the so lven t during the reaction, low er in g  the y ie ld  of the desired  
com pounds. The reaction w a s com pletely  stereoselective in all cases w ith  on ly  the E  
alkenes b ein g  obtained; the stereochem istry w a s  confirm ed through  N M R  spectral data 
of the m ethyl acrylates 8C syn th esized  in a m ore advanced  stage of the research.
Table 2.1 K n o even a g el C o n d en sa tio n  R ea ctio n  To F orm  the 2 -C y a n o a c ry la te s  8 B a - e
O ArCHO O O
 ^ 13a-e, piperidine N C ^ ^ J \NC
EtOH, 21 °C
OMe Ar OMe Ar
9B 8Ba-e 8Da-e
Entry Ar Product Time (min) Yield (%)
1 phenyl
4 2-pyridyl
5 3-pyridyl
8Ba 75
8Bb 90
8Bc 180
8Bd 45
8Be 20
75
89
58
68
a Yield of compounds 8Ba-e.
a
p
O
O
Ethanol w a s n ot a suitable so lven t for the condensation  of a -cyano  ester 9A, n ot on ly  
because it d oes n ot m ake the W ang resin sw ell, but also because the a-cyano  ester 
cou ld  be detached  from  the resin. For these reasons, the K noevenagel condensation
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reaction on  the so lid  p hase w a s perform ed u sin g  m icrow ave irradiation and, m ore 
im portantly, THF as so lven t (Table 2.2). The reactions n eed ed  tw o  runs to reach full 
conversion  (ev idenced  by the disappearance of the peaks at 2262 and 1750 cm -1 in the 
IR spectrum ). The C =N , C=O, and C=C stretching vibrations of com p ou n d s 8 A a -g  
decreased  at a rate proportional to the electron-donating effect of the aryl group.
Table 2.2 K n o even a g el C o n d en sa tio n  R ea ctio n  on S o lid  P hase To F orm  the 2 -C y a n o a c ry la te s  8 A a - g
O
NC^  X p O
9A
ArCHO O
13a-g, NH4OAC  ^ NC^  J O
THF, H.W, 45 min
Ar
O
8Aa-g
Entry Ar Product IR data (cm-1)a
phenyl
2-thienyl
nc .p D
indol-3-yl
NC^ JKpQ
4 2-pyridyl
5 3-pyridyl
6 4-methoxyphenyl
7 pyrrol-2-yl
MeO'
NC^ p D
8Aa 2223, 1726, 1605
8Ab 2221, 1722, 1599
8Ac 2216, 1713, 1591
8Ad 2229, 1731, 1620
8Ae 2226, 1721, 1614
8Af 2220, 1718, 1588
8Ag 2212, 1711, 1592
a Stretching vibrations for C=N, C=O, and C=C.
For reasons that w ill becom e clear later in  this chapter, it w a s d ecid ed  to d evelop  the  
m eth od  in  solution  phase and the fo llo w in g  m eth yl esters 8C a-m  w ere synthesized . 
Thus, m eth yl cyanoacetate 9C afforded the corresponding K noevenagel condensation  
products 8C a-m  u pon  reaction w ith  a range of arom atic a ldehyd es (Table 2.3). Initially, 
th ese reactions w ere perform ed u sin g  EtOH as solvent, but transesterification (up to 
3%) w a s observed  and the resulting m ixture of m eth y l and ethyl esters w a s  im p ossib le  
to separate. These reactions also took  p lace in THF (see entry 3), but required a longer  
reaction tim e.12 Finally, treatm ent of 9C w ith  a catalytic am ount of p iperid ine in  M eOH
1
2
3
h
h
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(except for entry 3 because of the lo w  solubility  of 13c in M eOH ) at room  tem perature  
produced  the desired  adducts 8C a-m  in excellen t y ields. A s in the case of the 4- 
m eth oxybenzyl acrylates 8B, all these com p ou n d s are on ly  sparingly  solub le in M eOH, 
a llo w in g  the pure crystalline products to be easily  collected  by filtration. These 
products can also be recrystallized from  M eOH  y ie ld in g  crystals of >99.5% purity. The
Table 2.3 K n o even a g el C o n d e n sa tio n  R ea c tio n  To F orm  the 2 -C y a n o a c ry la te s  8 C a - m
ArCHO
Entry
NC^ ^.CO2Me 13a-m, piperidine 
MeOH, 21 °C
N a  ,CO2Me
Ar
9C 8Ca-m
Ar Product Time (min) Yield (%)
phenyl
2-thienyl
NC. ,CO2Me
NC. ,CO2Me
3 indol-3-yl
4 2-pyridyl
5 3-pyridyl
6 4-methoxyphenyl
7 pyrrol-2-yl
8 1-methylpyrrol-2-yl
9 1-methylindol-3-yl
10 4-pyridyl
11 3,5-dimethoxyphenyl
12 1,3-benzodioxol-5-yl
13 3,4,5-trimethoxyphenyl
8Ca
8Cb
NC^ .CO2Me
8Cc
N
H
N^ C^O2Me
8Cd
8Ce
NC^ Cp2Me
Na ,CO?Me
MeO'
N^ C^p2Me
8Cf
8Cg
H
N^ /Cp2Me
Me
N /^Cp2Me
N"
Me
NC^ CO2Me
T
iT YN^1
8Ci
8Cj
8Ck
OMe 
NC^ XO2Me
< O ^  8Cl
Na ,CO2Me
NC^ CO2Me
MeO.
MeO'
8Cm
30
30
480a
30
90
30
30
8Ch 120
120
25
40
60
75
99
94
99
99
93
94 
99
95
99
99
99
99
a THF was used as solvent.
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reaction w a s com pletely  stereoselective in  all cases,1113 on ly  the E  alkenes w ere  
observed  as cou ld  be inferred from  the 13C N M R  cou p lin g  constants b etw een  the 
olefin ic proton and the carbon atom s of the ester and the nitrile.14 T hese va lues are 3J = 
6.6-6.9 H z for the carbonyl group and 3J = 13.6-13.9 H z for the cyano group. The 
K noevenagel adducts are stable at room  tem perature and unreactive tow ards the 
regular atm osphere, therefore rem ain unchanged  for m onths.
In order to investigate the scope of the K noevenagel condensation  reaction b etw een  
m eth yl 2-cyanoacetate 9C and arom atic a ldehydes, a large array of aryl groups w ere  
u sed , b eg inn in g  w ith  a sim p le p henyl (entry 1), then  a substituted  p henyl (entry 6), 
electron-rich heteroaryl (entries 2, 3, and 7), and finally  electron-poor heteroaryls 
(entries 4, 5, and 10). C om p ou nd s 8C h and 8C i (entries 8 and 9) w ere syn th esized  as 
substitutes for 8C g and 8Cc, respectively, because the latter gave problem s during the 
cycload d ition  step  of the synthesis. C om p ou nd s 8C k and 8Cl (entries 11 and 12) w ere  
syn th esized  to be in agreem ent w ith  the scaffolds from  Chapter 3. C om p ou nd  8Cm  
(entry 13) w a s  exc lu sively  syn th esized  for the form ation o f a hexahydropyrrolo- 
b en zazep in e (Chapter 6).
There are tw o  possib le m echanism s by  w h ich  the K noevenagel condensation  reaction  
can take p lace.9 The first is an aldol-type m echanism  (Schem e 2.3a), w here the base  
dehydronates15 the a-cyano ester 9 and the resulting enolate (or ketenim inide) 14 adds  
to the carbonyl group to form  the alkoxide 15. H ydronation  of this alkoxide y ie ld s the 
ß-hydroxy ester 16 that, u p on  dehydration  through an E1cB m echanism , g ives the final 
product 8. The elim ination  takes p lace from  the m ost stable conform er 17b, in  w h ich  
the aryl group is on the side of the cyano group (the sm allest of the tw o  groups), in  
agreem ent w ith  their A  va lues,16 g iv in g  exclu sively  the E  alkenes.
Scheme 2.3 M e c h a n ism s  o f  the K n o even a g el C o n d e n sa tio n  R eaction . 
a)
NC^/CO2R
9
b:
B: nc^ co2r
0
ArCHO
14
ro,cX> /
NC^V"Ar 
u  H
17a
0
nc£ Ç ° h
RO2C^)pH'Ar 
17b
nc^ co2r
©Ar o
15
0
BH
NC CO2R
A r^üH
16
NC »OÍRJ
8
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b) O
aA + R'2NH
R'-m'R'N 0 
II OH
A r^H
18
NC^„,CO2R
R'x® R'+ N ©
II UOH
A r^H
18
R''N R nc^_,c° 2r
A,A H 9
19
+ H2O
9
R^'R'N-n
a "Ar^VH
NC^,.CO2R
0
NC^  _CO2R 
,R'ArIN'i
R'
20
n^æ „co2r
-R'2NH
A © .h — 2—A r^ N  
R'' R'
21
NC CO2RJ
8
The second  is a M annich-type m echanism  (Schem e 2.3b), w h ere the am ine con d en ses  
w ith  the a ldehyd e form ing the im in iu m  hydroxide 18. Secondly, the hydroxide ion  
dehydronates the a-cyano ester 9 form ing the im in iu m  enolate 19. The ß-am ino ester 20 
is form ed after addition  of the enolate to the im in iu m  ion, w h ich  is in equilibrium  w ith  
the zw itterion  21. This zw itterion  perform s an elim ination  reaction sim ilar to that for
17 to afford the 2-cyanoacrylate 8.
2.2.2 1 ,3-D ipolar C ycload d ition  R eaction
The next step in  our syn th esis w as the form ation o f the pyrrolidine-core structures 
b y  a 1,3-dipolar cycload d ition  reaction u sin g  an azom eth ine ylide. This reaction is an 
im portant m ethod  for the form ation of pyrrolid ines17 and has been  u sed  in the  
synthesis of natural products.18 A m o n g  the vast num ber o f procedures for m aking  
azom eth ine y lid es,19 the decarboxylative condensation  of a -am ino acids w ith  
aldehydes, typ ically  heated  in to lu en e or DMF, w a s chosen . Thus, the reaction b etw een  
paraform aldehyde 22 and sarcosine 23 (N -m ethylglycine) in  refluxing to luene y ie ld ed  
the 1 ,3-dipole 24 in situ, w h ich  in the presence of the 2-cyanoacrylates 8 gave a (3+2) 
cycload d ition  reaction to form  the desired  pyrrolid ines (±)-7, contain ing the 2-arylethyl 
am ine m otif (Schem e 2.4). The sam e schem e depicts the form ation of the 1 ,3-dipole 24. 
Firstly, paraform aldehyde 22 m on om erizes on  h eatin g  to g iv e  form aldehyde 25.
Scheme 2.4 1 ,3 -D ip o la r  C y c lo a d d itio n  R ea ctio n  w i th  A zo m e th in e  Y lid es.
NC^/CO2R
O
(CH2°)n + MeHN^ A OH
Mei
_N- H2C @'CH2 
0
Ar
8
22 23 24
A A
Me O
H^ " H -H2O H2C' © ^  °  
25 26
\-CO2 
A \  Me
CN
O
27
O
co2r
'CNMeN I
'''Ar
(±)-7
24
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Subsequent condensation  w ith  sarcosine 23 form s the zw itterion  26, w h ich  is in  
equilibrium  w ith  the oxazo lid in on e 27. Finally, decarboxylation  of 27 b y  a  
cycloelim ination  reaction g ives the 1 ,3-dipole 24.20
The cycloadd ition  reaction w a s  perform ed w ith  the 2-cyanoacrylates 8B a-e to g ive  
the a-cyano esters (±)-7B a,b,d ,e,n  (Table 2.4).
Table 2.4 1 ,3 -D ip o la r  C y c lo a d d itio n  R ea ctio n  To F orm  the P yrro lid in e -C o re  S tru c tu re s  (± ) -7 B a ,b ,d ,e ,n  
O
NCV O'
8Ba-e
MeNHCH2CO2H 
(CH2O)n, PhMe, A
CO2pMB 
" CN
OMe
M eN ^
'''Ar 
(±)-7Ba,b,d,e,n
Entry Ar Product(s) Time (min) Yield (%)
phenyl
2 2-thienyl
3 indol-3-yl
4 2-pyridyl
3-pyridyl
e t
C°2pMB 
" CNMeN ^
"^ ''Ph
(±)-7Ba
C°2pMB
MeN f^"CN
'"D
(±)-7Bb
135
240
MeN f^
C°2pMB 
* CN NC.X°2pMB
N
NMe2
(±)-7Bn
C°2pMB 
*"CN
240
MeNc t
(±)-7Bd
8Bn
C°2pMB
N.
(±)-28Bd
CO^oMB 
* CN
120
120
78a,b
95
(±)-7Be
a Ratio (±)-7Bd/(±)-28Bd = 16:1 (calculated by integration of the 1H NMR signals of the 
crude reaction mixture). b Combined yield.
The reaction w a s clean  for 8Ba and 8Bd,e, but the reaction w ith  8Bb,c w a s slow er  
(due to the electron-donating effect of the aryl group) and stop p ed  after 60-70%  
conversion  (even  w ith  a  large excess of reagents), and w ith  8Bc both the substrate and  
the product w ere (d im ethylam ino)m ethylated  on  the indolic n itrogen  (com pounds  
(±)-7Bn and 8Bn, entry 3). In these cases, a dark brow n sticky precipitate w a s form ed  
u sin g  a large excess of reagents, w h ich  prevented  fu ll conversion  by  scaven gin g  the 
substrate. The reaction w a s totally  stereospecific in  all cases except for 8Bd, w h ich  w as  
on ly  partially stereospecific and gave a 16:1 diastereoisom eric m ixture (±)-7Bd and  
(±)-28Bd.21
a
1
+
2
+
5
N
25
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The form ation of com p ou n d  8Bn cou ld  be rationalized  as d ep icted  in  Schem e 2.5. 
O nce the d ip o le 24 is form ed, it dehydronates com p ou n d  8Bc g iv in g  im in iu m  in d o lid e  
29, w h ich  u p on  addition  of in d o lid e to the im in iu m  ion  form s com p ou n d  8Bn. 
C om p ou nd  (±)-7Bn is form ed by  cycloadd ition  of 24 and 8Bn.
Scheme 2.5 (D im e th y la m in o )m e th y la tio n  R ea ctio n  o f  C o m p o u n d  8B c. 
NCV_,CO2pMB
8Bc
Mei
H2C © 'C H 2
0
24
N C ./C O 2pMB
Me2N
8Bn
The cycloadd ition  reaction w a s also perform ed on the so lid  phase w ith  the 2-cyano­
acrylates 8 A a -g  (Table 2.5). After tw o  runs u sin g  an excess of the reagents, the IR
Table 2.5 1 ,3 -D ip o la r  C y c lo a d d itio n  R ea ctio n  on S o lid  P hase
O
NC
Ar
O'JJ
8Aa-g
Entry Ar
MeNHCH2CO2H 
(CH2O)n, PhMe 
A, 4 h
C O 2 - 0
/"■ /"C NM e N ^  
X^ '' 'A r  
7Aa,b,d-g,n
Product IR data (cm-1)a
1 phenyl
2 2-thienyl
3 indol-3-yl
4 2-pyridyl
5 3-pyridyl
6 4-methoxyphenyl
7 pyrrol-2-yl
MeN
c°2-0
N^f"CN
'''Ph
C°2-0 
CN
C°2-0
&N
 ^ NMe2
C °2 0
C f.
N
CO2-O
MeN/ J"
C°2“0CN
"CN
MeN f^
O^oMe
CO2O
7Aa
7Ab
7An
7Ad
7Ae
7Af
CN
2241, 1744
2242, 1740
2244, 1739
2243, 1740
2241, 1741
2242, 1739
7Ag 2240, 2192 (?), 1737
a Stretching vibrations for C=N and C=O.
H
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spectra of com p ou n d s 7 A a ,b ,d -f,n  sh o w ed  that the cycloadd ition  h ad  su cceed ed  in all 
cases, but for 8A g  (entry 7) it w a s n ot clear because som e u nexpected  peaks w ere  
observed  (see b elow , the cycloadd ition  reaction in solution).
Som e of the generated com pou n ds w ere cleaved  from  the so lid  support to confirm  
that the condensation  and the cycloadd ition  reactions had  succeeded . C om pound  7Aa 
w a s treated under various cond itions in order to obtain a single product, w h ich  cou ld  
be u nequ ivoca lly  characterized (Table 2.6). Thus, treatm ent w ith  TFA (entry 1) gave a 
product w ith  the right m ass o f (±)-30 (w ithout CF3CO 2H ), but the 1H N M R  spectrum  
w a s n ot con clu sive because of signal broaden ing and overlapping. O ther m eth ods for 
the cleavage w ere searched for. M essy  reactions w ere obtained under the substitution  
and reduction  cond itions sh o w ed  in the table (entries 2 and 3). A  clean m ixture of the 
a-cyano  ester (±)-7Ca and the a-cyano am ide (±)-31 w ere obtained u sin g  N H 3/M eO H
Table 2.6 C lea va g e  R ea ctio n s f r o m  the S o lid  S u p p o r t
MeN
co2- 0
/  / " C N cleavage
COR
CN
'Ar
M e N ^ f " CN
° ' " A r
Entry Ar Conditions Product(s) Yield (%)
1 phenyl
2 phenyl
3 phenyl
4 phenyl
5 phenyl
6 phenyl
1-[(dimethylamino)
methyl]indol-3-yl
8 4-methoxyphenyl
10% TFA/CH2O 2, 
21 °C, 1 h
KCN (cat.), MeOH, 
EtsN, PhMe, A, 48 h 
NaBH4, MeOH, 
THF, 21 °C, 24 h
7 N NHs/M eOH, 
CH2O 2, 21 °C, 36 h
MeOH, DIPEA, 
CH2Cl2, 30 h, A
MeOH, DIPEA, 
CH2O 2, |J.W, 1.5 h
MeOH, DIPEA, 
CH2Cl2, 30 h, A
MeOH, DIPEA, 
CH2Cl2, 30 h, A
C ° 2h
'CN
M e N ^
'Ph
■CF3CO2H
(±)-30 
Mess
Mess
C°2Me ÇONH2
CN
M e N ^ f " CN + M e N ^ f
"''Ph *''Ph
(±)-7Ca (±)-31
C°2Me
MeN f^'
2
■CN
'Ph
(±)-7Ca
C°2Me
^f"CN MeN /= \
n c PN
N^M(
(±)-7Cn
C°2Me
v f
'CN
a
(±)-7Cf
47-59a
57-72
10-15b
55-70
a Ratio (±)-7Ca/ (±)-31 = 1:9 (calculated by integration of the 1H NMR signals of the crude reaction 
mixture). b Yield after a single run.
7
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(entry 4). Finally, reaction w ith  M eO H  and DIPEA in  refluxing C H 2CI2 (procedure run  
tw ice over 30 h  each tim e) clean ly  gave the a-cyano ester (±)-7Ca (entry 5). The sam e  
reaction cond itions w ere tried under m icrow ave irradiation w ith  different pow er  
settings (entry 6), but this tim esav in g  m eth od  gave n oth in g  of com p ou n d  (±)-7Ca. The 
sam e successfu l reaction cond itions (M eO H , DIPEA, C H 2Q 2, A) w ere tried w ith  
substrates 8A n  and 8A f. Both reactions clean ly  gave the expected  com pou n ds (±)-7Cn  
and (±)-7Cf (entries 7 and 8, respectively). By this tim e, h ow ever, it w a s  d ecid ed  to no  
longer u se  so lid -phase chem istry (see below ) so that this part o f the investigation  w as  
abandoned.
W hen the cycload d ition  reaction w a s perform ed in  so lution  phase w ith  the 2-cyano­
acrylates 8C a-m  (Table 2.7), it w a s observed  that the reaction tim es w ere shorter and  
the reaction crude m ixtures w ere cleaner than for th ose w ith  8B. This w a s to such  an 
extent that in  som e cases an extraction (H 2O /E t2O) w a s all the purification n eed ed  (or 
just a short co lum n chrom atography), and as a consequence h igher y ie ld s w ere the 
result. The reaction w a s again  totally  stereospecific in  m ost cases, h igh ly  stereospecific  
for 8Cb (entry 2), and partially stereospecific for the electron-poor heteroaryls 8Cd,e  
and 8Cj (entries 4, 5, and 10). The m ixtures of d iastereoisom ers that arose cou ld  n o t be  
separated by  co lum n chrom atography. The reaction d id  n ot take p lace w ith  com pou n d  
8C g (entry 7); after 4 h  on ly  som e m inor unid en tified  com p ou n d s w ere form ed and  
m ost of the substrate w a s recovered, but there w a s no  trace of com p ou n d  (±)-7Cg. The 
reaction of substrate 8Ch d id  form  the product (±)-7Ch, but w ith  a low er y ield  
com pared  to all the others.
Table 2.7 1 ,3 -D ip o la r  C y c lo a d d itio n  R ea ctio n  To F orm  the P yrro lid in e -C o re  S tru c tu re s  ( ± ) - 7 C a ,b ,d - n  
NC^ ^CO2MeJ
8Ca-m
M e N H C H 2C O 2H 
( C H2O ) n, PhMe,  A
CO2Me
M e N ^ f " CN
^ " ' A r
(±)-7Ca,b,d-n
Entry Ar Product(s)a Time (min) Yield (%)
phenyl
2-thienyl
indol-3-yl
CNMeN/ |" 
0 "'Ph
(±)-7Ca
COoMe
/'''"/"CN MeN J + I
CO2Me
(±)-7Cb
S ^
(±)-28Cb
20
80
94
87b
CO2Me
/""-/"CNMeN
150 85
NMe2
(±)-7Cn
1
2
3 N
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10
2-pyridyl
3-pyridyl
4-methoxyphenyl
pyrrol-2-yl
1-methylpyrrol-2-yl
1-methylindol-3-yl
4-pyridyl
COoMe
/""/"CNMeN''--A .N^  + MeN
COoMe
(±)-7Cd
COoMe
/""/"CN MeN I
(±)-28Cd
MeN
N
(±)-7Ce (±)-28Ce
COoMe
/""/-CN MeN 1
OMe
(±)-7Cf
COoMe
d "CN
; q
(±)-7Cg
C(
N^f"
ue »M
(±)-7Ch
COoMe
/""/"CN MeN /= \
H c P
NMe
MeN
OoMe
"CN
(±)-7Ci
COoMe
CN
N ^ f  +
o
(±)-7Cj
COoMe
(±)-28Cj
COoMe
/""/"CNMeN .OMe
11 3,5-dimethoxyphenyl
12 1,3-benzodioxol-5-yl
13 3,4,5-trimethoxyphenyl
OMe
(±)-7Ck
O f '1
COoMe
CN
(±)-7Cl
COoMe
/"'"/"CN MeN I OMe
OMe
(±)-7Cm
45
25
75
240
120
80
45
80
80
45
90c
72d
99
52
95
85e
95
99
99
a Ratio calculated by integration of the 1H NMR signals of the crude reaction mixture. b (±)-7Cb/ 
(±)-28Cb = 70:1. c (±)-7Cd/(±)-28Cd = 6.5:1. d (±)-7Ce/(±)-28Ce = 6.6:1. e (±)-7Cj/(±)-28Cj = 5:1.
After analysis of the results obtained so far and those of Chapter 3, it w a s d ecid ed  to 
continue the research on ly  w ith  the diastereom erically  pure com pou n ds  
(± )-7C a,f,h ,i,k ,l for the construction of the library scaffolds (Chapter 5) and (±)-7Cm  for 
the synthesis of a h exahydropyrrolobenzazep ine (Chapter 6).
4
+
5
6
7
8
9
O
O
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Interestingly, com p ou n d  (±)-32 w a s form ed (ca. 15% conversion) w h en  attem pting to 
crystallize com p ou n d  (±)-7Cf from  h ot M eO H  (Schem e 2.6). A  p lausib le explanation  
for the form ation of com p ou n d  (±)-32 starts w ith  the m ethylation  of the tertiary am ine  
w ith  the m ethyl group from  another m olecu le form ing the am m oniu m  carboxylate 
(±)-33. D ue to the greater electronegativity  of the am m oniu m  group, this interm ediate  
is m ore prone to undergo the sam e reaction w ith  another m olecu le of (±)-7Cf 
(represented as Nu:) to g iv e  the am m onio carboxylate (±)-34. This zw itterion  m ay then  
perform  a Grob fragm entation , 22 lo s in g  carbon d ioxide, to y ie ld  product (±)-32.23 Traces 
of the corresponding com p ou n d  w ere also fou n d  during the purification of com pou n d  
(±)-7Cd after the cycloadd ition  reaction.
Scheme 2.6 F o rm a tio n  o f  C o m p o u n d  (±)-32 .
2.2.3 R ed u ction
In order to arrive at the required am ines, the nitrile function  of 7 A -C  had  to be 
reduced  under h om ogen eou s cond itions that cou ld  also be applied  on  the so lid  phase, 
but w ith o u t reducing the ester. In principle, nucleoph ilic m etal hydrid es reduce esters 
faster than nitriles. This fact w a s confirm ed u p on  the treatm ent of (±)-7Ca w ith  excess  
L iAlH 4 under different cond itions (Schem e 2.7): the h ydroxy  nitrile (±)-35 w a s obtained  
after stirring at 0 °C for 40 m in  and the cyano acetate (±)-36 w a s  obtained after 
refluxing in THF for 8  h  fo llo w ed  by  q uenching w ith  A c2O. From these results, it w as  
clear that the nitrile w a s very  h indered  (it is actually m ore h in d ered  than pivalonitrile). 
The ch em oselective reduction  of the nitrile cou ld  n ot be accom plished  u sin g  
electrophilic m etal hydrid es either (Schem e 2.7). Treatm ent of com p ou n d  (±)-7Ca w ith  
BH3 -SMe2 in  refluxing THF for 2.5 h  gave the am ino alcohol (±)-37 after w ork-up  (6  N  
H Q /H 2O fo llo w ed  by 2 M NaO H ). W hen the sam e reaction w a s  run at -7 8  °C for 30 
m in  a different result w a s found; com p ou n d  (±)-38 w a s form ed accom panied  b y  5% of 
com p ou n d  (±)-35, proving that the ester w a s reduced first. The reduction  o f (±)-7Ca 
w a s also attem pted u sin g  h om ogen eou s catalytic hydrogenation . Thus, d ifferent
30
Synthesis o f 3-(Aminomethyl)-4-arylpyrrolidine-3-carboxylates
catalysts ((Ph3P)3RhCl, (Pr^P^RhHCh, (Pr^P^RhH )24 w ere u nsu ccessfu lly  u sed  under a 
h yd rogen  atm osphere at different tem peratures (21-70 °C) and pressures (up to 30 
bar). The lack of p ositive  results, in  addition  to th ose obtained in our group for the 
attem pted reduction  of m eth yl trans-6-aryl-1-cyanocyclohex-3-ene-1-carboxylate (a 
sim ilar system  u sin g  cycloh exene instead  of a pyrrolid ine) ,25 led  to the h om ogen eou s  
reduction  b ein g  abandoned, h ence the so lid -p h ase chem istry cou ld  n ot be continued.
Scheme 2.7 R e d u c tio n  o f  (± )-7 C a  b y  A lu m in u m  a n d  B oron  H yd r id e s . 
-OH
LiAlH4, THF BH3-SMe2, THF
MeN
(±)-35
MeN
(±)-36
0 °C, 40 min
73%
■\ A
CO2Me
CN
1. LiAlH4, THF, A, 8 h /
2. Ac2O, 21 °C, 5 h
75%
M eN ^f"CN
^ '" P h
A, 2.5 h
76%
7Ca VBH3-SMe2, THF
MeN
OH
NH2
(±)-37
-7 8  °C, 30 min
MeN
,O
'CN
"Ph
(±)-35 (±)-38
The ch em oselective reduction  of the nitrile w a s  best ach ieved  by  a heterogen eou s  
catalytic hydrogenation  u sin g  R aney n ickel under a h yd rogen  atm osphere and h igh  
pressure (Table 2.8) .26 It w a s difficu lt to reproduce th ese results since th ey  d ep en d ed  on  
the am ount of Raney n ickel used . W e fou n d  that the addition  of N H 3 or EtaN w as  
crucial for the reaction to go to com p letion .27 Eventually, Et3N  w a s u sed  since w ith  
N H 3 am ide (±)-31 (Table 2.6) w a s form ed first. The reaction w a s  op tim ized  (entry 5) on  
sm all scale (50-200 m g) and the pure product (±)-6 Ca (purity >99% b y  GC analysis) 
w a s obtained after filtration over d iatom aceous earth w ith  a 95% yield .
Table 2.8 O p tim iz a tio n  o f  the R e d u c tio n  o f  (± )-7 C a  U s in g  R a n e y  N ick e l as C a ta ly s t
CO2Me CO2Me
CN H2, Ra-Ni  ^NH?MeN ------------- ► MeN
‘ M e O H  V — ,Ph Ph
(±)-7Ca (±) aC6
Entry Conditions Conversion (%)a Yield (%)
1 20 bar, 20 °C, 20 h 65 -
2 25 bar, 20 °C, 20 h 65 -
3 30 bar, 50 °C, 17 h 70 52
4 Et3N, 21 °C, 15 h >99.5 95
5 EtsN, 21 °C, 20 min >99.5 95
1 Measured by GC.
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W hen perform ing the reductions on  a large scale (up to 10 g), the reactions w ere left 
overn ight to reach fu ll conversion . U nder these conditions, the reaction y ie ld ed  
exc lu sive ly  the a -am in om eth yl esters 6C a ,f,h ,i,k -m  in  good  to excellent y ie ld s (Table 
2.9).
Table 2.9 R e d u c tio n  o f  the C y a n o  G ro u p  f r o m  the a -C y a n o  E sters  ( ± ) - 7 C a ,f ,h ,i ,k - m
H2, Ra-Ni, Et3N
CO2Me
/"--/"C N  MeN I
'''Ar
(±)-7Ca,f,h,i,k-m
MeOH, 21 <C, 15 h
CO2Me
M e N ^ " - NH2
'''Ar
(±)-6Ca,f,h,i,k-m
Entry Ar Product Yield (%)
1 phenyl
2 4-methoxyphenyl
3 1-methylpyrrol-2-yl
4 1-methylindol-3-yl
5 3,5-dimethoxyphenyl
6 1,3-benzodioxol-5-yl
7 3,4,5-trimethoxyphenyl
MeN ,NH2
CO2Me 
NH2
t í :
/\eN^ j'-
OMe
CO2Me 
.NH2
(±)-6Ca
(±)-6Cf
(±)-6Ch
MeN^ f''
.N-/Me
CO2Me 
/NH2
Cl
MeN^ f''
" r i  /)  (±)-6Ci
(±)-6Ck
'N'
Me
.NH2
OMe
C
MeN f^'- ,NH2
O
OMe
OMe
(±)-6Cl
(±)-6Cm
95
95
73
95
89
85
90
2
2
2
O
2
2.3 C o n clu sio n
In sum m ary, w e  h ave d evelop ed  a general h ig h -y ie ld in g  m eth od  for the synthesis of 
trans-4-aryl-substituted 3-(am inom ethyl)pyrrolidine-3-carboxylates. W e h ave sh ow n  
that these aryl groups can be p henyl or electron-rich aryls (4-m ethoxyphenyl, 3,5- 
d im eth oxyp henyl, 3 ,4 ,5-trim ethoxyphenyl, and 1 ,3-benzodioxol-5-yl) and electron-rich  
heteroaryls (1-m ethylpyrrol-2-yl and 1-m ethylindol-3-yl). A s a result, w e  anticipate 
that this m eth od o logy  can be su ccessfu lly  applied  for a w id e  range of aromatic groups, 
although  w ith  electron-poor heteroaryls (2-, 3-, and 4-pyridyl) m ixtures of c i s - t r a n s  
isom ers are form ed after the cycloadd ition  step. T hese com p ou n d s com bine the 
structures of the 2-arylethyl and the 3-arylpropyl am ine m oieties, rendering it a 
potential interesting m otif from  a pharm aceutical p o in t of v iew .
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W e h ave also sh ow n  that the K noevenagel reaction to form  2-cyanoacrylates and the 
1,3-dipolar cycloadd ition  reaction w ith  azom eth ine y lid es of the latter alkenes w ork  on  
the so lid  phase. A  h om ogen eou s procedure for the reduction  of the cyano group on the 
so lid  phase rem ains to be found.
2.4 A ck n o w led g em en ts
Carolina V alderas is ack n ow led ged  for her contribution to this chapter.
2.5 E xperim ental S ection
Reagents were obtained from commercial suppliers and were used without purification. 
Solvents were distilled from appropriate drying agents prior to use and were stored under 
nitrogen. Reactions were followed, and RF values were obtained, using thin-layer 
chromatography (TLC) on silica gel-coated plates (Merck 60 F254) with the indicated solvent 
mixture. Detection was performed with UV light and/or by charring at ca. 150 °C after dipping 
into a solution of KMnO4 or ninhydrin. Column or flash chromatography was carried out using 
ACROS silica gel (0.035-0.070 mm, pore diameter ca. 6  nm). IR spectra were recorded on an ATI 
Mattson Genesis Series FTIR spectrometer. High-resolution mass spectra were recorded on a 
JEOL AccuTOF (ESI) or a MAT900 (EI, CI, and ESI). Low-resolution ESI mass spectra were 
recorded on a Thermo Finnigan LCQ Advantage Max Ion Trap mass spectrometer. Elemental 
analyses were carried out using a Carlo Erba Instruments CHNS-O EA 1108 element analyzer. 
Melting points were analyzed with a Büchi melting point B-545 and are not corrected. Gas 
chromatography (GC) was performed on a Hewlett Packard 5890, containing a HP1 column (25 
m x 0.32 mm x 0.17 ^m), FID detection, and equipped with a HP3393A integrator. Microwave 
reactions were carried out in a CEM Discover microwave. NMR spectra were recorded at 298 K 
on a Bruker DMX 300 (300 MHz) and a Varian 400 (400 MHz) spectrometer in the solvent 
indicated. Chemical shifts are given in parts per million (ppm) with respect to tetramethylsilane 
(0.00 ppm), or CD3SOCHD2 (2.50 ppm), or CHD2OD (3.31 ppm) as internal standard for !H 
NMR; and CDCb (77.16 ppm), or CD3SOCD3 (39.52 ppm), or CD3OD (49.00 ppm) as internal 
standard for 13C NMR .28 Coupling constants are reported as J values in hertz (Hz). The 
multiplicity of the signals is described by the number of coupling constants, the number of 
peaks, and the pattern (Table 2.10). Thus, a signal presenting no coupling constant with one 
peak is a s in g le t  (s) and a signal presenting one coupling constant with two peaks (relative 
intensity 1:1) is a d o u b le t (d). A signal presenting multiple coupling constants and the maximum 
number of peaks (all with the same intensity) is described as a set of doublets. For example, a 
signal presenting two different coupling constants with four peaks (relative intensity 1 :1 :1 :1 ) is a 
d o u b le t o f  d o u b le ts  (dd) and a signal with three different coupling constants and eight peaks 
(relative intensity 1:1:1:1:1:1:1:1) is a d o u b le t o f  d o u b le t o f  d o u b le ts  (ddd). Signals presenting fewer 
peaks than the maximum number are due to peak overlap. The overlapping peaks yield a larger 
combined peak with a relative intensity equal to the addition of the intensity of these peaks. The 
signals with overlapping peaks are divided into: (1 ) signals presenting all the coupling 
constants with the same value, for example a t r ip le t  (t; two equal coupling constants with three 
peaks [relative intensity 1 :2 :1 ]) and a q u a r te t (q; three equal coupling constants with four peaks
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T able 2.10 Nuclear M agnetic Resonance Nom enclature System
N CCa NPb System c (C oupling Constants)
0 1 An (—)
1 2 AnB (Jab)
A nB2 (fab)
A nB C  (Jab -  Jac)
3  A nB C  (Jab / ac)
4  A nB C  (Jab *  J ac)
A nB 3 (Jab)
4  A nB 2C  (Jab =  /a c )
A nB C D  (Jab =  /ac  =  /a d )
A nB C D  (Jab =  /ac  /a d )
A nB C D  (Jab K  /a c  /a d )
g  A nB 2C  (/ab  ^  /a c  =  2  X J ab)
A nB C D  (/a b  =  Jac + Jad = Jab + J  ac O r  2  X J ab)
A nB 2 C  (Jab ^  Jac) 
A nB C D  (Jab =  Jac ^  /a d )
Patternd
Relative
intensity*3
M ultiplicity
Singlet (s)
1:1 Doublet (d)
1:2:1 Triplet (t)
1:2:1
Three-peaked doublet of 
doublets (dd(3))
1:1:1:1 Doublet of doublets (dd)
1:3:3:1 Q uartet (q)
1:3:3:1
Four-peaked doublet of doublet 
of doublets (ddd(4))
1:2:2:2:1 Five-peaked doublet of triplets (dt(5))
/  /
1:1:2:2:1:1 
1:2:1:1:2:1 
1:2:1:1:2:1
Doublet of triplets (dt)
6  A n B C D  (Jab «  /  ac ^  / a d )
1:1:2:2:1:1 
1:2:1:1:2:1 
1:2:1:1:2:1
Six-peaked doublet of doublet 
of doublets (ddd(6))
7  A n B C D  (Jab ^  / a c  ^  / a d  “  / a b  +  /a c ) 1:1:1:2:1:1:1 Seven-peaked doublet of doublet of doublets (ddd(7))
7  A n B C D  (Jab £  Jac £  Jad Jab +  / a c ) 1:1:1:2:1:1:1 Seven-peaked doublet of doublet of doublets (ddd(7))
1:1:1:1: 1: 1:1:1
Doublet of doublet of doublets 
(ddd)
A n B 3C  (Jab ¿  Jac =  2  X ƒ ab)
4  6  A n B 2C D  (/ a b  =  /a c  + Jad = Jab + Jac O r  2  X / ab)
A n B C D E  (/a b  =  Jac = Jad + J  ae = Jab + Jac O r  2  X  / ab)
6  A n B 3C  ( / a b  ^  Jac = 2 X  / a b )
A n B 3 C  ( / a b  ^  Jac = 3  X  J ab)
7  A n B 2 C D  (/ a b  =  Jac ^  / a d  =  3  X  J ab)
A n B C D E  (Jab = Jac = Jad í  J  ae = Jab +  Jac +  Jad O r  3  X J ab)
A n B 3C  (Jab ¿  Jac)
8  A n B 2C D  (/ a b  =  Jac i  Jad)
A n B C D E  (Jab = Jac = Jad + J  ae) u
jJUU
l i
li JL / Jj
l ( 2 x )  3  A B  (/a b )
1 :3 :1 :1 :3 :1
1 :3 :1 :1 :3 :1
1: 3 : 3 : 2 : 3 : 3 : 1
1 :1 : 3 : 3 : 3 : 3 : 1:1 
1 :3 :1 : 3 : 3 : 1: 3 : 1 
1 :3 :3 :1 :1 :3 :3 :1  / 
1: 3 : 3 : 1 :1 :3 :3 :1
Six-peaked doublet of quartets 
(dq(6))
Six-peaked doublet of doublet 
of doublet of doublets (dddd(6))
Seven-peaked doublet of 
quartets (dq(7))
Doublet of quartets (dq)
Three-peaked A B  system (2d(3))
a NCC: Number of coupling constants. b NP: Number of peaks.c The letters of the alphabet should be used depending on the difference in chemical shift relative to the ƒ coupling of the signals. For 
(jj example, an ABC system could be an ABX, or an AMX system.29 dThese signals were simulated with the program WinDNMR: D yn a m it NMR Spectra.30 e Distortion of the peaks is not considered.
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Chapter 2
[relative intensity 1:3:3:1]); (2) signals presenting two or three coupling constants with the same 
value and another one different, for example a d o u b le t o f  tr ip le ts  (dt; six peaks [relative intensity 
1:1:2:2:1:1 or 1:2:1:1:2:1, depending on the values of the coupling constants]) and a d o u b le t o f  
q u a r te ts  (dq; eight peaks [relative intensity 1:1:3:3:3:3:1:1, or 1:3:1:3:3:1:3:1, or 1:3:3:1:1:3:3:1, 
depending on the values of the coupling constants]); (3) signals presenting a coupling constant 
whose value is the addition of the value of other two or other three (it could also be considered 
as a multiple of one of the other coupling constants) that can present the same or a different 
value, for example a f iv e -p e a k e d  d o u b le t o f  tr ip le ts  (dt(5); five peaks [relative intensity 1:2:2:2:1]), a 
s ix -p ea k ed  d o u b le t o f  q u a r te ts  (dq(6); six peaks [relative intensity 1:3:4:4:3:1]), a seven -p ea k ed  d o u b le t  
o f  q u a r te ts  (dq(7); seven peaks [relative intensity 1:3:3:2:3:3:1]), and a seven -p ea k ed  d o u b le t o f  
d o u b le t o f  d o u b le ts  (ddd(7); seven peaks [relative intensity 1:1:1:2:1:1:1]); and (4) signals 
presenting different coupling constants, but close in value, with one or more overlapping peaks 
due to close proximity and line broadening of the peaks (the overlapping peaks in this case are 
broader and shorter than in the previous cases),31 for example a th ree-peaked  d o u b le t o f  d o u b le ts  
(dd(3); it resembles a triplet,32 so it presents three peaks with a relative intensity 1:2:1), a fo u r -  
peaked d o u b le t o f  d o u b le t o f  d o u b le ts  (ddd(4); it resembles a quartet, so it presents four peaks with a 
relative intensity 1:3:3:1), a s ix -p ea k ed  d o u b le t o f  d o u b le t o f  d o u b le ts  (ddd(6); it resembles a doublet 
of triplets, so it presents six peaks with a relative intensity 1:1:2:2:1:1 or 1:2:1:1:2:1, depending on 
the values of the coupling constants), a seven -p ea k ed  d o u b le t o f  d o u b le t o f  d o u b le ts  (ddd(7);33 seven 
peaks [relative intensity 1:1:1:2:1:1:1]), and a six -p ea k ed  d o u b le t o f  d o u b le t o f  d o u b le t o f  d o u b le ts  
(dddd(6); it resembles a six-peaked doublet of quartets, so it presents six peaks with a relative 
intensity 1:3:4:4:3:1). In addition, m u ltip le t  (m) is used for a signal with an undefined pattern 
(either because of second-order coupling or because of signal overlapping) and broad  (b) is used 
as an adjective of broad signals because of fast proton exchange (OH and NH), for protons on 
molecules with a dynamic equilibrium, and for protons with broad signals due to small 
coupling constants that cannot be measured. Finally, th ree-peaked  A B  s y s te m  (2d(3)) is used for 
strongly coupled AB systems (with two very distorted doublets) whose inner peaks are merged 
forming a large single peak and the outer peaks rise just above the background noise. Peak 
assignment in 1H and 13C spectra is based on 2D gDQCOSY, gHSQC, and gHMBC spectra, and 
DEPT 135 when needed. The assignment of signals marked with * is interchangeable.
" W a n g  r e s in y l"  2 -cy a n o a c e ta te  9A.
Diisopropylcarbodiimide (1.82 mL, 1.47 g, 11.66 mmol) was added to a mixture 
- J U )  of Wang resin 11 (3.99 g, 3.59-4.39 mmol) and HOBT (0.30 g, 2.17 mmol) in dry 
O THF (32 mL) under an argon atmosphere and the resulting mixture was stirred
over 30 min at 0 °C. A mixture of 2-cyanoacetic acid 10 (0.66 g, 7.78 mmol) in THF (3 mL) was 
then added and the resulting mixture was stirred over 20 h at room temperature. After this 
time, the mixture was filtered off and the resin was rinsed with DMF (10 mL), MeOH (10 mL), 
DMF (10 mL), MeOH (10 mL), CH2Cl2 (10 mL), MeOH (10 mL), CH2Cl2 (10 mL), MeOH (10 mL), 
CH2Cl2 (10 mL). This procedure was done twice. F T IR  [ V (cm-1), neat]: 2262, 1751.
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4 -M e th o x y b e n z y l 2 -c y a n o a c e ta te  9B.
A mixture of DIC (7.4 mL, 5.99 g, 47.0 mmol) in THF (10 mL) was
O
added to a mixture of 4-methoxybenzyl alcohol 12 (3.93 mL, 4.37 g,
32.0 mmol) and HOBT (0.61 g, 4.5 mmol) in dry THF (15 mL) under 
an argon atmosphere and the resulting mixture was stirred over 1 0  
min at 0 °C. A mixture of 2-cyanoacetic acid 10 (4.00 g, 47.0 mmol) in THF (10 mL) was then 
added dropwise and the resulting mixture was stirred over 2 h at 0 °C. After this time, the 
mixture was filtered off and the precipitate was washed with THF (40 mL). The filtrate was 
concentrated under reduced pressure and the residue was purified by column chromatography 
(heptane/AcOEt, 2:1) to afford 9B as a white solid (6.44 g, 98%). *H N M R  [200 MHz, 5 (ppm), 
CDCla]: 7.32-7.25 (m, 2 iH, 2'-CH + 6 ’-CH), 6.91-6.84 (m, 2 iH, 3'-CH + 5’-CH), 5.11 (s, 2 iH, 
OCH2Ar), 3.77 (s, 3 1H, OCH3), 3.41 (s, 2 1H, 2 -CH2). 13C N M R  [75 MHz, 5 (ppm), CDCla]: 162.5 
(CO2), 159.4 (4'-C), 130.0 (2'-C + 6 '-C), 126.1 (1'-C), 113.7 (3'-C + 5'-C), 112.9 (CN), 68.0 (OCH2Ar),
55.1 (OCH3), 24.6 (2-C). F T IR  [V (cm-1), neat]: 2985, 2943, 2837, 2262, 1747, 1612, 1514, 1247, 
1173, 823. R f: 0.32 (heptane/AcOEt, 2:1).
General Procedure for Knoevenagel Condensation Reaction of 9A. A suspension of 2- 
cyanoacetate 9A, the aldehyde 13 (10.0 equiv), and NH4OAc (1.0 equiv) in THF was reacted in 
the microwave at 500 W for 45 min. The reaction mixture was filtered and the resin was 
alternatively washed with MeOH and CH2Cl2 (3 cycles). The resin was dried for 17 h at 1 torr 
and 70 °C. To assure full conversion the reaction was repeated using the same reaction 
conditions.
nc^ A O
OMe
2'
2
4
5
" W a n g  r e s in y l"  (E )-2 -c y an o -3 -p h e n y la c ry la te  8A a.
O According to the general procedure, the reaction of 2-cyanoacetate 9A  (3.944 g,
•*O^0 3.55-4.34 mmol) with benzaldehyde 13a (4.244 g, 40.0 mmol) afforded 8 A a 
(4.173 g). F T IR  [ V (cm-1), neat]: 2223, 1726, 1605.
"W a n g  r e s in y l"  (E )-2 -c y an o -3 -(2 -th ie n y l)a c ry la te  8A b.
According to the general procedure, the reaction of 2-cyanoacetate 9A  (1.000 
O g, 0.9-1.1 mmol) with thiophene-2-carbaldehyde 13b (1.121 g, 10.0 mmol) 
afforded 8 A b  (1.092 g). F T IR  [ V (cm-1), neat]: 2221, 1722, 1599.
-S
" W a n g  r e s in y l"  (E )-2 -cy an o -3 -(1 H -in d o l-3 -y l)ac ry la te  8Ac.
O / —s. According to the general procedure, the reaction of 2-cyanoacetate 9A  
v°  (1.000 g, 0.9-1.1 mmol) with 1H-indole-3-carbaldehyde 13c (1.452 g, 10.0
mmol) afforded 8A c (1.127 g). F T IR  [ V (cm-1), neat]: 2216, 1713, 1591.
N'I
H
"W a n g  r e s in y l"  (E )-2 -c y an o -3 -(2 -p y rid y l)a c ry la te  8A d.
O According to the general procedure, the reaction of 2-cyanoacetate 9A  (1.000
g, 0.9-1.1 mmol) with pyridine-2-carbaldehyde 13d  (1.071 g, 10.0 mmol) 
afforded 8 A d  (1.103 g). F T IR  [ V (cm-1), neat]: 2229, 1731, 1620.
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"Wang resinyl" (E)-2-cyano-3-(3-pyridyl)acrylate 8 Ae.
O According to the general procedure, the reaction of 2-cyanoacetate 9A (1.000
NC^ '''< D ^ ^  g, 0.9-1.1 mmol) with pyridine-3-carbaldehyde 13e (1.071 g, 10.0 mmol)
afforded 8 Ae (1.098 g). FTIR [ V (cm-1), neat]: 2226, 1721, 1614.
'N  "
"Wang resinyl" (E)-2-cyano-3-(4-methoxyphenyl)acrylate 8Af.
O According to the general procedure, the reaction of 2-cyanoacetate 9A
O (1.000 g, 0.9-1.1 mmol) with 4-methoxybenzaldehyde 13f (1.361 g, 10.0 
mmol) afforded 8 Af (1.118 g). FTIR [ V (cm-1), neat]: 2220, 1718, 1588.
MeO' ^
"Wang resinyl" (E)-2-cyano-3-(1H-pyrrol-2-yl)acrylate 8Ag.
O According to the general procedure, the reaction of 2-cyanoacetate 9A (1.000
O g, 0.9-1.1 mmol) with 1H-pyrrole-2-carbaldehyde 13g (0.951 g, 10.0 mmol) 
afforded 8Ag (1.088 g). FTIR [ V (cm-1), neat]: 2212, 1711, 1592.
\ - N  
H
General Procedure for Knoevenagel Condensation Reaction of 9B. Piperidine (5 drops) was 
added to a solution of 2-cyanoacetate 9B and the aldehyde 13 (1.0 equiv) in EtOH. The resulting 
reaction mixture was stirred at room temperature for the time indicated in each case. The 
reaction mixture was filtered and the precipitate was recrystalized from EtOH. The filtrate was 
concentrated under reduced pressure and purified by recrystalization from EtOH.
4-M ethoxybenzyl (E)-2-cyano-3-phenylacrylate 8Ba.
O According to the general procedure, the reaction of 2-cyanoacetate
9B (1.000 g, 4.87 mmol) with benzaldehyde 13a (517 mg, 4.87
mmol) over 75 min afforded 8Ba (1.078 g, 75%) as a white solid.OMe ’ v 6  ’
!H NMR [200 MHz, 5 (ppm), CDCla]: 8.25 (s, 1 1H, 3-CH), 8.01­
7.94 (m, 2 1H, 2'-CH + 6 '-CH), 7.61-7.44 (m, 3 1H, 3'-CH + 4'-CH + 
5'-CH), 7.42-7.36 (m, 2 1H, 2"-CH + 6 "-CH), 6.95-6.89 (m, 2 1H, 3"-CH + 5"-CH), 5.30 (s, 2 1H, 
OCH2Ar), 3.82 (s, 3 1H, OCH3). «C  NMR [75 MHz, 5 (ppm), CDCla]: 161.7 (CO2), 159.3 (4''-C),
154.6 (3-C), 132.8 (4'-C), 130.9 (1'-C), 130.5 (2'-C + 6 '-C), 129.7 (2''-C + 6 ''-C), 128.7 (3'-C + 5'-C),
126.5 (1''-C), 114.8 (CN), 113.6 (3''-C + 5''-C), 102.5 (2-C), 67.7 (OCH2Ar), 55.0 (OCH3). FTIR [ V 
(cm-1), neat]: 3032, 2958, 2944, 2837, 2224, 1727, 1606, 1515, 1243, 1173, 807, 771, 681. HRMS [EI 
(m /z)] calcd for Ci8Hi5NO3 = 293.1052, found for [M+^ ] = 293.1052 (| A | = 0.0 ppm), peaks at 
(relative intensity): 293 (34), 121 (100), 77 (21). Elem. anal. calcd for C18H 15NO3: C 73.71%, H 
5.15%, N 4.78%; found C 73.77%, H 4.80%, N 4.85%. Rf: 0.52 (heptane/AcOEt, 1:1). Mp: 75.6 °C 
(from EtOH, small white needles). Purity: >99.5% (GC).
4-M ethoxybenzyl (E)-2-cyano-3-(2-thienyl)acrylate 8Bb.
O ' According to the general procedure, the reaction of 2-cyanoacetate
O ^ ^ 3' 9B (1.000 g, 4.87 mmol) with thiophene-2-carbaldehyde 13b (546 
OMe mg, 4.87 mmol) over 90 min afforded 8Bb (1.300 g, 89%) as a light
4 ' ^ ^  2' 
3'
4'
4' V s
5 yellow solid. *H NMR [200 MHz, 5 (ppm), CDO3]: 8.33 (s, 1 1H, 3-
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C H ), 7.81 (d d ; J = 3.8, 1.3 H z; 1 1H , 3 '-C H ), 7.78 (d d ; J = 5.1, 1.3 H z; 1 1H , 5 '-C H ), 7 .40-7 .35 (m , 2 
1H , 2 ''-C H  + 6 ''-C H ), 7.21 (dd ; J = 5.1, 3.8 H z; 1 1H , 4 '-C H ), 6 .93-6 .87  (m , 2 1H , 3 ''-C H  + 5 ''-C H ),
5.27 (s, 2 1H , O C H 2A r), 3.81 (s, 3 1H , O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D Q 3]: 162.3 (CO 2),
159.5 (4 ''-C ), 146.5 (3-C ), 137.0 (3 '-C ), 135.7 (2'-C ), 135.0 (5'-C ), 130.0 (2 ''-C  + 6 ''-C ), 128.4 (4 '-C ),
126.9 (1''-C), 115.4 (CN ), 113.9 (3''-C  + 5''-C), 99.1 (2-C), 67.8 (O C H 2A r), 55.3 (O C H 3). F T IR  [ V 
(cm -1), n ea t]: 3034, 2960, 2942, 2837, 2220, 1722, 1597, 1517, 1245, 1172, 809, 743. H R M S  [EI 
(m /z ) ]  ca lcd  fo r C 1ôH13N O 3S = 299.0616, fo u n d  fo r [M+^] = 299.1004, p e a k s  a t  (re la tiv e  in ten sity ): 
299 (30), 121 (100), 77 (15). E lem . a n a l.  ca lcd  fo r C 16H 13N O 3S: C  64.20% , H  4.38% , N  4.68% ; fo u n d  
C  64.11% , H  4.11% , N  4.71% . R f: 0.47 (h e p ta n e /A c O E t, 1:1). M p : 122.1 °C (from  E tO H , sm all 
lig h t y e llo w  n eed le s). P u rity : >99.5% (GC).
4-M ethoxybenzyl (E)-2-cyano-3-(1H-indol-3-yl)acrylate 8Bc.
O
OMe
A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , th e  re a c tio n  o f 2- 
c y a n o ac e ta te  9B (1.000 g, 4 .87  m m o l) w ith  1H -indo le -3 - 
c a rb a ld e h y d e  13c (707 m g, 4 .87 m m o l) o v e r 180 m in  a ffo rd e d  
8Bc (943 m g , 58% ) as  a  y e llo w  so lid  (fro m  the  p re c ip ita te ) . aH  
H N M R  [300 M H z, 5 (p p m ), C D 3SO C D 3]: 12.55 (s, 1 1H , N H ), 8.55
(s, 2 1H , 3 -C H  + 2 '-C H ), 7.92 (d, J = 8.1 H z , 1 1H , 4 '-C H ), 7.55 (d, J = 8.4 H z, 1 1H , 7 '-C H ), 7.40-7.36 
(m , 2 1H , 2 ''-C H  + 6 ''-C H ), 7 .31-7 .20 (m , 2 1H , 5 '-C H  + 6 '-C H ), 6 .97-6 .93 (m , 2 1H , 3 ''-C H  + 5 ''-C H ), 
5.23 (s, 2 1H , O C H 2A r), 3.75 (s, 3 1H , O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D 3SO C D 3]: 162.8 
(C O 2), 158.9 (4 ''-C ), 146.5 (3-C ), 135.9 (7 'a-C ), 132.6 (2'-C ), 129.7 (2 ''-C  + 6 ''-C ), 127.4 (1 ''-C ), 126.6 
(3'a-C), 123.4 (6'-C), 121.9 (5'-C), 118.3 (4'-C), 117.7 (CN ), 113.6 (3''-C  + 5''-C), 112.7 (7'-C), 109.8 (3'- 
C), 91.8 (2-C), 66.5 (O C H 2A r), 55.0 (O C H 3). F T IR  [ V (cm -1), n ea t]: 3252, 3010, 2954, 2942, 2833, 
2219, 1709, 1588, 1515, 1245, 1174, 807, 742. E lem . a n a l. ca lcd  fo r C 20H 16N 2O 3: C  72.28% , H  4.85%, 
N  8.43%; fo u n d  C  72.09%, H  4.58% , N  8.28% . R f: 0.36 (h e p ta n e /A c O E t, 1:1). M p : 180.7 °C (from  
E tO H , sm a ll y e llo w  flakes). P u rity : >99.5% (GC).
E th y l (E )-2 -cy an o -3 -(1 H -in d o l-3 -y l)ac ry la te  8D c.
A cc o rd in g  to  th e  g e n e ra l p ro c e d u re , the  re a c tio n  o f 2 -cy an o ace ta te  9B 
OEt (1.000 g, 4 .87 m m o l) w ith  1 H -in d o le -3 -ca rb a ld eh y d e  13c (707 m g, 4.87 
m m o l) o v e r  180 m in  a f fo rd e d  8D c (177 m g , 15%) as  a n  o ra n g e  so lid  (from  
the  filtra te ). *H N M R  [300 M H z, 5 (p p m ), C D 3SO C D 3]: 12.53 (s, 1 1H , N H ), 
8.54 (s, 1 1H , 3-CH)*, 8.51 (s, 1 1H , 2'-CH)*, 7.91 (d, J = 8.1 H z , 1 1H , 4 '-C H ), 7.55 (d, J = 8.4 H z, 1 
1H , 7 '-C H ), 7 .31-7 .20 (m , 2 1H , 5 '-C H  + 6 '-C H ), 4 .26 (q, J = 7.1 H z, 2 1H , C H 2C H 3), 1.30 (t, J = 7.1 
H z, 3 1H , C H 2C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D 3S O C D 3]: 162.8 (CO 2), 146.1 (3-C), 135.9 (7'a- 
C ), 132.3 (2'-C ), 126.6 (3 'a-C ), 123.3 (6 '-C ), 121.8 (5'-C ), 118.2 (4'-C ), 117.7 (C N ), 112.7 (7 '-C ), 109.7 
(3'-C), 92.1 (2-C), 61.3 (C H 2C H 3), 14.2 (C H 2C H 3). F T IR  [ V (cm -1), n ea t]: 3284, 3010, 2954, 2937, 
2833, 2216, 1712, 1684, 1590, 1573, 1510, 1236, 740. H R M S  [ESI (m /z ) ]  ca lcd  fo r (C14H 12N 2O 2 + 
H)+ = 241.09715, fo u n d  241.09770 ( | A | = 1.6 p p m ). M S  [ESI (m /z ) ]  ca lcd  fo r (C14H 12N 2O 2 -  H )- 
= 239, fo u n d  239. R f: 0.42 (h e p ta n e /A c O E t, 1:1). M p : 166.3 °C.
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4-M ethoxybenzyl (E)-2-cyano-3-(2-pyridyl)acrylate 8Bd.
O ' According to the general procedure, the reaction of 2-cyanoacetate
N<Xjp 1 O ^ j |^ j 3' 9B (1.000 g, 4.87 mmol) with pyridine-2-carbaldehyde 13d (522 
' N''" 3 6 ^rf^OM e mg, 4.87 mmol) over 45 min afforded 8 Bd (978 mg, 6 8 %) as a 
4, 3' brown solid. iH NMR [300 MHz, 5 (ppm), CDCla]: 8.77 (d, J = 4.5
Hz, 1 !H, 6 '-CH), 8.24 (s, 1 iH, 3-CH), 7.86 (d, J = 7.8 Hz, 1 iH, 3'-CH), 7.79 (dt; J = 1.8, 7.8 Hz; 1 
!H, 4'-CH), 7.40-7.33 (m, 3 1H, 5'-CH + 2''-CH + 6 ''-CH), 6.91-6.86 (m, 2 1H, 3''-CH + 5''-CH), 5.29 
(s, 2 1H, OCH2Ar), 3.80 (s, 3 1H, OCH3). 13C NMR [75 MHz, 5 (ppm), CDCls]: 161.6 (CO2), 159.6 
(4''-C), 153.2 (3-C), 150.2 (6 '-C), 149.7 (2'-C), 136.7 (4'-C), 130.1 (2''-C + 6 ''-C), 126.7 (1''-C), 126.3 (5'- 
C), 126.0 (3'-C), 114.4 (CN), 113.9 (3''-C + 5''-C), 106.6 (2-C), 68.2 (OCH2Ar), 55.3 (OCH3). FTIR [ V 
(cm-1), neat]: 3054, 2963, 2944, 2837, 2228, 1731, 1619, 1515, 1243, 1174, 807, 789, 738. HRMS [EI 
(m /z)] calcd for C17H 14N 2O3 = 294.1004, found for [M+^ ] = 294.1004 ( |A | = 0.0 ppm), peaks at 
(relative intensity): 294 (11), 249 (21), 158 (57), 130 (98), 121 (100), 78 (30). Elem. anal. calcd for 
C17H 14N 2O3: C 69.38%, H 4.79%, N 9.52%; found C 69.06%, H 4.47%, N 9.33%. Rf: 0.31 
(heptane/AcOEt, 1:1). Mp: 96.0 °C (from EtOH, light brown needles). Purity: >99.5% (GC).
4-M ethoxybenzyl (E)-2-cyano-3-(3-pyridyl)acrylate 8Be.
O According to the general procedure, the reaction of 2-cyanoacetate
"O''"'""]^^3' 9B (1.000 g, 4.87 mmol) with pyridine-3-carbaldehyde 13e (522 
O^Me mg, 4.87 mmol) over 20 min afforded 8Be (1.262 g, 88%) as a 
' N^ 2' brown solid. *H NMR [300 MHz, 5 (ppm), CDCls]: 8.87 (d, J = 2.1
Hz, 1 1H, 2'-CH), 8.71 (dd; J = 4.8, 1.5 Hz; 1 1H, 6'-CH), 8.51 (ddd; J = 8.1, 2.1, 1.5 Hz; 1 1H, 4'-CH), 
8.22 (s, 1 1H, 3-CH), 7.43 (dd; J = 8.1, 4.8 Hz; 1 1H, 5'-CH), 7.38-7.32 (m, 2 1H, 2''-CH + 6''-CH), 
6.91-6.86 (m, 2 1H, 3''-CH + 5''-CH), 5.28 (s, 2 1H, OCH2Ar), 3.79 (s, 3 1H, OCH3). 13C NMR [75 
MHz, 5 (ppm), CDCl3]: 163.4 (CO2), 159.8 (4''-C), 153.3 (3-C), 152.7 (6'-C), 151.3 (2'-C), 135.8 (4'-C),
130.3 (2''-C + 6''-C), 127.4 (3'-C), 126.7 (1''-C), 124.0 (5'-C), 114.7 (CN), 114.1 (3''-C + 5''-C), 105.6 (2- 
C), 68.5 (OCH2Ar), 55.5 (OCH3). FTIR [ V (cm-1), neat]: 3028, 2959, 2943, 2833, 2224, 1718, 1610, 
1515, 1243, 1174, 811, 698. HRMS [ESI (m /z)] calcd for (C17H 14N 2O3 + H)+ = 295.10772, found 
295.10767 (| A | = 2.0 ppm). Rf: 0.15 (heptane/AcOEt, 1:1).
General Procedure for Knoevenagel Condensation Reaction of 9C. Piperidine (5 drops) was 
added to a solution of methyl 2-cyanoacetate 9C and the aldehyde 13 (1.0 equiv) in MeOH. The 
resulting reaction mixture was stirred at room temperature for the time indicated in each case. 
The reaction mixture was filtered and the precipitate was recrystalized from MeOH. The filtrate 
was concentrated under reduced pressure and purified by recrystalization from MeOH.
Methyl (E)-2-cyano-3-phenylacrylate 8Ca.
O According to the general procedure, the reaction of methyl 2-cyanoacetate 9C
2 1 OMe (7.940 g, 80.13 mmol) with benzaldehyde 13a (8.504 g, 80.13 mmol) over 30
min afforded 8Ca (14.910 g, 99%) as a white solid. aH NMR [400 MHz, 5 
(ppm), CDO3]: 8.21 (s, 1 1H, 3-CH), 7.97-7.92 (m, 2 1H, 2'-CH + 6'-CH), 7.56­
7.43 (m, 3 1H, 3'-CH + 4'-CH + 5'-CH), 3.90 (s, 3 1H, OCH3). 13C NMR [75 MHz, 5 (ppm), CDO3]: 
162.5 (CO2), 154.9 (3-C), 133.1 (4'-C), 131.1 (1'-C), 130.8 (2'-C + 6'-C), 129.0 (3'-C + 5'-C), 115.2
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(CN), 102.4 (2-C), 53.4 (OCH3). FTIR [ V (cm-1), neat]: 3036, 2954, 2224, 1727, 1606, 1200, 767, 685. 
Elem. anal. calcd for C1 1H9NO2: C 70.58%, H 4.85%, N 7.48%; found C 70.39%, H 4.54%, N  
7.43%. R f: 0.63 (heptane/AcOEt, 1:1). Mp: 87.9 °C (from MeOH, colorless flake-like crystals). 
Purity: >99.5% (GC).
Methyl (E)-2-cyano-3-(2-thienyl)acrylate 8Cb.
O According to the general procedure, the reaction of methyl 2-cyanoacetate 9C
OMe (991 mg, 10.00 mmol) with thiophene-2-carbaldehyde 13b (1.121 g, 10.00 
mmol) over 30 min afforded 8Cb (1.816 g, 94%) as a light brown solid. *H 
NMR [400 MHz, 5 (ppm), CDCb]: 8.36 (s, 1 1H, 3-CH), 7.84 (d, J = 3.9 Hz, 1 
1H, 3'-CH), 7.80 (d, J = 4.9 Hz, 1 1H, 5'-CH), 7.24 (dd; J = 4.9, 3.9 Hz; 1 1H, 4'-CH), 3.92 (s, 3 1H, 
OCH3). 13C NMR [75 MHz, 5 (ppm), CDCb]: 162.9 (CO2), 146.7 (3-C), 137.2 (3'-C), 135.8 (2'-C),
135.2 (5'-C), 128.6 (4'-C), 115.6 (CN), 98.8 (2-C), 53.4 (OCH3). FTIR [ V (cm-1), neat]: 3087, 3028,
2964, 2216, 1718, 1590, 1271, 1214, 729. Elem. anal. calcd for C9H7NO2S: C 55.94%, H 3.65%, N  
7.25%; found C 55.98%, H 3.63%, N 7.23%. Rf: 0.61 (heptane/AcOEt, 1:1). Mp: 106.9 °C (from 
MeOH, light brown needles). Purity: >99.5% (GC).
Methyl (E)-2-cyano-3-(1H-indol-3-yl)acrylate 8Cc.
O According to the general procedure, the reaction of methyl 2-cyanoacetate
i ^ v ^ O M e  9C (991 mg, 10.00 mmol) with 1H-indole-3-carbaldehyde 13c (1.452 g,
3 10.00 mmol) in THF (15 mL) over 480 min afforded 8Cc (2.239 g, 99%) as a
N^' yellow solid. *H NMR [400 MHz, 5 (ppm), CD3SOCD3]: 12.64 (bs, 1 1H,
H NH), 8.64 (s, 1 1H, 2'-CH), 8.63 (s, 1 1H, 3-CH), 8.05-7.99 (m, 1 1H, 4'-CH),
7.67-7.63 (m, 1 1H, 7'-CH), 7.41-7.30 (m, 2 1H, 5'-CH + 6'-CH), 3.92 (s, 3 1H, OCH3). 13C NMR [75 
MHz, 5 (ppm), CD3SOCD3] : 163.3 (CO2), 146.3 (3-C), 135.9 (7'a-C), 132.4 (2'-C), 126.6 (3'a-C), 123.3 
(6'-C), 121.9 (5'-C), 118.3 (4'-C), 117.8 (CN), 112.7 (7'-C), 109.7 (3'-C), 91.8 (2-C), 52.6 (OCH3). FTIR 
[V (cm-1), neat]: 3266, 3132, 2989, 2943, 2212, 1695, 1589, 1241, 742. Elem. anal. calcd for 
C13H 10N 2O2: C 69.02%, H 4.46%, N 12.38%; found C 68.97%, H 4.38%, N 12.22%. Rf: 0.80 
(AcOEt). Mp: 189.5 °C (from MeOH, yellow needles). Purity: >99.5% (GC).
Methyl (E)-2-cyano-3-(2-pyridyl)acrylate 8Cd.
O According to the general procedure, the reaction of methyl 2-cyanoacetate 9C
NC. A
jp 1 OMe (991 mg, 10.00 mmol) with pyridine-2-carbaldehyde 13d (1.071 g, 10.00 
' N"2' 3 mmol) over 30 min afforded 8Cd (1.863 g, 99%) as a brown solid. *H NMR
4, ' 3' [400 MHz, 5 (ppm), CDO3]: 8.83 (ddd; J = 4.8, 1.6, 1.0 Hz; 1 1H, 6'-CH), 8.30 (s,
1 1H, 3-CH), 7.89 (ddd(6); J = 7.8, 1.2, 1.2 Hz; 1 1H, 3'-CH), 7.85 (ddd(6); J = 7.8, 7.8, 1.6 Hz; 1 1H, 
4'-CH), 7.44 (ddd; J = 7.3, 4.9, 1.5 Hz; 1 1H, 5'-CH), 3.96 (s, 3 1H, OCH3). 13C NMR [75 MHz, 5 
(ppm), CDO 3]: 162.6 (CO2), 153.7 (3-C), 150.7 (6'-C), 150.0 (2'-C), 137.1 (4'-C), 126.8 (5'-C), 126.4 
(3'-C), 114.8 (CN), 106.4 (2-C), 53.7 (OCH3). FTIR [ V (cm-1), neat]: 3050, 2963, 2220, 1720, 1278, 
1215, 781, 740. Elem. anal. calcd for C10H8N 2O2: C 63.83%, H 4.28%, N 14.89%; found C 64.06%, 
H 4.26%, N 14.79%. Rf: 0.34 (heptane/AcOEt, 1:1). Mp: 131.7 °C (from MeOH, small brown 
needles). Purity: >99.5% (GC).
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M e th y l (E )-2 -cy an o -3 -(3 -p y rid y l)ac ry la te  8Ce.
O A cc o rd in g  to  th e  g e n e ra l p ro c e d u re , th e  re a c tio n  of m e th y l 2 -cy an o ace ta te  9C
NC
' ' y i 1 OMe (991 m g , 10.00 m m o l) w ith  p y r id in e -3 -c a rb a ld e h y d e  13e (1.071 g, 10.00 m m o l)
o v e r 90 m in  a f fo rd e d  8 C e (1.750 g, 93%) as  a  lig h t y e llo w  d u s t. *H N M R  [300 
' N^ 2' M H z, 5 (p p m ), CDCla]: 8.91 (d, J = 1.8 H z, 1 iH , 2 '-C H ), 8.74 (d d ; J = 4.8, 1.8
H z; 1 1H , 6 '-C H ), 8 .57-8 .51 (m , 1 1H , 4 '-C H ), 8.26 (s, 1 1H , 3-C H ), 7.46 (dd ; J = 7.8, 4.8 H z; 1 1H , 5 '- 
C H ), 3.95 (s, 3 1H , O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), CDCla]: 161.9 (CO 2), 153.3 (3-C), 152.7 (6 '- 
C), 151.3 (2'-C), 135.8 (4'-C), 127.3 (3'-C), 123.9 (5'-C), 114.7 (CN ), 105.1 (2-C), 53.8 (O C H 3). F T IR  
[ V (cm -1), nea t]: 3031, 2959, 2223, 1722, 1280, 697. R f: 0.13 (h e p ta n e /A c O E t, 1:1). M p : 129.2 °C.
M e th y l (E )-2 -c y an o -3 -(4 -m e th o x y p h en y l)ac ry la te  8 Cf.
0  A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , th e  re a c tio n  of m e th y l 2-
NC^
0Me c y a n o ac e ta te  9C  (6.804 g, 68.66 m m o l) w ith  4 -m e th o x y b e n z a ld e h y d e  13f
(9.349 g, 6 8 .6 6  m m o l) o v e r 30 m in  a ffo rd e d  8 C f (14.020 g, 94%) as  a  w h ite  
Me0 -'"4>' f ^ 2, so lid . !H  N M R  [400 M H z, 5 (p p m ), CDCls]: 8.14 (s, 1 1H , 3-C H ), 8 .00-7 .95
(m , 2 1H , 2 '-C H  + 6 '-C H ), 7 .01-6 .95 (m , 2 1H , 3 '-C H  + 5 '-C H ), 3.91 (s, 3 1H , C O 2C H 3), 3.88 (s, 3 1H , 
O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D Q 3]: 163.8 (4'-C), 163.5 (CO 2), 154.5 (3-C), 133.6 (2'-C + 
6 '-C), 124.2 (1'-C), 116.1 (CN), 114.7 (3'-C + 5'-C), 98.8 (2-C), 55.6 (O C H 3), 53.1 (C O 2C H 3). F T IR  [ V 
(cm -1), nea t]: 3084, 2954, 2846, 2215, 1714, 1580, 1264, 1174, 841. E lem . a n a l.  ca lcd  fo r C 12H 11N O 3: 
C  66.35% , H  5.10% , N  6.45%; fo u n d  C  66.24% , H  4.98% , N  6.33% . R f: 0.58 (h e p ta n e /A c O E t, 1:1). 
M p : 104.1 °C (from  M eO H , o ff-w h ite  sm a ll cry sta ls) . P u rity : >99.5% (GC).
M e th y l (E )-2 -cy an o -3 -(1 H -p y rro l-2 -y l)ac ry la te  8C g.
O A c c o rd in g  to  the  g e n e ra l p ro c e d u re , th e  re a c tio n  o f m e th y l 2 -cy a n o ace ta te  9C
NC JLiffi OMe (991 m g , 10.00 m m o l) w ith  1 H -p y rro le -2 -c a rb a ld e h y d e  13g  (951 m g , 10.00
3' 2'^3
4' ,  m m o l) o v e r  30 m in  a ffo rd e d  8C g  (1.744 g, 99%) as  a  y e llo w  so lid . *H N M R
T  N' h [400 M H z, 5 (p p m ), C D Q 3] : 9.92 (bs, 1 1H , N H ), 8.02 (s, 1 1H , 3-C H ), 7.26-7.23
(m , 1 1H , 5 '-C H ), 6 .98-6 .94 (m , 1 1H , 3 '-C H ), 6.44 (dt; J = 3.9, 2.3 H z; 1 1H , 4 '-C H ), 3.89 (s, 3 1H , 
O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D Q 3]: 164.2 (CO 2), 142.8 (3-C), 128.4 (5'-C), 127.0 (2'-C),
124.7 (3'-C), 118.6 (CN ), 112.7 (4'-C), 91.8 (2-C), 53.0 (O C H 3). F T IR  [ V (cm -1), nea t]: 3300, 3032, 
2950, 2215, 1692, 1593, 1221, 750. E lem . a n a l.  ca lcd  fo r C 9H 8N 2O 2: C  61.36% , H  4.58% , N  15.90%; 
fo u n d  C  61.45% , H  4.58% , N  15.79%. Rf: 0.37 (h e p ta n e /A c O E t, 1:1). M p : 140.2 °C (from  M eO H , 
sm a ll th in  y e llo w  n ee d le s). P u rity : >99.5% (GC).
M e th y l (E )-2 -c y an o -3 -(1 -m eth y l-1 H -p y rro l-2 -y l)a c ry la te  8C h.
0  A c c o rd in g  to  the  g e n e ra l p ro c e d u re , the  re a c tio n  o f m e th y l 2 -cy a n o ace ta te  9C
NC A''l^P'OMe (7.107 g, 71.72 m m o l) w ith  1 -m e th y l-1 H -p y rro le -2 -ca rb a ld e h y d e  13h  (7.827 g,
3' 2' JJ 3
4' 71.72 m m o l) o v e r  120 m in  a ffo rd e d  8 C h  (12.932 g, 95%) as  a  y e llo w  so lid . *H
T  N Me N M R  [400 M H z, 5 (p p m ), C D C I3]: 8.08 (s, 1 1H , 3-CH ). 7.72 (d, J = 4.4 H z, 1
1H , 3 '-C H ), 7.01 (t, J = 1.8 H z , 1 1H , 5 '-C H ), 6 .39-6 .36  (m , 1 1H , 4 '-C H ), 3.89 (s, 3 1H , O C H 3), 3.78 
(s, 3 1H , N C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D O 3]: 164.8 (CO 2), 139.6 (3-C), 131.7 (5'-C), 127.5 
(2'-C), 120.0 (3'-C), 117.1(C N), 112.2 (4'-C), 92.8 (2-C), 53.0 (O C H 3), 34.4 (N C H 3). F T IR  [ V (cm -1), 
n ea t]: 3120, 2957, 2899, 2210, 1717, 1591, 1243, 748. E lem . a n a l. ca lcd  fo r C 10H 10N 2O 2: C  63.15% ,
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H  5.30% , N  14.73%; fo u n d  C  63.19% , H  5.09% , N  14.70%. Rf: 0.29 (h e p ta n e /A c O E t, 1:1). M p:
154.2 °C (from  M eO H , y e llo w  so lid ). P u rity : >99.5% (GC).
M e th y l (E )-2 -c y an o -3 -(1 -m eth y l-1 H -in d o l-3 -y l)a c ry la te  8 Ci.
O A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , th e  re a c tio n  of m e th y l 2 -cy an o ace ta te
2~^4'N^ v>|-2i''OMe 9C  (6.011 g, 60.66 m m o l) w ith  1 -m e th y l-1 H -in d o le -3 -ca rb a ld e h y d e  13i
6' \\ \ 3'a I
(9.656 m g , 60.66 m m o l) o v e r 120 m in  a f fo rd e d  8 C i (13.977 g, 96%) as  a
7 N^2' y e llo w  so lid . *H N M R  [400 M H z, 5 (p p m ), CD Cls]: 8.56 (s, 1 !H , 3-CH ),
Me 8.49 (s, 1 !H , 2 '-C H ), 7 .84-7 .80 (m , 1 !H , 4 '-C H ), 7 .42-7 .31 (m , 3 !H , 5 '-C H  +
6 '-C H  + 7 '-C H ), 3.91 (s, 3 !H , C O 2C H 3), 3.90 (s, 3 !H , N C H 3). 13C  N M R  [75 M H z, 5 (p p m ), CDCls]:
164.6 (CO 2), 146.2 (3-C), 137.0 (7'a-C), 134.9 (2'-C), 128.5 (3'a-C), 124.1 (6 '-C), 122.8 (5'-C), 118.6 (4'- 
C), 118.5 (CN ), 110.6 (7'-C), 110.1 (3'-C), 93.3 (2-C), 52.9 (O C H 3), 34.2 (N C H 3). F T IR  [ V (cm -1), 
n ea t]: 3118, 3026, 2950, 2222, 1701, 1586, 1255, 751. H R M S  [EI (m /z ) ]  ca lcd  fo r C 14H 12N 2O 2 = 
240.0899, fo u n d  fo r [M+^] = 240.0895 ( | A | = 1.6 p p m ), p e a k s  a t  (re la tiv e  in te n s ity ): 240 (100), 209 
(53), 140 (18), 49 (12). E lem . a n a l.  ca lcd  fo r C 14H 12N 2O 2: C  69.99% , H  5.03% , N  11.66%; fo u n d  C 
69.69% , H  4.85% , N  11.42%. Rf: 0.37 (h e p ta n e /A c O E t, 1:1). M p : 165.9 °C (from  M eO H , y e llo w  
so lid ). P u rity : >99.5% (GC).
M e th y l (E )-2 -cy an o -3 -(4 -p y rid y l)ac ry la te  8 Cj.
A cc o rd in g  to  th e  g e n e ra l p ro c e d u re , th e  re a c tio n  o f m e th y l 2 -cy a n o ace ta te  9C  
OMe (991 m g , 10.00 m m o l) w ith  p y r id in e -4 -c a rb a ld e h y d e  13j (1.071 g, 10.00 m m ol) 
o v e r 25 m in  a f fo rd e d  8 Cj (1.863 g, 99% ) as  a  p in k  so lid . *H N M R  [400 M H z, 5 
(p p m ), CDCIb]: 8.86-8 .80  (m , 2 !H , 2 '-C H  + 6 '-C H ), 8.23 (s, 1 !H , 3-C H ), 7.80­
7.74 (m , 2 !H , 3 '-C H  + 5 '-C H ), 3.97 (s, 3 !H , O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D C b]: 161.8 
(CO 2), 152.4 (3-C), 151.2 (2'-C + 6 '-C), 138.0 (4'-C), 123.3 (3'-C + 5'-C), 114.2 (CN ), 107.8 (2-C), 53.8 
(O C H 3). F T IR  [ V (cm -1), n ea t]: 3033, 2955, 2225, 1726, 1236, 1198, 818. E lem . a n a l. ca lcd  for 
C 10H 8N 2O 2: C  63.83% , H  4.28% , N  14.89%; fo u n d  C  63.94% , H  4.25% , N  14.75%. Rf: 0.12 
(h e p ta n e /A c O E t, 1:1). M p : 126.6 °C (from  M eO H , sm a ll p in k  n eed le s). P u rity : >99.5% (GC).
M e th y l (E )-2 -c y an o -3 -(3 ,5 -d im e th o x y p h e n y l)ac ry la te  8 C k.
O A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , the  re a c tio n  of m e th y l 2-
OMe c y a n o ac e ta te  9C  (5.835 g, 58.89 m m o l) w ith  3 ,5 -d im e th o x y b e n z a ld e h y d e  
13k  (9.785 g, 58.89 m m o l) o v e r  40 m in  a f fo rd e d  8 C k  (12.399 g, 99%) as  a 
y e llo w  so lid . *H N M R  [400 M H z, 5 (p p m ), CDCIb]: 8.17 (s, 1 !H , 3-CH ), 
OMe 7.15 (d, J = 2.4 H z, 2 !H , 2 '-C H  + 6 '-C H ), 6.65 (t, J = 2.4 H z, 1 !H , 4 '-C H ),
3.94 (s, 3 !H , C O 2C H 3), 3.84 (s, 6  !H , 2 x O C H 3). « C  N M R  [75 M H z, 5 (p p m ), CDCla]: 163.1 (CO 2),
161.2 (3'-C + 5'-C), 155.6 (3-C), 133.1 (1'-C), 115.6 (CN ), 108.7 (2'-C + 6 '-C), 106.4 (4'-C), 103.0 (2-C),
55.8 (2 x O C H 3), 53.6 (C O 2C H 3). F T IR  [ V (cm -1), nea t]: 3086, 2940, 2841, 2217, 1723, 1604, 1247, 
1167, 840. E lem . a n a l.  ca lcd  fo r C 13H 13N O 4: C  63.15% , H  5.30% , N  5.66%; fo u n d  C  63.22% , H  
5.14% , N  5.53% . Rf: 0.56 (h e p ta n e /A c O E t, 1:1). M p : 121.5 °C (from  M eO H , lo n g  lig h t y e llo w  
n ee d le s). P u rity : >99.5% (GC).
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Methyl (E)-3-(1,3-benzodioxol-5-yl)-2-cyanoacrylate 8 Cl.
According to the general procedure, the reaction of methyl 2- 
OMe cyanoacetate 9C (6.002 g, 60.57 mmol) with piperonal 13l (9.094 g, 60.57 
mmol) over 60 min afforded 8 Cl (13.836 g, 99%) as a light greenish solid. 
!H NMR [400 MHz, 5 (ppm), CDCls]: 8.12 (s, 1 iH, 3-CH), 7.71 (d, J = 1.9 
Hz, 1 !H, 4'-CH), 7.41 (ddd; J = 8.2, 1.9, 0.6 Hz; 1 iH, 6 '-CH), 6.91 (d, J = 8.2 Hz, 1 iH, 7'-CH), 6.09 
(s, 2 !H, 2 '-CH2), 3.92 (s, 3 ^ ,  OCH3). 13C NMR [75 MHz, 5 (ppm), CDCls]: 163.6 (CO2), 154.7 (3- 
C), 152.5 (7'a-C), 148.8 (3'a-C), 130.0 (6 '-C), 126.1 (5'-C), 116.1 (CN), 109.1 (4'-C), 109.0 (7'-C), 102.5 
(2'-C), 99.5 (2-C), 53.4 (OCH3). FTIR [V (cm-1), neat]: 3029, 2957, 2218, 1723, 1579, 1244, 1205, 
1041, 922, 819. HRMS [EI (m /z)] calcd for C12H9NO4 = 231.0532, found for [M+-] = 231.0532 
(| A | = 0.0 ppm), peaks at (relative intensity): 231 (100), 200 (21), 170 (32), 142 (12), 114 (21). 
Elem. anal. calcd for C12H9NO4: C 62.34%, H 3.92%, N 6.06%; found C 62.24%, H 3.86%, N  
6.00%. Rf: 0.60 (heptane/AcOEt, 1:1). Mp: 169.6 °C (from MeOH, light green cotton-like solid). 
Purity: >99.5% (GC).
O
Q.
O'
Methyl (E)-2-cyano-3-(3,4,5-trimethoxyphenyl)acrylate 8Cm.
O According to the general procedure, the reaction of methyl 2-
NC  ^ 1 OMe cyanoacetate 9C (991 mg, 10.00 mmol) with 3,4,5-trimethoxybenzalde-
Mea 5'J¿ 3 hyde 13m (1.962 g, 10.00 mmol) over 75 min afforded 8Cm (2.745 g, 99%)
4 '11 A
IVteO^'^^2' as a yellow solid. *H NMR [400 MHz, 5 (ppm), CDCb]: 8.16 (s, 1 ^ ,  3-
QMe CH), 7.30 (s, 2 !H, 2'-CH + 6'-CH), 3.96 (s, 3 ^ ,  4 '-OCHb), 3.94 (s, 3 ^ ,
CO2CH3), 3.92 (s, 6 1H, 3'-OCH3 + 5'-OCHb). i3C NMR [75 MHz, 5 (ppm), CDO 3]: 162.8 (CO2),
154.7 (3-C), 153.0 (3'-C + 5'-C), 142.6 (4'-C), 126.3 (1'-C), 115.8 (CN), 108.5 (2'-C + 6'-C), 100.6 (2-C),
61.1 (4'-OCH3), 56.3 (3'-OCH3 + 5'-OCH3), 53.4 (CO2CH3). FTIR [ V (cm-1), neat]: 3016, 2952, 2837, 
2216, 1730, 1598, 1575, 1251, 1128, 830. Elem. anal. calcd for C14H 15NO5: C 60.64%, H 5.45%, N  
5.05%; found C 60.31%, H 5.35%, N 4.91%. Rf: 0.45 (heptane/AcOEt, 1:1). Mp: 116.1 °C (from 
MeOH, bright yellow needles). Purity: >99.5% (GC).
General Procedure for 1,3-Dipolar Cycloaddition Reaction of 8A. A round-bottomed flask 
fitted with a Dean-Stark apparatus, a reflux condenser, and a drying tube containing calcium 
chloride was charged with 2-cyanoacrylate 8A and toluene. When the mixture was under 
reflux, sarcosine (N-methylglycine; 2.5 equiv) and paraformaldehyde (6.0 equiv) were added; 
the resulting mixture was stirred for 3 h. The reaction mixture was then filtered and the resin 
was alternatively washed with hot H2O, DMF, H2O, MeOH, H2O, MeOH, DCM, MeOH, DCM. 
The resin was dried for 17 h at 1 torr and 70 °C. To assure full conversion the reaction was 
repeated using the same reaction conditions.
"Wang resinyl" (3R,4R)-3-cyano-1-methyl-4-phenylpyrrolidine-3-carboxylate 7Aa.
CO; According to the general procedure, _the reaction of 2-cyanoacrylate 8Aa
MeN (2.000 g) afforded 7Aa (2.081 g). FTIR [ V (cm-1), neat]: 2241, 1744.
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"W a n g  r e s in y l"  (3 R ,4 R )-3 -c y a n o -1 -m e th y l-4 -(2 -th ie n y l)p y rro lid in e -3 -c a rb o x y la te  7A b.
CO According to the general procedure, the reaction of 2-cyanoacrylate 8A b
MeN (1.058 g) afforded 7A b  (1.092 g). F T IR  [ V (cm-1), neat]: 2242, 1740
"W a n g  r e s in y l"  (3 R ,4 R )-3 -c y a n o -4 -{ 1 -[(d im e th y la m in o )m e th y l]-1 H -in d o l-3 -y l} -1 -m e th y lp y r-  
CO ro lid in e -3 -c a rb o x y la te  7A n.
MeN
->2
■CN According to the general procedure, the reaction of 2-cyanoacrylate 8Ac 
^  /  (1.103 g) afforded 7 A n  (1.193 g). F T IR  [V (cm-1), neat]: 2244, 1739.
NMe2
"W a n g  r e s in y l"  (3 R ,4 R )-3 -c y a n o -1 -m e th y l-4 -(2 -p y r id y l)p y rro lid in e -3 -c a rb o x y la te  7A d.
r - \  According to the general procedure, the reaction of 2-cyanoacrylate 8 A d
CO2^^V
MeN (1.072 g) afforded 7 A d  (1.109 g). F T IR  [ V (cm-1), neat]: 2243, 1740.
"W a n g  r e s in y l"  (3 R ,4 R )-3 -c y a n o -1 -m e th y l-4 -(3 -p y r id y l)p y rro lid in e -3 -c a rb o x y la te  7A e.
CO According to the general procedure, the reaction of 2-cyanoacrylate 8A e
MeN
"Wang
MeN
C O 2 -0
' -CN
(1.062 g) afforded 7A e (1.091 g). F T IR  [ V (cm-1), neat]: 2241, 1741
s in y l"  (3 R ,4 R )-3 -c y a n o -4 -(4 -m e th o x y p h e n y l)-1 -m e th y lp y rro lid in e -3 -c a rb o x y la te  
7A f.
According to the general procedure, the reaction of 2-cyanoacrylate 8 A f 
(1.095 g) afforded 7 A f (1.135 g). F T IR  [ V (cm-1), neat]: 2242, 1739.
OMe
" W a n g  r e s in y l"  (3 R ,4 R )-3 -cy a n o -1 -m e th y l-4 -(1 H -p y rro l-2 -y l)p y rro lid in e -3 -c a rb o x y la te  7Ag.
CO; According to the general procedure, the reaction of 2-cyanoacrylate 8A g
MeN ~p“CN (1.057 g) could have afforded 7A g (1.144 g). F T IR  [ V (cm-1), neat]: 2240, 2192, 
1737.
G e n e ra l  P ro c e d u re  fo r  1 ,3 -D ip o la r  C y c lo a d d it io n  R e a c tio n  o f 8B a n d  8C. A round-bottomed 
flask fitted with a Dean-Stark apparatus, a reflux condenser, and a drying tube containing 
calcium chloride was charged with 2-cyanoacrylate 8 and toluene (0.20-0.25 M). When the 
mixture was under reflux, sarcosine (N-methylglycine; 1.2 equiv) and paraformaldehyde (3.6 
equiv) were added. This addition was repeated every 40 min until the substrate had completely 
reacted. Water (20 mL) was then added and the layers were separated. The aqueous layer was 
extracted with Et2O (3 x 30 mL) and the combined organic layers were dried (MgSO4), filtered, 
and concentrated in vacuo.
H
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MeN
OMe
(±)
(±)-4-Methoxybenzyl (3R,4R)-3-cyano-1-methyl-4-phenylpyrrolidme-3-carboxylate 7Ba.
According to the general procedure, 2-cyanoacrylate 8Ba (1.053 g, 
3.59 mmol) afforded (±)-7Ba (1.082 g, 8 6 %) as a white solid, after 
column chromatography (heptane/AcOEt, 3:1^2:1). *H NMR [300 
MHz, 5 (ppm), CDCls]: 7.28-7.16 (m, 7 !H, Ph + 2"-CH + 6 "-CH), 
6.86-6.82 (m, 2 !H, 3"-CH + 5"-CH), 5.18 (d, J = 11.7 Hz, 1 !H, 
OCHHAr), 5.11 (d, J = 11.7 Hz, 1 !H, OCHHAr), 3.94 (t, J = 7.8 Hz, 1 !H, 4-CH), 3.75 (s, 3 !H, 
OCH3), 3.29 (d, J = 9.9 Hz, 1 !H, 2-CHH), 3.17 (d, J = 9.9 Hz, 1 !H, 2-CHH), 3.03 (d, J = 7.8 Hz, 2 
!H, 5 -CH2), 2.41 (s, 3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDO3]: 167.2 (CO2), 159.4 (4"-C),
136.4 (1'-C), 129.9 (2"-C + 6"-C), 128.2 (2'-C + 6'-C), 128.1 (3'-C + 5'-C), 127.7 (4'-C), 126.4 (1"-C),
117.4 (CN), 113.7 (3"-C + 5"-C), 68.3 (OCH2Ar), 64.9 (2-C), 60.4 (5-C), 55.1 (OCH3), 54.7 (3-C), 52.2 
(4-C), 41.5 (NCH3). FTIR [ V (cm-1), neat]: 2943, 2837, 2787, 2245, 1738, 1514, 1246, 1174, 822, 769, 
706. MS [ESI (m /z)] calcd for (C21H22N 2O3 + H)+ = 351, found 351. Rf: 0.23 (heptane/AcOEt, 
1:1).
(±)-4-Methoxybenzyl (3R,4R)-3-cyano-1-methyl-4-(2-pyridyl)pyrrolidine-3-carboxylate 7Bd.
According to the general procedure, 2-cyanoacrylate 8Bd (921 mg, 
3.13 mmol) afforded (±)-7Bd (859 mg; 78%, combined yield 
including (±)-28Bd) as a light brown solid, after column 
chromatography (heptane/AcOEt, 3:1^2:1). aH NMR [300 MHz, 5 
(ppm), CDO3]: 8.56 (ddd; J = 4.8, 1.7, 1.2 Hz; 1 !H, 6'-CH), 7.60 (dt; J 
= 1.9, 7.6 Hz; 1 !H, 4'-CH), 7.36-7.29 (m, 2 !H, 2"-CH + 6''-CH), 7.20-7.12 (m, 2 !H, 3'-CH + 5'- 
CH), 6.91-6.85 (m, 2 !H, 3''-CH + 5''-CH), 5.28 (d, J = 11.7 Hz, 1 !H, OCHHAr), 5.20 (d, J = 11.7 
Hz, 1 !H, OCHHAr), 4.26 (t, J = 8.1 Hz, 1 !H, 4-CH), 3.78 (s, 3 !H, OCH3), 3.36 (d, J = 9.8 Hz, 1 !H,
2-CHH), 3.32-3.14 (m, 3 !H, 2-CHH + 5 -CH2), 2.46 (s, 3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), 
CDCl3]: 167.3 (CO2), 159.4 (4''-C), 156.4 (2'-C), 149.0 (6'-C), 136.1 (4'-C), 129.7 (2''-C + 6''-C), 126.5 
(1''-C), 122.7 (3'-C), 122.3 (5'-C), 117.2 (CN), 113.6 (3''-C + 5''-C), 68.3 (OCH2Ar), 64.7 (2-C), 58.9 (5- 
C), 55.1 (OCH3), 53.4 (3-C), 53.0 (4-C), 41.5 (NCH3). MS [ESI (m /z)] calcd for (C20H21N 3O3 + H)+ 
= 352, found 352. Rf: 0.11 (heptane/AcOEt, 1:1).
(±)-4-Methoxybenzyl (3R,4R)-3-cyano-1-methyl-4-(3-pyridyl)pyrrolidine-3-carboxylate 7Be.
According to the general procedure, 2-cyanoacrylate 8Be (1.204 g,
4.09 mmol) afforded (±)-7Be (1.363 g, 95%) as a light yellow oil, 
after column chromatography (heptane/AcOEt, 3:1^2:1). *H NMR 
[300 MHz, 5 (ppm), CDQ 3]: 8.52 (dd; J = 4.8, 1.6 Hz; 1 !H, 6'-CH),
8.46 (d, J = 1.9 Hz, 1 !H, 2'-CH), 7.68 (ddd(6); J = 8.3, 1.9, 1.9 Hz; 1 
!H, 4'-CH), 7.31-7.24 (m, 3 !H, 5'-CH + 2''-CH + 6''-CH), 6.91-6.85 (m, 2 !H, 3''-CH + 5''-CH), 5.20 
(d, J = 11.7 Hz, 1 !H, OCHHAr), 5.13 (d, J = 11.7 Hz, 1 !H, OCHHAr), 3.94 (t, J = 7.6 Hz, 1 !H, 4- 
CH), 3.76 (s, 3 !H, OCH3), 3.24 (s, 2 !H, 2 -CH2), 2.99 (d, J = 7.6 Hz, 2 !H, 5 -CH2), 2.41 (s, 3 !H, 
NCH3). MS [ESI (m /z)] calcd for (C20H21N 3O3 + H)+ = 352, found 352. Rf: 0.14 (heptane/AcOEt, 
1:1).
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(±)-Methyl (3R,4R)-3-cyano-1-methyl-4-phenylpyrrolidine-3-carboxylate 7Ca.
2 CO2Me According to the general procedure, 2-cyanoacrylate 8 Ca (5.342 g, 28.54
!H, OCH3), 3.25 (d, J = 9.9 Hz, 1 !H, 2-CHH), 3.18 (d, J = 9.9 Hz, 1 !H, 2-CHH), 3.04 (dd; J = 9.6,
7.8 Hz; 1 !H, 5-CHH), 3.00 (dd; J = 9.6, 8.1 Hz; 1 !H, 5-CHH), 2.38 (s, 3 !H, NCH3). 13C NMR [75 
MHz, 5 (ppm), CDCl3]: 167.6 (CO2), 136.6 (1'-C), 128.0 (2'-C + 6 '-C), 127.9 (3'-C + 5'-C), 127.5 (4'- 
C), 117.2 (CN), 64.9 (2-C), 60.2 (5-C), 54.4 (3-C), 53.5 (CO2CH3), 51.8 (4-C), 41.1 (NCH3). FTIR [ V 
(cm-1), neat]: 2950, 2846, 2790, 2241, 1740, 1247, 772, 699. MS [ESI (m /z)] calcd for (C14H 16N 2O2 + 
H)+ = 245, found 245. RF: 0.24 (heptane/AcOEt, 1:1). Mp: 53.3 °C (from heptane, colorless 
crystals). Purity: >99.5% (GC).
(±)-Methyl (3R,4R)-3-cyano-1-methyl-4-(2-thienyl)pyrrolidine-3-carboxylate 7Cb.
2 CO2Me According to the general procedure, 2-cyanoacrylate 8 Cb (720 mg, 3.73 mmol)
1.0 Hz; 1 !H, 3'-CH), 6.98 (dd; J = 5.1, 3.6 Hz; 1 !H, 4'-CH), 4.32 (dd(3), J = 7.8 Hz, 1 !H, 4-CH), 
3.85 (s, 3 !H, OCH3), 3.40 (d, J = 9.9 Hz, 1 !H, 2-CHH), 3.24 (dd; J = 9.6, 7.2 Hz; 1 !H, 5-CHH), 3.17 
(d, J = 9.9 Hz, 1 !H, 2-CHH), 3.00 (dd; J = 9.6, 8.4 Hz; 1 !H, 5-CHH), 2.46 (s, 3 !H, NCH3). MS [ESI 
(m /z)] calcd for (C12H 14N 2O2S + H)+ = 251, found 251. RF: 0.31 (heptane/AcOEt, 1:1). Purity: 
97.6% (GC).
(±)-Methyl (3R,4R)-3-cyano-4-{1-[(dimethylammo)methyl]-1H-mdol-3-yl}-1-methylpyrroli- 
2 CO2Me dine-3-carboxylate 7Cn.
CH), 7.05 (ddd(7); J = 7.8, 6.9, 1.0 Hz; 1 !H, 5'-CH), 4.69 (d, J = 12.9 Hz, 1 !H, NCHHN), 4.58 (d, J 
= 12.9 Hz, 1 !H, NCHHN), 4.40 (dd; J = 9.3, 7.6 Hz; 1 !H, 4-CH), 3.67 (s, 3 !H, OCH3), 3.43 (d, J =
10.0 Hz, 1 !H, 2-CHH), 3.17 (d, J = 10.0 Hz, 1 !H, 2-CHH), 3.16 (dd; J = 9.3, 7.6 Hz; 1 !H, 5-CHH),
3.04 (t, J = 9.3 Hz, 1 !H, 5-CHH), 2.42 (s, 3 !H, 1 -NCH3), 2.23 (s, 6 !H, N(CH3)2). 13C NMR [75 
MHz, 5 (ppm), CDCl3]: 168.5 (CO2), 136.7 (7'a-C), 127.5 (3'a-C), 126.9 (2'-C), 121.9 (6'-C), 119.4 (5'- 
C), 118.3 (4'-C), 118.0 (CN), 110.21 (3'-C), 110.17 (7'-C), 68.6 (NCH2N), 65.3 (2-C), 60.7 (5-C), 55.1 
(3-C), 53.8 (OCH3), 44.8 (4-C), 42.7 (N(CH3)2), 41.8 (NCH3). FTIR [V (cm-1), neat]: 3049, 2942, 
2842, 2778, 2242, 1740, 1460, 1239, 729. Elem. anal. calcd for C19H24N4O2: C 67.04%, H 7.11%, N  
16.46%; found C 66.98%, H 7.05%, N 16.18%. Rf: 0.19 (AcOEt). Mp: 105.8 °C.
mmol) afforded (±)-7Ca (6.524 g, 94%) as a white solid, after column 
chromatography (heptane/AcOEt, 3:1^2:1). 1H NMR [400 MHz, 5 (ppm), 
CDCl3]: 7.33-7.19 (m, 5 !H, Ph), 4.00 (dd(3), J = 7.8 Hz, 1 !H, 4-CH), 3.70 (s, 3
afforded (±)-7Cb (814 mg; 87%, combined yield including (±)-28Cb) as a 
yellow oil, after column chromatography (heptane/AcOEt, 1:1). 1H NMR [300 
MHz, 5 (ppm), CDCl3]: 7.23 (dd; J = 5.1, 1.0 Hz; 1 !H, 5'-CH), 7.04 (dt; J = 3.6,(±) 5'
:__5  According to the general procedure, 2-cyanoacrylate 8Cc (1.512 g, 6.68
_ ƒ 6' mmol) afforded (±)-7Cn (1.929 g, 85%) as a yellow solid. 1H NMR [300
?'a  7'
MHz, 5 (ppm), CDO3]: 7.45 (d, J = 7.8 Hz, 1 !H, 4'-CH), 7.36 (d, J = 8.1 Hz, 1 
NMe2 iH, 7'-CH), 7.24 (s, 1 !H, 2'-CH), 7.14 (ddd(7); J = 8.1, 6.9, 1.0 Hz; 1 !H, 6'-
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(±)-Methyl (3R,4R)-3-cyano-1-methyl-4-(2-pyridyl)pyrrolidine-3-carboxylate 7Cd.
2 3 CO2Me According to the general procedure, 2-cyanoacrylate 8 Cd (1.006 g, 5.35 mmol)
(±) 4' (Measured from a 6.5:1 mixture of (±)-7Cd/ (±)-28Cd) 1H NMR [400 MHz, 5 
(ppm), CDCIb]: 8.61 (d, J = 4.8 Hz, 1 1H, 6 '-CH), 7.68 (ddd(6); J = 7.6, 7.6, 1.8 Hz; 1 1H, 4'-CH), 7.30 
(d, J = 7.8 Hz, 1 1H, 3'-CH), 6.91 (ddd; J = 7.6, 4.8, 0.7 Hz; 1 1H, 5'-CH), 4.30 (t, J = 8.0 Hz, 1 1H, 4- 
CH), 3.88 (s, 3 1H, OCH3), 3.38 (d, J = 9.6 Hz, 1 1H, 2-CHH), 3.28 (dd; J = 9.3, 8.0 Hz; 1 1H, 5- 
CHH), 3.26 (d, J = 9.6 Hz, 1 1H, 2-CHH), 3.22 (dd; J = 9.3, 8.0 Hz; 1 1H, 5-CHH), 2.49 (s, 3 1H, 
NCH3). MS [ESI (m /z)] calcd for (C13H 15N 3O2 + H)+ = 246, found 246. Rf: 0.07 (heptane/AcOEt, 
1:1).
(±)-Methyl (3R,4R)-3-cyano-1-methyl-4-(3-pyridyl)pyrrolidine-3-carboxylate 7Ce.
2 CO2Me According to the general procedure, 2-cyanoacrylate 8Ce (2.969 g, 15.78
(±) N (CH2Cl2/M eOH, 29:1). (Measured from a 6.6:1 mixture of (±)-7Ce/(±)-28Ce) 
1H NMR [400 MHz, 5 (ppm), CDQ 3]: 8.56 (dd; J = 4.9, 1.7 Hz; 1 1H, 6'-CH), 8.56-8.54 (m, 1 1H, 2'- 
CH), 7.81 (ddd(6); J = 8.0, 2.0, 2.0 Hz; 1 1H, 4'-CH), 7.33 (ddd; J = 8.0, 4.9, 0.5 Hz; 1 1H, 5'-CH),
4.06 (dd(3), J = 7.7 Hz, 1 1H, 4-CH), 3.84 (s, 3 1H, OCH3), 3.32 (d, J = 10.0 Hz, 1 1H, 2-CHH), 3.28 
(d, J = 10.0 Hz, 1 1H, 2-CHH), 3.09 (dd; J = 9.5, 7.8 Hz; 1 1H, 5-CHH), 3.06 (dd; J = 9.5, 7.6 Hz; 1 
1H, 5-CHH), 2.47 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDO 3]: 168.0 (CO2), 150.1 (2'-C), 
149.65 (6'-C), 135.9 (4'-C), 133.2 (3'-C), 123.5 (5'-C), 117.6 (CN), 65.1 (2-C), 60.6 (5-C), 54.4 (3-C),
54.1 (CO2CH3), 49.4 (4-C), 41.3 (NCH3). MS [ESI (m /z)] calcd for (C13H 15N 3O2 + H)+ = 246, found 
246. Rf: 0.10 (heptane/AcOEt, 1:1).
(±)-Methyl (3R,4S)-3-cyano-1-methyl-4-(3-pyridyl)pyrrolidine-3-carboxylate 28Ce.
2 CO2Me According to the general procedure, 2-cyanoacrylate 8Ce (2.969 g, 15.78
1H NMR [400 MHz, 5 (ppm), CDQ 3]: 8.56-8.54 (m, 1 1H, 2'-CH), 8.53 (dd; J = 4.9, 1.7 Hz; 1 1H, 6'- 
CH), 7.69 (ddd(6); J = 8.0, 2.0, 2.0 Hz; 1 1H, 4'-CH), 7.25 (ddd; J = 8.0, 4.9, 0.5 Hz; 1 1H, 5'-CH), 
4.07-4.04 (m, 1 1H, 4-CH), 3.40 (d, J = 10.2 Hz, 1 1H, 2-CHH), 3.35 (d, J = 10.2 Hz, 1 1H, 2-CHH),
3.27 (s, 3 1H, OCH3), 3.09 (dd; J = 9.3, 6.6 Hz; 1 1H, 5-CHH), 2.97 (dd; J = 9.3, 8.6 Hz; 1 1H, 5- 
CHH), 2.51 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDQ 3]: 166.6 (CO2), 150.0 (2'-C), 149.60 
(6'-C), 135.9 (4'-C), 131.9 (3'-C), 123.2 (5'-C), 120.2 (CN), 63.4 (2-C), 59.6 (5-C), 53.4 (4-C), 53.1 
(CO2CH3), 52.4 (3-C), 41.2 (NCH3). Rf: 0.10 (heptane/AcOEt, 1:1).
(±)-Methyl (3R,4R)-3-cyano-4-(4-methoxyphenyl)-1-methylpyrrolidine-3-carboxylate 7Cf.
2 CO2Me According to the general procedure, 2-cyanoacrylate 8Cf (6.162 g, 28.37
afforded a 6.5:1 mixture of (±)-7Cd/(±)-28Cd (1.182 g; 90%, combined yield) 
as a white solid, after column chromatography (CH2Cl2/M eO H , 24:1).
mmol) afforded a 6.6:1 mixture of (±)-7Ce/(±)-28Ce (2.782 g; 72%, combined 
yield) as a light yellow sticky solid, after column chromatography
mmol) afforded a 6.6:1 mixture of (±)-7Ce/(±)-28Ce (2.782 g; 72%, combined 
yield) as a light yellow sticky solid, after column chromatography 
(CH2Cl2/M eOH, 29:1). (Measured from a 6.6:1 mixture of (±)-7Ce/(±)-28Ce)
mmol) afforded (±)-7Cf (7.688 g, 99%) as a yellow oil. 1H NMR [400 MHz, 
5 (ppm), CDCl3]: 7.28-7.22 (m, 2 1H, 2'-CH + 6'-CH), 6.87-6.82 (m, 2 1H, 3'- 
CH + 5'-CH), 3.98 (dd(3), J = 8.0 Hz, 1 1H, 4-CH), 3.80 (s, 3 1H, CO2CH3),
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3.76 (s, 3 1H, OCH3), 3.31 (d, J = 9.9 Hz, 1 1H, 2-CHH), 3.20 (d, J = 9.9 Hz, 1 1H, 2-CHH), 3.07 (dd; 
J = 9.6, 7.8 Hz; 1 1H, 5-CHH), 3.02 (dd; J = 9.6, 8.1 Hz; 1 1H, 5-CHH), 2.44 (s, 3 1H, NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDCI3]: 168.1 (CO2), 159.1 (4'-C), 129.4 (2'-C + 6 '-C), 128.6 (1'-C), 117.8 
(CN), 113.8 (3'-C + 5'-C), 65.2 (2-C), 60.8 (5-C), 55.2 (OCH3), 54.9 (3-C), 53.9 (CO2CH3), 51.8 (4-C),
41.6 (NCH3). FTIR [ V (cm-1), neat]: 2951, 2836, 2788, 2243, 1740, 1247, 832. MS [ESI (m /z)] calcd 
for (C15H 18N 2O3 + H)+ = 275, found 275. Rf: 0.23 (heptane/AcOEt, 1:1). Purity: 98.9% (GC).
(±)-Methyl (3R,4R)-3-cyano-1-methyl-4-(1-methyl-1H-pyrrol-2-yl)pyrrolidine-3-carboxylate
2 CO2Me 7Ch
MeN JT"CN According to the general procedure, 2-cyanoacrylate 8Ch (1.132 g, 5.95 mmol)
5 4 y ^ \ 4' afforded (±)-7Ch (765 mg, 52%) as a yellow oil, after column chromatography 
N^v 4Me a (heptane/AcOEt, 3:1^2:1). 1H NMR [400 MHz, 5 (ppm), CDCh]: 6.62 (dd; J = 
(±) 2.7, 1.7 Hz; 1 1H, 5'-CH), 6.28 (dd; J = 3.6, 1.7 Hz; 1 1H, 3'-CH), 6.14 (dd; J = 3.6,
2.7 Hz; 1 1H, 4'-CH), 4.25 (dd(3), J = 8.2 Hz, 1 1H, 4-CH), 3.87 (s, 3 1H, OCH3), 3.57 (s, 3 1H, 1'- 
NCH3), 3.45 (d, J = 9.9 Hz, 1 1H, 2-CHH), 3.26 (dd; J = 9.5, 7.6 Hz; 1 1H, 5-CHH), 3.04 (d, J = 9.9 
Hz, 1 1H, 2-CHH), 2.84 (dd(3), J = 9.1 Hz, 1 1H, 5-CHH), 2.44 (s, 3 1H, 1 -NCH3). 13C NMR [75 
MHz, 5 (ppm), CDCl3]: 168.9 (CO2), 128.2 (2'-C), 123.5 (5'-C), 117.2 (CN), 108.7 (4'-C), 107.6 (3'-C),
65.2 (2-C), 61.3 (5-C), 54.2 (OCH3), 53.8 (3-C), 43.7 (4-C), 41.5 (1 -NCH3), 34.0 (1'-NCH3). FTIR [ V 
(cm-1), neat]: 2951, 2888, 2791, 2242, 1741, 1241, 717. MS [ESI (m /z)] calcd for (C13H 17N 3O2 + H)+ 
= 248, found 248. Rf: 0.23 (heptane/AcOEt, 1:1). Purity: 98.2% (GC).
(±)-Methyl (3R,4R)-3-cyano-1-methyl-4-(1-methyl-1H-indol-3-yl)pyrrolidine-3-carboxylate
CO2Me 7Ci.
MeN
3 -
■CN 4' 5' According to the general procedure, 2-cyanoacrylate 8 Ci (9.241 g, 38.46
3' 3'a/ .
"  ^ / ) 6' mmol) afforded (±)-7Ci (10.831 g, 95%) as a yellow solid, after column 
(±)¿ "N 'a 7 chromatography (heptane/AcOEt, 3:1^2:1). 1H NMR [400 MHz, 5 (ppm), 
Me CDCl3]: 7.50 (dt; J = 8.1, 1.0 Hz; 1 1H, 4'-CH), 7.29 (dt; J = 8.3, 1.0 Hz; 1 1H,
7'-CH), 7.22 (ddd(7); J = 8.3, 7.1, 1.0 Hz; 1 1H, 6'-CH), 7.19 (s, 1 1H, 2'-CH), 7.10 (ddd(7); J = 8.1,
7.0, 1.0 Hz; 1 1H, 5'-CH), 4.43 (dd; J = 9.6, 7.5 Hz; 1 1H, 4-CH), 3.76 (s, 3 1H, OCH3), 3.74 (s, 3 1H, 
1'-NCH3), 3.51 (d, J = 10.2 Hz, 1 1H, 2-CHH), 3.25 (d, J = 10.2 Hz, 1 1H, 2-CHH), 3.23 (dd; J = 9.6,
7.5 Hz; 1 1H, 5-CHH), 3.08 (t, J = 9.6 Hz, 1 1H, 5-CHH), 2.51 (s, 3 1H, 1 -NCH3). 13C NMR [75 
MHz, 5 (ppm), CDCl3]: 169.0 (CO2), 136.8 (7'a-C), 127.7 (3'a-C), 127.4 (2'-C), 122.1 (6'-C), 119.5 (5'- 
C), 118.7 (4'-C), 118.5 (CN), 109.63 (3'-C), 109.58 (7'-C), 65.3 (2-C), 60.9 (5-C), 55.1 (3-C), 53.9 
(OCH3), 45.2 (4-C), 42.0 (1 -NCH3), 33.0 (1'-NCH3). FTIR [V (cm-1), neat]: 3045, 2948, 2842, 2786, 
2243, 1741, 1474, 1243, 742. HRMS [EI (m /z)] calcd for C17H 19N 3O2 = 297.1477, found for [M+-] = 
297.1467 ( |A | = 3.5 ppm), peaks at (relative intensity): 297 (17), 144 (16), 57 (100), 42 (21). RF: 
0.17 (heptane/AcOEt, 1:1). Mp: 92.6 °C. Purity: 98.8% (GC).
(±)-Methyl (3R,4R)-3-cyano-1-methyl-4-(4-pyridyl)pyrrolidine-3-carboxylate 7Cj.
2 CO2Me According to the general procedure, 2-cyanoacrylate 8Cj (1.037 g, 5.51 mmol) 
/—^^CNMeN r  5' afforded a 5:1 mixture of (±)-7Cj/(±)-28Cj (1.145 g; 85%, combined yield) as a
light yellow oil, after column chromatography (CH2Cl2/M eO H , 24:1).
3 '\^N
(±) 2' (Measured from a 5:1 mixture of (±)-7Cj/(±)-28Cj) 1H NMR [400 MHz, 5 
(ppm), CDCl3]: 8.62-8.58 (m, 2 1H, 2'-CH + 6'-CH), 7.32-7.28 (m, 2 1H, 3'-CH + 5'-CH), 4.03
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CO2Me
MeN
OMe
OMe
(dd(3), J = 7.6 H z , 1 1H , 4-C H ), 3.86 (s, 3 1H , O C H 3), 3.32 (d, J = 10.0 H z, 1 1H , 2-C H H ), 3.26 (d, J =
10.0 H z, 1 1H , 2-C H H ), 3.09 (dd ; J = 9.8, 7.2 H z; 1 1H , 5 -C H H ), 3.06 (d d ; J = 9.8, 7.8 H z; 1 1H , 5- 
C H H ), 2 .47 (s, 3 1H , N C H 3). M S  [ESI (m /z ) ]  ca lcd  fo r (C13H 15N 3O 2 + H)+ = 246, fo u n d  246. Rf: 
0.06 (h e p ta n e /A c O E t, 1:1).
(± )-M e th y l (3 R ,4 R )-3 -c y a n o -4 -(3 ,5 -d im e th o x y p h e n y l)-1 -m e th y lp y rro lid in e -3 -c a rb o x y la te  7C k.
A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , 2 -cy a n o acry la te  8 C k  (9.745 g, 39.41 
m m o l) a f fo rd e d  (±)-7C k (11.398 g, 95%) as  a  w h ite  so lid , a f te r  c o lu m n  
c h ro m a to g ra p h y  ( h e p ta n e /  A cO E t, 3 :1 ^ 2 :1 ) . 1H  N M R  [400 M H z, 5 (p p m ), 
C D O 3]: 6.51 (d, J = 2.2 H z, 2 1H , 2 '-C H  + 6 '-C H ), 6.41 (t, J = 2.2 H z, 1 1H , 4 '- 
C H ), 3.99 (dd(3), J = 7.9 H z, 1 1H , 4-C H ), 3.84 (s, 3 1H , C O 2C H 3), 3.78 (s, 6 
1H , 2 x O C H 3), 3.30 (d, J = 9.9 H z , 1 1H , 2-C H H ), 3.24 (d, J = 9.9 H z, 1 1H , 2 -C H H ), 3.09 (d d ; J = 
9.6, 7.8 H z; 1 1H , 5 -C H H ), 3.06 (dd ; J = 9.6, 8.0 H z; 1 1H , 5 -C H H ), 2.47 (s, 3 1H , N C H 3). 13C  N M R  
[75 M H z, 5 (p p m ), C D C b]: 168.8 (CO 2), 161.1 (3'-C + 5'-C), 139.4 (1'-C), 118.1 (CN ), 107.0 (2'-C + 
6'-C), 100.2 (4'-C), 65.7 (2-C), 60.7 (5-C), 55.6 (2 x O C H 3), 54.8 (3-C), 54.2 (C O 2C H 3), 52.6 (4-C),
41.8 (N C H 3). F T IR  [ V (cm -1), nea t]: 2948, 2837, 2790, 2243, 1743, 1595, 1203, 1155. H R M S  [EI 
(m /z ) ]  ca lcd  fo r GL6H 20N 2O 4 = 304.1423, fo u n d  fo r [M+^] = 304.1436 ( | A |  = 4.2 p p m ), p e a k s  a t 
(re la tiv e  in ten s ity ): 304 (16), 261 (18), 193 (11), 57 (100), 42 (20). E lem . a n a l. ca lcd  fo r C 16H 2oN2O 4: 
C  63.14% , H  6.62%, N  9.20%; fo u n d  C  63.33% , H  6.65%, N  9.19% . R f: 0.19 (h e p ta n e /A c O E t, 1:1). 
M p : 94.7 °C (from  h e p ta n e , co lo rless  cry sta ls) . P u rity : >99.5% (GC).
(± )-M e th y l (3 R ,4 R )-4 -(1 ,3 -b e n z o d io x o l-5 -y l)-3 -c y an o -1 -m e th y lp y rro lid in e -3 -ca rb o x y la te  7Cl.
2 CO2Me A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , 2 -cy an o acry la te  8C l (9.774 g, 42.27
M e ^ T ™  m m o l) a ffo rd e d  (±)-7Cl (12.041 g, 99%) as  a  w h ite  so lid . 1H  N M R  [400
5 T  7  > 2' M H z, 5 (p p m ), C D C l3]: 6.88 (d, J = 1.7 H z, 1 1H , 4 '-C H ), 6.81 (dd ; J = 8.0, 
(±) Y  7'a O 1.7 H z; 1 1H , 6 '-C H ), 6.77 (d, J = 8.0 H z , 1 1H , 7 '-C H ), 5.95 (2d(3), J = 1.6 H z, 
2 1H , 2'-CH2), 3 .97 (t, J = 7.8 H z, 1 1H , 4-C H ), 3.84 (s, 3 1H , O C H 3), 3.28 (d, J = 9.9 H z, 1 1H , 2- 
C H H ), 3.23 (d, J = 9.9 H z , 1 1H , 2-C H H ), 3.06 (dd ; J = 9.5, 7.8 H z; 1 1H , 5 -C H H ), 3.01 (dd ; J = 9.5,
7.8 H z; 1 1H , 5 -C H H ), 2.45 (s, 3 1H , N C H 3). 13C  N M R  [75 M H z, 5 (p p m ), CDCfe]: 168.5 (CO 2),
147.9 (3'a-C), 147.5 (7'a-C), 130.8 (5'-C), 122.0 (6'-C), 117.9 (CN ), 108.8 (7'-C), 108.3 (4'-C), 101.2 (2'- 
C), 65.3 (2-C), 60.8 (5-C), 54.8 (3-C), 54.0 (O C H 3), 52.1 (4-C), 41.5 (N C H 3). F T IR  [ V (cm -1), nea t]:
2965, 2900, 2788, 2242, 1740, 1249, 1036, 929. H R M S  [EI (m /z ) ]  ca lcd  fo r C 15H 16N 2O 4 = 288.1110, 
fo u n d  fo r [M+^] = 288.1097 ( | A |  = 4.5 p p m ), p e a k s  a t  (re la tiv e  in ten sity ): 288 (13), 57  (100), 42 
(11). E lem . a n a l.  ca lcd  fo r C 15H 16N 2O 4: C  62.49% , H  5.59% , N  9.72%; fo u n d  C  62.56% , H  5.61% , N  
9.69% . Rf: 0.22 (h e p ta n e /A c O E t, 1:1). M p : 87.6 °C (from  h e p ta n e , co lo rless  cry sta ls) . P u rity : 
>99.5% (GC).
CO2Me
MeN
OMe
(± )-M e th y l (3 R ,4 R )-3 -c y a n o -1 -m e th y l-4 -(3 ,4 ,5 -trim e th o x y p h e n y l)p y rro lid in e -3 -c a rb o x y la te  
7C m .
A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , 2 -cy a n o ac ry la te  8 C m  (1.154 g, 4.16 
m m o l) a ffo rd e d  (±)-7C m  (1.381 g, 99%) as  a  w h ite  so lid . 1H  N M R  [400 
OMe M H z, 5 (p p m ), C D C b]: 6.60 (s, 2 1H , 2 '-C H  + 6 '-C H ), 3.99 (t, J = 8.1 H z, 1 
1H , 4-C H ), 3.86 (s, 6 1H , 3'-OCH3 + 5'-OCH3), 3.84 (s, 3 1H , C O 2C H 3)*, 3.83 
(s, 3 1H , 4'-OCH3)*, 3.28 (s, 2 1H , 2 -C H 2), 3.08 (d, J = 8.1 H z, 2 1H , 5 -C H 2), 2.48 (s, 3 1H , N C H 3). M S
6'
(±) 5'
OMe
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[ESI (m /z)] calcd for (C17H22N 2O5 + H)+ = 335, found 335. RF: 0.16 (heptane/ AcOEt, 1:1). Purity: 
97.9% (GC).
(±)-(3R,4R)-3-Cyano-1-methyl-4-phenylpyrrolidine-3-carboxamide 31.
2 C0NH2 a-Cyano ester (±)-7Ca (244 mg, 1.00 mmol) was dissolved in 7 N NH 3/M eO H  
/""-■^ ■CNMeN 2' (7 mL). The resulting reaction mixture was stirred at room temperature over 1
6'\ X^^ 4'
5'
h. The solvent was then evaporated under reduced pressure and the crude 
(±) ' f  was washed with boiling hexane to afford a yellow solid. This solid was 
recrystallized from Pr'OH to afford the a-cyano amide (±)-31 (190 mg, 83%) as small white 
needles. *H NMR [300 MHz, 5 (ppm), CDCls]: 7.41-7.26 (m, 5 1H, Ph), 6.58 (s, 1 1H, NHH), 6.40 
(s, 1 !H, NHH), 3.99 (dd(3), J = 8.1 Hz, 1 !H, 4-CH), 3.34 (d, J = 9.8 Hz, 1 !H, 2-CHH), 3.16 (dd(3), 
J = 8.7 Hz, 1 !H, 5-CHH), 3.12 (d, J = 9.8 Hz, 1 !H, 2-CHH), 3.03 (dd(3), J = 8.9 Hz, 1 !H, 5-CHH), 
2.47 (s, 3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDO3]: 169.4 (CON), 137.1 (1'-C), 128.6 (2'-C + 
6 '-C), 128.4 (3'-C + 5'-C), 128.2 (4'-C), 119.0 (CN), 65.2 (2-C), 60.9 (5-C), 55.9 (3-C), 53.1 (4-C), 41.6 
(NCH3). FTIR [ V (cm-1), neat]: 3334, 3192, 2950, 2846, 2794, 2241, 1684, 772, 698. Elem. anal. 
calcd for C13H 15N 3O: C 68.11%, H 6.59%, N 18.33%; found C 68.10%, H 6.48%, N 18.13%. Rf: 0.40 
(AcOEt). Mp: 121.7 °C (from propan-2-ol, small white needles). Purity: >99.5% (GC).
(±)-2-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]acrylonitrile 32.
3^ Cn 1H NMR [400 MHz, 5 (ppm), CDO3]: 7.21-7.16 (m, 2 !H, 2''-CH + 6 ''-
Me N  ^ CH), 6.91-6.86 (m, 2 !H, 3''-CH + 5''-CH), 5.92 (s, 1 !H, 3-CHH), 5.80 (dd; J2N
2 '  I I  I  = 1.0, 0.5 Hz; 1 !H, 3-CHH), 3.79 (s, 3 !H, OCH3), 3.63 (bdd; J = 10.0, 6.1
(±) 5' OMe Hz; 1 !H, 1'-CH), 2.93 (dd; J = 12.7, 10.0 Hz; 1 !H, 2'-CHH), 2.53 (dd; J = 
12.7, 6.1 Hz; 1 !H, 2'-CHH), 2.28 (s, 6  !H, N(CH3)2). 13C NMR [75 MHz, 5 (ppm), CDO3]: 158.8 
(4''-C), 131.1 (1''-C)*, 130.3 (3-C), 128.5 (2''-C + 6 ''-C), 126.2 (2-C)*, 118.0 (CN), 114.3 (3''-C + 5''-C),
62.7 (2'-C), 55.5 (OCH3), 47.9 (1'-C), 45.8 (N(CHb)2).
General Procedure for Reduction. An excess (7-8 heaped teaspoons) of freshly washed (with 
MeOH) Raney nickel was added to a solution of a-cyano ester (±)-7C with Et3N (ca. 1 equiv) in 
MeOH (0.25-0.30 M). The mixture was stirred for 15 h at room temperature under a hydrogen 
atmosphere (1 atm). The catalyst was separated by filtration with suction through a glass filter 
with a 0.5 cm layer of diatomaceous earth. The catalyst was washed thoroughly with MeOH. 
The combined methanolic solutions were concentrated on a rotary evaporator.
(±)-Methyl (3R,4S)-3-(aminomethyl)-1-methyl-4-phenylpyrrolidine-3-carboxylate 6 Ca.
2 CO2Me According to the general procedure, a-cyano ester (±)-7Ca (5.040 g, 20.63 
MeN^ f"""N H2 mmol) afforded (±)-6 Ca (4.858 g, 95%) as a colorless oil. iH NMR [200 MHz, 5 
5 4 (ppm), C DO 3]: 7.36-7.21 (m, 5 !H, Ph), 3.93 (dd; J = 8 .6 , 7.3 Hz; 1 !H, 4-CH),
(±) 6 V '^ 4 3.79 (s, 3 !H, OCH3), 3.35 (d, J = 9.6 Hz, 1 !H, 2-CHH), 3.08 (dd; J = 9.2, 7.3 Hz;
1 !H, 5-CHH), 2.77 (dd(3), J = 9.0 Hz, 1 !H, 5-CHH), 2.62 (d, J = 13.0 Hz, 1 !H, CHHNH2), 2.52 (d, 
J = 13.0 Hz, 1 !H, CHHNH2), 2.48 (d, J = 9.6 Hz, 1 !H, 2-CHH), 2.41 (s, 3 !H, NCH3), 1.78 (bs, 2 
!H, NH2). 13C NMR [75 MHz, 5 (ppm), CDQ 3]: 175.9 (CO2), 138.4 (1'-C), 128.7 (2'-C + 6 '-C), 127.9 
(3'-C + 5'-C), 126.6 (4'-C), 64.0 (2-C), 61.6 (5-C), 58.6 (3-C), 52.2 (CO2CH3), 49.9 (4-C), 46.7 
(CH2NH 2), 42.2 (NCH3). FTIR [ V (cm-1), neat]: 3386, 3028, 2946, 2781, 1727, 1601, 1455, 1174, 772,
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703. H R M S  [ESI (m /z ) ]  ca lcd  fo r (C14H 20N 2O 2 + H)+ = 249.16030, fo u n d  249.15963 ( | A |  = 2.71 
p p m ). Rf: 0.30 (C H 2O 2/M e O H , 8:1). P u rity : 99.1% (GC).
(± )-M e th y l (3 R ,4 S )-3 -(a m in o m e th y l)-4 -(4 -m e th o x y p h e n y l)-1 -m e th y lp y rro lid in e -3 -c a rb o x y la te  
2 CO2Me 6Cf.
NHMeN 2' 2 A cc o rd in g  to  the  g e n e ra l p ro c e d u re , a -c y a n o  e s te r  (±)-7C f (6.997 g, 25.51
5 \\ ^  m m o l) a ffo rd e d  (±)-6C f (6.731 g, 95% ) as  a  co lo rless  oil. *H N M R  [400
6'
(±) 5' 4' OMe M H z, 5 (p p m ), C D O 3] : 7 .27-7 .23 (m , 2 iH , 2 '-C H  + 6 '-C H ), 6 .86-6 .82  (m , 2 
!H , 3 '-C H  + 5 '-C H ), 3.88 (dd(3 ), J = 8.0 H z, 1 1H , 4-C H ), 3.79 (s, 3 1H , C O 2C H 3), 3.78 (s, 3 1H , 
O C H 3), 3.33 (d, J = 9.9 H z , 1 1H , 2 -C H H ), 3.06 (dd ; J = 8.8, 7.8 H z; 1 1H , 5 -C H H ), 2.71 (dd(3 ), J =
8.9 H z , 1 1H , 5 -C H H ), 2.63 (d, J = 13.2 H z , 1 1H , C H H N H 2), 2.52 (d, J = 13.2 H z, 1 1H , C H H N H 2),
2.46 (d, J = 9.9 H z, 1 1H , 2-C H H ), 2.40 (s, 3 1H , N C H 3), 0.92 (bs, 2 1H , N H 2). 13C  N M R  [75 M H z, 5 
(p p m ), C D C l3]: 176.1 (CO 2), 158.2 (4'-C), 130.3 (1'-C), 129.7 (2'-C + 6'-C), 113.5 (3'-C + 5'-C), 64.1 
(2-C), 61.8 (5-C), 58.6 (3-C), 55.2 (O C H 3), 52.3 (C O 2C H 3), 49.2 (4-C), 46.8 (C H 2N H 2), 42.3 (N C H 3). 
F T IR  [ V (cm -1), nea t]: 3383, 3222, 2947, 2834, 2779, 1724, 1247, 834. H R M S  [ESI (m /z ) ]  ca lcd  for 
(C15H 22N 2O 3 + H)+ = 279.17087, fo u n d  279.17006 ( | A |  = 2.87 p p m ). Rf: 0.27 (C H 2O 2/  M eO H , 
8:1). P u rity : 98.1% (GC).
(± )-M e th y l (3 R ,4 S )-3 -(a m in o m e th y l)-1 -m e th y l-4 -(1 -m e th y l-1 H -p y rro l-2 -y l)p y rro lid m e -3 -c a r-
2 CO2Me b o x y la te  6 C h .
MeN [ ' ' ' ^ NH2 A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , a -c y a n o  e s te r  (± )-7C h (752 m g , 3.04
3'
5  4 m m o l) a f fo rd e d  (±)-6C h (559 m g , 73% ) as  a  lig h t y e llo w  oil, a f te r  c o lu m n
MeN a c h ro m a to g ra p h y  (C H 2O 2/M e O H , 9:1). *H N M R  [400 M H z, 5 (p p m ), CDCla]: 
(±) 6.54 (d d ; J = 2.4, 1.8 H z; 1 1H , 5 '-C H ), 6.07 (d d ; J = 3.6, 2 .7 H z; 1 1H , 4 '-C H ), 6.04
(dd ; J = 3.8, 1.7 H z; 1 1H , 3 '-C H ), 4.10 (dd ; J = 10.5, 7.2 H z; 1 1H , 4-C H ), 3.78 (s, 3 1H , O C H 3), 3.60 
(s, 3 1H , 1'-NCH3), 3.39 (d, J = 9.9 H z, 1 1H , 2 -C H H ), 3.19 (dd(3 ), J = 8.2 H z , 1 1H , 5 -C H H ), 2.72 (d, 
J = 13.2 H z , 1 1H , C H H N H 2), 2.62 (d, J = 13.2 H z, 1 1H , C H H N H 2), 2.47 (dd(3 ), J = 9.8 H z, 1 1H , 5- 
C H H ), 2.35 (s, 3 1H , 1 -N C H 3), 2.21 (d, J = 9.9 H z , 1 1H , 2 -C H H ), 1.35 (bs, 2 1H , N H 2). 13C  N M R  
[75 M H z, 5 (p p m ), C D Q 3]: 177.1 (CO 2), 129.8 (2'-C), 122.3 (5'-C), 107.8 (3'-C), 107.3 (4'-C), 65.3 (2- 
C), 62.5 (5-C), 58.4 (3-C), 52.5 (O C H 3), 46 .7  (C H 2N H 2), 42.2 (1 -N C H 3), 40.9 (4-C), 34.2 (1'-NCH3). 
F T IR  [ V (cm -1), nea t]: 3390, 3099, 2946, 2839, 2780, 1729, 1242, 712. H R M S  [ESI (m /z ) ]  ca lcd  for 
(C13H 21N 3O 2 + H)+ = 252.17120, fo u n d  252.17083 ( | A |  = 1.49 p p m ). R f: 0.24 (C H 2O 2/  M eO H , 
8:1). P u rity : 97.7% (GC).
(± )-M e th y l (3 R ,4 S )-3 -(a m m o m e th y l)-1 -m e th y l-4 -(1 -m e th y l-1 H -m d o l-3 -y l)p y rro lid m e -3 -c a r-
CO2Me b o x y la te  6 C i.
M e H - N4 l5 '  A cc o rd in g  to  th e  g e n e ra l p ro c e d u re , a -c y a n o  e s te r  (±)-7C i (7.628 g, 25.65 
5 4 ' ' ' [ T \  /^6' m m o l) a f fo rd e d  (±)-6Ci (7.337 g, 95%) as  a  y e llo w  oil, a f te r  c o lu m n
(±) N 7a 7 c h ro m a to g ra p h y  (C H 2C l2/M e O H , 9:1). aH  N M R  [400 M H z, 5 (p p m ), 
Me C D C l3]: 7.72 (dt; J = 8.0, 1.0 H z; 1 1H , 4 '-C H ), 7.28 (dt; J = 8.0, 1.0 H z; 1 1H ,
7'-C H ), 7.21 (d d d ; J = 8.0, 6.8, 1.0 H z; 1 1H , 6 '-C H ), 7.11 (ddd (7 ); J = 8.0, 6.8, 1.0 H z; 1 1H , 5 '-C H ), 
6.98 (s, 1 1H , 2 '-C H ), 4.32 (dd ; J = 9.3, 7.3 H z; 1 1H , 4-C H ), 3.83 (s, 3 1H , O C H 3), 3.76 (s, 3 1H , 1'- 
N C H 3), 3.43 (d, J = 10.0 H z , 1 1H , 2-C H H ), 3.17 (dd ; J = 9.3, 7.3 H z; 1 1H , 5 -C H H ), 2.75 (d, J = 13.2 
H z , 1 1H , C H H N H 2), 2.68 (t, J = 9.3 H z , 1 1H , 5 -C H H ), 2.60 (d, J = 13.2 H z, 1 1H , C H H N H 2), 2.45
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(d, J = 10.0 Hz, 1 1H, 2-CHH), 2.42 (s, 3 1H, 1-NCHa), 1.04 (bs, 2 1H, NH2). 13C NMR [75 MHz, 5 
(ppm), CDCIb]: 177.1 (CO2), 136.9 (7'a-C), 128.3 (3'a-C), 127.3 (2'-C), 122.0 (6 '-C), 119.9 (5'-C), 119.3 
(4'-C), 112.0 (3'-C), 109.3 (7'-C), 64.8 (2-C), 62.5 (5-C), 58.4 (3-C), 52.4 (OCH3), 47.1 (CH2NH 2), 42.5 
(4-C), 41.6 (1 -NCH3), 32.9 (1 -NCH3). FTIR [V (cm-1), neat]: 3386, 3047, 2946, 2834, 2779, 1720, 
1472, 1172, 741. HRMS [EI (m /z)] calcd for C17H23N 3O2 = 301.1790, found for [M+-] = 301.1776 
(| A| = 4.7 ppm), peaks at (relative intensity): 301 (7), 284 (93), 228 (18), 157 (100), 144 (22), 57 
(27). Rf: 0.22 (CH2Ck/M eOH, 8:1). Purity: 98.0% (GC).
“ • v ï r N ^
(±)-Methyl (3R,4S)-3-(aminomethyl)-4-(3,5-dimethoxyphenyl)-1-methylpyrrolidine-3-carbox-
2 3C°2Me ylate 6Ck.
OMe According to the general procedure, a-cyano ester (±)-7Ck (7.452 g, 25.06 
6'„ ^ 4' mmol) afforded (±)-6Ck (6.730 g, 89%) as a yellow oil, after column 
(±) OMe chromatography (CH2Cl2/M eO H , 9:1). 1H NMR [400 MHz, 5 (ppm),
CDCl3]: 6.51 (d, J = 2.2 Hz, 2 1H, 2'-CH + 6'-CH), 6.35 (t, J = 2.2 Hz, 1 1H, 4'-CH), 3.87 (dd(3), J =
7.9 Hz, 1 1H, 4-CH), 3.80 (s, 3 1H, CO2CH3), 3.78 (s, 6 1H, 2 x OCH3), 3.31 (d, J = 9.8 Hz, 1 1H, 2- 
CHH), 3.06 (dd; J = 9.0, 7.8 Hz; 1 1H, 5-CHH), 2.72 (dd(3), J = 8.8 Hz, 1 1H, 5-CHH), 2.71 (d, J =
13.0 Hz, 1 1H, CHHNH2), 2.58 (d, J = 13.0 Hz, 1 1H, CHHNH2), 2.48 (d, J = 9.8 Hz, 1 1H, 2-CHH), 
2.40 (s, 3 1H, NCH3), 1.45 (bs, 2 1H, NH2). 13C NMR [75 MHz, 5 (ppm), CDQ3]: 176.5 (CO2), 160.6 
(3'-C + 5'-C), 141.2 (1'-C), 107.5 (2'-C + 6'-C), 98.6 (4'-C), 64.2 (2-C), 61.6 (5-C), 58.7 (3-C), 55.3 (2 x 
OCH3), 52.4 (CO2CH3), 50.0 (4-C), 46.6 (CH2NH 2), 42.3 (NCH3). FTIR [ V (cm-1), neat]: 3380, 3188, 
2942, 2835, 2781, 1723, 1593, 1203, 1152. HRMS [ESI (m /z)] calcd for (C16H24N 2O4 + H)+ = 
309.18143, found 309.18062 (| A | = 2.62 ppm). Rf: 0.30 (CH2O 2/M eO H , 8:1). Purity: 98.2% (GC).
(±)-Methyl (3R,4S)-3-(aminomethyl)-4-(1,3-benzodioxol-5-yl)-1-methylpyrrolidine-3-carbox-
2 3 CO2Me ylate 6Cl.
MeN According to the general procedure, a-cyano ester (±)-7Cl (7.009 g, 24.31
V—{^-,5^^s3^O
5 || [ \ 2' mmol) afforded (±)-6Cl (6.055 g, 85%) as a light yellow oil, after column 
6 ' \ ^ - - O „(±) 7' 7a chromatography (CH2Cl2/M eOH, 9:1). 1H NMR [400 MHz, 5 (ppm),
CDCl3]: 6.88 (d, J = 1.7 Hz, 1 1H, 4'-CH), 6.78 (dd; J = 8.1, 1.5 Hz; 1 1H, 6'-CH), 6.72 (d, J = 8.1 Hz,
1 1H, 7'-CH), 5.92 (s, 2 1H, 2'-CH2), 3.83 (dd(3), J = 7.7 Hz, 1 1H, 4-CH), 3.78 (s, 3 1H, OCH3), 3.27
(d, J = 9.9 Hz, 1 1H, 2-CHH), 3.01 (dd; J = 9.3, 7.6 Hz; 1 1H, 5-CHH), 2.67 (dd(3), J = 8.7 Hz, 1 1H,
5-CHH), 2.66 (d, J = 12.9 Hz, 1 1H, CHHNH2), 2.53 (d, J = 12.9 Hz, 1 1H, CHHNH2), 2.48 (d, J =
9.9 Hz, 1 1H, 2-CHH), 2.38 (s, 3 1H, NCH3), 1.01 (bs, 2 1H, NH2). 13C NMR [75 MHz, 5 (ppm), 
CDO3]: 176.3 (CO2), 147.4 (3'a-C), 146.3 (7'a-C), 132.5 (5'-C), 122.0 (6'-C), 109.3 (4'-C), 107.8 (7'-C),
100.8 (2'-C), 63.8 (2-C), 61.8 (5-C), 58.6 (3-C), 52.1 (OCH3), 49.5 (4-C), 46.6 (CH2NH 2), 42.0 (NCH3). 
FTIR [ V (cm-1), neat]: 3320, 3317, 2946, 2841, 2776, 1721, 1248, 1232, 1034, 929. HRMS [ESI 
(m /z)] calcd for (C15H20N 2O4 + H)+ = 293.15013, found 293.14936 ( |A | = 2.63 ppm). Rf: 0.25 
(CH2Cl2/M eOH, 8:1). Purity: 97.4% (GC).
(±)-Methyl (3R,4S)-3-(aminomethyl)-1-methyl-4-(3,4,5-trimethoxyphenyl)pyrrolidine-3-car-
2 3CO2Me boxylate 6Cm.
/ > ,  NH2
MeN^^J ''-^2' OMe According to the general procedure, a-cyano ester (±)-7Cm (1.016 g, 3.03
5 [| L mmol) afforded (±)-6Cm (923 mg, 90%) as a whitish oil. 1H NMR [400
(±) OMe ^  MHz, 5 (ppm), CDQ 3]: 6.58 (s, 2 1H, 2'-CH + 6'-CH), 3.87 (dd(3), J = 8.0
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Hz, 1 1H, 4-CH), 3.86 (s, 6  1H, 3'-OCHb + 5'-OCHa), 3.83 (s, 3 1H, CO2CH3), 3.81 (s, 3 1H, 4'-OCHa), 
3.30 (d, J = 9.9 Hz, 1 1H, 2-CHH), 3.05 (dd(3), J = 8.4 Hz, 1 1H, 5-CHH), 2.77 (dd(3), J = 8.8  Hz, 1 
1H, 5-CHH), 2.72 (d, J = 13.2 Hz, 1 1H, CHHNH2), 2.61 (d, J = 13.2 Hz, 1 1H, CHHNH2), 2.57 (d, J 
= 9.9 Hz, 1 1H, 2-CHH), 2.42 (s, 3 1H, NCH3), 1.76 (bs, 2 1H, NH2). 13C NMR [75 MHz, 5 (ppm), 
CDCla]: 176.2 (CO2), 152.7 (3'-C + 5'-C), 136.8 (4'-C), 134.3 (1'-C), 106.1 (2'-C + 6 '-C), 64.1 (2-C),
61.8 (5-C), 61.0 (4'-OCHb), 58.9 (3-C), 56.3 (3'-OCHb + 5'-OCHb), 52.4 (CO2CH3), 50.2 (4-C), 46.8 
(CH2NH 2), 42.4 (NCH3). FTIR [V (cm-1), neat]: 3379, 3190, 2938, 2835, 2782, 1724, 1586, 1238, 
1122. HRMS [EI (m /z)] calcd for C17H26N 2O5 = 338.1842, found for [M+-] = 338.1830 (| A| = 3.5 
ppm), peaks at (relative intensity): 338 (1), 321 (63), 262 (19), 194 (100), 179 (23), 69 (21), 57 (52). 
Rf: 0.24 (CH2O 2/M eOH, 8:1). Purity: 97.7% (GC).
(±)-(3R,4R)-3-(Hydroxymethyl)-1-methyl-4-phenylpyrrolidine-3-carbonitrile 35.
^OH Compound (±)-7Ca (202 mg, 0.83 mmol) in dry THF (10 mL) was added to a 
solution of LiAlH4 (125 mg, 3.29 mmol) in dry THF (10 mL) under an argon 
atmosphere at 0 °C. The resulting reaction mixture was stirred over 40 min. 
The mixture was then quenched by addition of 1 N HCl (6 mL). 
Tetrahydrofuran was evaporated and Et2O (40 mL) was added. N ew  addition of 1 N  HCl (6 mL) 
was followed by separation of layers. The aqueous phase was extracted with Et2O (2 x 30 mL) 
and then a 1 M NaOH solution was added to the aqueous layer (pH 9-10). Finally, the aqueous 
layer was extracted with CHCl3 (2 x 20 mL). The combined organic extracts were dried 
(Na2SO4) and the solvent was evaporated under reduced pressure. The residue afforded (±)-35 
(131 mg, 73%) as a yellow oil, after column chromatography (CH2Q 2/  AcOEt, 3:2). 1H NMR [200 
MHz, 5 (ppm), CDO3]: 7.50-7.22 (m, 5 1H, Ph), 3.89 (d, J = 10.8 Hz, 1 1H, CHHOH), 3.79 (d, J =
10.8 Hz, 1 1 H, CHHOH), 3.43 (dd(3), J = 8.1 Hz, 1 1H, 4-CH), 3.19 (dd; J = 9.2, 7.3 Hz; 1 1H, 5- 
CHH), 3.16 (d, J = 9.9 Hz, 1 1H, 2-CHH), 2.96 (d, J = 9.9 Hz, 1 1H, 2-CHH), 2.81 (dd(3), J = 9.1 Hz,
1 1H, 5-CHH), 2.57 (bs, 1 1H, OH), 2.43 (s, 3 1H, NCH3). FTIR [V (cm-1), neat]: 3370, 2941, 2839, 
2789, 2237, 1450, 772, 703. MS [ESI (m /z)] calcd for (C13H 16N 2O + H)+ = 217, found 217.
(±)-[(3R,4R)-3-Cyano-1-methyl-4-phenylpyrrolidin-3-yl]methyl acetate 36.
^OAc Compound (±)-7Ca (110 mg, 0.45 mmol) in dry THF (7 mL) was added to a 
solution of LiAlH4 (68 mg, 1.79 mmol) in dry THF (8 mL) under an argon 
atmosphere at room temperature. The resulting reaction mixture was heated to 
(±) reflux and stirred over 8 h. The reaction mixture was then cooled to room
temperature, Ac2O (4 mL) was added, and the new reaction mixture was stirred over 5 h. Water 
(15 mL) was then added and the solution was extracted with Et2O (3 x 20 mL). The combined 
organic extracts were dried (Na2SO4) and the solvent was removed under reduced pressure. 
The residue afforded (±)-36 (87 mg, 75%) as a yellow oil, after column chromatography (AcOEt). 
1H NMR [200 MHz, 5 (ppm), CDQ 3]: 7.46-7.20 (m, 5 1H, Ph), 4.33 (d, J = 10.8 Hz, 1 1H, 
CHHOAc), 4.23 (d, J = 10.8 Hz, 1 1H, CHHOAc), 3.33 (dd; J = 8.7, 7.4 Hz; 1 1H, 4-CH), 3.14 
(dd(3), J = 8.4 Hz, 1 1H, 5-CHH), 3.09 (d, J = 9.9 Hz, 1 1H, 2-CHH), 3.03 (d, J = 9.9 Hz, 1 1H, 2- 
CHH), 2.94 (dd(3), J = 9.1 Hz, 1 1H, 5-CHH), 2.46 (s, 3 1H, NCH3), 2.10 (s, 3 1H, COCH3). FTIR [ V 
(cm-1), neat]: 2924, 2850, 2788, 2241, 1748, 1222, 770, 703. MS [ESI (m /z)] calcd for (C15H 18N 2O2 + 
H)+ = 259, found 259.
54
Synthesis of 3-(AmiwomethyZ)-4-aryZpyrroZidiwe-3-carboxyZates
(±)-[(3R,4S)-3-(Aminomethyl)-1-methyl-4-phenylpyrrolidin-3-yl]methanol 37.
oh The complex BH3 SMe2 (614 |J,L, 1.23 mmol; 2 M solution in THF) was added 
MeN 2 dropwise to a refluxing solution of compound (±)-7Ca (100 mg, 0.41 mmol) in
temperature and 6  N HCl (614 |J,L, 3.68 mmol) was added. The new reaction mixture was heated 
to reflux over 30 min. Then, the reaction mixture was cooled to 0 °C and 2 M NaOH (5 mL, up 
to pH 12) was added. The mixture was extracted with AcOEt (3 x 8 mL). The combined organic
was purified through an Isolute® SPE column (flash SCX-2, 5 g)34 to afford (±)-37 (69 mg, 76%) 
as a yellow oil. *H NMR [200 MHz, 5 (ppm), CDCla]: 7.41-7.16 (m, 5 1H, Ph), 3.86 (d, J = 10.5 Hz,
1 1H, CHHOH), 3.79 (d, J = 10.5 Hz, 1 1H, CHHOH), 3.31 (dd(3), J = 7.9 Hz, 1 1H, 4-CH), 3.09 (dd; 
J = 9.2, 7.6 Hz; 1 1H, 5-CHH), 2.97 (bs, 3 1H, OH + NH2), 2.76 (d, J = 9.5 Hz, 1 1H, 2-CHH), 2.71 
(dd; J = 9.2, 8 .6  Hz; 1 1H, 5-CHH), 2.60 (s, 2 1H, CH2NH 2), 2.38 (s, 3 1H, NCH3), 2.30 (d, J = 9.5 Hz,
1 1H, 2-CHH). FTIR [V (cm-1), neat]: 3360, 3278, 3196, 2933, 2833, 2777, 1450, 772, 703. MS [ESI 
(m /z)] calcd for (C13H20N 2O + H)+ = 221, found 221. Rf: 0.10 (CH2O 2/M eOH, 4:1).
(±)-(1R,5R,6R)-5-Cyano-1-methyl-4-oxo-6-phenyl-3-oxa-1-aza-2-borabicyclo[3.2.1]octan-1-ium-
O 2-uide 38.
was heated to room temperature and 6  N  HCl (0.6 mL) was added. The new reaction mixture 
was stirred over 20 min. Then, the reaction mixture was cooled to 0 °C and 2 M NaOH (5 mL, 
pH 12) was added. The mixture was extracted with AcOEt (3 x 8 mL). The combined organic
decomposed on a silica column. (Measured from the crude) *H NMR [200 MHz, 5 (ppm), 
CD3OD]: 7.47-7.25 (m, 5 1H, Ph), 4.42 (dd; J = 13.0, 7.0 Hz; 1 1H, 6-CH), 4.00 (d, J = 12.4 Hz, 1 1H, 
8 -CHH), 3.74 (dd; J = 11.1, 7.0 Hz; 1 1H, 7-CHH), 3.65 (d, J = 12.4 Hz, 1 1H, 8 -CHH), 3.58 (dd; J =
13.0, 11.1 Hz; 1 1H, 7-CHH), 2.98 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDO3]: 169.0 (4- 
C), 135.6 (1'-C), 129.2 (2'-C + 6 '-C), 128.8 (3'-C + 5'-C), 128.7 (4'-C), 120.8 (CN), 72.8 (8 -C), 67.5 (7- 
C), 59.6 (5-C), 56.0 (6-C), 51.8 (NCH3). FTIR [V (cm-1), neat]: 2950, 2920, 2850, 2341, 2273, 2242, 
1634, 1452, 1370, 773, 698.
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the magnetic field, and the frequency of the spectrometer used. The values of the coupling 
constants measured when this phenomenon happens are not always accurate.
32 This signal is sometimes called an apparent triplet (app t) in the literature.
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CHAPTER 3
Synthesis of 3-Amino-4-arylpyrrolidine-3-
carboxylates
CO2Me
M e N ^ f " NH2
X^ ' - Ar MeO^ ^ A  o^ / ^ A
O2N  -CO2Me ----- »  Ar = MeO
CO2Me
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Abstract
A general three- or four-step synthesis of cis- and trans-4-aryl-substituted 
cucurbitine (3-aminopyrrolidine-3-carboxylic acid) derivatives from methyl 2- 
nitroacetate is reported. The first step utilizes a Knoevenagel condensation reaction 
with five different aromatic imines or their corresponding aldehydes to form Z/E 
mixtures of 2-nitroacrylates. The second step gives rise to the pyrrolidine-core 
structures of the title compounds by a 1,3-dipolar cycloaddition reaction using an 
azomethine ylide. The last step consists of reduction of the nitro group to yield both 
diastereoisomers of the corresponding 4-arylcucurbitine methyl esters.
P a r t o f th is  c h a p te r  w a s  p u b lis h e d  in: B lanco -A n ia , D.; H e rm k e n s , P. H . H .; S lied reg t, L. A . J. 
M .; S cheeren , H . W .; R utjes, F. P. J. T. T etrah edron  2009, 65, 5393-5401.
Chapter 3
3.1 Introduction
It is impossible not to associate the compounds presented in this chapter with 
cucurbitine 1, (-)-(S)-3-aminopyrrolidine-3-carboxylic acid (Figure 3.1). Cucurbitine, 
found in some Cucurbitaceae (e.g., pumpkin and zucchini), is known to have 
antiparasitic properties, and particularly anthelmintic activity against Schistosoma 
japonicum.1
c o 2h
H N ^ f-NH2
1
F ig u re  3.1 C u c u rb itin e  1.
Cucurbitine is also known as a hypohistaminaemic agent as it inhibits the formation 
of histamine, a well-known mediator of allergies. The hypohistaminaemic activity 
arises from the ability to block the usual function of histidine decarboxylase—the 
enzyme responsible for the conversion of histidine to histamine. The administration of 
cucurbitine contributes to a decreased histamine concentration in the blood serum and 
tissues. Cucurbitine is also used in cosmetic (notably dermatologic) products in order 
to soothe greatly irritated, stressed, or allergy-affected skin (use patented by Christian 
Dior Parfums).2 Despite its interesting biological activity, only six total syntheses of this 
diamino acid have been published.1-3
Although much is known about cucurbitine itself, information on 4-aryl derivatives 
is rather scarce. The latter compounds possess the 2-arylethyl amine moiety, thoroughly 
described in Chapter 1. There is only one example in the literature describing methyl 4- 
phenylcucurbitinate4 and a few random and isolated examples of the synthesis of 4- 
aryl derivatives,5 but there are no examples of 4-heteroaryl compounds. The idea of 
combining two known privileged structures (cucurbitine and 2-arylethyl amine) to 
generate a product with possible new biological activity is interesting from a 
pharmaceutical point of view (Scheme 3.1). In this case, the 2-arylethyl amine moiety is 
contained twice within the structure.
S c h e m e  3.1 The C o m b in a tio n  o f  T w o  P r iv ile g e d  S tru c tu re s .
c o 2h
NH2
H N ^ f - ^  + A^ N H 2  ----------------- -  H N ^ f
Ar
possible new 
biological activity
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Thus, we herein present a general procedure for the synthesis of both possible 
diastereisomeric (trans and cis) racemates of 4-aryl-substituted cucurbitine derivatives, 
possessing different aryl groups, such as phenyl, alkoxyphenyl, furyl, and indolyl. 
These products were used at a later stage for library synthesis (see Chapters 4 and 6).
3.2 Results and Discussion
A retrosynthetic analysis similar to the one in Chapter 2 can be envisioned for these 
compounds (Scheme 3.2). There is a one-carbon atom difference between the two 
families. Thus, the amino group of compounds (±)-2 and (±)-3 could be derived from 
another masked amino function, such as a nitro group, also by reduction. Compounds 
(±)-4 and (±)-5 possess the same pattern as the corresponding compounds from 
Chapter 2 for a 1,3-cycloaddition reaction between an azomethine ylide and an 
electron-deficient alkene. This would leave the 3-aryl-2-nitroacrylates 6 as starting 
materials, which could be prepared by a Knoevenagel condensation reaction of methyl 
2-nitroacetate 7 with an aromatic aldehyde.
S c h e m e  3.2 R e tr o sy n th e tic  A n a ly s is  f o r  the S y n th e s is  o f  M e th y l  3 -A m in o -4 -a ry lp y r r o lid in e -3 -  
ca rb o x y la tes  (± )-2  a n d  (± )-3 .
(±)-3 (±)-5
3.2.1 Knoevenagel Condensation Reaction
The synthesis of compounds (±)-2 and (±)-3 commenced with methyl 2-nitroacetate 7, 
available from a known (and several times modified) procedure involving the self 
condensation of nitromethane.67 Next, the condensation of methyl 2-nitroacetate 7 with 
the aromatic aldehydes 8a-e and with the corresponding N-phenyl imines 9a-e to 
obtain the 2-nitroacrylates was studied. As outlined in Chapter 2, the reaction 
conditions for this condensation are critical and depend on the electron-withdrawing 
groups bound to the activated methylene.8 There are three general procedures for 
accomplishing Knoevenagel condensation reactions with 2-nitroacetates, namely 
reaction with (1) an aldehyde, TiCU, and 4-methylmorpholine in ethers,9 (2) an 
aldehyde and Et2NH •HCl,10 and (3) an imine and Ac2O.11
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We initially performed the Knoevenagel condensation reactions using the last 
method, which had previously given good results for similar reactions.11a In general, 
the equilibrium in imine formation is shifted towards the product by removal of H2O, 
either by distillation or by use of a drying agent. We developed a highly practical 
procedure for the synthesis of N-phenyl imines 9b,c and 9e starting from the solid 
aromatic aldehydes 8b,c and 8e, by combining both methods of dehydration. Addition 
of aniline to the neat aromatic aldehyde, with MgSO4 as dehydrating agent, and 
reaction at the melting point temperature of the aldehydes for 4-6 h gave conversions 
of >90%. Addition of CH2Q 2, removal of the solid by filtration and subsequent 
distillation of CH2Q 2 and H2O provided the corresponding N-phenyl imines in 
quantitative yields. For liquid aldehydes 8a and 8d the reaction was run in THF at 
room temperature (Table 3.1).12
T a b le  3.1 N -P h e n y l  Im in e  F o rm ation
O
aA ,
8a-e
PhNH2, solvent
MgSO4, 21-70 °C, 4-6 h
N 'Ph
aA
9a-e
E n try A r S o lv en t T e m p e ra tu re  (°C) P ro d u c t Y ield  (%)
1 p h e n y l TH F
2 3 ,5 -d im e th o x y p h e n y l -
3 1 ,3 -benzod ioxo l-5 -y l -
4 2 -fu ry l TH F
5 1 -m eth y lin d o l-3 -y l -
21
46
37
21
70
-Ph
1  
Ph H
9a 99
N
MeO.
y  h 9b
OMe
99
N 'Ph
< P ^ ^ h 9c 99
,-Ph
N
9d 90b
.Ph
h 9e 99
N
Me
a Isolated yield. b Conversion calculated by integration of the 1H NMR signals of the crude reaction 
mixture, not isolated yield.
a
H
O
With the N-phenyl imines 9a-e in hand, we proceeded with the Knoevenagel 
condensation reactions, which were run overnight with methyl 2-nitroacetate 7 in 
acetic anhydride to yield the 2-nitroacrylates 6a-e in generally good yields and varying 
Z/E  ratios (Table 3.2).13
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T a b le  3.2 K n o even a g el C o n d en sa tio n  R ea ctio n  To F orm  the 2 -N itro a c ry la te s  6 a - e
,-Ph
O2N^  ,^CO2Me
N'
aA
9a-e
Ac2O, 50 °C, 17 h
O2N^ ^,CO2MeO2^^.,CO2Me O2
J  * .A r  Ar
(Z)-6a—e (£)-6a—e
x
E n try A r P ro d u c ts R atio  (Z /E )a  Y ield  (%)
p h e n y l
2 3 ,5 -d im e th o x y p h e n y l
O2^ C^O2Me O2N^.œ2Me
* \ h  
(E)-6a
Ph
(Z)-6a
O2N ^ _,„,CO2Me O2N ^ _,,,-CO2Me
MeO OMe
OMe
(Z )-6b
OMe
(E)-6b
O 2 ^^x CÛ2Me O2N ,s -^CO2Me
T T
1 ,3 -benzod ioxo l-5 -y l <
(Z)-6c (E)-6c
O^ N^COM O2^ ^CO2Me
2 -fu ry l
5 1 -m eth y lin d o l-3 -y l
V-O 
(Z )-6d
O-ff 
(E)-6d
O2N ^ _,.-CO2Me O2N ^ _,.-CO2Me
N"
Me
(Z )-6e
"N
Me 
(E)-6e
3:1
3:2
3:1
2:1
40:1b
81
69
69
74
a Calculated by integration of the 1H NMR signals of the crude reaction mixture. b Product obtained by 
precipitation from  the reaction mixture.
The reaction sequence of this reaction is in fact an example of the broad scope of N- 
acyl iminium ion chemistry.14 Firstly, the imine is acetylated to form the N-acetyl- 
iminium acetate 10 (Scheme 3.3). Secondly, the acetate ion dehydronates methyl 2-
S c h e m e  3.3 R ea c tio n  S equ en ce  o f  the K n o even a g el C o n d en sa tio n  R ea c tio n  o f  N -P h e n y l  Im in es 9 a - e  
a n d  M e th y l  2 -N itro a c e ta te  7.
N Ph
aA
9a-e
* Ac2O
CbN^ XÜ2Me *
O
J i . ®  Ph N 0  
II OAc
A r  H 
10
O
„ A ® ,P h
- N 0
‘ II OAc
A r^ "H
10
O
_ A ® ,P h
N O2N^„,CO2Me * AcOH 
A e
A r ^ H
11
O
„ A ® ,P h
N ^  O2N^„,CO2Me 
0
Ar VH
A ^ N Ac
Ph
-AcNHPh O2N v^ ^CO2Me
A r ^
6a-e
7
1
*
3
*
4
*
7
O 2N v__^C O 2 M e
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nitroacetate 7 forming the iminium enolate (or nitronate) 11. Addition of the enolate to 
the iminium ion, followed by elimination of acetanilide by an E1cB mechanism, gives 
the condensed products 6a-e.
In spite of our best endeavors, the yield for the condensation of 9d dropped 
dramatically when an attempt was made to scale up the reaction to 10 g. To solve this 
inconvenience, the reaction was repeated using aldehyde 8d instead. Under the 
conditions depicted in Scheme 3.4,9c product 6d was then synthesized in a higher yield, 
independent of the scale.15 All other reactions could be readily scaled up under the 
stated conditions.
S c h e m e  3.4 K n o even a g el C o n d en sa tio n  R ea ctio n  o f  A ld e h y d e  8d .
Oo
OoN.^COoMe * CHO
8d
Me , TiCl4, THF
21 °C, 20 h 
87%
O2N^  ,CO2Me
6d
(Z/E = 4:1)
7
Although in some cases the separation of the Z/E  mixtures could be achieved by 
recrystallization,9a this was not investigated any further as it was apparent from the 
next step that Z-E isomerization proceeds considerably faster than the cycloaddition, 
probably due to the push-pull effect.16
3.2.2 1,3-Dipolar Cycloaddition Reaction
The next step in the synthesis was the formation of the pyrrolidine-core structures by 
a 1,3-dipolar cycloaddition reaction using an azomethine ylide. The same procedure 
used for the cycloaddition of 2-cyanoacrylates (Chapter 2) was chosen. Thus, sarcosine 
with paraformaldehyde in refluxing toluene in the presence of the 2-nitroacry lates 6a-e 
cleanly provided a ca. 1:1 mixture of the diastereoisomeric cycloadducts (±)-4a-e and 
(±)-5a-e,17 independent of the Z/E  ratio of the substrate (Table 3.3). The separation of 
these products using column chromatography was straightforward in all cases, as a 
result of the large Rf difference between the diastereoisomers. On NMR spectroscopy 
the methyl group of the ester of the cis isomers (±)-5a-e presented a chemical shift 
(2.94-3.48 ppm) 0.38-0.88 ppm lower than the methyl group of the trans isomers 
(±)-4a-e (3.82-3.86 ppm). This chemical-shift difference is due to the shielding effect of 
the aryl group and confirms the relative stereochemistry of the isomers (the chemical 
shift of the methyl group of the trans isomers of the corresponding cyano compounds 
from Chapter 2 was 3.67-3.88 ppm).
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T a b le  3.3 1 ,3 -D ip o la r  C y c lo a d d itio n  R ea ctio n  To F orm  the P yrro lid in e -C o re  S tru c tu re s  ( ± ) - 4 a - e  an d  
( ± ) - 5 a - e
CO2Me CO2Me
O2N
Ar
CO2Me MeNHCH2CO2H  ^
(CH2O)n, PhMe, A
M e N ^ f  '
6a—e
NO2 
'Ar 
(±)-4a—e
MeN
NO2C tAr
(±)-5a—e
E n try A r P ro d u c ts T im e (m in) Y ield  (%)
p h e n y l
2 3 ,5 -d im e th o x y p h e n y l
1 ,3 -benzod ioxo l-5 -y l
2 -fu ry l
5 1 -m eth y lin d o l-3 -y l
CO2Me
MeN^f"^
^'"Ph
NO2
y—/<<rMeN I
(±)-4a
CO2Me'
NO2
CO
N ' t^ P h
(±)-5a
CO2Me
OMe MeN
MeN f^'
OMe
(±)-4b
CO2Me 
NO2
c o
(±)-4c
CO2Me
OMe
MeN
OMe
(±)-5b 
CO2Me
C f,
■NO2
(±)-5c
CO2Me
O
(±)-4d
CO2Me
-N
Me
(±)-4e
-N
Me
(±)-5e
45
60
110
60
105
90
84
85
82
82
a Com bined yield.
The cycloaddition reaction also gave trace amounts of the trans 
de(methoxycarbonyl)ated products (±)-12a-e via a Krapcho reaction (Scheme 3.5).18 
Once the cycloadduct is formed, any nucleophile (e.g., sarcosine) can perform a 
substitution on the ester's methyl to form the a-nitro carboxylate (±)-13, which 
decarboxylates at the temperature of the reaction conditions. The resulting nitronate 
(±)-14 is probably hydronated to a mixture of trans and cis de(methoxycarbonyl)ated 
products ((±)-12a-e and (±)-15a-e, respectively), which then equilibrates to the more 
stable trans-3-aryl-4-nitropyrrolidines (±)-12a-e, or directly to the trans isomer, since 
the cis isomer was not observed.
S c h e m e  3.5 K rapcho  R ea ctio n  o f  the C y c lo a d d u c ts  (± )-4  a n d  (±)-5 .
Me-
& T O
MeN
V "Ar 
(±)-4,(±)-5
O
NO2 Nu
Í-7  O
. .  .. T"N© —CO2 MeN I O© -------- 1
(±)-13
O®O® H+ 
^ N'O e  
MeN ^v A  \ H+Ar 
(±)-14
_ , NO2
MeN
'''Ar 
(±)-15a—e
Isomerization
MeN I 
^ " 'A r  
(±)-12a—e
+
a
+
1
+
+3
4 +
+
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Experiments to confirm the assumption about the Z-E equilibration of the 2-nitro- 
acrylates before cycloaddition were performed. In the first experiment, two separate 
reactions were run with pure (Z)-6d or (Z)-6e (obtained by recrystallization). The 
reaction was followed by GC and TLC. An isomeric mixture of the corresponding 
products (±)-4 and (±)-5 was observed from the beginning. The reactions were stopped 
after 2 h and analyzed by NMR spectroscopy, giving a product ratio close to 1:1 in both 
cases.
The second experiment was to verify that the products (±)-4 and (±)-5 did not 
isomerize into each other under the stated reaction conditions. Thus, (±)-4d and (±)-5d 
were heated separately to reflux in toluene. Sarcosine and paraformaldehyde were 
added every 40 min. No noticeable isomerization was observed after 2 h. After 6 h, 
(±)-4d yielded a 9:1 mixture (calculated by NMR spectroscopy) of (±)-4d and (±)-5d, 
whereas (±)-5d gave a 40:1 mixture of (±)-5d and (±)-4d. This isomerization could take 
place through a retro-Mannich reaction to form the zwitterionic intermediate 16, 
followed by equilibration of rotamers (16a 16b), and ring closure (Scheme 3.6). 
Analysis of these results led to the conclusion that the Z-E isomerization is faster than 
cycloaddition.
S c h e m e  3.6 R ea ctio n  S equ en ce  f o r  ( ± ) - 4 d - ( ± ) - 5 d  Iso m eriza tio n .
O O O OCO2Me
NO2
(±)-4d
% N ® e  
MeO Z y r  o
H
oO
(±)-16b
M eN ^f
NO2
CO2Me
O - /
(±)-5d
3.2.3 Reduction
The reduction of nitro compounds is perhaps the most versatile reduction of a 
functional group in organic chemistry, potentially giving rise to a variety of products. 
There is, however, a difference in reduction between aromatic and aliphatic nitro 
compounds. In the case of the aliphatic compounds there is also a difference between 
tertiary nitro compounds and primary and secondary ones. Reduction of the nitro 
group in aromatic or aliphatic compounds may lead to nitroso compounds,19 oximes,20 
hydroxylamines,21 amines,22 hydrocarbons,23 azoxy compounds,24 azo compounds25 
and hydrazo compounds26 (Scheme 3.7). In principle, there are optimal conditions for 
obtaining any of these products, but it is fairly common to form mixtures, especially for 
aliphatic nitro compounds.
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S c h e m e  3.7 V a r ie ty  o f  P ro d u c ts  in  the R e d u c tio n  o f  N i tr o  C o m p o u n d s.
Ar—NHOH Alk-NO
Ar-NH2 k i Alk'HC=NOH
H
In our case, the reduction of the nitro group to the amine was more problematic than 
anticipated. Initially, we tried the conditions previously optimized in our group 
(SnCl2-2H2O, THF/H 2O) for nitro groups on molecules with a similar structure,11a but 
the reaction provided the desired amines in low yields (<30%) accompanied by a 
mixture of unidentified side products. Among the different products obtained, we 
identified the rearranged oxime (±)-17 resulting from acid-catalyzed fragmentation of 
nitroso compound (±)-18, the first product of reduction of the nitro group, followed by 
Pictet-Spengler cyclization reaction (see Chapter 6) of the intermediate iminium ion 
(±)-19 (Scheme 3.8).
S c h e m e  3.8 R e a rra n g em e n t f o r  the F o rm a tio n  o f  C o m p o u n d  (±)-17 . 
CC
n c í :MeN
O2Me 
NO2
OMe 2 H+ + 2 e-
- h2o
CO2Me
/"-/"NO MeN u+
V -A ,, -^OMe H
OMe • fOMe
(±)-4b (±)-18
Me
O r f e
Me
fragmentation MeO OMe Pictet-Spengler 
cyclization
(±)-19
OMe
(±)-17
As a result of the above observations, it was decided not to use dissolving metal 
conditions for this type of reaction. Instead, the reduction was performed using 
catalytic hydrogenation with Raney nickel in MeOH at room temperature; the same 
conditions as for the reduction of the cyano group (Chapter 2). It was also evident in 
this case that addition of Et3N was crucial,27 leading to exclusive formation of the 
amine, rather than a mixture of the amine and the corresponding hydroxylamine.28 
Thus, compounds (±)-4a-e were reacted under these conditions to complete the
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synthesis of the 4-arylcucurbitinates. After elimination of Raney nickel by filtration 
through diatomaceous earth and evaporation of MeOH and EfeN, the reaction gave the 
a-amino esters (±)-2a-e as the major products (ratio >90% by NMR spectroscopy). 
Compounds (±)-2a-e were isolated in pure form after column chromatography. The 
minor side products (±)-20a-e and (±)-21a-e were also formed along with the 
cucurbitinates, resulting from the reduction of C-3 of the heterocycle (Table 3.4) and 
will be discussed in detail below.2930
T a b le  3.4 R e d u c tio n  o f  the N itr o  G ro u p  fro m  the  T ra n s  D ia ste re o iso m e rs  ( ± ) - 4 a - e
COoMe COoMe COoMe >COoMe
MeN I ..~OI, ol MeN | " ,,i; + MeN | + M e N ^ ]
,, nos ^  Ra-N Et3N
'  'Ar 
(±)-4a-e
e ^ " NHo  e N ^ rMeOH, oi °C, 8 h MeN^ j ^
'Ar Ar
(±)-2a-e (±)-20a-e
'Ar 
(±)-21a-e
E n try A r P ro d u c ts R a tioa Y ield  (%)b
1 p h e n y l
COoMe
MeN f^"NHo
^'"Ph
(±)-2a
COoMe
.. M^f"NHo MeN o
+ (±)-20a + (±)-21a 94:5:1 80
2 3 ,5 -d im e th o x y p h e n y l
T
+ (±)-20b + (±)-21b 93:5:2 79
3 1 ,3 -benzod ioxo l-5 -y l
OMe
(±)-2b
COoMe
MeN^fNHo
a }
+ (±)-20c + (±)-21c 92:6:2 80
4 2 -fu ry l
(±)-2c
COoMe
MeN^fNHo
" " O  
(±)-2d 
COoMe f o
+ (±)-20d + (±)-21d 92:7:1 65
5 1 -m eth y lin d o l-3 -y l
MeN^ T"NHoi=\
a t P
NMe
(±)-2e
+ (±)-20e + (±)-21e 93:6:1 62
a Calculated by integration of the aH NMR signals of the crude reaction mixture. b Isolated yield of the 
m ajor products (±)-2a-e.
When compounds (±)-5a-e were reacted under the reduction conditions used above, 
the a-amino esters (±)-3a-e were obtained with yields similar to those for (±)-2a-e and 
similar ratios of the side products (Table 3.5). To the best of our knowledge, this is the 
only general procedure for synthesizing all diastereomeric 4-arylcucurbitinates.
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T a b le  3.5 R e d u c tio n  o f  the N itr o  G ro u p  fro m  the  C is D ia ste re o iso m e rs  ( ± ) - 5 a - e  
COoMe COoMe
MeN
NOoc t ,
(±)-5a-e
Ho, Ra-Ni, Et3N 
MeOH, o i °C, 8 h
MeN
NHo
C t.
(±)-3a-e
COoMe
+ MeN I
V" ' A r
(±)-20a-e
^ CO°
+ MeN
X" ^ A r
(±)-21a-e
E n try A r P ro d u c ts R a tioa Y ield  (%)b
p h e n y l
2 3 ,5 -d im e th o x y p h e n y l
3 1 ,3 -benzod ioxo l-5 -y l
2 -fu ry l
5 1 -m eth y lin d o l-3 -y l
NHo
co
iN/ ''f" 
^ P h
(±)-3a
COoMe
OMe
(±)-3b
COoMe 
"NHo
MeN
¿ ^ 0  
(±)-3c
COoMe
O^
(±)-3d
COoMe
\  Û 
N
Me
(±)-3e
+ (±)-20a + (±)-21a
+ (±)-20b + (±)-21b
\ ’V O  + (±)-20c + (±)-21c
+ (±)-20d + (±)-21d
+ (±)-20e + (±)-21e
93:4:3 77
90:6:4 71
90:7:3 76
90:7:3 61
:8:4 60
a Calculated by integration of the aH NMR signals of the crude reaction mixture. b Isolated yield of the 
m ajor products (±)-3a-e.
An explanation for the formation of products (±)-20a-e and (±)-21a-e is not 
straightforward. One could speculate that the regular nitro reduction to give the amine 
is in competition with a radical reduction to form a nickel enolate, which is 
subsequently hydrogenated. There is no example like this in the literature, but a 
combination of statements could support this rationalization. Firstly, it is known that 
reduction, by a radical mechanism, of different groups alpha with respect to a carbonyl 
group is easier than in other positions, as is known for a-halo ketones.31 Moreover, a- 
nitro nitriles, a-nitro ketones, and a-nitro esters can be denitrated by this mechanism 
while regular nitro compounds cannot.32 Secondly, it is also known that thiol and 
sulfide reduction with Raney nickel follows a radical mechanism.33 Thirdly, the fact 
that stereoisomeric substrates gave the same stereoisomeric products means that they 
form a common intermediate or that the products isomerize into each other under the 
reaction conditions. In this case, isomerization can be ruled out because the product 
ratio is not the same for both substrates. And last, ester nickel C-enolates are more 
stable than O-enolates34 but they can be in equilibrium with each other.35 Considering 
all of this, we propose the following reaction sequence for the formation of (±)-20 and
1
4
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(±)-21 (Scheme 3.9): (1) the nitro group is adsorbed onto the surface of Raney nickel and 
reduced to the radical anion (±)-24 or (±)-25, (2) this intermediate cleaves to form the 
radical (±)-26, which is hydrogenated from the side where the nitro group was to form 
(±)-20 or (±)-21, or reduced to the nickel C-enolate (±)-27 or (±)-28, and (3) these C- 
enolates can be hydrogenated to (±)-20 or (±)-21, or can equilibrate through the O- 
enolate (±)-29 and then be hydrogenated to (±)-20 and (±)-21.36
S c h e m e  3.9 P ro p o sed  R ea ctio n  Sequence  f o r  the D e n itra tio n  o f  C o m p o u n d s  ( ± ) - 4 a - e  a n d  (± ) -5 a -e .
MeO
COoMe COoMe COoMe
M e ^ ; N°o J N U  ^  M e ^ ; N° ^  - iN G ,  M - Q f ^  or e-
'Ar 'Ar 'Ar 'Ar
MeN
(±)-4
xCOoMe
MeO
MeN
'Ar 
(±)-21
[Ni]—H
[Ni]—H or e' 
MeN
\
MeO
O
'Ar
M e ^ " C° 2Me=
'''Ar 
(±)-28
NO“
*i N°L  M e ^ " C° 2Me
S  G
(±)-24
.[Ni]
(±)-26
COoMe 
[Ni]
\^H-[Ni]
'Ar 
(±)-29
M e ^ " [N
'''Ar
(±)-27
(±)-26
'Ar 
(±)-25
MeN ƒ  ' CG
^"'A r
NG2-[Ni]
/ - - / c °
MeN
'''Ar
(±)-20
NOo
OoMe ^NL MeN^ f  "COoMe
'Ar 
(±)-5
e
During the purification of compounds (±)-2a-e and (±)-3a-e, it was found that 
compounds (±)-30-(±)-33 were formed by a slow chloromethylation reaction with 
CH2Q 2 (Scheme 3.10). Compound (±)-30e was isolated and fully characterized. The 
formation of these by-products can be avoided if CHCl3 is used as eluent instead of 
CH2Q 2 for large scale synthesis.
S c h e m e  3.10 C h lo ro m e th y la tio n  R ea ctio n  o f  C o m p o u n d s ( ± ) - 2 a - e  a n d  (± ) -3 a -e
M eN ^ f
COoMe 
NHo
'Ar 
(±)-2a-e
MeN
COoMe 
NHoc t
(±)-3a-e
CH2CI2
MeOH, oi °C
CH2CI2
MeOH, 21 °C
Cl Cl COoMe
k N ^ f " NHo
Me' v A
'Ar
(±)-30a-e
Cl®Cl CGoMe 
k®/--- f"NHo
Me';n'v A ,Ar
(±)-32a-e
Cl CGoMe 
M e.<W "NHo
I'" ^ ' ' ' ArCl Ar
(±)-31a-e
Cl CGoMe 
M e.<W "NHo
'Ar 
(±)-33a-e
+
+
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3.3 Conclusion
In summary, we have developed a general method for the synthesis of 4-aryl- 
substituted cucurbitine derivatives. We have shown that suitable aryl groups can be 
phenyl, electron-rich aryls (3,5-dimethoxyphenyl and 1,3-benzodioxol-5-yl), and 
electron-rich heteroaryls (2-furyl and 1-methylindol-3-yl). As a result, we anticipate 
that this methodology can be successfully applied to a much wider range of aromatic 
groups. These compounds combine the structure of cucurbitine (an allergy mediator 
and an anthelmintic agent) with the 2-arylethyl amine moiety (core structure with 
central nervous system activity), rendering it a potentially interesting motif from a 
pharmaceutical point of view. In addition, we have developed a high-yielding method 
for the synthesis of N-phenyl imines from solid aromatic aldehydes.
4' 2'
3'
3.4 Experimental Section
F or g e n e ra l e x p e r im e n ta l d e ta ils , see S ec tion  2.5 (p 33).
C o m p o u n d s  (±)-12a, (±)-12c, (±)-12e, (±)-21a, (±)-21c, (±)-21d, (±)-22a, (±)-22d, (±)-22e, a n d  23c 
c o u ld  n o t be iso la te d  in  a  su ffic ie n t a m o u n t /p u r i ty  fo r fu ll ch a ra c te riz a tio n .
G e n e ra l  P ro c e d u re  1 fo r  I m in e  F o rm a tio n . A n ilin e  (1 eq u iv ) w a s  a d d e d  to  a  m ix tu re  of 
a ro m a tic  a ld e h y d e  8  a n d  d ry  M gS O 4 (0.28 eq u iv ) in  T H F  (3 M ) a n d  s tirre d  a t  ro o m  te m p e ra tu re  
fo r 5 h . T he so lu tio n  w a s  d ilu te d  w ith  C H 2C l2, filte red , a n d  e v a p o ra te d  to  d ry n ess .
(E )-N -B e n z y lid e n e a n il in e  o r (E )-N ,1 -d ip h e n y lm e th a n im in e  9a.
A cc o rd in g  to  th e  g e n e ra l p ro c e d u re  1, the  re a c tio n  of b e n z a ld e h y d e  8 a  (10.0 
g, 94.2 m m o l) w ith  an ilin e  (8 .8  g, 94.2 m m o l) a ffo rd e d  9 a  (17.0 g, 99%) as  a 
lig h t y e llo w  so lid . iH  N M R  [400 M H z, 5 (p p m ), CD C ls]: 8.37 (s, 1 !H , C H N ), 
7 .89-7 .82 (m , 2 !H , 2 '-C H  + 6 '-C H ), 7 .43-7 .37  (m , 3 !H , 3 '-C H  + 4 '-C H  + 5 '-C H ), 
7 .37-7 .29 (m , 2 ^ ,  3 -C H  + 5-C H ), 7 .21-7 .13 (m , 3 ^ ,  2 -C H  + 4 -C H  + 6 -CH ). 
13C  N M R  [75 M H z, 5 (p p m ), CDCla]: 160.3 (C H N ), 152.1 (1-C), 136.2 (1'-C), 131.4 (4'-C), 129.2 (3- 
C  + 5-C), 128.83 (3'-C + 5'-C), 128.76 (2'-C + 6 '-C), 126.0 (4-C), 120.9 (2-C + 6 -C). F T IR  [ V (cm -1), 
n ea t]: 3056, 2876, 1625, 1589, 1577, 764, 691. M p : 51.4 °C (from  h e p ta n e , lig h t y e llo w  crysta ls). 
P u rity : >99.5% (GC).
(E )-N -F u rfu ry l id e n e a n il in e  o r (E )-1 -(2 - fu ry l) -N -p h e n y lm e th a n im in e  9d.
A cc o rd in g  to  the  g e n e ra l p ro c e d u re  1, th e  re a c tio n  of fu ra ld e h y d e  8 d  (10.0 g,
104.1 m m o l) w ith  an ilin e  (9.7 g, 104.1 m m o l) a ffo rd e d  9 d  (17.7 g, c o n v e rs io n  
90%) as  a  b ro w n  oil. *H N M R  [400 M H z, 5 (p p m ), C D C b]: 8.30 (s, 1 !H , 
C H N ), 7.62 (d, J = 1.8 H z, 1 !H , 5 '-C H ), 7 .41-7 .35 (m , 2 !H , 3 -C H  + 5-C H ), 7.26­
5' 7.21 (m , 3 !H , 2 -C H  + 4 -C H  + 6 -C H ), 6.96 (d, J = 3.5 H z, 1 !H , 3 '-C H ), 6.56 (dd ; 
J = 3.5, 1.8 H z; 1 !H , 4 '-C H ). R f: 0.49 (h e p ta n e /A c O E t, 2:1). P u rity : 93.8% (GC).
G e n e ra l  P ro c e d u re  2 fo r  I m in e  F o rm a tio n . A  m ix tu re  of the  a ro m a tic  a ld e h y d e  8 , an ilin e  
(1.02 eq u iv  fo r 9b ,c a n d  1.20 e q u iv  fo r 9e), a n d  M gS O 4 (0.28 eq u iv ) w a s  s tirre d  w ith o u t so lv e n t
71
Chapter 3
a n d  h e a te d  a t  th e  m e ltin g  p o in t  te m p e ra tu re  o f th e  a ld e h y d e  fo r 4 h  fo r 9b ,c a n d  fo r 6  h  fo r 9e. 
T he re a c tio n  m ix tu re  w a s  co o led  d o w n  to  ro o m  te m p e ra tu re  a n d  th e  so lid  re s id u e  w a s  
d is so lv e d  in  C H 2C l2 (40 m L  fo r 9b ,c a n d  300 m L  fo r 9e). T he so lid  h y d ra te d  M gS O 4 w a s  filte re d  
off a n d  th e  f iltra te  w a s  c o n c e n tra te d  u n d e r  re d u c e  p re ssu re . W h e n  th e  so lv e n t w a s  e v a p o ra te d , 
the  sa m p le  w a s  k e p t u n d e r  re d u c e d  p re s su re  fo r 1 h  (at a  b a th  te m p e ra tu re  of 40 °C) fo r 9b,c 
a n d  2 h  (at a  b a th  te m p e ra tu re  of 75 °C) fo r 9e. T he sa m p le  w a s  le ft o v e rn ig h t u n d e r  h ig h  
v a c u u m .
MeO
(E ) -N -(3 ,5 -D im e th o x y b e n z y lid e n e )a m lin e  o r (E )-1 -(3 ,5 -d im e th o x y p h e n y l)-N -p h e n y lm e th a n -  
im in e  9b.
A c c o rd in g  to  th e  g e n e ra l p ro c e d u re  2, th e  re a c tio n  o f 3,5- 
d im e th o x y b e n z a ld e h y d e  8 b  (10.0 g, 60.2 m m o l) w ith  an ilin e  (5.7 g, 61.4 
m m o l) a t  46 °C a f fo rd e d  9b  (14.5 g, 99%) as  a  lig h t y e llo w  so lid . *H N M R  
OMe [400 M H z, 5 (p p m ), CD Cls]: 8.37 (s, 1 ^ ,  C H N ), 7 .43-7 .36 (m , 2 ^ ,  3 -C H
+ 5-C H ), 7 .27-7 .18 (m, 3 !H , 2 -C H  + 4 -C H  + 6 -CH ), 7.07 (d, J = 2.4 H z, 2 !H , 2 '-C H  + 6 '-C H ), 6.59 
(t, J = 2.4 H z , 1 !H , 4 '-C H ), 3.86 (s, 6  !H , 2 x O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), CDCla]: 161.2 
(3'-C + 5'-C), 160.4 (C H N ), 152.1 (1-C), 138.4 (1'-C), 129.3 (3-C + 5-C), 126.1 (4-C), 121.0 (2-C + 6 - 
C), 106.6 (2'-C + 6 '-C), 104.4 (4'-C), 55.7 (2 x O C H 3). F T IR  [ V (cm -1), nea t]: 2836, 1633, 1594, 1151, 
833, 764, 691. H R M S  [EI (m /z ) ]  ca lcd  fo r C 15H 1sN O 2 = 241.1103, fo u n d  fo r [M+-] = 241.1095 ( | A | 
= 3.2 p p m ), p e a k s  a t  (re la tiv e  in ten s ity ): 241 (100), 240 (89), 211 (26), 104 (16), 77 (55), 51 (15). R F: 
0.53 (h e p ta n e /A c O E t, 2:1). M p : 45.7 °C. P u rity : 98.6% (GC).
O
(E )-N -P ip e ro n y lid e n e a n ilin e  o r (E )-1 -(1 ,3 -b e n z o d io x o l-5 -y l)-N -p h e n y lm e th a n im in e  9c.
A c c o rd in g  to  th e  g e n e ra l p ro c e d u re  2, the  re a c tio n  of p ip e ro n a l 8 c (10.0 g,
6 6 .6  m m ol) w ith  an ilin e  (6.3 g, 67.9 m m ol) a t  37 °C a f fo rd e d  9c (15.0 g, 
99% ) as  a  l ig h t y e llo w  so lid . *H N M R  [400 M H z, 5 (p p m ), CDCla]: 8.33 (s,
1 !H , C H N ), 7.53 (d, J = 1.6 H z, 1 ^ ,  4 '-C H ), 7 .41-7 .35 (m , 2 ^ ,  3 -C H  + 5- 
C H ), 7.27 (dd ; J = 8.1, 1.6 H z; 1 ^ ,  6 '-C H ), 7 .24-7 .16 (m , 3 ^ ,  2 -C H  + 4- 
C H  + 6 -C H ), 6 .8 8  (d, J = 8.1 H z , 1 !H , 7'-C H ), 6.04 (s, 2 !H , 2 '-C H 2). 13C  N M R  [75 M H z, 5 (ppm ), 
CDCla]: 159.5 (C H N ), 152.2 (1-C), 150.7 (7'a-C), 148.6 (3'a-C), 131.4 (5'-C), 129.3 (3-C + 5-C), 125.8 
(4-C + 6 '-C), 121.0 (2-C + 6 -C), 108.4 (7'-C), 107.0 (4'-C), 101.8 (2'-C). F T IR  [ V (cm -1), nea t]: 3059, 
2892, 2783, 1624, 1600, 1581, 1453, 1262, 1039, 935, 812, 766, 698. H R M S  [EI (m /z ) ]  ca lcd  fo r 
C i4H iiN O 2 = 225.0790, fo u n d  fo r [M+^] = 225.0790 ( | A | = 0.0 p p m ), p e a k s  a t  (re la tiv e  in ten sity ): 
225 (100), 224 (78), 77 (34), 51 (10). E lem . a n a l. ca lcd  fo r Q 4H n N O 2: C  74.65% , H  4.92% , N  6.22%; 
fo u n d  C  74.87% , H  4.79% , N  6.06% . R f: 0.51 (h e p ta n e /A c O E t, 3:1). M p : 67.5 °C (from  h e p ta n e , 
w h ite  co tto n -lik e  so lid ). P u rity : >99.5% (GC).
3
(E )-N -[(1 -M e th y l-1 H -m d o l-3 -y l)m e th y lid e n e ]a m lm e  o r (E )-1 -(1 -m eth y l-1 H -in d o l-3 -y l)-N - 
p h e n y lm e th a n im in e  9e.
A cc o rd in g  to  th e  g e n e ra l p ro c e d u re  2, the  re a c tio n  o f 1 -m eth y l-1 H - in d o le -
3 -c a rb a ld e h y d e  8 e (10.0 g, 62.8 m m o l) w ith  an ilin e  (7.0 g, 75.4 m m o l) a t  70 
°C a f fo rd e d  9e (14.6 g, 99%) as  a  lig h t b ro w n  so lid . *H N M R  [400 M H z, 5 
Me (p p m ), C D O 3] : 8.63 (s, 1 1H , C H N ), 8 .50-8 .45 (m , 1 1H , 4 '-C H ), 7.54 (s, 1 1H ,
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2 '-C H ), 7 .42-7 .27  (m , 5 1H , 3 -C H  + 5 -C H  + 5 '-C H  + 6 '-C H + 7'-C H ), 7.25-7.21 (m , 2 1H , 2 -C H  + 6 - 
C H ), 7 .20-7 .14 (m , 1 1H , 4-C H ), 3.86 (s, 3 1H , N C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D C b]: 154.3 
(C H N ), 153.7 (1-C), 138.0 (7'a-C), 134.3 (2'-C), 129.2 (3-C + 5-C), 126.2 (3'a-C), 124.9 (4-C), 123.4 
(6 '-C), 122.4 (4'-C), 121.8 (5'-C), 121.1 (2-C + 6 -C), 115.2 (3'-C), 109.6 (7'-C), 33.5 (N C H 3). F T IR  [ V 
(cm -1), n ea t]: 3055, 2848, 1612, 1583, 1573, 1463, 771, 750, 696. H R M S  [EI (m /z ) ]  ca lcd  fo r 
C 16H 14N 2 = 234.1157, fo u n d  for [M+^] = 234.1157 ( | A |  = 0.0 p p m ), p e a k s  a t  (re la tiv e  in ten s ity ): 
234 (100), 233 (89), 218 (10), 77 (19). E lem . a n a l.  ca lcd  fo r C 16H 14N 2: C  82.02% , H  6.02% , N  
11.96%; fo u n d  C  81.90% , H  6.05% , N  11.75%. R f: 0.36 (h e p ta n e /A c O E t, 2:1). M p : 132.5 °C (from  
h e p ta n e , lig h t y e llo w  p o w d e r) . P u rity : >99.5% (GC).
G e n e ra l  P ro c e d u re  fo r  K n o e v e n a g e l C o n d e n s a t io n  R e a c tio n . A  so lu tio n  of m e th y l 2- 
n itro a c e ta te  7 in  A c2O  (1.0 M ) w a s  h e a te d  to  50 °C. Im in e  9 (1.1 eq u iv ) w a s  a d d e d  to  th is  
so lu tio n  a n d  s tirre d  a t  50 °C  fo r 17 h. A fte r th is  tim e, H 2O  (100 m L) w a s  a d d e d . T he rea c tio n  
m ix tu re  w a s  s tirre d  fo r 10 m in  a n d  th e n  e x tra c te d  w ith  C H 2C l2 (3 x 100 m L). T he co m b in ed  
o rg an ic  la y e rs  w e re  w a s h e d  w ith  b r in e  (50 m L ), d r ie d  (M gSO 4), filte red , a n d  c o n c e n tra te d  in  
vacu o .
M e th y l 2 -n itro -3 -p h e n y la c ry la te  (Z)-6 a/(E )-6 a  (3:2).
A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , th e  re a c tio n  of m e th y l 2 -n itro ac e ta te  7 (3.57 g, 30.0 m m ol) 
w ith  im in e  9 a  (5.98 g, 33.0 m m o l) a f fo rd e d  6 a  (5.04 g, 81% y ie ld ) as  a  stick y  y e llo w  so lid  a f te r  
c o lu m n  c h ro m a to g ra p h y  (h e p ta n e /A c O E t, 4:1). F T IR  [ V (cm -1), nea t]: 3059, 2956, 1735, 1731, 
1643, 1536, 1533, 1269, 765, 687. R f: 0.28 (h e p ta n e /A c O E t, 4:1). P u rity : >99.5% (GC).
M e th y l (Z ) -2 -n itro -3 -p h e n y la c ry la te  (Z )-6 a.
O !H  N M R  [400 M H z, 5 (p p m ), CDCla]: 7.55 (s, 1 1H , 3-C H ), 7 .54-7 .40 (m , 5 1H , 
° 2N\ z ' i ^ OMe P h), 3.92 (s, 3 1H , O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), CDCla]: 159.8 (CO 2),
140.0 (2-C), 133.4 (3-C), 132.4 (4'-C), 129.9 (2'-C + 6 '-C), 129.54 (3'-C + 5'-C),
129.00 (1'-C ), 53.7 (O C H 3).
] 2
6' '
J 3
5'
4 ' ^ ^ 2 '  
3'
M e th y l (E )-2 -n itro -3 -p h e n y la c ry la te  (E)-6 a.
1O2N il L / v r r  // v /O *H N M R  [400 M H z, 5 (p p m ), CDCla]: 8.10 (s, 1 1H , 3-C H ), 7 .54-7 .40 (m , 5 1H ,
OMe P h), 3.96 (s, 3 1H , O C H 3). 13C  N M R  [75 M H z, 5 (p p m ), C D C b]: 161.8 (CO 2), 141.9 
(2-C), 137.1 (3-C)
C), 53.8 (O C H 3).
2 I,
3 ^ ' ^ 3 '  ), 132.6 (4'-C), 130.5 (2'-C + 6 '-C), 129.51 (3'-C + 5'-C), 129.02 (1'-
6' ^
5 '
M e th y l 3 - (3 ,5 -d im e th o x y p h e n y l)-2 -n itro a c ry la te  (Z)-6 b/(E )-6 b  (2.2:1).
A c c o rd in g  to  th e  g e n e ra l p ro c e d u re , th e  re a c tio n  of m e th y l 2 -n itro ac e ta te  7 (3.57 g, 30.0 m m ol) 
w ith  im in e  9b  (8.0 g, 33.0 m m o l) a f fo rd e d  6 b  (7.0 g, 8 8 % y ie ld ) as  a  y e llo w  so lid  a f te r  c o lu m n  
c h ro m a to g ra p h y  (h e p ta n e /A c O E t, 4 :1 ^ 3 :1 ) . F T IR  [ V (cm -1), n ea t]: 3003, 2958, 2841, 1736, 1731, 
1643, 1591, 1536, 1205, 1157, 1060, 844. H R M S  [EI (m /z ) ]  ca lcd  fo r C 12H 13N O 6 = 267.0743, fo u n d  
fo r [M+^] = 267.0742 ( | A | = 0.3 p p m ), p e a k s  a t  (re la tiv e  in te n s ity ): 267 (100), 166 (82), 135 (26), 59 
(43). E lem . a n a l. ca lcd  fo r C 12H 13N O 6: C  53.93% , H  4.90% , N  5.24% ; fo u n d  C  54.15% , H  4.83% , N  
5.23% . R f :  0.41 (h e p ta n e /A c O E t, 2:1). M p : 48.0 °C. P u rity : >99.5% (GC).
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M ethyl (Z)-3-(3,5-dimethoxyphenyl)-2-nitroacrylate (Z)-6 b.
O
Metts'
OMe
OMe
1H NM R [400 MHz, 5 (ppm), CDCI3]: 7.48 (s, 1 iH, 3-CH), 6.58-6.54 (m, 3 
!H, 2'-CH + 4'-CH + 6 '-CH), 3.92 (s, 3 iH, CO2CH3), 3.78 (s, 6  iH, 2 x 
OCH3). 13C NM R [75 MHz, 5 (ppm), CDCI3]: 161.4 (3'-C + 5'-C), 159.8 
(CO2), 140.3 (2-C), 133.5 (3-C), 130.58 (1'-C), 107.5 (2'-C + 6 '-C), 104.7 (4'- 
C), 55.63 (2 x OCH3), 53.7 (CO2CH3).
M ethyl (E)-3-(3,5-dimethoxyphenyl)-2-nitroacrylate (E)-6 b.
O
o2n
OMe
6'^V 
OMe
1H NM R [400 MHz, 5 (ppm), CDCI3]: 8.02 (s, 1 ^ ,  3-CH), 6.63 (d, J = 2.2 Hz,
2 !H, 2'-CH + 6 '-CH), 6.59 (t, J = 2.2 Hz, 1 ^ ,  4'-CH), 3.96 (s, 3 ^ ,  CO2CH3), 
3.80 (s, 6 !H, 2 x OCH3). 13C NM R [75 MHz, 5 (ppm), CDCI3]: 161.8 (CO2),
161.4 (3'-C + 5'-C), 142.2 (2-C), 137.1 (3-C), 130.61 (1'-C), 108.2 (2'-C  + 6'-C),
104.8 (4'-C), 55.64 (2 x OCH3), 53.8 (CO2CH3).
M ethyl 3-(1,3-benzodioxol-5-yl)-2-nitroacrylate (Z)-6c/(E)-6c (4.5:1).
According to the general procedure, the reaction of m ethyl 2-nitroacetate 7 (3.57 g, 30.0 mmol) 
w ith  imine 9c (7.4 g, 33.0 mmol) afforded 6c (5.2 g, 69% yield) as a yellow solid after column 
chrom atography (heptane/A cO Et, 4:1^3:1). FTIR [ V (cm-1), neat]: 3003, 2950, 2846, 2784, 1721, 
1630, 1528, 1502, 1244, 1035, 921, 827. HRM S [EI (m /z)] calcd for C11H 9NO 6 = 251.0430, found 
for [M+^] = 251.0420 (| A| = 3.9 ppm ), peaks at (relative intensity): 251 (100), 204 (43), 173 (31), 
146 (48), 59 (31). Elem. anal. calcd for C11H 9NO 6: C 52.60%, H 3.61%, N 5.58%; found C 52.49%, 
H 3.66%, N 5.59%. Rf: 0.26 (heptane/A cO Et, 3:1). Mp: 114.7 °C (from heptane, yellow crystals). 
Purity: >99.5% (GC).
M ethyl (Z )-3-(1,3-benzodioxol-5-yl)-2-nitroacrylate (Z )-6c.
O 1H NM R [400 M Hz, 5 (ppm), CDCls]: 7.42 (s, 1 iH, 3-CH), 7.00 (dd; J = 8.0, 
O,N^ A .
* 1 OMe 2.0 Hz; 1 1H, 6'-CH), 6.87 (d, J = 2.0 Hz, 1 1H, 4'-CH), 6.84 (d, J = 8.0 Hz, 1
/-\ 3'a 5' -J 3
1H, 7'-CH), 6.04 (s, 2 1H, 2'-CH2), 3.90 (s, 3 1H, OCH3). 13C NM R [75 MHz,
O - t S ^ 6' 5 (ppm), CDCla]: 160.9 (CO2), 151.5 (7'a-C), 149.0 (3'a-C), 138.2 (2-C), 133.1
(3-C), 127.7 (6'-C), 122.92 (5'-C), 109.2 (7'-C), 108.3 (4'-C), 102.3 (2'-C), 53.5 (OCH3).
M ethyl (E)-3-(1,3-benzodioxol-5-yl)-2-nitroacrylate (E)-6c.
O 1H NM R [400 MHz, 5 (ppm), C D O 3]: 8.00 (s, 1 1H, 3-CH), 7.09 (dd; J = 8.0,
O2N
2.0 Hz; 1 1H, 6'-CH), 6.94 (d, J = 2.0 Hz, 1 1H, 4'-CH), 6.88 (d, J = 8.0 Hz, 1 1H,
O-^ 2' 7'-CH), 6.07 (s, 2 1H, 2'-CH2), 3.98 (s, 3 1H, OCH3). 13C NM R [75 M Hz, 5 
, ™~0  (ppm), CDCl3]: 162.2 (CO2), 151.9 (7'a-C), 148.9 (3'a-C), 140.0 (2-C), 137.1 (3- 
C), 128.7 (6'-C), 122.91 (5'-C), 109.3 (7'-C), 108.8 (4'-C), 102.4 (2'-C), 53.8 (OCH3).
M ethyl (Z)-3-(1-methyl-1H-indol-3-yl)-2-nitroacrylate (Z)-6e.
0  According to the general procedure, the reaction of methyl 2-nitroacetate 7
^ 0Me (3 .5 7  g, 30.0 mmol) w ith  imine 9e (7.7 g, 33.0 mmol) afforded 6e (5.8 g, 74% 
yield) as a bright yellow solid after w ashing the precipitate from the 
MN 2 reaction m ixture w ith  cold (-70 °C) AcOEt. 1H NM R [400 MHz, 5 (ppm),
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C D O 3]: 7.98 (s, 1 1H, 3-CH), 7.79-7.76 (m, 1 1H, 4'-CH), 7.69 (s, 1 1H, 2'-CH), 7.41-7.30 (m, 3 1H, 
5'-CH + 6 '-CH + 7'-CH), 3.92 (s, 3 1H, OCH3), 3.86 (s, 3 1H, NCH3). 13C NM R [75 MHz, 5 (ppm), 
C D O 3]: 161.0 (CO2), 137.0 (7'a-C), 134.7 (2-C), 133.7 (2'-C), 128.4 (3'a-C), 127.0 (3-C), 123.9 (6 '-C),
122.5 (5'-C), 118.4 (4'-C), 110.4 (7'-C), 105.8 (3'-C), 53.1 (OCH3), 34.0 (NCH3). FTIR [ V (cm-1), 
neat]: 3119, 3035, 2955, 1710, 1621, 1523, 1261, 747. HRM S [EI (m /z)] calcd for C13H 12N 2O4 = 
260.0797, found for [M+^] = 260.0806 (| A | = 3.4 ppm), peaks at (relative intensity): 260 (100), 213 
(27), 158 (20), 155 (40), 149 (62), 121 (41). Elem. anal. calcd for C13H 12N 2O4: C 60.00%, H 4.65%, N 
10.76%; found C 60.02%, H 4.84%, N 10.56%. Rf: 0.33 (heptane/A cO Et, 2:1). Mp: 170.2 °C (from 
AcOEt, bright yellow needles). Purity: >99.5% (GC).
M ethyl (E)-3-(1-methyl-1H-indol-3-yl)-2-nitroacrylate (E)-6e.
O (M easured from a 2:1 m ixture of (Z)-6e/(E)-6e) 1H NM R [400 M Hz, 5 (ppm),
°?N.  CDCl3]: 8.51 (s, 1 1H, 3-CH), 7.99 (s, 1 1H, 2'-CH), 7.79-7.75 (m, 1 1H, 4'-CH),
7.41-7.30 (m, 3 1H, 5'-CH + 6'-CH + 7'-CH), 3.98 (s, 3 1H, OCH3), 3.89 (s, 3 1H, 
NCH3). 13C NM R [75 MHz, 5 (ppm), C D Q 3]: 163.5 (CO2), 137.4 (7'a-C), 135.8 
(2'-C), 135.5 (2-C), 131.8 (3-C), 128.9 (3'a-C), 124.1 (6'-C), 122.8 (5'-C), 118.6 (4'- 
C), 110.6 (7'-C), 106.1 (3'-C), 53.3 (OCH3), 34.1 (NCH3).
N
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Procedure for m ethyl 3-(2-furyl)-2-nitroacrylate 6d. A 0.1 M solution of TiCU (133.6 mmol) in 
THF (1.2 L) was prepared by the addition  of a 1.0 M solution of TiCU in CH 2Cl2 at 0 °C, 
followed by the addition of a mixture of m ethyl 2-nitroacetate 7 (8.00 g, 66.8 mmol) and 
furaldehyde 8d (9.62 g, 100.2 mmol) in THF (130 mL) at 0 °C. A 1.0 M solution of 4- 
m ethylm orpholine (27.10 g, 267.5 mmol) in  THF (235 mL) was then added  by syringe over 2 h  at
0 °C. The reaction m ixture was stirred at room  tem perature for 24 h. W ater (800 mL) was then 
added  and the solution w as extracted w ith  Et2O (3 x 800 mL). The combined organic layers 
were dried (MgSO4), filtered, and concentrated in  vacuo. The brow n solid residue was purified 
by recrystallization from M eOH to afford pure (Z)-6d (5.23 g, 40% yield) as light brow n crystals. 
The filtrate was concentrated under reduce pressure and purified by colum n chrom atography 
(heptane/A cO Et, 3:1) to afford a 1.7:1 mixture of (Z)-6d/(E)-6d (6.21 g, 47% yield) as a dark 
brow n solid. Total yield 87%.
M ethyl (Z)-3-(2-furyl)-2-nitroacrylate (Z)-6d.
O 1H NM R [400 MHz, 5 (ppm), C D Q 3]: 7.62 (d, J = 1.8 Hz, 1 1H, 5'-CH), 7.37 (s, 
OMe 1 1H, 3-CH), 6.94 (d, J = 3.5 Hz, 1 1H, 3'-CH), 6.57 (dd; J = 3.5, 1.8 Hz; 1 1H, 4'- 
CH), 3.90 (s, 3 1H, OCH3). 13C NM R [75 MHz, 5 (ppm), C D Q 3]: 160.0 (CO2),
148.2 (5'-C), 145.5 (2'-C), 136.2 (2-C), 121.0 (3'-C), 120.0 (3-C), 113.4 (4'-C), 53.6 
(OCH3). FTIR [ V (cm-1), neat]: 3131, 3059, 2957, 1721, 1642, 1535, 1263, 1210, 747. HRM S [EI 
(m /z)] calcd for C8H 7NOs = 197.0324, found for [M+^] = 197.0324 ( | A|  = 0.0 ppm), peaks at 
(relative intensity): 197 (14), 122 (15), 96 (28), 92 (25), 83 (100), 63 (34). Elem. anal. calcd for 
C8H 7NO 5: C 48.74%, H 3.58%, N 7.10%; found C 48.84%, H 3.58%, N 7.11%. Rf: 0.40 
(heptane/A cO Et, 2:1). Mp: 84.6 °C (from MeOH, light brow n crystals). Purity: >99.5% (GC).
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M ethyl (E)-3-(2-furyl)-2-nitroacrylate (E)-6 d.
O (M easured from a 1.7:1 mixture of (Z)-6 d /(E )-6 d) *H NM R [400 MHz, 5 (ppm),
° 2lN ^ '- f '0Me CDCI3]: 7.87 (s, 1 !H, 3-CH), 7.66 (d, J = 1.8 Hz, 1 iH, 5'-CH), 7.07 (d, J = 3.5 Hz, 1
3' ----  - - -  - - - - -  - ~~ - - 1H1H, 3-CH), 6.62 (dd; J = 3.5, 1.8 Hz; 1 1H, 4'-CH), 4.00 (s, 3 1H, OCH3). 13C NM R 
[75 MHz, 5 (ppm), CDCI3]: 161.4 (CO2), 148.7 (5'-C), 145.4 (2'-C), 138.6 (2-C), 122.9 
(3-C + 3'-C), 113.9 (4'-C), 53.6 (OCH3).
G eneral Procedure for 1,3-Dipolar C ycloaddition Reaction. A round-bottom ed flask fitted 
w ith  a D ean-Stark apparatus, a reflux condenser, and a drying tube containing calcium chloride 
was charged w ith  2-nitroacrylate 6 , MgSO4 (0.5 equiv), and toluene (0.20-0.25 M). W hen the 
mixture was under reflux, sarcosine (N-methylglycine; 1.2 equiv) and paraform aldehyde (3.6 
equiv) were added. This addition w as repeated every 40 m in until the substrate had completely 
reacted. W ater (20 mL) was then added  and the layers were separated. The aqueous layer was 
extracted w ith  Et2O (3 x 30 mL) and the com bined organic layers were dried (MgSO4), filtered, 
and concentrated in  vacuo.
C om pounds (±)-4a and  (±)-5a.
According to the general procedure, 2-nitroacrylate 6 a (2.51 g, 12.1 mmol) afforded (±)-4a (1.38 
g, 43%) as a colorless oil and (±)-5a (1.50 g, 47%) as a yellow oil after colum n chrom atography 
(heptane/ AcOEt, 3:1^2:1).
(±)-M ethyl (3R,4R)-1-m ethyl-3-m tro-4-phenylpyrrolidine-3-carboxylate 4a.
2 C°2Me 1H NM R [300 MHz, 5 (ppm), CDCls]: 7.34-7.21 (m, 5 1H, Ph), 4.49 (dd(3), J = 
MeN^ f " N°22 7.5 Hz, 1 1H, 4-CH), 3.83 (s, 3 1H, OCH3), 3.78 (d, J = 11.7 Hz, 1 1H, 2-CHH), 
5 4 3.26 (d, J = 11.7 Hz, 1 1H, 2-CHH), 3.10 (dd; J = 9.4, 7.2 Hz; 1 1H, 5-CHH), 3.06
(±) 6 (dd; J = 9.4, 7.8 Hz; 1 1H, 5-CHH), 2.48 (s, 3 1H, NCH3). 13C NM R [75 MHz, 5
(ppm), CDCla]: 164.5 (CO2), 136.0 (1'-C), 128.6 (2'-C + 6 '-C)*, 128.4 (3'-C + 5'-C)*, 128.2 (4'-C), 101.1 
(3-C), 63.5 (2-C), 61.1 (5-C), 54.0 (OCH3), 51.5 (4-C), 41.8 (NCH3). FTIR [ V (cm-1), neat]: 2954, 
2845, 2792, 1755, 1552, 1450, 1247, 754, 698. MS [ESI (m /z)] calcd for (C13H 16N 2O4 + H)+ = 265, 
found 265. Rf: 0.23 (heptane/A cO Et, 1:1). Purity: 98.5% (GC).
(±)-Methyl (3R,4S)-1-m ethyl-3-nitro-4-phenylpyrrolidine-3-carboxylate 5a.
2 C°2Me 1H NM R [300 MHz, 5 (ppm), C D Q 3]: 7.34-7.19 (m, 5 1H, Ph), 4.72 (dd(3), J =
8.1 Hz, 1 1H, 4-CH), 3.65 (d, J = 11.4 Hz, 1 1H, 2-CHH), 3.52 (d, J = 11.4 Hz, 1 
3' 1H, 2-CHH), 3.31 (dd(3), J = 8.4 Hz, 1 1H, 5-CHH), 3.16 (s, 3 1H, OCH3), 2.80
4'
(±) 5 ' (dd(3), J = 9.0 Hz, 1 1H, 5-CHH), 2.43 (s, 3 1H, NCH 3). 13C NM R [75 MHz, 5 
(ppm), CDCl3]: 164.8 (CO2), 136.2 (1'-C), 129.0 (2'-C + 6'-C)*, 128.2 (3'-C + 5'-C)*, 127.8 (4'-C), 102.9 
(3-C), 64.9 (2-C), 61.7 (5-C), 53.0 (CO2CH3), 51.4 (4-C), 41.5 (NCH3). FTIR [ V (cm-1), neat]: 2950, 
2837, 2788, 1750, 1554, 1450, 1243, 754, 699. MS [ESI (m /z)] calcd for (C13H 16N 2O4 + H)+ = 265, 
found 265. Rf: 0.54 (heptane/A cO Et, 1:1). Purity: 98.7% (GC).
76
Synthesis o f 3-Amino-4-arylpyrrolidine-3-carboxylates
Compounds (±)-4b, (±)-5b, and (±)-12b.
According to the general procedure, 2-nitroacrylate 6 b (9.99 g, 37.4 mmol) afforded (±)-4b (4.85 
g, 40%) as a yellow oil, (±)-5b (5.33 g, 44%) as a yellow solid, and traces of (±)-12b after column 
chromatography (heptane/ AcOEt, 3:1^2:1).
(±)-Methyl (3R,4R)-4-(3,5-dimethoxyphenyl)-1-methyl-3-nitropyrrolidine-3-carboxylate 4b.
C° ,Me 1H NMR [400 MHz, 5 (ppm), CDCla]: 6.51 (d, J = 2.3 Hz, 2 1H, 2'-CH + 6 '-
2 3f
M e^ " ' NC)2 CH), 6.36 (t, J = 2.3 Hz, 1 1H, 4'-CH), 4.42 (dd(3), J = 7.4 Hz, 1 1H, 4-CH),
W-k i>4x3v°Me5 4 ''i f 3.85 (s, 3 1H, CO2CH3), 3.77 (d, J = 11.6 Hz, 1 1H, 2-CHH), 3.75 (s, 6  1H, 2 x
6'  ^ sCs4'(±) OCH3), 3.26 (d, J = 11.6 Hz, 1 1H, 2-CHH), 3.08 (dd; J = 9.4, 6.9 Hz; 1 1H, 5-
° Me CHH), 3.02 (dd; J = 9.4, 7.9 Hz; 1 1H, 5-CHH), 2.47 (s, 3 1H, NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDQ3]: 166.7 (CO2), 160.5 (3'-C + 5'-C), 138.4 (1'-C), 107.0 (2'-C + 6'-C),
100.9 (3-C), 99.9 _(4'-C), 63.3 (2-C), 61.0 (5-C), 55.2 (2 x OCH3), 53.8 (CO2CH3), 51.4 (4-C), 41.4 
(NCH3). FTIR [ V (cm-1), neat]: 2951, 2838, 2792, 1752, 1594, 1552, 1458, 1431, 1202, 1154, 1067, 
845. HRMS [EI (m/z)] calcd for C15H20N2O6 = 324.1321, found for [M+-] = 324.1314 (|A | = 2.3 
ppm), peaks at (relative intensity): 324 (13), 278 (100), 246 (73), 235 (57), 218 (49), 175 (91). Rf: 
0.17 (heptane/AcOEt, 1:1). Purity: 98.1% (GC).
(±)-Methyl (3R,4S)-4-(3,5-dimethoxyphenyl)-1-methyl-3-nitropyrrolidine-3-carboxylate 5b.
2 C° sMe 1H NMR [400 MHz, 5 (ppm), CDO3]: 6.49 (d, J = 2.4 Hz, 2 1H, 2'-CH + 6'-
MeN^ T  '"N°2? CH), 6.36 (t, J = 2.4 Hz, 1 1H, 4'-CH), 4.65 (dd; J = 8.6, 7.6 Hz; 1 1H, 4-CH),
5 4 II 1 3.77 (s, 6 1H, 2 x OCH3), 3.66 (d, J = 11.6 Hz, 1 1H, 2-CHH), 3.51 (d, J = 11.6
6'^ X^ 4'
(±) i f  Hz, 1 1H, 2-CHH), 3.31 (dd; J = 9.2, 7.6 Hz; 1 1H, 5-CHH), 3.30 (s, 3 1H,
° Me CO2CH3), 2.75 (dd(3), J = 9.1 Hz, 1 1H, 5-CHH), 2.42 (s, 3 1H, NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDCb]: 165.2 (CO2), 160.7 (3'-C + 5'-C), 138.7 (1'-C), 107.2 (2'-C + 6'-C),
102.9 (3-C), 99.8 _(4'-C), 64.8 (2-C), 61.6 (5-C), 55.4 (2 x OCH3), 53.1 (CO2CH3), 51.4 (4-C), 41.3 
(NCH3). FTIR [ V (cm-1), neat]: 2950, 2839, 2793, 1749, 1594, 1554, 1457, 1431, 1203, 1155, 1061, 
841. HRMS [EI (m/z)] calcd for C15H20N2O6 = 324.1321, found for [M+-] = 324.1309 (|A | = 3.8 
ppm), peaks at (relative intensity): 324 (5), 278 (99), 246 (100), 235 (72), 218 (34), 175 (99). Rf: 0.42 
(heptane/AcOEt, 1:1). Mp: 84.4 °C (from hexane, small white needles). Purity: 98.9% (GC).
(±)-(3R,4S)-3-(3,5-Dimethoxyphenyl)-1-methyl-4-nitropyrrolidine 12b.
^ ^ n o 2 (Measured from a 31:1 mixture of (±)-4b/(±)-12b) 1H NMR [400 MHz, 5
MeV - l  3>°Me (ppm), CDCl3]: 6.43 (d, J = 2.4 Hz, 2 1H, 2'-CH + 6'-CH), 6.36 (t, J = 2.4 Hz,
2 3 'ilJ  1 1H, 4'-CH), 4.93 (ddd; J = 7.8, 5.2, 3.9 Hz; 1 1H, 4-CH), 3.97 (dt; J = 5.2, 7.9
(±) 5T° Me Hz; 1 1H, 3-CH), 3.80 (s, 6 1H, 2 x OCH3), 3.39 (dd; J = 11.0, 3.9 Hz; 1 1H, 5- 
CHH), 3.27 (m, 1 1H, 2-CHH), 2.96 (dd; J = 11.0, 7.8 Hz; 1 1H, 5-CHH), 2.56 (dd; J = 9.4, 7.9 Hz; 1 
1H, 2-CHH), 2.40 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDO3]: 161.2 (3'-C + 5'-C), 142.7 
(1'-C), 105.6 (2'-C + 6'-C), 98.9 (4'-C), 91.4 (4-C), 62.9 (5-C)*, 60.6 (2-C)*, 55.3 (2 x OCH3), 50.1 (3-C),
41.4 (NCH3).
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Compounds (±)-4c and (±)-5c.
According to the general procedure, 2-nitroacrylate 6 c (10.05 g, 40.0 mmol) afforded (±)-4c (4.92 
g, 40%) as a colorless oil and (±)-5c (5.52 g, 45%) as a yellow oil after column chromatography 
(heptane/ AcOEt, 3:1^2:1).
(±)-Methyl (3R,4R)-4-(1,3-benzodioxol-5-yl)-1-methyl-3-mtropyrrolidme-3-carboxylate 4c.
2 3C°2Me iH NMR [400 MHz, 5 (ppm), CDCls]: 6 .8 8  (d, J  = 1.8 Hz, 1 !H, 4'-CH), 6.80
M eNW  ' 'N042 (ddd; J  = 8.0, 1.9, 0.4 Hz; 1 !H, 6 ’-CH), 6.69 (d, J  = 8.0 Hz, 1 !H, 7'-CH), 5.90
5 y I >2' (s, 2 !H, 2 '-CH2), 4.41 (dd(3), J  = 7.3 Hz, 1 iH, 4-CH), 3.83 (s, 3 iH, OCH3), 
(±) 7' 7'a 0  3 . 7 7  (d, J  = 11.8 Hz, 1 1H, 2-CHH), 3.21 (d, J  = 11.8 Hz, 1 1H, 2-CHH), 3.04 
(dd; J  = 9.4, 6.9 Hz; 1 1H, 5-CHH), 2.99 (dd; J  = 9.4, 7.6 Hz; 1 1H, 5-CHH), 2.45 (s, 3 1H, NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDCla]: 166.7 (CO2), 147.6 (3'a-C), 147.5 (7'a-C), 129.7 (5'-C), 122.4 (6 '-C),
109.1 (4'-C), 108.1 (7'-C), 101.2 (2'-C), 101.0 (3-C), 63.2 (2-C), 61.1 (5-C), 53.8 (OCH3), 51.1 (4-C),
41.5 (NCH3). FTIR [ V (cm-1), neat]: 2966, 2878, 2782, 1753, 1552, 1504, 1486, 1237, 1037, 930, 730. 
HRMS [EI (m /z)] calcd for C14H16N 2O6 = 308.1008, found for [M+-] = 308.1002 (| A | = 2.1 ppm), 
peaks at (relative intensity): 308 (16), 262 (71), 219 (83), 202 (29), 189 (74), 159 (43), 31 (100). Rf: 
0.22 (heptane/AcOEt, 1:1). Purity: 98.4% (GC).
(±)-Methyl (3R,4S)-4-(1,3-benzodioxol-5-yl)-1-methyl-3-nitropyrrolidine-3-carboxylate 5c.
2 3C°2Me 1H NMR [400 MHz, 5 (ppm), CDCla]: 6 .8 8  (d, J  = 1.7 Hz, 1 1H, 4'-CH), 6.82
MeN T "N042 (dd; J  = 8.0, 1.7 Hz; 1 1H, 6 '-CH), 6.73 (d, J  = 8.0 Hz, 1 1H, 7'-CH), 5.94 (s, 2
5 1  | >2' 1H, 2 '-CH2), 4.64 (dd(3), J  = 8.1 Hz, 1 1H, 4-CH), 3.62 (d, J  = 11.4 Hz, 1 1H, 
(±) T  7'a 0  2-CHH), 3.53 (d, J  = 11.4 Hz, 1 1H, 2-CHH), 3.33 (s, 3 1H, OCH3), 3.28 (dd; J  
= 9.3, 7.6 Hz; 1 1H, 5-CHH), 2.74 (dd(3), J  = 9.0 Hz, 1 1H, 5-CHH), 2.42 (s, 3 1H, NCH3). 13C NMR 
[75 MHz, 5 (ppm), CDCla]: 165.3 (CO2), 147.7 (3'a-C), 147.3 (7'a-C), 130.0 (5'-C), 122.7 (6 '-C), 109.6 
(4'-C), 108.1 (7'-C), 102.8 (3-C), 101.3 (2'-C), 64.8 (2-C), 61.8 (5-C), 53.2 (OCH3), 51.2 (4-C), 41.4 
(NCH3). FTIR [ V (cm-1), neat]: 2951, 2844, 2789, 1748, 1555, 1504, 1488, 1251, 1237, 1038, 930. 
HRMS [EI (m /z)] calcd for C14H16N 2O6 = 308.1008, found for [M+-] = 308.1001 (| A | = 2.4 ppm), 
peaks at (relative intensity): 308 (10), 262 (8 6 ), 219 (100), 202 (33), 189 (83), 159 (51). Rf: 0.48 
(heptane/AcOEt, 1:1). Purity: 98.5% (GC).
Compounds (±)-4d, (±)-5d, and (±)-12d.
According to the general procedure, 2-nitroacrylate 6 d (8.00 g, 40.6 mmol) afforded (±)-4d (4.02 
g, 39%) as a yellow oil, (±)-5d (4.44 g, 43%) as a yellow oil, and traces of (±)-12d after column 
chromatography (heptane/ AcOEt, 3:1^2:1).
(±)-Methyl (3R,4R)-4-(2-furyl)-1-methyl-3-nitropyrrolidine-3-carboxylate 4d.
C°2Me 1H NMR [400 MHz, 5 (ppm), CDCfe]: 7.33 (dd; J  = 1.9, 0.9 Hz; 1 1H, 5'-CH), 6.29
MeN^ J  " N° 32 (dd; J  = 3.4, 1.9 Hz; 1 1H, 4'-CH), 6.26 (bd, J  = 3.2 Hz, 1 1H, 3'-CH), 4.61 (dd; J  =
5 4""f^V  8.9, 7.3 Hz; 1 1H, 4-CH), 3.86 (s, 3 1H, OCH3), 3.66 (d, J  = 11.4 Hz, 1 1H, 2-CHH), 
O^v
(±) * 3.42 (d, J  = 11.4 Hz, 1 1H, 2-CHH), 3.21 (dd; J  = 9.2, 7.3 Hz; 1 1H, 5-CHH), 2.98 
(dd(3), J  = 9.1 Hz, 1 1H, 5-CHH), 2.47 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDQ 3]: 166.3 
(CO2), 149.2 (2'-C), 143.0 (5'-C), 110.6 (4'-C), 109.2 (3'-C), 98.9 (3-C), 62.7 (2-C), 59.1 (5-C), 54.0
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(OCH3), 45.5 (4-C), 41.6 (NCH3). FTIR [ V (cm-1), neat]: 2953, 2845, 2796, 1754, 1554, 1254, 1010, 
743. HRM S [EI (m /z)] not found for [M+-], calcd for (CuHmNOs^ = 208.0974, found 208.0977 
(| A | = 1.9 ppm); [CI (m /z)] calcd for (C11H 14N 2O5 + H)+ = 255.0981, found 255.0981 (| A | = 0.0 
ppm ). Rf: 0.19 (heptane/A cO Et, 1:1). Purity: 98.9% (GC).
(±)-M ethyl (3R,4S)-4-(2-furyl)-1-methyl-3-nitropyrrolidine-3-carboxylate 5d.
2 CO2Me !H NM R [400 MHz, 5 (ppm), CDCI3]: 7.36 (dd; J = 1.8, 0.8 Hz; 1 1H, 5'-CH), 6.32
Me^ A L " N° 32 (dd; J = 3.2, 1.9 Hz; 1 1H, 4'-CH), 6.26 (d, J = 3.2 Hz, 1 1H, 3'-CH), 4.84 (dd(3), J =
^ T ^ V '  8.4 Hz, 1 1H, 4-CH), 3.74 (d, J = 11.2 Hz, 1 1H, 2-CHH), 3.48 (s, 3 1H, OCH3), 3.39 
O^y
(±) * (d, J = 11.2 Hz, 1 1H, 2-CHH), 3.41-3.35 (m, 1 1H, 5-CHH), 2.73 (dd(3), J = 9.2 
Hz, 1 1H, 5-CHH), 2.41 (s, 3 1H, NCH3). 13C NM R [75 M Hz, 5 (ppm), CDCI3]: 164.9 (CO2), 149.9 
(2'-C), 142.7 (5'-C), 110.7 (4'-C), 109.0 (3'-C), 101.1 (3-C), 64.1 (2-C), 59.4 (5-C), 53.6 (OCH3), 45.3 (4- 
C), 41.2 (NCH3). FTIR [ V (cm-1), neat]: 2953, 2845, 2794, 1750, 1558, 1258, 1011, 741. HRM S [EI 
(m /z)] not found for [M+^], calcd for (CnHi4NO3)+ = 208.0974, found 208.0978 (| A | = 2.1 ppm); 
[CI (m /z)] calcd for (C11H 14N 2O5 + H)+ = 255.0981, found 255.0981 ( | A|  = 0.0 ppm ). Rf: 0.49 
(heptane/A cO Et, 1:1). Purity: >99.5% (GC).
(±)-(3R,4S)-3-(2-Furyl)-1-methyl-4-nitropyrrolidine 12d.
5 ^ N O 2 (M easured from a 32:1 m ixture of (±)-4d/(±)-12d) aH NM R [400 MHz, 5 
MeN I (ppm ) CDCIo]: 7 36 (d d  J = 1 9 0 9 H z  1 1(pp ), l3]: 7.36 (dd; J  1.9, 0.9 z; 1 1H, 5'-CH), 6.32 (dd; J = 3.2, 1.9 Hz; 1
2
O > 4' 1H, 4'-CH), 6.19 (d, J = 3.2 Hz, 1 1H, 3'-CH), 5.00 (ddd(7); J = 7.6, 4.8, 3.0 Hz; 1 
(±) 5' 1H, 4-CH), 4.17 (ddd(6); J = 8.0, 8.0, 4.8 Hz; 1 1H, 3-CH), 3.45 (dd; J = 11.1, 3.2 
Hz; 1 1H, 5-CHH), 3.28 (dd(3), J = 8.5 Hz, 1 1H, 2-CHH), 2.90 (dd; J = 11.1, 7.6 Hz; 1 1H, 5-CHH), 
2.57 (dd(3), J = 8.7 Hz, 1 1H, 2-CHH), 2.41 (s, 3 1H, NCH3). 13C NM R [75 MHz, 5 (ppm), CDCfe]:
152.5 (2'-C), 142.4 (5'-C), 110.5 (4'-C), 106.7 (3'-C), 88.9 (4-C), 60.3 (2-C + 5-C), 43.3 (3-C), 41.4 
(NCH3).
C om pounds (±)-4e and  (±)-5e.
According to the general procedure, 2-nitroacrylate 6e (9.01 g, 34.6 mmol) afforded (±)-4e (4.17 
g, 38%) as a yellow solid and (±)-5e (4.83 g, 44%) as a light yellow solid after colum n 
chrom atography (heptane/ AcOEt, 3:1^2:1).
(±)-M ethyl (3R,4R)-1-methyl-4-(1-methyl-1H-mdol-3-yl)-3-mtropyrrolidme-3-carboxylate 4e.
2 CO2Me *H NM R [400 MHz, 5 (ppm), CDCfe]: 7.82 (ddd(6); J = 7.9, 1.0, 1.0 Hz; 1 1H,
Me^A r" NO2/4=\5' 4'-CH), 7.23 (ddd; J = 8.2, 1.5, 0.8 Hz; 1 1H, 7'-CH), 7.20 (ddd(7); J = 8.2, 6.5,
3'iy \ b'4 'r— \\ /) 1 9  H ? ' 1 1W a . r m  7 1^ (Vlrlrl<'7V T = 7 Q  R 1 R  H ? '  1 15 ' 11 \ _ V  1.2 z; 1 1H, 6'-CH), 7.13 (ddd(7); J = 7.9, 6.5, 1.5 z; 1 1H, 5'-CH), 6.95 (s, 1
(± r 'N 7'a 7' 1H, 2'-CH), 4.88 (dd; J = 9.2, 6.9 Hz; 1 1H, 4-CH), 3.82 (s, 3 1H, OCH3), 3.77 
Me
(d, J = 11.7 Hz, 1 1H, 2-CHH), 3.68 (s, 3 1H, 1'-NCH3), 3.44 (d, J = 11.7 Hz, 1 
1H, 2-CHH), 3.18 (dd; J = 9.2, 6.9 Hz; 1 1H, 5-CHH), 2.98 (t, J = 9.2 Hz, 1 1H, 5-CHH), 2.49 (s, 3 1H,
1 -NCH3). 13C NM R [75 MHz, 5 (ppm), CDCb]: 167.0 (CO2), 136.6 (7'a-C), 128.1 (3'a-C), 127.5 (2'- 
C), 122.0 (6'-C), 119.6 (5'-C), 119.5 (4'-C), 109.3 (7'-C), 109.0 (3'-C), 101.2 (3-C), 63.6 (2-C), 61.9 (5- 
C), 53.8 (OCH3), 43.9 (4-C), 41.7 (1 -NCH3), 32.9 (1'-NCH3). FTIR [ V (cm-1), neat]: 3049, 2948, 
2844, 2790, 1752, 1548, 1473, 1251, 740. HRM S [EI (m /z)] calcd for C16H 19N 3O4 = 317.1376, found
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for [M+^] = 317.1386 (| A| = 3.2 ppm ), peaks at (relative intensity): 317 (16), 271 (18), 228 (100), 
168 (22). Elem. anal. calcd for C16H 19N 3O4: C 60.56%, H 6.03%, N 13.24%; found C 60.74%, H 
6.06%, N 13.30%. Rf: 0.16 (heptane/A cO Et, 1:1). Mp: 117.8 °C (from MeOH, light yellow 
crystals). Purity: >99.5% (GC).
(±)-Methyl (3R,4S)-1-methyl-4-(1-methyl-1H-indol-3-yl)-3-mtropyrrolidme-3-carboxylate 5e.
!H NM R [400 MHz, 5 (ppm), CDCb]: 7.76 (bd, J = 7.9 Hz, 1 1H, 4'-CH), 7.25 
(bd, J = 8.4 Hz, 1 1H, 7'-CH), 7.20 (dd(3), J = 7.5 Hz, 1 1H, 6'-CH), 7.13-7.09 
6' (m, 1 1H, 5'-CH), 7.00 (s, 1 1H, 2'-CH), 5.12 (dd(3), J = 8.0 Hz, 1 1H, 4-CH),
3.73 (s, 3 1H, 1'-NCH3), 3.67 (d, J = 11.6 Hz, 1 1H, 2-CHH), 3.55 (d, J = 11.6 
Hz, 1 1H, 2-CH H), 3.38 (dd(3), J = 8.3 Hz, 1 1H, 5-CHH ), 2.94 (s, 3 1H, 
OCH3), 2.77 (dd(3), J = 8.9 Hz, 1 1H, 5-CHH), 2.44 (s, 3 1H, 1 -NCH3). 13C NM R [75 MHz, 5 (ppm), 
CDCfe]: 165.5 (CO2), 136.7 (7'a-C), 128.1 (2'-C), 127.6 (3'a-C), 122.1 (6'-C), 119.9 (5'-C), 119.5 (4'-C),
109.7 (3'-C), 109.2 (7'-C), 102.9 (3-C), 64.6 (2-C), 62.2 (5-C), 52.5 (OCH3), 43.0 (4-C), 41.4 (1 -NCH3),
32.9 (1'-NCH3). FTIR [ V (cm-1), neat]: 3049, 2947, 2841, 2791, 1749, 1552, 1473, 1254, 742. HRMS 
[EI (m /z)] calcd for C16H 19N 3O4 = 317.1376, found for [M+^] = 317.1384 (| A| = 2.8 ppm), peaks 
at (relative intensity): 317 (11), 271 (7), 228 (100), 168 (20). Rf: 0.34 (heptane/A cO Et, 1:1). Mp:
110.0 °C. Purity: 99.0% (GC).
G eneral Procedure for Reduction. A n excess (7-8 heaped teaspoons) of freshly w ashed (with 
MeOH) Raney nickel was added  to a solution of a-nitro ester w ith  Et3N (ca. 1 equiv) in MeOH 
(0.25-0.30 M). The m ixture was stirred for 8 h  at room tem perature under a hydrogen 
atm osphere (1 atm). The catalyst w as separated by filtration w ith  suction through a glass filter 
w ith  a 0.5 cm layer of diatom aceous earth. The catalyst was w ashed thoroughly w ith  MeOH. 
The combined methanolic solutions were concentrated on a rotary evaporator.
C om pounds (±)-2a and  (±)-20a. According to the general procedure, a-nitro ester (±)-4a (1.03 
g, 3.9 mmol) afforded (±)-2a (731 mg, 80%) as a light yellow oil and (±)-20a (34 mg, 4%) as a 
yellow oil, after colum n chrom atography (CH2Cl2/M eO H , 9:1).
(±)-M ethyl (3R,4R)-3-am ino-1-m ethyl-4-phenylpyrrolidine-3-carboxylate 2a.
2 rCO2Me !H NM R [400 MHz, 5 (ppm), CDCh]: 7.34-7.18 (m, 5 1H, Ph), 3.89 (t, J = 8.3 
M eN ^ f '"NH22 Hz, 1 1H, 4-CH), 3.79 (s, 3 1H, OCH3), 3.42 (d, J = 9.8 Hz, 1 1H, 2-CHH), 3.09 (d,
5 4 C ^ 3' J = 8.3 Hz, 2 1H, 5 -CH2), 2.57 (d, J = 9.8 Hz, 1 1H, 2-CHH), 2.47 (s, 3 1H, NCH3), 
(±) 5' 1.75 (bs, 2 1H, NH 2). 13C NM R [75 MHz, 5 (ppm), CDCh]: 176.3 (CO2), 136.8 
(1'-C), 129.1 (2'-C + 6'-C)*, 128.6 (3'-C + 5'-C)*, 127.5 (4'-C), 68.2 (2-C), 66.5 (3-C), 59.8 (5-C), 53.3 
(4-C), 52.8 (OCH3), 42.5 (NCH3). FTIR [ V (cm-1), neat]: 3372, 3298, 2949, 2842, 2790, 1730, 1453, 
1224, 770, 702. MS [ESI (m /z)] calcd for (C13H 18N 2O2 + H)+ = 235, found 235. Rf: 0.34 
(CH2Cl2/M eO H , 8:1). Purity: 97.8% (GC).
C O 2 M e
MeN
(±)
Me
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(±)-Methyl (3R,4S)-1-methyl-4-phenylpyrrolidme-3-carboxylate 20a.
2 3 ,,CO2Me NMR [400 MHz, 5 (ppm), CDCI3]: 7.33-7.27 (m, 4 1H, 2'-CH + 3'-CH + 5'- 
MeN. ' 2' CH + 6 '-CH), 7.24-7.19 (m, 1 1H, 4'-CH), 3.70 (dt; J = 8.1, 7.0 Hz; 1 1H, 4-CH), 
5 X  _J4' 3.68 (s, 3 1H, OCH3), 3.10 (ddd(4), J = 7.2 Hz, 1 1H, 3-CH), 3.04 (dd; J = 9.4, 8.1 
(±) 5' Hz; 1 1H, 5-CHH), 2.96-2.92 (m, 2 1H, 2 -CH2), 2.64 (dd; J = 9.4, 7.0 Hz; 1 1H, 5- 
CHH), 2.40 (s, 3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 174.8 (CO2), 143.9 (1'-C), 128.7 
(3'-C + 5'-C)*, 127.5 (2'-C + 6'-C)*, 126.7 (4'-C), 64.3 (5-C), 59.9 (2-C), 52.2 (3-C), 52.1 (OCH3), 47.8 
(4-C), 42.1 (NCH3). FTIR [V (cm-1), neat]: 2948, 2840, 2789, 1734, 1227, 764, 698. HRMS [EI 
(m/z)] calcd for C13H17NO2 = 219.12593, found for [M+-] = 219.12605 (| A | = 0.55 ppm). Rf: 0.48 
(CH2Cl2/MeOH, 8:1).
Compounds (±)-2b, (±)-20b, (±)-21b, (±)-22b, and 23b. According to the general procedure, a- 
nitro ester (±)-4b (3.84 g, 11.8 mmol) afforded (±)-2b (2.75 g, 79%) as a colorless oil, (±)-20b (99 
mg, 3%) as a yellow oil, (±)-21b (31 mg, 1%) as a yellow oil, (±)-22b (9 mg, 0.3%) as a brown oil, 
and traces of 23b after column chromatography (CH2Cl2/MeOH, 9:1).
M e v J “ 2
(±)-Methyl (3R,4R)-3-ammo-4-(3,5-dimethoxyphenyl)-1-methylpyrrolidme-3-carboxylate 2b.
C°2Me ih  NMR [400 MHz, 5 (ppm), CDQ3]: 6.36 (s, 3 !H, 2'-CH + 4'-CH + 6'-
NHp
2 .' OMe CH), 3.84 (t, J = 8.3 Hz, 1 ^ ,  4-CH), 3.79 (s, 3 ^ ,  CO2CH3), 3.77 (s, 6 ^ ,  2 
° Í  T  X OCH3), 3.37 (d, J = 9.8 Hz, 1 !H, 2-CHH), 3.04 (d, J = 8.3 Hz, 2 !H, 5- 
(±) OMte CH2), 2.54 (d, J = 9.8 Hz, 1 !H, 2-CHH), 2.45 (s, 3 !H, NCH3), 1.52 (bs, 2 !H, 
NH2). 13C NMR [75 MHz, 5 (ppm), CDCb]: 176.3 (CO2), 160.9 (3'-C + 5'-C), 139.5 (1'-C), 107.2 (2'- 
C + 6'-C), 99.1 (4'-C), 68.4 (2-C), 66.6 (3-C), 59.7 (5-C), 55.4 (2 x OCH3), 53.5 (4-C), 52.7 (CO2CH3),
42.4 (NCH3). FTIR [ V (cm-1), neat]: 3375, 3301, 2943, 2836, 2787, 1728, 1594, 1456, 1430, 1203, 
1153, 1063, 838. HRMS [EI (m/z)] calcd for C15H22N2O4 = 294.1580, found for [M+-] = 294.1569 
(|A | = 3.6 ppm), peaks at (relative intensity): 294 (53), 206 (24), 164 (62), 57 (100), 42 (65). RF: 
0.29 (CH2O 2/MeOH, 8:1). Purity: 98.2% (GC).
(±)-Methyl (3R,4S)-4-(3,5-dimethoxyphenyl)-1-methylpyrrolidine-3-carboxylate 20b.
,CO2Me iH NMR [400 MHz, 5 (ppm), CDO3]: 6.48 (d, J = 2.2 Hz, 2 !H, 2'-CH + 6'- 
MeN 1 CH), 6.33 (t, J = 2.2 Hz, 1 !H, 4'-CH), 3.78 (s, 6 !H, 2 x OCH3), 3.69 (s, 3 iH,
CO2CH3), 3.64 (ddd(4), J = 7.4 Hz, 1 1H, 4-CH), 3.10 (ddd(6); J = 8.2, 6.7, 6.7 
OMe Hz; 1 1H, 3-CH), 3.02 (dd; J = 9.3, 8.2 Hz; 1 1H, 5-CHH), 2.95-2.88 (m, 2 1H,
2 -CH2), 2.64 (dd; J = 9.3, 7.1 Hz; 1 1H, 5-CHH), 2.38 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), 
CDCl3]: 161.0 (3'-C + 5'-C), 105.7 (2'-C + 6'-C), 98.5 (4'-C), 64.0 (5-C), 59.8 (2-C), 55.5 (2 x OCH3),
52.2 (CO2CH3), 51.9 (3-C), 48.0 (4-C), 42.1 (NCH3). FTIR [ V (cm-1), neat]: 2948, 2836, 1733, 1606, 
1597, 1205, 1155, 912, 744. GCMS [EI (m/z)] calcd for C15H21NO4 = 279, found for [M+-] = 279. 
Rf: 0.62 (CH2O 2/MeOH, 8:1).
(±)-Methyl (3R,4R)-4-(3,5-dimethoxyphenyl)-1-methylpyrrolidine-3-carboxylate 21b.
(±)
1H NMR [400 MHz, 5 (ppm), CDCfe]: 6.39 (d, J = 2.2 Hz, 2 1H, 2'-CH + 6'- 
V ^ ^ 1iAá>OMe CH), 6.32 (t, J = 2.2 Hz, 1 1H, 4'-CH), 3.77 (s, 6 1H, 2 x OCH3), 3.70 (ddd(6); 
e l  J 4' J = 9.3, 9.3, 7.1 Hz; 1 1H, 4-CH), 3.45 (ddd(6); J = 10.5, 7.6, 7.6 Hz; 1 1H, 3-
OMe CH), 3.26 (s, 3 1H, CO2CH3), 3.22-3.12 (m, 2 1H, 2-CHH + 5-CHH), 2.97(±)
MeN I 2 '
. , , - 3 '
5
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(dd; J = 9.8, 7.3 Hz; 1 iH, 2-CHH), 2.75 (t, J = 9.3 Hz, 1 iH, 5-CHH), 2.51 (s, 3 iH, NCH3). 13C 
NM R [75 MHz, 5 (ppm), CDCI3]: 173.3 (CO2), 160.6 (3'-C + 5'-C), 106.6 (2'-C + 6 '-C), 99.1 (4'-C),
61.8 (5-C), 58.1 (2-C), 55.5 (2 x OCH3), 51.5 (CO2CH3), 49.1 (3-C), 47.8 (4-C), 42.1 (NCH3). FTIR [ V 
(cm-1), neat]: 2935, 2837, 1732, 1606, 1596, 1203, 1155, 911, 744. HRM S [EI (m /z)] calcd for 
Ci5H 2iNO 4 = 279.1471, found for [M+^] = 279.1462 (| A | = 3.1 ppm), peaks at (relative intensity): 
279 (24), 218 (12), 164 (24), 71 (20), 57 (100), 43 (26). Rf: 0.52 (CH2Cl2/M eO H , 8:1).
(±)-M ethyl 4-(3,5-dimethoxyphenyl)-1-m ethyl-4,5-dihydro-1H-pyrrole-3-carboxylate 22b.
^ ^ C O 2Me 1H NM R [400 M Hz, 5 (ppm), CDCI3]: 7.17 (d, J = 0.7 Hz, 1 1H, 2-CH), 6.42 
MeNv- k > - W OMe (d, J = 2.2 Hz, 2 1H, 2'-CH + 6'-CH), 6.31 (t, J = 2.2 Hz, 1 1H, 4'-CH), 4.21 
5 (dd; J = 11.5, 5.1 Hz; 1 1H, 4-CH), 3.78 (dd; J = 11.5, 10.5 Hz; 1 1H, 5-CHH),
(±) 0 Me 3.77 (s, 6 1H, 2 x OCH3), 3.66 (s, 3 1H, CO2CH3), 3.33 (dd; J = 10.5, 5.1 Hz; 1 
1H, 5-CHH), 2.85 (s, 3 1H, NCH3). 13C NM R [75 MHz, 5 (ppm), CDCI3]: 161.0 (3'-C + 5'-C), 153.0 
(2-C), 147.8 (i'-C), 105.4 (2'-C + 6'-C), 104.7 (3-C), 98.4 (4'-C), 63.3 (5-C), 55.4 (2 x OCH3), 50.5 
(CO2CH3), 47.0 (4-C), 37.1 (NCH3). GCM S [EI (m /z)] calcd for C15H 19NO 4 = 277, found for [M+-] 
= 277. Rf: 0.92 (CH2Cl2/M eO H , 8:1).
2
MeN
M ethyl 4-(3,5-dimethoxyphenyl)-1-m ethyl-1H-pyrrole-3-carboxylate 23b.
C02Me (M easured from a 10:1 m ixture of (±)-22b/23b) 1H NM R [400 MHz, 5
0Me (ppm), CDCI3]: 7.30 (d, J = 2.4 Hz, 1 1H, 2-CH), 6.66 (d, J = 2.2 Hz, 2 1H, 2'- 
6' ^ ^ ,  CH + 6'-CH), 6.63 (d, J = 2.4 Hz, 1 1H, 5-CH), 6.40 (t, J = 2.2 Hz, 1 1H, 4'- 
0 Me CH), 3.80 (s, 6 1H, 2 x OCH3), 3.73 (s, 3 1H, CO2CH3), 3.69 (s, 3 1H, NCH3). 
GCM S [EI (m /z)] calcd for C15H 19NO 4 = 275, found for [M+-] = 275. Rf: 0.92 (CH2Cl2/  MeOH, 
8:1).
C om pounds (±)-2c, (±)-20c, and  (±)-22c. According to the general procedure, a-nitro  ester (±)- 
4c (3.00 g, 9.7 mmol) afforded (±)-2c (2.17 g, 80%) as a light brow n solid, (±)-20c (102 mg, 4%) as 
a yellow oil, and (±)-22c (12 mg, 0.5%) as a yellow oil, after colum n chrom atography 
(CH2Cl2/M eO H , 19:1).
(±)-M ethyl (3R,4R)-3-amino-4-(1,3-benzodioxol-5-yl)-1-methylpyrrolidine-3-carboxylate 2c.
2 3C0 2 Me 1H NM R [400 MHz, 5 (ppm), CDCfe]: 6.75 (d, J = 8.0 Hz, 1 1H, 7'-CH), 6.74
MeN T "NH4^  (d, J = 1.5 Hz, 1 1H, 4'-CH), 6.66 (dd; J = 8.0, 1.5 Hz; 1 1H, 6'-CH), 5.94 (d, J
5 \\ I >2' = 1.5 Hz, 1 1H, 2'-CHH), 5.93 (d, J = 1.5 Hz, 1 1H, 2'-CHH), 3.81 (dd(3), J = 
(±) 7' 7'a w 8.3 Hz, 1 1H, 4-CH), 3.78 (s, 3 1H, OCH3), 3.44 (d, J = 10.0 Hz, 1 1H, 2- 
CHH), 3.09 (dd(3), J = 8.4 Hz, 1 1H, 5-CHH), 3.03 (dd(3), J = 9.2 Hz, 1 1H, 5-CHH), 2.59 (d, J =
10.0 Hz, 1 1H, 2-CHH), 2.49 (s, 3 1H, NCH3), 1.88 (bs, 2 1H, N H2). 13C NM R [75 M Hz, 5 (ppm), 
C D O 3]: 176.0 (CO2), 147.9 (3'a-C), 147.0 (7'a-C), 130.2 (5'-C), 122.3 (6'-C), 109.4 (4'-C), 108.3 (7'-C),
101.2 (2'-C), 68.0 (2-C), 66.5 (3-C), 60.0 (5-C), 53.0 (4-C), 52.8 (OCH3), 42.6 (NCH3). FTIR [V 
(cm-1), neat]: 3376, 3317, 2946, 2841, 2785, 1727, 1503, 1489, 1252, 1236, 1036, 929. MS [ESI (m /z)] 
calcd for (C14H 18N 2O4 + H)+ = 279, found 279. Rf: 0.21 (CH2Cl2/M eO H , 8:1). Purity: 97.4% (GC).
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(±)-M ethyl (3R,4S)-4-(1,3-benzodioxol-5-yl)-1-methylpyrrolidine-3-carboxylate 20c.
2 3 ,CO2Me 1H NM R [400 MHz, 5 (ppm), CDCI3]: 6.84 (d, J = 1.6 Hz, 1 !H, 4'-CH), 6.75
M e N ^ Y *  a o (dd; J = 8.0, 1.6 Hz; 1 !H, 6'-CH), 6.72 (d, J = 8.1 Hz, 1 !H, 7'-CH), 5.92 (s, 2
5 ) 2' !H, 2'-CH2), 3.68 (s, 3 !H, OCH3), 3.61 (ddd(4), J = 7.3 Hz, 1 !H, 4-CH),
o
(±) 7' 7'a 3.06-2.85 (m, 4 !H, 2 -CH2 + 3-CH + 5-CHH), 2.62 (dd; J = 9.2, 6.9 Hz; 1 !H,
5-CHH), 2.38 (s, 3 !H, NCH3). 13C NM R [75 MHz, 5 (ppm), CDCI3]: 174.7 (CO2), 147.9 (3'a-C),
146.3 (7'a-C), 137.9 (5'-C), 120.5 (6'-C), 108.3 (7'-C), 107.9 (4'-C), 101.0 (2'-C), 64.3 (5-C), 59.7 (2-C),
52.4 (3-C), 52.1 (OCH3), 47.6 (4-C), 42.1 (NCH3). FTIR [ V (cm-1), neat]: 2948, 2841, 2784, 1243, 
1037, 929. Rf: 0.43 (CH2CI2/M eO H , 8:1).
(±)-Methyl 4-(1,3-benzodioxol-5-yl)-1-methyl-4,5-dihydro-1H-pyrrole-3-carboxylate 22c.
CO2Me 1H NM R [400 MHz, 5 (ppm), CDCI3]: 7.15 (d, J = 0.6 Hz, 1 !H, 2-CH), 6.75- 
MeN 4' 6.70 (m, 3 !H, 4'-CH + 6'-CH + 7'-CH), 5.90 (2d(3), J = 1.6 Hz, 2 !H, 2'-CH2),
6 'V ^ K  4.20 (dd; J = 11.3, 5.1 Hz; 1 !H, 4-CH), 3.76 (dd(3), J = 11.0 Hz, 1 !H, 5-
(±) Y ^ 'a O
CHH), 3.56 (s, 3 !H, CO2CH3), 3.29 (dd; J = 10.6, 5.1 Hz; 1 !H, 5-CHH), 2.85 
(s, 3 !H, NCH3). Rf: 0.91 (CH2C k/M eO H , 8:1).
C om pounds (±)-2d and  (±)-20d. According to the general procedure, a-nitro  ester (±)-4d (3.10 
g, 12.2 mmol) afforded (±)-2d (1.78 g, 65%) as a yellow oil and (±)-20d (51 mg, 2%), as an  orange 
oil, after colum n chrom atography (CH2Cl2/M eO H , 19:1^15:1).
(±)-Methyl (3R,4R)-3-amino-4-(2-furyl)-1-methylpyrrolidine-3-carboxylate 2d.
2 CO2Me 1H NM R [400 MHz, 5 (ppm), C D Q 3]: 7.36 (dd; J = 2.0, 0.7 Hz; 1 !H, 5'-CH), 6.32
MeN^ f  ' lhJH32 (dd; J = 3.2, 2.0 Hz; 1 !H, 4'-CH), 6.18 (dt; J = 3.2, 0.7 Hz; 1 !H, 3'-CH), 3.95 (dd; J
5 4 ' ' y \ a -  = 9.3, 7.8 Hz; 1 !H, 4-CH), 3.80 (s, 3 !H, OCH3), 3.39 (d, J = 9.8 Hz, 1 !H, 2- 
O^v
(±) * CHH), 3.10 (dd; J = 9.3, 7.8 Hz; 1 !H, 5-CHH), 2.95 (t, J = 9.3 Hz, 1 !H, 5-CHH), 
2.48 (d, J = 9.8 Hz, 1 !H, 2-CHH), 2.43 (s, 3 !H, NCH3), 1.59 (bs, 2 !H, NH 2). 13C NM R [75 MHz, 5 
(ppm), CDCl3]: 175.8 (CO2), 151.9 (2'-C), 142.3 (5'-C), 110.3 (4'-C), 108.1 (3'-C), 68.2 (2-C), 66.4 (3- 
C), 58.4 (5-C), 52.8 (OCH3), 47.8 (4-C), 42.3 (NCH3). FTIR [ V (cm-1), neat]: 3379, 3314, 2946, 2838, 
2786, 1728, 1224, 1007, 736. HRM S [EI (m /z)] calcd for C11H 16N 2O3 = 224.1161, found for [M+-] =
224.1150 (| A | = 4.9 ppm ), peaks at (relative intensity): 224 (16), 101 (26), 94 (42), 57 (100), 42 (39). 
Rf: 0.24 (CH2O 2/M eO H , 8:1). Purity: 98.8% (GC).
(±)-M ethyl (3R,4R)-4-(2-furyl)-1-methylpyrrolidine-3-carboxylate 20d.
2 3 ,C0 2Me 1H NM R [400 MHz, 5 (ppm), C D Q 3]: 7.32 (dd; J = 1.9, 0.8 Hz; 1 !H, 5'-CH), 
MeNCX 3' 6.28 (dd; J = 3.2, 1.9 Hz; 1 !H, 4'-CH), 6.10 (d, J = 3.2 Hz, 1 !H, 3'-CH), 3.82 
5 ^ ^ 4 '  (ddd(4), J = 7.2 Hz, 1 !H, 4-CH), 3.71 (s, 3 !H, OCH3), 3.19 (ddd(6); J = 8.3, 6.2, 
(±) 5' 6.2 Hz; 1 !H, 3-CH), 2.99 (dd; J = 9.0, 8.5 Hz; 1 !H; 5-CHH), 2.92 (dd; J = 9.4, 5.8 
Hz; 1 !H, 2-CHH), 2.86 (dd(3), J = 9.0 Hz, 1 !H, 2-CHH), 2.66 (dd; J = 9.0, 7.0 Hz; 1 !H, 5-CHH), 
2.37 (s, 3 !H, NCH3).
C om pounds (±)-2e, (±)-20e, and  (±)-21e. According to the general procedure, a-nitro  ester 
(±)-4e (2.90 g, 9.1 mmol) afforded (±)-2e (1.63 g, 62%) as a sticky light brow n solid, (±)-20e (52
83
Chapter 3
mg, 2 %) as a yellow oil, and (±)-2 1 e (2 0  mg, 0 .8 %) as a yellow oil, after column chromatography 
(CH2CI2/  MeOH, 19:1).
(±)-Methyl (3R,4R)-3-amino-1-methyl-4-(1-methyl-1H-mdol-3-yl)pyrrolidme-3-carboxylate 2e.
C02Me 1H NMR [400 MHz, 5 (ppm), CDCls]: 7.49 (d, J  = 8.1 Hz, 1 !H, 4'-CH), 7.29
1^ " ^ .  (d, J  = 8.1 Hz, 1 iH, 7'-CH), 7.21 (ddd(7); J  = 8.1, 6.5, 1.2 Hz; 1 !H, 6 '-CH),
V.^/, 3' 3'a/ \
5 4 7.09 (ddd(7); J  = 8.1, 6.5, 1.0 Hz; 1 1H, 5'-CH), 7.01 (s, 1 1H, 2'-CH), 4.27 (dd;
(±)2 N 7a 7' J  = 9.8, 7.6 Hz; 1 1H, 4-CH), 3.77 (s, 3 1H, OCH3), 3.76 (s, 3 1H, 1'-NCHs), 3.53 
Me (d, J  = 9.8 Hz, 1 1H, 2-CHH), 3.17 (dd; J  = 8.9, 7.6 Hz; 1 1H, 5-CHH), 3.06
(dd(3), J  = 9.5 Hz, 1 1H, 5-CHH), 2.59 (d, J  = 9.8 Hz, 1 1H, 2-CHH), 2.50 (s, 3 1H, 1 -NCH3), 1.65 
(bs, 2 1H, NH2). 13C NMR [75 MHz, 5 (ppm), CDCb]: 176.3 (CO2), 136.9 (7'a-C), 127.89 (3'a-C), 
127.86 (2'-C), 121.9 (6 '-C), 119.3 (5'-C), 119.1 (4'-C), 109.3 (7'-C), 108.9 (3'-C), 68.0 (2-C), 65.4 (3-C),
60.1 (5-C), 52.6 (OCH3), 45.6 (4-C), 42.6 (1 -NCH3), 32.8 (1'-NCHb). FTIR [ V (cm-1), neat]: 3369, 
3299, 3047, 2945, 2836, 2783, 1725, 1474, 1216, 741. HRMS [ESI (m /z)] calcd for (C16H 21N 3O2 + 
H)+ = 288.17120, found 288.17104 (| A | = 0.57 ppm). Rf: 0.16 (CH2O 2/M eOH, 8:1). Purity: 96.5% 
(GC).
(±)-Methyl (3R,4S)-1-methyl-4-(1-methyl-1H-mdol-3-yl)pyrrolidme-3-carboxylate 20e.
2 3o-C024Me 5. 1H NMR [400 MHz, 5 (ppm), CDCb]: 7.67 (dt; J  = 7.9, 1.0 Hz; 1 1H, 4'-CH), 
MeN 1 3'a -' 7.27 (dt; J  = 8.2, 1.0 Hz; 1 1H, 7'-CH), 7.21 (ddd(7); J  = 8.2, 6.9, 1.0 Hz; 1 1H,
2'"-N 7'a (±) N
7' 6 '-CH), 7.09 (ddd(7); J  = 7.9, 6.9, 1.0 Hz; 1 1H, 5'-CH), 3.99 (ddd(4), J  = 7.5 
Me Hz, 1 1H, 4-CH), 3.70 (s, 3 1H, 1'-NCHb), 3.67 (s, 3 1H, OCH3), 3.23 (ddd; J  =
8 .6 , 7.0, 5.8 Hz; 1 1H, 3-CH), 3.11 (dd(3), J  = 8.7 Hz, 1 1H, 5-CHH), 3.00 (dd; J  = 9.2, 5.8 Hz; 1 1H,
2-CHH), 2.95 (dd; J  = 9.2, 8 .6  Hz; 1 1H, 2-CHH), 2.75 (dd; J  = 9.1, 7.5 Hz; 1 1H, 5-CHH), 2.42 (s, 3 
1H, 1 -NCH3). 13C NMR [75 MHz, 5 (ppm), CDO 3]: 175.2 (CO2), 137.4 (7'a-C), 126.9 (3'a-C), 125.7 
(2'-C), 121.7 (6 '-C), 119.5 (4'-C), 118.9 (5'-C), 116.4 (3'-C), 109.4 (7'-C), 63.1 (5-C), 59.5 (2-C), 52.0 
(OCH3), 50.7 (3-C), 42.1 (1 -NCH3), 39.6 (4-C), 32.6 (1 '-NCH3). FTIR [ V (cm-1), neat]: 3050, 2947, 
2836, 2782, 1730, 1473, 1238, 1156, 740. HRMS [ESI (m /z)] calcd for (C16H20N 2O2 + H)+ = 
273.16030, found 273.16229 (| A | = 7.29 ppm). Rf: 0.51 (CH2O 2/M eO H , 8:1). Purity: 93.9% (GC).
(±)-Methyl (3R,4R)-1-methyl-4-(1-methyl-1H-mdol-3-yl)pyrrolidme-3-carboxylate 21e.
2 3 X 0 2Me 1H NMR [400 MHz, 5 (ppm), CDCb]: 7.62 (d, J  = 7.8 Hz, 1 1H, 4'-CH), 7.25 
-' (d, J  = 8.1 Hz, 1 1H, 7'-CH), 7.19 (ddd(7); J  = 8.1, 7.0, 1.0 Hz; 1 1H, 6 '-CH),
7.09 (ddd(7); J  = 7.8, 7.0, 1.0 Hz; 1 1H, 5'-CH), 4.12 (ddd(6 ); J  = 9.5, 6 .6 , 6 .6
(±) 1Me Hz; 1 1H, 4-CH), 3.73 (s, 3 1H, 1 '-NCH3), 3.54 (ddd(6 ); J  = 10.1, 7.7, 7.7 Hz; 1 
1H, 3-CH), 3.23-3.13 (m, 2 1H, 2-CHH + 5-CHH), 3.02-2.95 (m, 1 1H, 2-CHH), 2.97 (s, 3 1H, 
OCH3), 2.79 (dd(3), J  = 10.0 Hz, 1 1H, 5-CHH), 2.52 (s, 3 1H, 1 -NCH3). 13C NMR [75 MHz, 5 
(ppm), CDCl3]: 174.0 (CO2), 136.7 (7'a-C), 128.0 (3'a-C), 126.8 (2'-C), 121.6 (6 '-C), 119.3 (4'-C), 118.9 
(5'-C), 112.8 (3'-C), 109.1 (7'-C), 62.0 (5-C), 58.1 (2-C), 50.9 (OCH3), 48.6 (3-C), 42.3 (1 -NCH3), 38.8 
(4-C), 32.8 (1 '-NCH3). FTIR [ V (cm-1), neat]: 3049, 2944, 2834, 2784, 1728, 1473, 1198, 1170, 740. 
HRMS [ESI (m /z)] calcd for (C16H20N 2O2 + H)+ = 273.16030, found 273.16180 (| A | = 5.50 ppm). 
Rf: 0.36 (CH2O 2/M eOH, 8:1).
MeN 4'
5 4'"':
5
2
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C om pounds (±)-3a and  (±)-20a. According to the general procedure, a-nitro ester (±)-5a (0.95 
g, 3.6 mmol) afforded (±)-3a (649 mg, 77%) as a yellow oil and (±)-20a (16 mg, 2%) as a yellow 
oil, after colum n chrom atography (CH2Cl2/M eO H , 9:1).
(±)-M ethyl (3R,4S)-3-am ino-1-m ethyl-4-phenylpyrrolidine-3-carboxylate 3a.
2 C02Me 1H NM R [400 MHz, 5 (ppm), CDCb]: 7.32-7.15 (m, 5 1H, Ph), 3.36 (dd; J = 9.3,
6.9 Hz; 1 1H, 4-CH), 3.27 (dd; J = 9.3, 6.9 Hz; 1 1H, 5-CHH), 3.23 (d, J = 9.9 Hz, 
3' 1 1H, 2-CHH), 3.19 (s, 3 1H, OCH3), 2.89 (t, J = 9.3 Hz, 1 1H, 5-CHH), 2.87 (d, J =
4'
(±) 5' 9.9 Hz, 1 1H, 2-CHH), 2.47 (s, 3 1H, NCH3), 2.07 (bs, 2 1H, NH2). 13C NM R [75 
MHz, 5 (ppm), C D O 3]: 173.6 (CO2), 138.3 (1'-C), 127.89 (2'-C + 6'-C)*, 127.87 (3'-C + 5'-C)*, 126.9 
(4'-C), 70.2 (3-C), 67.2 (2-C), 61.1 (5-C), 60.5 (4-C), 51.7 (OCH3), 42.3 (NCH3). FTIR [ V (cm-1), 
neat]: 3369, 3300, 2952, 2842, 2792, 1731, 1450, 1221, 768, 699. MS [ESI (m /z)] calcd for 
(C13H 18N 2O2 + H)+ = 235, found 235. Rf: 0.18 (CH2Cl2/M eO H , 8:1). Purity: 98.1% (GC).
C om pounds (±)-3b, (±)-20b, (±)-21b, (±)-22b, and  23b. According to the general procedure, a- 
nitro ester (±)-5b (3.70 g, 11.4 mmol) afforded (±)-3b (2.38 g, 71%) as a whitish-colorless oil, 
(±)-20b (68 mg, 2%) as a yellow oil, (±)-21b (30 mg, 1%) as a yellow oil, (±)-22b (4 mg, 0.1%) as a 
brow n oil, and traces of 23b after colum n chrom atography (CH2Cl2/M eO H , 9:1).
(±)-M ethyl (3R,4S)-3-am ino-4-(3,5-dim ethoxyphenyl)-1-m ethylpyrrolidine-3-carboxylate 3b.
1H NM R [400 MHz, 5 (ppm), C D O 3]: 6.37 (d, J = 2.2 Hz, 2 1H, 2'-CH + 6'- 
CH), 6.33 (t, J = 2.2 Hz, 1 1H, 4'-CH), 3.77 (s, 6 1H, 2 x OCH3), 3.33 (s, 3 1H,
0Me
CO2CH3), 3.32 (dd; J = 9.3, 6.8 Hz; 1 1H, 4-CH), 3.27 (dd; J = 8.8, 6.8 Hz; 1 
1H, 5-CHH), 3.21 (d, J = 10.0 Hz, 1 1H, 2-CHH), 2.92 (d, J = 10.0 Hz, 1 1H, 2- 
CHH), 2.87 (dd(3), J = 9.0 Hz, 1 1H, 5-CHH), 2.48 (s, 3 1H, NCH3), 2.26 (bs, 
2 1H, NH 2). 13C NM R [75 M Hz, 5 (ppm), C D O 3]: 174.1 (CO2), 160.6 (3'-C + 5'-C), 140.5 (1'-C),
106.3 (2'-C + 6'-C), 99.1 (4'-C), 70.0 (3-C), 67.1 (2-C), 61.0 (5-C), 60.4 (4-C), 55.4 (2 x OCH3), 51.9 
(CO2CH3), 42.2 (NCH3). FTIR [ V (cm-1), neat]: 3373, 3305, 2944, 2837, 2784, 1728, 1594, 1460, 
1430, 1203, 1152, 1065, 842. HRM S [EI (m /z)] calcd for C15H 22N 2O4 = 294.1580, found for [M+-] = 
294.1586 ( | A|  = 2.1 ppm ), peaks at (relative intensity): 294 (25), 206 (29), 164 (66), 57 (100), 42 
(20). Rf: 0.22 (CH2Cl2/M eO H , 8:1). Purity: >99.5% (GC).
C om pounds (±)-3c and  (±)-20c. According to the general procedure, a-nitro  ester (±)-5c (3.50 
g, 11.4 mmol) afforded (±)-3c (2.40 g, 76%) as an  off-white solid and (±)-20c (156 mg, 5%) as a 
yellow oil, after colum n chrom atography (CH2Cl2/M eO H , 19:1^9:1).
(±)-Methyl (3R,4S)-3-amino-4-(1,3-benzodioxol-5-yl)-1-methylpyrrolidine-3-carboxylate 3c.
C02Me
MeN
0
1H NM R [400 MHz, 5 (ppm), C D O 3]: 6.76 (d, J = 1.7 Hz, 1 1H, 4'-CH), 6.71 
(d, J = 8.1 Hz, 1 1H, 7'-CH), 6.68 (dd; J = 8.1, 1.7 Hz; 1 1H, 6'-CH), 5.91 (s, 2 
~)2' 1H, 2'-CH2), 3.34 (s, 3 1H, OCH3), 3.29 (dd; J = 8.6, 6.8 Hz; 1 1H, 4-CH), 3.23 
(±) y  73 0  (d, J = 10.0 Hz, 1 1H, 2-CHH), 3.22 (dd; J = 8.8, 6.8 Hz; 1 1H, 5-CHH), 2.87 
(d, J = 10.0 Hz, 1 1H, 2-CHH), 2.84 (dd(3), J = 8.8 Hz, 1 1H, 5-CHH), 2.47 (s, 3 1H, NCH3), 2.15 (bs, 
2 1H, NH2). 13C NM R [75 MHz, 5 (ppm), C D Q 3]: 174.1 (CO2), 147.5 (3'a-C), 146.7 (7'a-C), 132.0
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(5'-C), 121.4 (6 '-C), 108.5 (4'-C), 108.0 (7'-C), 101.0 (2'-C), 70.0 (3-C), 67.0 (2-C), 61.2 (5-C), 60.1 (4- 
C), 51.9 (OCH3), 42.2 (NCH3). FTIR [ V (cm-1), neat]: 3363, 3293, 2946, 2844, 2786, 1728, 1503, 
1488, 1249, 1037, 930, 807. HRM S [EI (m /z)] calcd for C14H 18N 2O4 = 278.1267, found for [M+-] = 
278.1260 (| A | = 2.4 ppm ), peaks at (relative intensity): 278 (30), 148 (87), 57 (100), 42 (27). Rf: 
0.20 (CH2CI2/M eO H , 8:1). Mp: 58.7 °C. Purity: 99.1% (GC).
C om pounds (±)-3d and  (±)-20d. According to the general procedure, a-nitro  ester (±)-5d (3.16 
g, 12.4 mmol) afforded (±)-3d (1.7 g, 61%) as a yellow oil and (±)-20d (47 mg, 2%) as a yellow oil, 
after colum n chrom atography (CH2C h/M eO H , 19:1^9:1).
(±)-Methyl (3R,4S)-3-amino-4-(2-furyl)-1-methylpyrrolidine-3-carboxylate 3d.
2 C0 2Me !H NM R [400 MHz, 5 (ppm), CDCb]: 7.30 (dd; J = 1.9, 0.6 Hz; 1 1H, 5'-CH), 6.28 
(dd; J = 3.2, 1.9 Hz; 1 1H, 4'-CH), 6.07 (d, J = 3.2 Hz, 1 1H, 3'-CH), 3.49 (dd; J = 
4' 9.8, 7.0 Hz; 1 1H, 4-CH), 3.44 (s, 3 1H, OCH3), 3.29 (dd; J = 9.2, 7.0 Hz; 1 1H, 5- 
(±) 5' CHH), 3.11 (d, J = 9.8 Hz, 1 1H, 2-CHH), 2.89 (d, J = 9.8 Hz, 1 1H, 2-CHH), 2.78 
(dd(3), J = 9.5 Hz, 1 1H, 5-CHH), 2.45 (s, 3 1H, NCH3), 2.12 (bs, 2 1H, N H 2). 13C NM R [75 MHz, 5 
(ppm), CDCl3]: 173.9 (CO2), 152.2 (2'-C), 141.6 (5'-C), 110.1 (4'-C), 106.3 (3'-C), 68.7 (3-C), 66.3 (2- 
C), 59.1 (5-C), 53.4 (4-C), 52.1 (OCH3), 41.9 (NCH3). FTIR [ V (cm-1), neat]: 3374, 3297, 2946, 2840, 
2785, 1726, 1207, 1008, 735. HRM S [EI (m /z)] calcd for C11H 16N 2O3 = 224.1161, found for [M+-] =
224.1150 (| A | = 4.9 ppm ), peaks at (relative intensity): 224 (16), 101 (26), 94 (42), 57 (100), 42 (39). 
R f: 0.21 (CH2O 2/M eO H , 8:1). Purity: 98.9% (GC).
C om pounds (±)-3e, (±)-20e, and  (±)-21e. According to the general procedure, a-nitro  ester 
(±)-5e (3.20 g, 10.1 mmol) afforded (±)-3e (1.74 g, 60%) as a very light yellow oil, (±)-20e (98 mg, 
4%) as a yellow oil, and (±)-21e (108 mg, 4%) as a yellow oil, after colum n chrom atography 
(CH2Cl2/MeOH, 19:1^9:1).
C 02Me
MeN
(±) N
Me
(±)-Methyl (3R,4S)-3-amino-1-methyl-4-(1-methyl-1H-indol-3-yl)pyrrolidine-3-carboxylate 3e.
!H NM R [400 MHz, 5 (ppm), C D O 3]: 7.66 (ddd(6); J = 8.0, 1.0, 1.0 Hz; 1 1H, 
4'-CH), 7.23 (ddd(6); J = 8.1, 1.0, 1.0 Hz; 1 1H, 7'-CH), 7.18 (ddd(7); J = 8.1, 
6.8, 1.2 Hz; 1 1H, 6'-CH), 7.09 (ddd(7); J = 8.0, 6.8, 1.2 Hz; 1 1H, 5'-CH), 6.89 
(s, 1 1H, 2'-CH ), 3.77 (dd; J = 10.0, 6.8 Hz; 1 1H, 4-CH ), 3.69 (s, 3 1H, 1'- 
NCH3), 3.31 (dd; J = 9.3, 6.8 Hz; 1 1H, 5-CHH), 3.29 (d, J = 10.0 Hz, 1 1H, 2- 
CHH), 3.12 (s, 3 1H, OCH3), 2.96 (d, J = 10.0 Hz, 1 1H, 2-CHH), 2.94 (dd(3), J = 9.5 Hz, 1 1H, 5- 
CHH), 2.55 (bs, 2 1H, NH 2), 2.51 (s, 3 1H, 1 -NCH3). 13C NM R [75 M Hz, 5 (ppm), CDCb]: 174.4 
(CO2), 136.7 (7'a-C), 128.0 (3'a-C), 126.5 (2'-C), 121.7 (6'-C), 119.2 (5'-C)*, 119.1 (4'-C)*, 110.9 (3'-C),
109.1 (7'-C), 70.1 (3-C), 66.5 (2-C), 61.5 (5-C), 51.6 (OCH3), 51.5 (4-C), 42.3 (1-NCH3), 32.7 (1'- 
NCH3). FTIR [ V (cm-1), neat]: 3361, 3295, 3049, 2944, 2840, 2787, 1727, 1473, 1210, 740. HRMS 
[EI (m /z)] calcd for Ci6H 2iN 3O2 = 287.1634, found for [M+^] = 287.1636 (| A| = 0.8 ppm), peaks 
at (relative intensity): 287 (29), 157 (100), 144 (32), 57 (45). Rf: 0.14 (CH2C k/M eO H , 8:1). Purity: 
97.9% (GC).
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(±)-Methyl 2-(6,8-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolm-4-yl)-2-(hydroxyimmo)- 
Me acetate 17.i
0  3^ N^|i Compound (±)-4b (211 mg, 0.65 mmol) was dissolved in a 1 M solution
X A ^ ' Ä , ' 01^  of SnCl2 2H2O (6.5 mL, 6.5 mmol) in THF/H 2O (9:1). The resulting
reaction mixture was stirred at room temperature for 18 h. After this 
time, AcOEt (10 mL) was added and the pH was raised to >11 with 2
M NaOH (11 mL). The layers were then separated and the aqueous layer was extracted with 
AcOEt (3 x 12 mL). The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated i n  v a c u o .  The residue was purified by column chromatography (CH2Cl2/M eOH, 
8:1) to afford (±)-17 (11 mg, 5%) as a yellow oil. *H NMR [400 MHz, 5 (ppm), CDCh]: 6.39 (d, J  =
2.2 Hz, 1 1H, 5-CH), 6.31 (d, J  = 2.2 Hz, 1 1H, 7-CH), 4.74 (bd, J  = 4.9 Hz, 1 1H, 4-CH), 4.07 (dd; J  = 
15.1, 1.2 Hz; 1 1H, 1-CHH), 3.91 (s, 3 1H, CO2CHb), 3.78 (s, 3 1H, 8 -OCH3), 3.74 (s, 3 1H, 6 -OCH3), 
3.28 (dd; J  = 15.1, 1.2 Hz; 1 1H, 1-CHH), 2.99 (ddd(6 ); J  = 12.0, 1.5, 1.5 Hz; 1 1H, 3-CHH), 2.77 (dd; 
J  = 12.0, 4.9 Hz; 1 1H, 3-CHH), 2.60 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCh]: 166.7 
(CO2), 159.9 (6 -C), 156.7 (8 -C), 149.9 (CNOH), 132.5 (4a-C), 114.2 (8a-C), 103.7 (5-C), 97.5 (7-C),
55.51 (6 -OCH3), 55.46 (8 -OCH3), 53.6 (3-C), 53.2 (CO2CH3), 51.7 (1-C), 44.2 (NCH3), 38.0 (4-C). 
FTIR [ V (cm-1), neat]: 2952, 2838, 2789, 1723, 1609, 1598, 1148, 828. HRMS [ESI (m /z)] calcd for 
(C15H2üN2O5 + H)+ = 309.14509, found 309.14505 ( | A|  = 0.15 ppm). Rf: 0.47 (CH2Cl2/  MeOH, 
8 :1 ).
(±)-(1R,3R,4R)-3-Ammo-1-(chloromethyl)-3-(methoxycarbonyl)-1-methyl-4-(1-methyl-1H-m- 
Ö dol-3-yl)pyrrolidinium chloride 30e.
(CH2Cl2/M eOH, 9:1) to afford (±)-30e (10 mg, 8 %) as a white foam. *H NMR [400 MHz, 5 
(ppm), CDCl3]: 7.45 (s, 1 1H, 2'-CH), 7.34 (d, J  = 7.9 Hz, 1 1H, 4'-CH), 7.29 (d, J  = 8.2 Hz, 1 1H, 7'- 
CH), 7.23 (dd(3), J  = 7.5 Hz, 1 1H, 6 '-CH), 7.10 (dd(3), J  = 7.4 Hz, 1 1H, 5'-CH), 6.23 (d, J  = 9.1 Hz,
1 1H, CHHCl), 6.13 (d, J  = 9.1 Hz, 1 1H, CHHCl), 4.89 (dd; J  = 13.2, 11.4 Hz; 1 1H, 5-CHH), 4.56 (d, 
J  = 13.4 Hz, 1 1H, 2-CHH), 4.51 (dd; J  = 13.2, 6.9 Hz; 1 1H, 4-CH), 4.34 (d, J  = 13.4 Hz, 1 1H, 2- 
CHH), 4.11 (dd; J  = 11.4, 6.9 Hz; 1 1H, 5-CHH), 3.72 (s, 3 1H, 1'-NCHs), 3.70 (s, 3 1H, 1-NCHs), 
3.63 (s, 3 1H, OCH3), 2.29 (bs, 2 1H, NH2). 13C NMR [75 MHz, 5 (ppm), CDCls]: 173.2 (CO2), 136.9 
(7'a-C ), 129.3 (2'-C ), 127.3 (3'a-C ), 122.4 (6 '-C ), 119.8 (5'-C ), 118.1 (4'-C ), 109.9 (7'-C ), 102.7 (3'-C ),
73.7 (2-C ), 71.8 (C H 2Cl), 6 6 .6  (5-C ), 65.6 (3-C ), 53.4 (OC H 3), 50.7 (1-NC H3), 44.8 (4-C ), 33.1 (1'- 
NCH3). FTIR [ V (cm-1), neat]: 3369, 3299, 3047, 2945, 2836, 2783, 1725, 1474, 1216, 741. HRMS 
[ESI (m /z)] calcd for (C17H23ClN3O2)+ = 336.14788, found 336.14761 ( | A|  = 0.80 ppm). Rf: 0.05 
(CH2Cl2/M eOH, 8:1). Mp: 198.0 °C.
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Synthesis of Hydantoins and Thiohydantoins 
Spiro-Fused to Pyrrolidines
In this chapter, the solution-phase synthesis of a 144-com pound library of 
hydantoins and 2-thiohydantoins spiro-fused to pyrrolidines is described. These 
com pounds are synthesized from ß-arylpyrrolidines, providing products that combine 
the 2-arylethyl am ine m oiety w ith a (2 -thio)hydantoin, privileged structures w ith a 
w id e range of biological and pharmacological properties. A ll possible stereoisomers of 
the two-stereocenter products are synthesized. The 80-membered hydantoin sub­
library w as obtained w ith yields ranging from 58 to >99% (87% average) and purities 
from 51 to >99% (87% average) and the 64-membered thiohydantoin sub-library was  
obtained w ith  yields ranging from 65 to >99% (89% average) and purities from 67 to 
>99% (93% average).
R R
(±) (±)
Abstract
Part of this chapter was published in: Blanco-Ania, D.; Hermkens, P. H. H.; Sliedregt, L. A. J. 
M.; Scheeren, H. W.; Rutjes, F. P. J. T. J. Comb. Chem. 2009, 11, 527-538.
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4.1 Introduction
Hydantoin 1 and 2-thiohydantoin 2 (Figure 4.1)1-im id azo lid in e-2 /4-dione and 2- 
thioxoim idazolidin-4-one, respectively—are present in natural products as w ell as in a 
w ide range of biologically active synthetic compounds.
H N ^ hn4
O
1
O
2
Figure 4.1 Hydantoin 1 and 2-Thiohydantoin 2.
Hydantoin w as discovered by A dolf von Baeyer in 18612 — although its structure w as  
not assigned correctly until 1870—w ho prepared it by hydrogenation of allantoin, 
hence the name.
Some natural products w ith a hydantoin ring are depicted in Figure 4.2. 
Hydantocidin 3 is a potent herbicide produced from Streptom yces hygroscopicus.3 
Aplysinopsin 4 is found in Thorecta sp. and belongs to the aplysinopsin family, known  
for its cytotoxicity towards cancer cells and its ability to affect neurotransmitters .4  
M idpacamide 5 is found in the marine sponges of the genus Agelas and has the 
capacity to deter feeding by the om nivorous Caribbean reef fish Thalassoma bifasciatum .5 
A gesam ide A 6  is one of the last natural products found w ith a hydantoin ring . 6 Its 
structure is similar to m idpacam ide's and is found in the same sponges. N o activity 
studies have been conducted on this com pound yet.
O,
y—NH
HNV"'WO.. V  / /-OH
HO^ OH 
3
O O
N^ u 'N^  
H Me b
N-Me ar~ ~ \  N H
4 5
Figure 4.2 Natural Products Containing a Hydantoin Ring.
O
N-Me 
HIW HN
O O
Brx Br
N ^
N ^O  
H
6
There is a plethora of synthetic com pounds, w hich are biologically active, presenting  
a hydantoin ring in their structure. A m ongst som e of their know n activities, they can 
be antiarrhythmic , 7  antiepileptic , 8 antitumor , 9 and anxiolytic1 0  agents. The best three 
examples of clinically important drugs based upon this heterocyclic scaffold (Figure 
4.3) are phenytoin 7 (Dilantin®), w hich has been used for decades to treat epilepsy ; 11  
nilutam ide 8  (Nilandron®), w hich is used for the treatment of prostate cancer; 1 2  and
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dantrolene 9 (Dantrium® IV), w hich is the only specific and effective treatment for 
m alignant hyperthermia . 13
7 8 9
Figure 4.3 Drugs Based upon a Hydantoin Ring: Phenytoin 7, Nilutamide 8 and Dantrolene 9.
Although 2-thiohydantoins were know n for som e time, the scientific com m unity  
became thoroughly acquainted w ith their existence after the discovery of the Edman 
degradation . 1 4  This degradation is a m ethod for sequencing proteins, w hich is still used  
now adays thanks to the developm ent of an automated protein sequencer . 1 5  Initially, 
the protein 10 (Scheme 4.1) is reacted w ith phenyl isothiocyanate 11 and, follow ing the 
Edman degradation procedure, two products are formed: a new  protein 12, having one 
amino acid residue fewer at the N-terminus, and the 2-thiohydantoin 13. Com pound 13 
is analyzed and the structure of the amino acid residue is studied. The procedure is 
then repeated until the w hole amino acid sequence of the protein is known.
Scheme 4.1 Edman Degradation.
O
H2N^ A n. protein
^  r2 HR1 H O 12 
H NA f' H^ A r Protein + Ph-NCS ------Edman------ .
H2N T  : H 11 degradation S
O r2 ^  HN"A
10 I N-Ph
hn
R1 - - VO
13
A related synthesis of 2-thiohydantoins is believed to happen in nature (Scheme 4.2). 
The glucosinolates 14, contained in cruciferous vegetables such as brussels sprouts and 
broccoli, enzym atically form isothiocyanates 15 that can react w ith  amino acids 16 to 
form 2-thiohydantoins 17 in actual foods a n d / or in the intestinal tracts of animals and 
hum ans . 16
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Scheme 4.2 Possible Formation o f 2-Thiohydantoins in Nature.
O
H* N-  'O H
/OH O O R2 S
hO ^ ^ sx Ä 9 j e 7 y m -  -------------16---------------- X V
^ O H  ^ N -glUC0Se S R2"'^
R1 -S O 42- 15 O
14 17
There are also m any biologically active synthetic com pounds having a 2- 
thiohydantoin, such as anticarcinogenic , 1 7  anticonvulsant , 18 and anti-HIV agents , 19  
herbicides , 2 0 germicides , 21 and pesticides . 22
With all these features in mind, w e  envisioned the solution-phase synthesis of 
libraries of com pounds that com bined a (2 -thio)hydantoin ring w ith the 2-arylethyl 
am ine m oiety (thoroughly described in Chapter 1) and to test their activities. Moreover, 
these com pounds are meant to be rigid in order to have high specificity, so both 
privileged structures could be part of a spiranic framework.
The anticipated spiro com pounds are potential central nervous system  (CNS) 
ligands. In the course of our research, several publications on this new  scaffold have 
been published . 2 3 The reported com pounds possess the substructure 18 and were 
show n to be LFA-1 antagonists. A lthough this is not a CNS application, it demonstrates 
the potential of this class of com pounds to bind to com plex biom olecules. We 
constructed a library from com pounds having structures based on 18 and 19, and also 
20 and 21 (which include the thiohydantoin moiety; Figure 4.4), and in each case all 
combinations of stereoisomers were generated.
R2 R2 R2 R2
OV-'N % -N  ^ v -N  Ov -N/-"-L /--L ^ s /--i. ^ Sri-nCCn ri-nC^n r1-OTh ri-0^h
Ar Ar Ar Ar
18 19 20 21
Figure 4.4 9-Arylspiro[hydantoin-5,3'-pyrrolidines] 18 and 19, and 9-Arylspiro[pyrrolidine-3,5'- 
thiohydantoins] 20 and 21.
4.2 R esults and D iscussion . Synthesis of Spiro (Thio)hydantoin Library
The substrates utilized for the library synthesis in this chapter are depicted in Figure 
4.5. The synthesis of these a-am ino esters (±)-22-(±)-29 has been described in Chapter
3.
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Figure 4.5 Substrates (±)-22-(±)-29 for the Library Synthesis.
One possible route to the formation of a (thio)hydantoin ring from an a-am ino ester 
is through the formation of an a-(thio)ureido ester by addition of the amino group onto 
an iso(thio)cyanate. Depending on the reactivity of the ester and the acidity of the 
(thio)urea, the cyclization step to form the hydantoin can take place spontaneously, on 
standing at room  temperature or at reflux, or w ith the help of a base or an acid. 
Optim ization of the spiro hydantoin synthesis had been carried out w ith the a-am ino  
esters (±)-30 and (±)-31 (described in Chapter 3) before it w as decided not to use these 
com pounds for the library synthesis (see Chapter 6 ). The com pounds (±)-30 and (±)-31 
were reacted w ith phenyl isocyanate in CH 2Q 2 at room  temperature to quantitatively  
form the a-ureido esters (±)-32 and (±)-33 (Scheme 4.3). The next step in the sequence 
involved the cyclization of (±)-32 and (±)-33 into the spiro hydantoins. From previous 
work , 24 KOBuf w as show n to be the base of choice for the cyclization to occur. Thus, the 
spiro hydantoins (±)-34 and (±)-35 w ere synthesized w ith high yields using 1 equiv of 
this base in THF (Scheme 4.3).
Scheme 4.3 Formation o f Spiro Hydantoins (±)-34 and (±)-35.
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'Ph 
(±)-30
MeN
CO
'Ct,
2Me
nh2
Ph
(±)-31
PhNCO, CH2Cl2 
21 °C, 40 min
PhNCO, CH2Cl2 
21 °C, 40 min
MeN f ^ N Ph 
H H 
'Ph
(±)-32
O
H  A  .MeN N N
v \ h h
Ph
(±)-33
Ph
KOBu', THF 
21 °C, 2 h
KOBu', THF 
21 °C, 2 h
Ph
O N
MeN |"'NH
"Ph
y=O
(±)-34 
88% (2 steps)
Ph
O N
MeN H
Ph
(±)-35 
90% (2 steps)
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The conversion of substrates (±)-22-(±)-29 into chemsets (±)-37-(±)-44 was 
accom plished using annulation of a hydantoin ring w ith reagent chem set 36. Ten 
isocyanates 36a-j (alkyl, electron-rich aryl, electron-poor aryl, and heteroaryl 
isocyanates; Figure 4.6) were selected for the generation of an 80-com pound sub­
library.
e f g h
Figure 4.6 Isocyanates 3 6 a -j Used for the Annulation o f Substrates (±)-22-(±)-29.
After optim ization of the annulation w ith all the reagents and substrates, it was 
concluded that the reaction conditions were dependent on the reagent used, not on the 
substrate. The conditions originally found for this transformation had to be changed  
(time, solvent, temperature) for som e reactions to go to completion. The reactions of 
(±)-22-(±)-29 w ith 36a-d in CH 2Q 2 for 15 h at room  temperature afforded the 
corresponding a-ureido esters, w ith 36e-g  afforded a mixture of the a-ureido esters 
and small amounts of the spiro hydantoins, whereas w ith 36h-j som e residual 
substrate w as left (even after refluxing). The slow ness of the reaction w ith reagent 36h 
w as m ost likely a result of the electron-donating effect of the ethoxy group and in the 
case of 36i,j w as probably due to the low  solubility in CH 2Q 2 . Therefore, DMF at 80 °C 
for 15 h w as used for the reactions w ith these last three reagents to afford the a-ureido  
esters. After evaporation of the solvent, the crude mixture w as dissolved in THF and 1 
M KOBuf in THF (1 equiv) w as added. The reactions w ere stirred at room  temperature 
for 15 h (except for reactions w ith 36d, which w ere only stirred for 3 h to avoid  
secondary reactions) and the solvent evaporated. Liquid-liquid extraction afforded all 
the expected 80 new  9-arylspiro[hydantoin-5,3'-pyrrolidines] (±)-37(a-j)-(±)-44(a-j) 
w ith yields ranging from 58 to >99% (87% average) and w ith purities ranging from 51 
to >99% (87% average; Scheme 4.4 and Tables 4.1 and 4.2) according to LC-MS analysis 
(also confirmed by XH NMR spectroscopy).
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Scheme 4.4 Spiro Hydantoin Sub-Library from  Substrates (±)-22-(±)-29.
<O.
MeNct
COoMe
NH2
Ar
(±)-22-(±)-29
1. RNCO 36a-g, CH2Cl2
21 °C, 15 h or 
RNCO 36h-j, DMF 
80 °C, 15 h
2. KOBu', THF, 21 <C, 15 h
R
,N
MeN 'N
"Ar
(±)-37(a-j)-(±)-44(a-j)
R = Et a, Bu' b, PhCH2CH2 c, EtO2CCH2CH2 d, Ph e, 4-CF3C6H4 f, 
2-thienyl g, 4-EtOC6H4 h, 3-NCC6H4 i, 3-Py j
The reactions carried out in CH 2CI2 gave products w ith purities in the range 77 to 
>99% (93% average), whereas the purities of the products from the reactions run in 
DMF w ere in the range 51 to 96% (76% average). The lower purities could be caused by 
partial decom position of the isocyanates at the temperature used for the reactions in 
DMF. Although the reactions w ith 36d were only run for 3 h, a mixture of the ethyl 
esters (±)-37d-(±)-44d and the m ethyl esters (±)-37k-(±)-44k w as found (Tables 4.1 and 
4.2). This mixture results from transesterification of the ethyl ester on the R group by  
m ethoxide, formed in the cyclization.
Follow ing a similar procedure, the conversion of substrates (±)-22-(±)-29 into 
chem sets (±)-46-(±)-53 w as achieved using annulation of a 2-thiohydantoin ring w ith  
reagent chem set 45. Eight isothiocyanates 45a-h (alkyl, electron-rich aryl, electron-poor 
aryl, and heteroaryl isothiocyanates; Figure 4.7) were selected for the generation of a 
64-com pound sub-library.
a b c d
e f g h
Figure 4.7 Isothiocyanates 45a-h  Used for the Annulation o f Substrates (±)-22-(±)-29.
The synthesis of the spiro thiohydantoins w as conducted as above and it was 
observed that for the formation of (±)-46(a-h)-(±)-53(a-h) no external base was 
required under any of the conditions. Thioureas are approximately 106 tim es more 
acidic than ureas , 2 5  m eaning that as soon as the a-ureido esters w ere formed, they were  
dehydronated by the tertiary amine w ithin the m olecule so that the cyclization took  
place without actually observing the a-ureido esters. In first instance, the reactions 
were run in CH 2Q 2, but those containing the aliphatic isothiocyanates 45a-c did not go 
to com pletion at any temperature, even w ith an excess of the reagent. On the contrary,
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all the reactions w ith the aromatic isothiocyanates 45d-h  were com plete w ithin 40 h at 
room  temperature . 26 Secondly, it w as found that all the reactions, except w ith 45a, w ent 
to com pletion very cleanly in DMF2 7  at 40 °C for 40 h (most of the reactions w ith  
aromatic isothiocyanates finished w ithin 3-15 h). Subsequent evaporation of the 
solvent yielded the 64 new  9-arylspiro[pyrrolidine-3,5'-thiohydantoins] (±)-46(a-h)- 
(±)-53(a-h) (Scheme 4.5). It also appeared that com pounds (±)-50(a-h)-(±)-53(a-h) were  
very insoluble in diethyl ether. Thus, the crude mixtures of these com pounds were  
w ashed w ith 1 mL of Et2O per 0.05 m m ol of product (for (±)-52a-h, 1 mL per 0.075 
m m ol of product) to im prove the purity. Com pounds (±)-46(a-h)-(±)-49(a-h) were 
better soluble and the w ashing step w as carried out w ith 1 mL of Et2O per 0.1 m m ol of 
product. Com pounds (±)-48a-c and (±)-48e w ere not w ashed w ith  Et2O because of their 
high solubility in this solvent, and w ere analyzed im m ediately after evaporation of the 
solvent. Thus, spiro thiohydantoins (±)-46(a-h)-(±)-53(a-h) w ere obtained w ith yields 
ranging from 65 to >99% (89% average) and purities ranging from 67 to >99% (93% 
average; Tables 4.3 and 4.4) according to LC-MS analysis (also confirmed by XH NMR  
spectroscopy). It can be seen from the table that the use of the more reactive aryl 
isothiocyanates28 45d-h  did not result in a big difference in reactivity between the more 
hindered a-am ino esters (±)-22-(±)-25 and a-am ino esters (±)-26-(±)-29. The reaction 
w ith the alkyl isothiocyanates 45a-c, however, worked better w ith the less hindered a ­
amino esters (±)-26-(±)-29 (see, for example, the reactions of (±)-22-(±)-25 w ith  45a 
where residual substrate w as present).
Scheme 4.5 Spiro Thiohydantoin Sub-Library from  Substrates (±)-22-(±)-29.
MeN
COpMe t  2r"NH2
Ar
(±)-22-(±)-29
RNCS
45a-h, DMF
40 °C, 40 h
R
O ^ N
MeN '"'H
"Ar
(±)-46(a-h)-(±)-53(a-h)
R = Et a, PhCH2CH2 b, EtO2CCH2CH2 c, Ph d, 4-CF3C6H4 e, 
4-EtOC6H4 f, 3-NCC6H4 g, 3-Py h
4.3 C onclusion
In conclusion, w e  have developed an efficient m ethod for the synthesis of a library 
containing all possible stereoisomers of hydantoins and 2 -thiohydantoins spiro-fused  
to the 3-position of pyrrolidines. These products all present the privileged 2-arylethyl 
am ine moiety, rigidified in the pyrrolidine ring, in combination w ith a (thio)hydantoin, 
another com m on privileged structure. W e have show n that these aryl groups can be 
3,5-dim ethoxyphenyl, 1,3-benzodioxol-5-yl, 2-furyl, and 1-methylindol-3-yl. As a 
result, w e  anticipate that this m ethodology can be successfully applied for a w ide
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range of aromatic groups. All 144 com pounds were synthesized in moderate to good  
yields and purities.
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Table 4.1 S o lu tio n -P h a se  S y n th e s is  o f  S p iro  H y d a n to in  S u b -L ib ra r y  ( ± ) - 3 7 ( a - k ) - ( ± ) - 4 0 ( a - k ) a'h
^ 4  ^ °
MeN "N
OMe
(±)-37a 
>99% (90%)
,CF3
r
y=O
MeN J H___ ^ '- , , ^ ^ . O M e
OMe
(±)-37f 
>99% (89%)
o . V o
"N
" t o
(±)-38a 
99% (99%)
y = O
°> O
(±)-38f 
>99% (91%)
T " n
>=°
(±)-37b 
64% (78%)
/ - J  ^ °
MeN 'N
(±)-37g 
93% (97%)
"4"
■ e N ^
■ c o
(±)-38b 
68% (92%)
>=°
' 0 0
(±)-38g 
>99% (98%)
^ °
“ • O C Ï U - O M .
OMe
(±)-37c 
>99% (78%)
MeN I 'N
OMe
(±)-37h 
>99% (60%)
N^ °
N
' Ü 0
(±)-38c 
>99% (80%)
^ °
MeN 'N
t o
(±)-38h 
69% (73%)
Ph
^ N ^
CT ^ °
/ - - X  ^ = 0
^ V C V ^ O M e
OMe
(±)-37d,k 
76% (99%)c
f j ^ V "C N
MeN ]  HV - " 1' ,.1 .-OMe
OMe
(±)-37i 
85% (74%)
> = °
?
(±)-38d,k 
75% (>99%)c
a T  ^ °
MeN I 'N
C O
(±)-38i 
85% (85%)
R
CT ) = °
^0
M eN  T 'H
OMe
(±)-37e 
77% (96%)
f^N
M eN  J 'H
(±)-37j 
73% (90%)
Ph
v N ,
/ - 4 .  ^ °
MeN I 'N
(±)-38e 
74% (92%)
p
MelN X 'H
> = °
C O
(±)-38j 
74% (82%)
0J>
(±)-39a 
>99% (>99%)
rJ , =^0
MeN I "N
" ° 0  
(±)-39f 
>99% (97%)
Q r  
> = °  
r O
M ® ^  J !"H
0 ^  
(±)-39b 
59% (98%)
Vs
aT'V°
MeN "N
" O
(±)-39g 
95% (96%)
0 ^  
(±)-39c 
>99% (94%)
a 4  ^ °
MeN "N
" O
(±)-39h 
88% (96%)
OJ
(±)-39d,k
78% (>99%)c
/ 4  ^ °
MeN ''N
° 0  
(±)-39i 
82% (88%)
/ - i .  > = °  
MeN J 'H
OJ 
(±)-39e 
60% (90%)
a 4  ^ °
MeN "N
" O
(±)-39j 
62% (87%)
(±)-40a 
88% (97%)
(
V
MeN J  "H
(±)-40f 
>99% (90%)
(±)-40b 
72% (80%)
<ps
/  - r . . N^ °
r i>
N
Me
(±)-40g 
>99% (94%)
(±)-40c 
97% (83%)
(
V-N
c t ^ oMeN^ | 'H <Ç~~\
NMe
(±)-40h 
>99% (90%)
(±)-40d,k 
78% (99%)c
(±)-40i 
97% (65%)
(±)-40e 
79% (93%)
>=0
(±)-40j 
90% (52%)
a % = Crude yield based on mass recovery. b (%) = Purity determined by LC-MS at 215 nm. c Mixture of 
compounds, R = CH2CH2CO2Et d and CH2CH2CO2Me k.
R
OO OO O
,0 M e
OMe
S
O O O OO
RO
O
F3
0O O O O
O O O
O O 0 O
R0O O 0.
MeN I H MeN I H
N N
Me
N
Me
N
Me
O Q
MeN I H MeN J  H
N
Me
N
Me
N
Me
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Table 4.2 S o lu tio n -P h a se  S y n th e s is  o f  S p iro  H y d a n to in  S u b -L ib ra r y  ( ± ) - 4 1 ( a - k ) - ( ± ) - 4 4 ( a - k ) a'b
MeN ]" 'N
' 1J W  ,° M e
OMe
(±)-41a 
83% (89%)
MeN T "H
OMe
(±)-41f 
>99% (93%)
(±)-42a 
83% (96%)
CF3
(±)-42f 
99% (92%)
° J  
(±)-43a 
81% (99%)
° J  
(±)-43f 
96% (92%)
(±)-44a 
76% (98%)
Me
(±)-44f 
98% (91%)
/ "V =^°
M®N ^ . ^ „ Q M e
OMe
(±)-41b 
84% (85%)
y=°
MeN J U „ ° M e
OMe
(±)-41g 
97% (97%)
(±)-42b 
95% (94%)
(±)-42g 
95% (98%)
MeN ]  H
o j  
(±)-43b 
94% (97%)
° J  
(±)-43g 
89% (99%)
4  ^ °| 'N
-OMe
OMe
(±)-41c 
93% (93%)
(±)-44b 
84% (77%)
(±)-44g 
>99% (97%)
OMe
(±)-41h 
>99% (80%)
Ph
(±)-42c 
93% (94%)
QEt
(±)-42h 
>99% (74%)
° J  
(±)-43c 
92% (97%)
° J  
(±)-43h 
94% (91%)
/  - i '  ^ °  
Me^ „ ^ . ° M e
OMe
(±)-41d,k 
70% (94%)c
MeN T "N
‘ J W  ,-QMe
OMe
(±)-41i 
95% (74%)
(±)-42d,k 
58% (98%)c
(±)-42i 
91% (70%)
° J  
(±)-43d,k 
60% (>99%)c
MeN T  H
0~J 
(±)-43i 
89% (70%)
(±)-44c 
99% (84%)
(±)-44d,k 
58% (96%)c
Me
(±)-44h 
97% (88%)
Me
(±)-44i 
88% (69%)
/  ^ °
M®N ' ^ „ ° M e
OMe
(±)-41e 
96% (97%)
MeN T "N
■ J W  „.OMe
OMe
(±)-41j 
87% (51%)
MeN I H
(±)-42e 
93% (95%)
MeN T "H
(±)-42j 
83% (69%)
° J  
(±)-43e 
>99% (96%)
MeN ] 'H
Ó~J 
(±)-43j 
78% (74%)
(±)-44e 
99% (92%)
Me
(±)-44j 
82% (60%)
a % = Crude yield based on mass recovery. b (%) = Purity determined by LC-MS at 215 nm. c Mixture of 
compounds, R = CH2CH2CO2Et d and CH2CH2CO2Me k.
R
R
R
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Table 4.3 S o lu tio n -P h a se  S y n th e s is  o f  S p iro  T h io h y d a n to in  S u b -L ib ra r y  ( ± ) - 4 6 ( a - h ) - ( ± ) - 4 9 ( a - h ) a'b
^ S
OMe
(±)-46a 
69% (67%)c
CF3
r
>=s
OMe
(±)-46e 
85% (96%)
^ s
OMe
(±)-46b 
65% (73%)
OEt
f
>=S
OMe
(±)-46f 
92% (90%)
/ ' ' ' T  ^ S
Me0 . 1 ' t U  « M e
OMe
(±)-46c 
73% (75%)
^ S
MeN T " N
OMe
(±)-46g 
98% (87%)
^ s
MeNJ . . , ' H ^ 0 M e
OMe
(±)-46d 
95% (83%)
^ S
MeN T " N
OMe
(±)-46h 
95% (96%)
MeN T 'H
>
(±)-47a 
70% (78%)d
(
M e N ^ J '" H
^ S
>
(±)-47e 
83% (96%)
MeN T  H
>
(±)-47b 
68% (76%)
(
M e N ^ J '" H
)
(±)-47f 
98% (95%)
^ s
MeN I N
(±)-47c 
71% (86%)
l f \ - C N
^ S
> 
O
(±)-47g 
97% (96%)
C 0 2Et
> = S
■>
(±)-47d 
90% (92%)
f^N
^ s
>
(±)-47h 
97% (93%)
a4  ^ s
MeN "N
" 0O
(±)-48a 
>99% (85%)e
^ s
MeN ] "H
" O
(±)-48e 
>99% (98%)
MeN T ' H
0 ^  
(±)-48b 
>99% (94%)
/-"X '^=S
MeN I "N
" ° 0  
(±)-48f 
90% (97%)
Ph
(±)-48c 
>99% (92%)
a4  ^ s
MeN 'N
0O
(±)-48g 
>99% (93%)
C 0 2Et
^ S
MeN 'N
(±)-48d 
76% (98%)
^ s
MeN "N
(±)-48h 
98% (>99%)
MeN J j  'H
^S ^S
(±)-49a 
79% (82%)f
CF3
(
-N
MeN J " 'H
(±)-49e 
84% (97%)
(±)-49b 
86% (93%)
OEt
MeN J " 'H
(±)-49f 
90% (93%)
(±)-49c 
81% (94%)
f\~CN
(±)-49g 
82% (93%)
(±)-49d 
82% (97%)
MeN J ,"H
)^S
C y j
N
(±)-49h 
95% (96%)
a % = Crude yield based on mass recovery. b (%) = Purity determined by LC-MS at 215 nm. c Plus (±)-22 
(16%). d Plus (±)-23 (8%). e Plus (±)-24 (15%). f Plus (±)-25 (12%).
O O OO
N
H
'N 
-  H
O O O O
O O O O
MeN I H
O O
QO
MeN I H
O
0 0 O
0 Q 0 0
O OQ O
MeN I H'N.. H
N
Me
N
Me
N
Me
N
Me
O OO
MeN I H
N
Me
N
Me
N
Me
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Table 4.4 S o lu tio n -P h a se  S y n th e s is  o f  S p iro  T h io h y d a n to in  S u b -L ib ra r y  ( ± ) - 5 0 ( a - h ) - ( ± ) - 5 3 ( a - h ) ah
OMe
(±)-50a 
89% (94%)
OMe
(±)-50e 
73% (>99%)
(±)-51a 
85% (85%)
(±)-51e 
95% (>99%)
M eN h
OMe
(±)-50b 
84% (>99%)
) = S
MeN J U x M e
OMe
(±)-50f 
90% (>99%)
(±)-51b 
86% (97%)
(±)-51f 
99% (99%)
MeN T "N
' - w N ^  ,QMe
OMe
(±)-50c 
94% (95%)
M eN T h
OMe
(±)-50g 
>99% (>99%)
C °2Et
(±)-51c 
98% (97%)
(±)-51g 
>99% (97%)
OMe
(±)-50d 
93% (98%)
M eN T "H
OMe
(±)-50h 
97% (94%)
(±)-51d 
98% (>99%)
(±)-51h 
>99% (>99%)
C 0 2Et
MeN '
) = S
° J  
(±)-52a 
91% (95%)
MeN T N
<0 > 
(±)-52e 
79% (96%)
(±)-53a 
88% (90%)
CF3
^ S
0 ~j7  
(±)-52b 
88% (98%)
^ s
° J  
(±)-52f 
93% (99%)
(±)-53b 
88% (83%)
OEt
(±)-52c 
89% (96%)
f \ r^CN
> S
° J  
(±)-52g 
93% (99%)
(±)-53c 
85% (93%)
MeN, 1 H
^ s
M e N __P .
(±)-52d 
95% (99%)
f ^ N
^ s
MeN T ’H
(±)-52h 
>99% (>99%)
(±)-53d 
85% (96%)
MeN I ' " .
(±)-53e 
75% (99%)
(±)-53f 
97% (96%)
(±)-53g 
99% (97%)
(±)-53h 
>99% (96%)
1 % = Crude yield based on mass recovery. b (%) = Purity determined by LC-MS at 215 nm.
N
Me
N
Me
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4.5 Experimental Section
For general experimental details, see Section 2.5 (p 33). LC-MS measurements were run on a 
Shimadzu LC-10A VP series liquid chromatography system, equipped with an SPD-10A VP 
UV-VIS detector and a LCMS-2010A mass spectrometer. The column used for the LC analysis 
was an Agilent Zorbax Extend C18 (3.5 |j,m, 4.6 x 150 mm) and it was eluted at 1 m L/min with a 
gradient made up of two solvent mixtures. Solvent A consisted of 0.1% TFA in H2O and solvent 
B consisted of 0.1% TFA in MeCN. The gradient was run as follows: t = 0 min, 50% A; t = 5 min, 
5% A; t = 10 min, 5% A; t = 12.5 min, 50% A; t = 20 min, 50% A. A wavelength of 215 nm was 
selected for the analysis of purity.
General Procedure for a-Ureido Ester Formation from (±)-30 and (±)-31. Phenyl isocyanate 
(1 equiv) was added to a solution of a-amino ester in CH2Cl2 (0.15 M). The resulting reaction 
mixture was stirred for 40 min and the solvent was then evaporated.
(±)-Methyl (3R,4R)-1-methyl-4-phenyl-3-(3-phenylureido)pyrrolidine-3-carboxylate 32.
MeO
2
MeN
^ ° °
" X 3'
"N N'1" 
N N
According to the general procedure, the reaction of a-amino ester 
(±)-30 (157 mg, 670 |amol) afforded (±)-32 (236 mg, 99%) as a white 
foam. !H NMR [400 MHz, 5 (ppm), CDCls]: 7.30-7.17 (m, 6  1H, Ph + 3'- 
NH), 7.13-7.08 (m, 2 1H, 3''-CH + 5''-CH), 7.00-6.94 (m, 3 1H, 2''-CH + 
(±) 4''-CH + 6 ''-CH), 5.32 (s, 1 1H, 1'-NH), 3.82 (dd(3), J = 7.9 Hz, 1 1H, 4-
CH), 3.76 (s, 3 1H, OCH3), 3.69 (d, J = 10.6 Hz, 1 1H, 2-CHH), 3.07 (dd; J = 9.4, 7.6 Hz; 1 1H, 5- 
CHH), 2.97 (d, J = 10.6 Hz, 1 1H, 2-CHH), 2.96 (dd(3), J = 8 . 8  Hz, 1 1H, 5-CHH), 2.41 (s, 3 1H, 
NCH3). MS [ESI (m/z)] calcd for (C2ÜH23N 3O3 + H)+ = 354, found 354. Rf: 0.48 (CH2Cl2/  MeOH, 
8 :1 ).
MeO
2
O O 2'' 
' X 3'
MeN "N N ' 1"' 
JH N
5 ’
(±)-Methyl (3R,4S)-1-methyl-4-phenyl-3-(3-phenylureido)pyrrolidine-3-carboxylate 33.
According to the general procedure, the reaction of a-amino ester 
(±)-31 (171 mg, 730 |j,mol) afforded (±)-33 (257 mg, 99%) as a white 
foam. !H NMR [400 MHz, 5 (ppm), CDCb]: 7.45-7.40 (m, 2 1H, 2"-CH 
+ 6 "-CH), 7.31-7.15 (m, 8  1H, Ph + 3'-NH + 3''-CH + 5''-CH), 7.03-6.98 
(±) (m, 1 1H, 4''-CH), 6.34 (s, 1 1H, 1'-NH), 3.80 (bs, 1 1H, 4-CH), 3.40 (s, 2
1H, 2-CH2), 3.33 (dd(3), J = 7.9 Hz, 1 1H, 5-CHH), 3.17 (s, 3 1H, OCH3), 2.93 (dd(3), J = 8.9 Hz, 1 
1H, 5-CHH), 2.54 (s, 3 1H, NCH3). MS [ESI (m/z)] calcd for (C2üH23N3 0 3  + H)+ = 354, found 354. 
Rf: 0.37 (CH2Cl2/MeOH, 8:1).
General Procedure for Spiro Hydantoin Formation from (±)-32 and (±)-33. A 1 M solution of 
KOBut in THF (1 equiv) was added to a solution of a-ureido ester in THF (0.15 M). The resulting 
reaction mixture was stirred for 2 h. Brine (1 mL per mmol) was then added. The layers were 
separated and the aqueous phase was extracted with CH2Cl2. The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (CH2Cl2 /MeOH, 19:1).
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MeN
(±)-(5R,9R)-7-Methyl-3,9-diphenyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 34.
According to the general procedure, the reaction of a-ureido ester (±)-32 (236 
mg, 670 |amol) afforded (±)-34 (190 mg, 8 8 %) as a white solid. *H NMR [400
r f  6'
<Ov4 N MHz, 5 (ppm), CDCls]: 7.46-7.40 (m, 2 iH, 3'-CH + 5'-CH), 7.37-7.31 (m, 3 iH,
4’-CH + 3"-CH + 5"-CH), 7.31-7.24 (m, 3 XH, 2'-CH + 6 '-CH + 4"-CH), 7.23-7.19 
(m, 2 !H, 2"-CH + 6 "-CH), 6.25 (s, 1 XH, NH), 4.04 (dd; J = 9.2, 6.2 Hz; 1 XH, 9- 
CH), 3.34 (dd; J = 9.8, 6.2 Hz; 1 !H, 8 -CHH), 3.13 (d, J = 9.7 Hz, 1 !H, 6 -CHH),
3.07 (d, J = 9.7 Hz, 1 XH, 6 -CHH), 2.97 (dd(3), J = 9.6 Hz, 1 XH, 8 -CHH), 2.48 (s,
3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 173.6 (4-C), 154.8 (2-C), 136.6 (1"-C), 131.6 (1'- 
C), 129.2 (3'-C + 5'-C), 129.1 (3''-C + 5''-C), 128.4 (4'-C), 128.13 (2''-C + 6 ''-C), 128.10 (4''-C), 126.2 
(2'-C + 6 '-C), 70.4 (5-C), 65.5 (6 -C), 59.8 (8 -C), 53.1 (9-C), 42.0 (NCH3). FTIR [ V (cm-1), neat]: 3273, 
2939, 2841, 2794, 1776, 1716, 1406, 765, 700. MS [ESI (m/z)] calcd for (C19H19N 3O2 + H)+ = 322, 
found 322. Rf: 0.47 (CH2Cl2 /MeOH, 8:1). Purity: >99.5% (GC).
4 V5| /=O
'"N 2„ 
HZ'
(±)
(±)-(5R,9S)-7-Methyl-3,9-diphenyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 35.
According to the general procedure, the reaction of a-ureido ester (±)-33 (257 
mg, 730 |amol) afforded (±)-35 (211 mg, 90%) as a white solid. *H NMR [400 
MHz, 5 (ppm), CDCl3]: 8 . 8 8  (s, 1 XH, NH), 7.34-7.20 (m, 8  XH, 3'-CH + 4'-CH + 
5'-CH + Ph''), 6.72-6.68 (m, 2 XH, 2'-CH + 6 '-CH), 3.72 (dd; J = 12.3, 6.1 Hz; 1 
!H, 9-CH), 3.39 (d, J = 10.7 Hz, 1 !H, 6 -CHH), 3.36 (dd; J = 9.4, 6.1 Hz; 1 !H, 8 - 
CHH), 3.21 (dd; J = 12.3, 9.4 Hz; 1 1H, 8 -CHH), 3.17 (d, J = 10.7 Hz, 1 1H, 6 - 
CHH), 2.61 (s, 3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDO3 ]: 173.1 (4-C),
156.0 (2-C), 134.0 (1''-C), 131.0 (1'-C), 128.7 (3'-C + 5'-C), 128.5 (3''-C + 5''-C), 128.0 (4'-C)*, 127.94 
(4''-C)*, 127.88 (2''-C + 6 ''-C), 126.0 (2'-C + 6 '-C), 70.7 (5-C), 63.6 (6 -C), 58.4 (8 -C), 56.2 (9-C), 41.7 
(NCH3). Elem. anal. calcd for C19H19N 3O2 : C 71.01%, H 5.96%, N 13.07%; found C 70.94%, H 
5.79%, N 12.98%. Rf: 0.39 (CH2O 2/MeOH, 8:1). Mp: 220.1 °C (colorless crystals). Purity: >99.5% 
(GC).
O. . 4 m
/=O  
MeN T"H 2'
“ ' 3'' 
4''
(±) *
43
5
2
General Procedure 1 for Spiro Hydantoin Formation Using Parallel Synthesis. A solution of 
isocyanate 36 (0.12 mmol for a,b, 0.10 mmol for c-g) from a 0.3 M stock solution in CH2Cl2 was 
added to a solution of a-amino ester (0.10 mmol) in CH2Cl2 (1.5 mL). The resulting reaction 
mixture was stirred at room temperature for 15 h. After that time, the solvent was evaporated 
and THF (1.5 mL) and 1 M KOBut in THF (0.10 mmol) were added. The reaction mixture was 
then stirred at room temperature for 15 h (3 h for 36d). A saturated solution of NaHCO3 (0.6 
mL) was added and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2 
x 1.5 mL) and the combined organic layers were evaporated to dryness under vacuum.
General Procedure 2 for Spiro Hydantoin Formation Using Parallel Synthesis. A solution of 
isocyanate 36h-j (0.10 mmol) from a 0.3 M stock solution in DMF was added to a solution of a­
amino ester (0.10 mmol) in DMF (1.5 mL). The resulting reaction mixture was stirred at 80 °C 
for 15 h. After that time, the solvent was evaporated and THF (1.5 mL) and 1 M KOBut in THF 
(0.10 mmol) were added. The reaction mixture was then stirred at room temperature for 15 h. A 
saturated solution of NaHCO3 (0.6 mL) was added and the layers were separated. The aqueous
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layer was extracted with CH2Cl2 (2 x 1.5 mL) and the combined organic layers were evaporated 
to dryness under vacuum.
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-3-ethyl-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
37a.
(From (±)-22) MS [APCI (m/z)] calcd for (C17H23N 3O4 + H)+ = 334, found
(±)
OMe
(±)-(5R,9R)-3-£er£-Butyl-9-(3,5-dimethoxyphenyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 37b.
(From (±)-22) MS [APCI (m/z)] calcd for (C19H27N 3O4 + H)+ = 362, found 
362. Crude yield: 64%. Purity: 78% (LC).
(±)
OMe
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-phenethyl-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 37c.
(From (±)-22) MS [APCI (m/z)] calcd for (C23H27N 3O4 + H)+ = 410, found 
410. Crude yield: quantitative. Purity: 78% (LC).
(±)
OMe
(±)-Ethyl 3-{(5R,9R)-9-(3,5-dimethoxyphenyl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-
3-yl}propanoate 37d.
(From (±)-22) MS [APCI (m/z)] calcd for (C2oH27N 3O6 + H)+ = 406, found
406. Crude yield: 76% (combined yield of (±)-37d and (±)-37k). Purity: 
99% (LC; combined purity of (±)-37d and (±)-37k).
(±) OMe
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-phenyl-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 37e.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCl3]: 7.48-7.40 (m, 2 1H, 3''- 
CH + 5''-CH), 7.39-7.28 (m, 3 1H, 2"-CH + 4"-CH + 6 ''-CH), 6.36 (s, 3 1H, 2'- 
CH + 4'-CH + 6 '-CH), 6.27 (bs, 1 1H, NH), 3.95 (dd; J = 9.0, 5.7 Hz; 1 1H, 9- 
CH), 3.73 (s, 6  1H, 2 x OCH3), 3.30 (dd; J = 9.9, 5.7 Hz; 1 1H, 8 -CHH), 3.07 
(2d(3), J = 10.2 Hz, 2 1H, 6 -CH2), 2.92 (dd(3), J = 9.5 Hz, 1 1H, 8 -CHH), 2.45 
(±) ~,,,c (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCls]: 173.9 (4-C), 161.4 (3'- 
C + 5'-C), 154.9 (2-C), 139.3 (1'-C), 131.7 (1''-C), 129.2 (3''-C + 5''-C), 128.3 (4''-C), 126.2 (2''-C + 6 ''- 
C), 106.3 (2'-C + 6 '-C), 99.3 (4'-C), 70.3 (5-C), 65.7 (6 -C), 59.8 (8 -C), 55.5 (2 x OCH3), 53.1 (9-C), 41.9
OMe
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(NCH3). FTIR [ V (cm-1), neat]: 3189, 2938, 2838, 2791, 1776, 1714, 1595, 1203, 1153, 857, 763, 702. 
MS [APCI (m/z)] calcd for (C21H23N3O4 + H)+ = 382, found 382. Crude yield: 77%. Purity: 96% 
(LC).
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-[4-(trifluoromethyl)phenyl]-1,3,7-triazaspiro
[4.4]nonane-2,4-dione 37f.
(From (±)-22) MS [APCI (m/z)] calcd for (C22H22F3N3O4 + H)+ = 450, 
found 450. Crude yield: quantitative. Purity: 89% (LC).
(±) OMe
OMe
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-(2-thienyl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 37g.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3 ]: 7.45 (dd; J = 3.9, 1.2 
Hz; 1 !H, 3"-CH), 7.15 (dd; J = 5.4, 1.2 Hz; 1 !H, 5"-CH), 6.98 (dd; J = 5.4,
3.9 Hz; 1 !H, 4"-CH), 6.37 (bs, 1 ^ ,  NH), 6.34 (t, J = 2.1 Hz, 1 ^ ,  4'-CH), 
6.31 (d, J = 2.1 Hz, 2 !H, 2'-CH + 6 '-CH), 3.94 (dd; J = 9.0, 5.4 Hz; 1 ^ ,  9- 
CH), 3.70 (s, 6  !H, 2 x OCH3), 3.30 (dd; J = 9.9, 5.4 Hz; 1 iH, 8 -CHH), 3.05 
(±) (2d(3), J = 10.2 Hz, 2 1H, 6 -CH2), 2.92 (dd(3), J = 9.5 Hz, 1 1H, 8 -CHH), 2.45
(s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 172.5 (4-C), 161.4 (3'-C + 5'-C), 153.6 (2-C),
139.1 (1'-C), 132.2 (2"-C), 125.2 (4"-C), 121.8 (5"-C), 120.1 (3"-C), 106.2 (2'-C + 6 '-C), 99.5 (4'-C), 70.0 
(5-C), 65.8 (6 -C), 59.9 (8 -C), 55.4 (2 x OCH3), 53.1 (9-C), 41.9 (NCH3 ). FTIR [V (cm-1), neat]: 3194, 
2937, 2838, 2789, 1778, 1719, 1595, 1203, 1156, 834, 691. MS [APCI (m/z)] calcd for (C19H21N3O4S 
+ H)+ = 388, found 388. Crude yield: 93%. Purity: 97% (LC).
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-3-(4-ethoxyphenyl)-7-methyl-1,3,7-triazaspiro[4.4]non- 
ane-2,4-dione 37h.
(From (±)-22) MS [APCI (m/z)] calcd for (C23H27N 3O5 + H)+ = 426, found 
426. Crude yield: quantitative. Purity: 60% (LC).
OEt
(±) OMe
(±)-3-{(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}' 
/^^V'CN benzonitrile 37i.
O
/ -i. ^ O 
M6^ ; ^ . G M e
(±)
(From (±)-22) MS [APCI (m/z)] calcd for (C22H22N4O4 + H)+ = 407, found
407. Crude yield: 85%. Purity: 74% (LC).
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(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-(3-pyridyl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
f f ^ N  dione 37j.
' (From (±)-22) MS [APCI (m/z)] calcd for (C20H22N4O4 + H)+ = 383, found
383. Crude yield: 73%. Purity: 90% (LC).
V 7
-N
'N
„OMe
MeN
MeN
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-3-ethyl-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
^  38a.
~ (From (±)-23) ^  NMR [300 MHz, 5 (ppm), CDCI3 ]: 6.70 (d, J = 8.1 Hz, 1
1H, 7'-CH), 6 . 6 8  (d, J = 1.8 Hz, 1 XH, 4'-CH), 6.56 (dd; J = 8.1, 1.8 Hz; 1 XH, 
6 '-CH), 6.16 (bs, 1 !H, NH), 5.93 (s, 2 iH, 2 '-CH2), 3.81 (dd; J = 9.0, 6.0 Hz; 1 
!H, 9-CH), 3.56-3.42 (m, 2 1H, CH2CH3), 3.17 (dd; J = 9.9, 6.0 Hz; 1 1H, 8 - 
CHH), 2.98 (d, J = 9.9 Hz, 1 1H, 6 -CHH), 2.91 (d, J = 9.9 Hz, 1 1H, 6 -CHH), 
2.89 (dd(3), J = 9.3 Hz, 1 1H, 8 -CHH), 2.43 (s, 3 1H, NCH3), 1.13 (t, J = 7.2 Hz, 3 1H, CH2CH3). 13C 
NMR [75 MHz, 5 (ppm), CDCI3 ]: 174.7 (4-C), 156.0 (2-C), 148.2 (3'a-C), 147.2 (7'a-C), 130.7 (5'-C),
121.5 (6 '-C), 108.5 (7'-C), 108.2 (4'-C), 101.3 (2'-C), 70.4 (5-C), 65.3 (6 -C), 60.4 (8 -C), 52.4 (9-C), 42.0 
(NCH3), 33.7 (CH2CH3), 13.5 (CH2CH3). FTIR [ V (cm-1), neat]: 3270, 2940, 2841, 2788, 1771, 1703, 
1253, 1236, 1037, 928. MS [APCI (m/z)] calcd for (C16H19N 3O4 + H)+ = 318, found 318. Crude 
yield: 99%. Purity: 99% (LC).
O
(±)
MeN
O
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-3-£er£-butyl-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 38b.
(From (±)-23) ^  NMR [300 MHz, 5 (ppm), CDCI3 ]: 6.72 (d, J = 8.1 Hz, 1 
1H, 7'-CH), 6.69 (d, J = 1.8 Hz, 1 1H, 4'-CH), 6.58 (dd; J = 8.1, 1.8 Hz; 1 1H, 
6 '-CH), 5.94 (s, 2 1H, 2 '-CH2), 5.55 (bs, 1 1H, NH), 3.76 (dd; J = 9.0, 5.7 Hz; 1 
1H, 9-CH), 3.13 (dd; J = 9.9, 5.7 Hz; 1 1H, 8 -CHH), 2.93 (d, J = 9.6 Hz, 1 1H,
6 -CHH), 2.87 (d, J = 9.6 Hz, 1 1H, 6 -CHH), 2.85 (dd(3), J = 9.3 Hz, 1 1H, 8 - 
CHH), 2.41 (s, 3 1H, NCH3), 1.53 (s, 9 1H, C(CH3)3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 175.8 (4- 
C), 156.8 (2-C), 148.2 (3'a-C), 147.1 (7'a-C), 131.1 (5'-C), 121.4 (6 '-C), 108.5 (7'-C), 108.2 (4'-C), 101.3 
(2'-C), (39.2 (5-C), 65.6 (6 -C), 60.5 (8 -C), 57.9 (C(CH3)3), 52.8 (9-C), 42.0 (NCH3), 28.7 (C(CH3)3). 
FTIR [ V (cm-1), neat]: 3226, 2936, 2841, 2786, 1764, 1702, 1253, 1235, 1037, 927. MS [APCI (m/z)] 
calcd for (C18H23N3O4 + H)+ = 346, found 346. Crude yield: 6 8 %. Purity: 92% (LC).
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-phenethyl-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 38c.
(From (±)-23) MS [APCI (m/z)] calcd for (C22H23N3O4 + H)+ = 394, found 
394. Crude yield: quantitative. Purity: 80% (LC).
(±)
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(±)-Ethyl 3-{(5R,9R)-9-(1,3-benzodioxol-5-yl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3- 
p°2 Et yl}propanoate 38d.
O r  (From (±)-23) MS [APCI (m/z)] calcd for (C19H23N3O6 + H)+ = 390, found
^=O 390. Crude yield: 75% (combined yield of (±)-38d and (±)-38k). Purity: 
MeN^ -  >99% (LC; combined purity of (±)-38d and (±)-38k).
w
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-phenyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
38e.
(From (±)-23) MS [APCI (m/z)] calcd for (C2oH19N3O4 + H)+ = 366, found
366. Crude yield: 74%. Purity: 92% (LC).
-O
>
'O  
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-[4-(trifluoromethyl)phenyl]-1,3,7-triazaspiro-
[4.4]nonane-2,4-dione 38f.
(From (±)-23) MS [APCI (m/z)] calcd for (C21H18F3N 3O4 + H)+ = 434, found 
434. Crude yield: quantitative. Purity: 91% (LC).
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-(2-thienyl)-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 38g.
(From (±)-23) MS [APCI (m/z)] calcd for (C18H17N3O4S + H)+ = 372, found
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-3-(4-ethoxyphenyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane 
OEt -2,4-dione 38h.
(From (±)-23) MS [APCI (m/z)] calcd for (C22H23N3Os + H)+ = 410, found 
410. Crude yield: 69%. Purity: 73% (LC).
(±)
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(±)-3-{(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}- 
benzonitrile 38i.
(From (±)-23) MS [APCI (m/z)] calcd for (C21H 18N4O4 + H)+ = 391, found 
391. Crude yield: 85%. Purity: 85% (LC).
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-(3-pyridyl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 38j.
(From (±)-23) MS [APCI (m/z)] calcd for (C19H18N4O4 + H)+ = 367, found
367. Crude yield: 74%. Purity: 82% (LC).
D
>
O 
(±)
(±)-(5R,9R)-3-Ethyl-9-(2-furyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 39a.
(From (±)-24) MS [APCI (m/z)] calcd for (C13H17N3O3 + H)+ = 264, found 264.
MeN |"'N
y=O Crude yield: quantitative. Purity: >99% (LC).
I I
(±)
(±)-(5R,9R)-3-£er£-Butyl-9-(2-furyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 39b.
(From (±)-24) MS [APCI (m/z)] calcd for (C15H21N3O3 + H)+ = 292, found 292. 
Crude yield: 59%. Purity: 98% (LC).
/-4 ,
MeN
(±)
(±)-(5R,9R)-9-(2-Furyl)-7-methyl-3-phenethyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 39c.
(From (±)-24) 1H NMR [300 MHz, 5 (ppm), CDCh]: 7.35-7.17 (m, 6  1H, 5'- 
CH + Ph), 6.41 (bs, 1 1H, NH), 6.27 (dd; J = 3.0, 1.8 Hz; 1 1H, 4'-CH), 6.06 (d, 
J = 3.0 Hz, 1 1H, 3'-CH), 3.93 (dd; J = 9.3, 6.3 Hz; 1 1H, 9-CH), 3.74 (t, J = 7.6 
Hz, 2 1H, NCH2CH2), 3.21 (dd; J = 9.6, 6.3 Hz; 1 1H, 8 -CHH), 2.98-2.87 (m, 2 
1H, NCH2CH2), 2.87 (d, J = 9.6 Hz, 1 1H, 6 -CHH), 2.86 (dd(3), J = 9.6 Hz, 1 
1H, 8 -CHH), 2.79 (d, J = 9.6 Hz, 1 1H, 6 -CHH), 2.38 (s, 3 1H, NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDCh]: 174.3 (4-C), 156.1 (2-C), 151.0 (2'-C), 142.9 
(5'-C), 137.9 (1''-C), 129.0 (2''-C + 6 ''-C), 128.6 (3''-C + 5''-C), 126.7 (4''-C),
110.4 (4'-C), 107.9 (3'-C), 69.7 (5-C), 65.4 (6 -C), 58.1 (8 -C), 46.0 (9-C), 41.8 (NCH3), 39.9 
(NCH2CH2), 34.0 (NCH2CH2). FTIR [ V (cm-1), neat]: 3266, 2943, 2841, 2796, 1770, 1709, 766, 739, 
699. MS [APCI (m/z)] calcd for (C19H 21N3 O3  + H)+ = 340, found 340. Crude yield: quantitative. 
Purity: 94% (LC).
(±)
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(±)-Ethyl 3-{(5R,9R)-9-(2-furyl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}propanoate 
39d.
(From (±)-24) MS [APCI (m/z)] calcd for (C16H21N3O5 + H)+ = 336, found
336. Crude yield: 78% (combined yield of (±)-39d and (±)-39k). Purity: 
>99% (LC; combined purity of (±)-39d and (±)-39k).
(±)
(±)-(5R,9R)-9-(2-Furyl)-7-methyl-3-phenyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 39e.
/ f \  (From (±)-24) MS [APCI (m/z)] calcd for (C17H17N3O3 + H)+ = 312, found 312. 
Crude yield: 60%. Purity: 90% (LC).
^=O
O-  -N
MeN J"'N
O ^
(±)
(±)-(5R,9R)-9-(2-Furyl)-7-methyl-3-[4-(trifluoromethyl)phenyl]-1,3,7-triazaspiro[4.4]nonane- 
CF3 2,4-dione 39f.
f \  (From (±)-24) MS [APCI (m/z)] calcd for (C18H16F3N 3O3 + H)+ = 380, found
380. Crude yield: quantitative. Purity: 97% (LC).
=^O
MeN 1"'N
O ^
(±)
(±)-(5R,9R)-9-(2-Furyl)-7-methyl-3-(2-thienyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione 39g.
(From (±)-24) MS [APCI (m/z)] calcd for (C15H15N 3O3S + H)+ = 318, found 318.
Crude yield: 95%. Purity: 96% (LC).
/ s T
MeN "N
c O
(±)
(±)-(5R,9R)-3-(4-Ethoxyphenyl)-9-(2-furyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
OEt 39h.
I f  "\j (From (±)-24) MS [APCI (m/z)] calcd for (C19H21N3O4 + H)+ = 356, found 356. 
Crude yield: 8 8 %. Purity: 96% (LC).
O^  -N
MeN T 'N
^ O
II
ó 3 >
(±)
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(±)-3-{(5R,9R)-9-(2-Furyl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}benzomtrile 39i.
r ' V , CN (From (±)-24) MS [APCI (m/z)] calcd for (C18H16N4O3 + H)+ = 337, found 
337. Crude yield: 82%. Purity: 8 8 % (LC).
MeN
(±)
(±)-(5R,9R)-9-(2-Furyl)-7-methyl-3-(3-pyridyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione 39j.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3 ]: 8.73 (d, J = 2.4 Hz, 1 1H, 2"- 
CH), 8.60 (dd; J = 4.8, 1.5 Hz; 1 1H, 6 ''-CH), 7.78 (ddd; J = 8.1, 2.4, 1.5 Hz; 1 1H, 
4"-CH), 7.41 (ddd; J = 8.1, 4.8, 0.6 Hz; 1 1H, 5"-CH), 7.37 (d, J = 1.8 Hz, 1 1H, 5'- 
CH), 6.60 (bs, 1 !H, NH), 6.33 (dd; J = 3.0, 1.8 Hz; 1 !H, 4'-CH), 6.21 (d, J = 3.0 
Hz, 1 !H, 3'-CH), 4.12 (dd; J = 9.6, 6.9 Hz; 1 ^ ,  9-CH), 3.28 (dd; J = 9.6, 6.9 Hz;
1 !H, 8 -CHH), 3.14 (d, J = 9.9 Hz, 1 !H, 6 -CHH), 3.02 (d, J = 9.9 Hz, 1 !H, 6 - 
CHH), 2.98 (t, J = 9.6 Hz, 1 !H, 8 -CHH), 2.46 (s, 3 !H, NCH3). 13C NMR [75 
MHz, 5 (ppm), CDCI3 ]: 173.1 (4-C), 154.3 (2-C), 150.7 (2'-C), 149.0 (6 ''-C), 147.1 (2''-C), 143.2 (5'-C),
133.3 (4''-C), 128.9 (3''-C), 123.7 (5''-C), 110.6 (4'-C), 108.2 (3'-C), 70.0 (5-C), 65.2 (6 -C), 57.8 (8 -C),
47.0 (9-C), 41.8 (NCH3). FTIR [V (cm-1), neat]: 3233, 2945, 2849, 2795, 1777, 1719, 716. MS [APCI 
(m/z)] calcd for (Ci6Hi6N4O3 + H)+ = 313, found 313. Crude yield: 62%. Purity: 87% (LC).
MeN NH 3'
(±)
(±)-(5R,9R)-3-Ethyl-7-methyl-9-(1-methyl-1H-mdol-3-yl)-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 40a.
(From (±)-25) MS [APCI (m/z)] calcd for (C18H22N4O2 + H)+ = 327, four 
327. Crude yield: 8 8 %. Purity: 97% (LC).
Me
(±)
(±)-(5R,9R)-3-£er£-Butyl-7-methyl-9-(1-methyl-1H-mdol-3-yl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 40b.
(From (±)-25) MS [APCI (m/z)] calcd for (C20H26N4O2 + H)+ = 355, found 
355. Crude yield: 72%. Purity: 80% (LC).
Me
(±)
(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-3-phenethyl-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 40c.
(From (±)-25) MS [APCI (m/z)] calcd for (C24H26N4O2 + H)+ = 403, found 
403. Crude yield: 97%. Purity: 83% (LC).
Me
(±)
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(±)-Ethyl 3-{(5R,9R)-7-methyl-9-(1-methyl-1H-mdol-3-yl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan 
-3-yl}propanoate 40d.
(From (±)-25) MS [APCI (m/z)] calcd for (C21H26N4O4 + H)+ = 399, found
399. Crude yield: 78% (combined yield of (±)-40d and (±)-40k). Purity: 99% 
(LC; combined purity of (±)-40d and (±)-40k).
Me
(±)
(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-3-phenyl-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 40e.
(From (±)-25) MS [APCI (m/z)] calcd for (C22H22N4O2 + H)+ = 375, found
375. Crude yield: 79%. Purity: 93% (LC).
MeN
N
Me
(±)
Me
(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-3-[4-(trifluoromethyl)phenyl]-1,3,7-triaza- 
spiro[4.4]nonane-2,4-dione 40f.
(From (±)-25) *H NMR [300 MHz, 5 (ppm), CDCI3 ]: 7.69-7.60 (m, 2 1H, 3''- 
CH + 5"-CH), 7.46 (d, J = 8.1 Hz, 1 1H, 4'-CH), 7.35-7.30 (m, 2 1H, 2"-CH + 
6"-CH), 7.28 (d, J = 8.1 Hz, 1 1H, 7'-CH), 7.22 (ddd(7); J = 8.1, 6.9, 0.9 Hz; 1 
1H, 6'-CH), 7.04 (ddd(7); J = 7.8, 6.6, 1.2 Hz; 1 1H, 5'-CH), 6.99 (s, 1 1H, 2'- 
CH), 6.17 (bs, 1 !H, NH), 4.36 (dd; J = 9.0, 6.9 Hz; 1 !H, 9-CH), 3.73 (s, 3 !H, 
1'-NCH3), 3.27 (dd; J = 9.6, 6.9 Hz; 1 !H, 8-CHH), 3.24 (d, J = 9.9 Hz, 1 !H, 6- 
CHH), 3.07 (dd(3), J = 9.3 Hz, 1 ^ ,  8-CHH), 3.04 (d, J = 9.9 Hz, 1 !H, 6- 
CHH), 2.50 (s, 3 !H, 7 -NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 174.1 (4-C), 154.4 (2-C), 137.3 
(7'a-C), 134.8 (q, J = 1.4 Hz, 1''-C), 130.0 (q, J = 32.7 Hz, 4''-C), 127.4 (3'a-C), 127.2 (2'-C), 126.3 (2''- 
C + 6 ''-C), 126.1 (q, J = 3.7 Hz, 3''-C + 5''-C), 123.9 (q, J = 270.5 Hz, CF3), 122.5 (6 '-C), 119.9 (5'-C),
118.6 (4'-C), 109.9 (3'-C + 7'-C), 70.0 (5-C), 65.7 (6 -C), 60.2 (8 -C), 45.3 (9-C), 42.0 (7 -NCH3), 33.0 (1'- 
NCH3). FTIR [V (cm-1), neat]: 3228, 2938, 2842, 2790, 1776, 1716, 1323, 840, 738. MS [APCI 
(m/z)] calcd for (C23H2iF3N4O2 + H)+ = 443, found 443. Crude yield: quantitative. Purity: 90% 
(LC).
(±)
(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-3-(2-thienyl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 40g.
(From (±)-25) MS [APCI (m/z)] calcd for (C20H20N4O2S + H)+ = 381, found
381. Crude yield: quantitative. Purity: 94% (LC).
Me
(±)
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(±)-(5R,9R)-3-(4-Ethoxyphenyl)-7-methyl-9-(1-methyl-1H-indol-3-yl)-1,3,7-triazaspiro[4.4]non- 
OEt ane-2,4-dione 40h.
(From (±)-25) iH NMR [400 MHz, 5 (ppm), CDCI3 ]: 7.51 (d, J = 7.9 Hz, 1 
1H, 4"-CH), 7.28 (d, J = 8.2 Hz, 1 XH, 7"-CH), 7.24-7.19 (m, 1 XH, 6 "-CH),
7.10-7.01 (m, 1 1H, 5"-CH), 7.00 (s, 1 1H, 2"-CH), 7.01-6.96 (m, 2 1H, 2'-CH + 
' 6 -CH), 6.89-6.84 (m, 2 !H, 3'-CH + 5'-CH), 6.04 (bs, 1 !H, NH), 4.35 (dd; J = 
6" 8.9, 7.0 Hz; 1 XH, 9-CH), 4.00 (q, J = 7.0 Hz, 2 XH, CH2CH3), 3.73 (s, 3 XH, 1"- 
NCH3), 3.28 (dd; J = 9.3, 7.0 Hz; 1 XH, 8 -CHH), 3.22 (d, J = 9.8 Hz, 1 XH, 6 - 
(±) CHH), 3.07 (dd(3), J = 9.1 Hz, 1 iH, 8 -CHH), 3.05 (d, J = 9.8 Hz, 1 iH, 6 -
CHH), 2.50 (s, 3 1H, 7-NCHs), 1.39 (t, J = 7.0 Hz, 3 1H, CH2CH3). 13C NMR [75 MHz, 5 (ppm), 
CDCls]: 174.6 (4-C), 158.8 (4'-C), 155.5 (2-C), 137.3 (7"a-C), 127.7 (2'-C + 6 '-C), 127.5 (3"a-C), 127.2 
(2"-C), 124.0 (1'-C), 122.4 (6 "-C), 119.9 (5"-C), 118.8 (4"-C), 115.0 (3'-C + 5'-C), 110.1 (3"-C), 109.8 
(7"-C), 69.9 (5-C), 65.8 (6 -C), 63.8 (CH2CH3), 60.3 (8 -C), 45.0 (9-C), 42.0 (7 -NCH3), 33.0 (1 "-NCH3),
14.9 (CH2CH3). FTIR [ V (cm-1), neat]: 3236, 2933, 2846, 2793, 1771, 1715, 827, 741. MS [APCI 
(m/z)] calcd for (C24H26N 4O3 + H)+ = 419, found 419. Crude yield: quantitative. Purity: 90% 
(LC).
(±)-3-{(5R,9R)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}-
(From (±)-25) MS [APCI (m/z)] calcd for (C23H21N5O2 + H)+ = 400, found
400. Crude yield: 97%. Purity: 65% (LC).
Me
(±)
(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-3-(3-pyridyl)-1,3,7-triazaspiro[4.4]nonane-
(From (±)-25) MS [APCI (m/z)] calcd for (C21H21N5O2 + H)+ = 376, found
376. Crude yield: 90%. Purity: 52% (LC).
Me
(±)
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-3-ethyl-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
41a.
(From (±)-26) MS [APCI (m/z)] calcd for (C17H23N 3O4 + H)+ = 334, found
(±) OMe
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(±)-(5R,9S)-3-£er£-Butyl-9-(3,5-dimethoxyphenyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 41b.
(From (±)-26) MS [APCI (m/z)] calcd for (C19H2 7N3O4 + H)+ = 362, found 
362. Crude yield: 84%. Purity: 85% (LC).
(±)
OMe
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-phenethyl-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 41c.
(From (±)-26) MS [APCI (m/z)] calcd for (C23H27N 3O4 + H)+ = 410, found 
410. Crude yield: 93%. Purity: 93% (LC).
(±)
OMe
(±)-Ethyl 3-{(5R,9S)-9-(3,5-dimethoxyphenyl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-
(From (±)-26) MS [APCI (m/z)] calcd for (C20H2 7N3O6 + H)+ = 406, found 
406. Crude yield: 70% (combined yield of (±)-41d and (±)-41k). Purity:
(±) OMe
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-phenyl-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 41e.
(From (±)-26) *H NMR [400 MHz, 5 (ppm), CDCls]: 8.42 (bs, 1 1H, NH),
7.36-7.24 (m, 3 1H, 3"-CH + 4"-CH + 5"-CH), 6.88-6.81 (m, 2 1H, 2"-CH + 
6 "-CH), 6.43 (d, J = 2.2 Hz, 2 1H, 2'-CH + 6 '-CH), 6.39 (t, J = 2.2 Hz, 1 1H, 4'- 
CH), 3.71 (s, 6  1H, 2 x OCH3), 3.66 (dd; J = 12.2, 6.2 Hz; 1 1H, 9-CH), 3.37 
(d, J = 10.8 Hz, 1 1H, 6 -CHH), 3.33 (dd; J = 9.2, 6.2 Hz; 1 1H, 8 -CHH), 3.12 
(±) —~ (dd; J = 12.2, 9.2 Hz; 1 1H, 8 -CHH), 3.11 (d, J = 10.8 Hz, 1 1H, 6 -CHH), 2.57 
(s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCl3]: 173.4 (4-C), 160.9 (3'-C + 5'-C), 156.0 (2-C),
136.6 (1'-C), 131.4 (1''-C), 129.0 (3''-C + 5''-C), 128.2 (4''-C), 126.3 (2''-C + 6 ''-C), 106.0 (2'-C + 6 '-C),
100.0 (4'-C), 70.7 (5-C), 63.7 (6 -C), 58.5 (8 -C), 56.0 (9-C), 55.5 (2 x OCH3), 41.7 (NCH3). FTIR [V 
(cm-1), neat]: 3187, 2939, 2839, 2795, 1777, 1714, 1595, 1203, 1153, 857, 774, 694. MS [APCI (m/z)] 
calcd for (C21H23N3O4 + H)+ = 382, found 382. Crude yield: 96%. Purity: 97% (LC).
OMe
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(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-[4-(trifluoromethyl)phenyl]-1,3,7-triazaspiro-
[4.4]nonane-2,4-dione 41f.
(From (±)-26) MS [APCI (m/z)] calcd for (C22H22F3N3O4 + H)+ = 450, 
found 450. Crude yield: quantitative. Purity: 93% (LC).
(±) OMe
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-(2-thienyl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 41g.
(From (±)-26) *H NMR [400 MHz, 5 (ppm), CDCI3 ]: 8.36 (bs, 1 !H, NH),
7.09 (dd; J = 5.5, 1.3 Hz; 1 !H, 5"-CH), 6.97 (dd; J = 3.8, 1.3 Hz; 1 !H, 3''- 
CH), 6 . 8 8  (dd; J = 5.5, 3.8 Hz; 1 !H, 4"-CH), 6.37 (d, J = 2.2 Hz, 2 !H, 2'-CH 
+ 6 '-CH), 6.34 (t, J = 2.2 Hz, 1 ^ ,  4'-CH), 3.70 (s, 6  !H, 2 x OCH3), 3.62 (dd; 
J = 12.2, 6.0 Hz; 1 XH, 9-CH), 3.34 (d, J = 10.8 Hz, 1 XH, 6 -CHH), 3.35-3.31 
(±) (m, 1 1H, 8 -CHH), 3.12 (d, J = 10.8 Hz, 1 iH, 6 -CHH), 3.13-3.07 (m, 1 iH, 8 -
CHH), 2.57 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 172.2 (4-C), 160.9 (3'-C + 5'-C),
154.9 (2-C), 136.3 (1'-C), 131.6 (2''-C), 125.3 (4''-C), 122.7 (5''-C), 121.5 (3''-C), 105.8 (2'-C + 6 '-C),
100.3 (4'-C), 70.6 (5-C), 64.0 (6 -C), 58.6 (8 -C), 56.1 (9-C), 55.4 (2 x OCH3), 41.7 (NCH3 ). FTIR [ V 
(cm-1), neat]: 3195, 2940, 2839, 2797, 1780, 1722, 1595, 1203, 1153, 834, 691. MS [APCI (m/z)] 
calcd for (C19H21N3O4S + H)+ = 388, found 388. Crude yield: 97%. Purity: 97% (LC).
OMe
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-3-(4-ethoxyphenyl)-7-methyl-1,3,7-triazaspiro[4.4]non-
OEt ane-2,4-dione 41h.
(From (±)-26) MS [APCI (m/z)] calcd for (C23H27N3Os + H)+ = 426, found 
426. Crude yield: quantitative. Purity: 80% (LC).
(±) OMe
(±)-3-{(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}-
jj \v^C N
O N
/  "i. '>=O 
“  T J w  ,O M .
benzonitrile 41i.
(From (±)-26) MS [APCI (m/z)] calcd for (C22H22N 4O4 + H)+ = 407, found 
407. Crude yield: 95%. Purity: 74% (LC).
(±)
OMe
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(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-(3-pyridyl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 41j.
(From (±)-26) MS [APCI (m/z)] calcd for (C20H22N 4O4 + H)+ = 383, found 
383. Crude yield: 87%. Purity: 51% (LC).
(±)
OMe
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-3-ethyl-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
42a.
(From (±)-27) MS [APCI (m/z)] calcd for (C16H19N3O4 + H)+ = 318, found 
MeN T " N 318. Crude yield: 83%. Purity: 96% (LC).
O
(±)
MeN
' Ns2_
^= O  
"N 4 
;h" ^ on 
■ y
(±) 7'
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-3-£er£-butyl-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 42b.
(From (±)-27) *H NMR [400 MHz, 5 (ppm), CDCI3 ]: 7.63-7.44 (m, 1 1H, 
NH), 6.73 (d, J = 1.5 Hz, 1 1H, 4'-CH), 6.72 (d, J = 8.1 Hz, 1 1H, 7'-CH), 6.67 
(dd; J = 8.1, 1.5 Hz; 1 1H, 6 '-CH), 5.91 (d, J = 1.5 Hz, 1 1H, 2'-CHH), 5.90 (d, 
J = 1.5 Hz, 1 1H, 2'-CHH), 3.43 (dd; J = 12.3, 6.1 Hz; 1 1H, 9-CH), 3.22-3.17 
(m, 1 1H, 8 -CHH), 3.18 (d, J = 10.4 Hz, 1 1H, 6 -CHH), 3.00 (d, J = 10.4 Hz, 1 
1H, 6 -CHH), 2.97 (dd; J = 12.3, 9.0 Hz; 1 1H, 8 -CHH), 2.51 (s, 3 1H, NCH3), 1.26 (s, 9 1H, C(CH3)). 
13C NMR [75 MHz, 5 (ppm), CDCI3]: 175.4 (4-C), 157.8 (2-C), 147.7 (3'a-C), 147.3 (7'a-C), 128.2 (5'- 
C), 121.6 (6 '-C), 108.7 (4'-C), 108.2 (7'-C), 101.1 (2'-C), 69.5 (5-C), 63.7 (6 -C), 58.8 (8 -C), 57.4 
(C(CH3)3), 56.0 (9-C), 41.8 (NCH3), 28.4 (C(CH3)3). FTIR [V (cm-1), neat]: 3251, 2937, 2846, 2784, 
1762, 1702, 1253, 1231, 1037, 928. MS [APCI (m/z)] calcd for (C18H23N3O4 + H)+ = 346, found 
346. Crude yield: 95%. Purity: 94% (LC).
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-phenethyl-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 42c.
(From (±)-27) *H NMR [400 MHz, 5 (ppm), CDCI3 ]: 8.02 (bs, 1 1H, NH),
7.28-7.22 (m, 2 1H, 3''-CH + 5''-CH ), 7.21-7.15 (m, 1 1H, 4''-CH ), 7.12-7.07 
(m, 2 1H, 2''-CH + 6 ''-CH), 6.75 (d, J = 1.3 Hz, 1 1H, 4'-CH), 6.71 (d, J = 8.0 
Hz, 1 1H, 7'-CH), 6 . 6 8  (dd; J = 8.0, 1.3 Hz; 1 1H, 6 '-CH), 5.87 (s, 2 1H, 2'- 
CH2), 3.53 (dd; J = 12.2, 6.2 Hz; 1 1H, 9-CH), 3.43 (dd(3), J = 8.0 Hz, 2 1H, 
NCH 2CH2), 3.24 (dd; J = 9.1, 6.2 Hz; 1 1H, 8 -CHH), 3.21 (d, J = 11.0 Hz, 1 
1H, 6 -CHH), 3.03 (dd; J = 12.2, 9.1 Hz; 1 1H, 8 -CHH), 2.95 (d, J = 11.0 Hz, 1 
1H, 6 -CHH), 2.52 (s, 3 1H, NCH3), 2.48 (dt; J = 13.6, 8.0 Hz; 1 1H, NCH2CHH), 2.32 (dt; J = 13.6,
7.8 Hz; 1 1H, NCH2CHH). 13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 174.2 (4-C), 156.7 (2-C), 147.8 
(3'a-C), 147.4 (7'a-C), 138.0 (1''-C), 128.8 (2''-C + 6 ''-C), 128.6 (3''-C + 5''-C), 127.9 (5'-C), 126.6 (4''- 
C), 121.6 (6 '-C), 108.6 (4'-C), 108.3 (7'-C), 101.2 (2'-C), 70.7 (5-C), 63.7 (6 -C), 59.0 (8 -C), 55.3 (9-C),
41.7 (NCH3), 39.5 (NCH2CH2), 33.8 (NCH2CH2). FTIR [V (cm-1), neat]: 3258, 2941, 2842, 2789,
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1770, 1706, 1253, 1236, 1037, 928, 769, 699. MS [APCI (m/z)] calcd for (C22H23N 3O4 + H)+ = 394, 
found 394. Crude yield: 93%. Purity: 94% (LC).
(±)-Ethyl 3-{(5R,9S)-9-(1,3-benzodioxol-5-yl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3- 
yl}propanoate 42d.
(From (±)-27) MS [APCI (m/z)] calcd for (C19H23N3O6 + H)+ = 390, found
(±)
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-phenyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
42e.
(From (±)-27) MS [APCI (m/z)] calcd for (C2oH19NsO4 + H)+ = 366, found
366. Crude yield: 93%. Purity: 95% (LC).
-O
>
'O  
(±)
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-[4-(trifluoromethyl)phenyl]-1,3,7-triazaspiro-
[4.4]nonane-2,4-dione 42f.
(From (±)-27) MS [APCI (m/z)] calcd for (C21H18F3N 3O4 + H)+ = 434, found
434. Crude yield: 99%. Purity: 92% (LC).
(±)
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-(2-thienyl)-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 42g.
(From (±)-27) MS [APCI (m/z)] calcd for (C18H17N3O4S + H)+ = 372, found 
372. Crude yield: 95%. Purity: 98% (LC).
(±)
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-3-(4-ethoxyphenyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-
2,4-dione 42h.
(From (±)-27) MS [APCI (m/z)] calcd for (C22H23N3O5 + H)+ = 410, found 
410. Crude yield: quantitative. Purity: 74% (LC).
(±)
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(±)-3-{(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}- 
benzonitrile 42i.
(From (±)-27) MS [APCI (m/z)] calcd for (C21H18N4O4 + H)+ = 391, found 
391. Crude yield: 91%. Purity: 70% (LC).
(±)
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-(3-pyridyl)-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 42j.
(From (±)-27) MS [APCI (m/z)] calcd for (C19H18N4O4 + H)+ = 367, found
367. Crude yield: 83%. Purity: 69% (LC).
D
>
O 
(±)
(±)-(5R,9S)-3-Ethyl-9-(2-furyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 43a.
O (From (±)-28) MS [APCI (m/z)] calcd for (C13H17N3O3 + H)+ = 264, found 264. 
^=O Crude yield: 81%. Purity: 99% (LC).
MeN T"H
(±)
(±)-(5R,9S)-3-£er£-Butyl-9-(2-furyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 43b.
(From (±)-28) MS [APCI (m/z)] calcd for (C15H21N3O3 + H)+ = 292, found 292.
O„ ,N Crude yield: 94%. Purity: 97% (LC). 
MeN 1 H
o í /
(±)
(±)-(5R,9S)-9-(2-Furyl)-7-methyl-3-phenethyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 43c.
(From (±)-28) MS [APCI (m/z)] calcd for (C19H21N 3O3 + H)+ = 340, 
340. Crude yield: 92%. Purity: 97% (LC).
(±)
(±)-Ethyl 3-{(5R,9S)-9-(2-furyl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}propanoate 
CO2 Et 43d.
(From (±)-28; measured from a 3:2 mixture of (±)-43d/(±)-43k) *H NMR 
[400 MHz, 5 (ppm), CDCls]: 7.52 (bs, 1 1H, NH), 7.29 (bs, 1 1H, 5"-CH), 6.30 
(dd; J = 3.2, 1.8 Hz; 1 1H, 4"-CH), 6.15 (d, J = 3.2 Hz, 1 1H, 3"-CH), 4.12 (q, J 
= 7.2 Hz, 2 1H, CH2CH3), 3.69 (dd; J = 11.6, 6 . 8  Hz; 1 1H, 9'-CH), 3.67-3.60
5''
(±) (m, 2 1H, 3 -CH2), 3.34 (dd; J = 9.1, 6 . 8  Hz; 1 1H, 8 '-CHH), 3.18 (d, J = 10.5 Hz,
MeN NH 3''
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1 iH, 6 -CHH), 2.93 (d, J = 10.5 Hz, 1 iH, 6 '-CHH), 2.84 (dd; J = 11.6, 9.1 Hz; 1 iH, 8 '-CHH), 2.48 
(s, 3 1H, NCH3), 2.46-2.29 (m, 2 1H, 2 -CH2), 1.24 (t, J = 7.2 Hz, 3 1H, CH2CH3). 13C NMR [75 MHz,
5 (ppm), CDCI3 ]: 173.4 (4'-C), 170.7 (CO2), 156.3 (2'-C), 149.7 (2"-C), 142.2 (5"-C), 110.6 (4"-C),
107.5 (3''-C), 69.8 (5'-C), 64.3 (6 '-C), 60.9 (CH2CH3), 58.3 (8 '-C), 49.8 (9'-C), 41.6 (NCH3), 34.2 (3-C),
32.3 (2-C), 14.3 (CH2CH3). FTIR [ V (cm-1), neat]: 3313, 2949 2846, 2793, 1774, 1710, 747. MS 
[APCI (m/z)] calcd for (C16H21N3Os + H)+ = 336, found 336. Crude yield: 60% (combined yield 
of (±)-43d and (±)-43k). Purity: >99% (LC; combined purity of (±)-43d and (±)-43k).
(±)-(5R,9S)-9-(2-Furyl)-7-methyl-3-phenyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 43e.
(From (±)-28) MS [APCI (m/z)] calcd for (C17H17N3O3 + H)+ = 312, found 312. 
Crude yield: quantitative. Purity: 96% (LC).
MeN
(±)
(±)-(5R,9S)-9-(2-Furyl)-7-methyl-3-[4-(trifluoromethyl)phenyl]-1,3,7-triazaspiro[4.4]nonane-
2,4-dione 43f.
(From (±)-28) MS [APCI (m/z)] calcd for (C18H16F3N 3O3 + H)+ = 380, found
380. Crude yield: 96%. Purity: 92% (LC).
MeN
(±)
(±)-(5R,9S)-9-(2-Furyl)-7-methyl-3-(2-thienyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione 43g.
(From (±)-28) MS [APCI (m/z)] calcd for (C15H15N3O3S + H)+ = 318, found 318. 
Crude yield: 89%. Purity: 99% (LC).
MeN
(±)
(±)-(5R,9S)-3-(4-Ethoxyphenyl)-9-(2-furyl)-7-methyl-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
OEt 43h.
(From (±)-28) 1H NMR [400 MHz, 5 (ppm), CDCl3]: 7.33 (d, J = 1.3 Hz, 1 1H, 
5''-CH), 7.14 (bs, 1 1H, NH), 6.99-6.94 (m, 2 1H, 2'-CH + 6 '-CH), 6.90-6.84 (m, 2 
1H, 3'-CH + 5'-CH), 6.34 (dd; J = 3.2, 1.8 Hz; 1 1H, 4''-CH), 6.21 (d, J = 3.2 Hz, 1 
1H, 3''-CH), 4.01 (q, J = 7.0 Hz, 2 1H, CH2CH3), 3.81 (dd; J = 11.6, 6 . 6  Hz; 1 1H, 
9-CH), 3.38 (dd; J = 9.1, 6 . 6  Hz; 1 1H, 8 -CHH), 3.32 (d, J = 10.6 Hz, 1 1H, 6 - 
CHH), 3.04 (d, J = 10.6 Hz, 1 1H, 6 -CHH), 2.92 (dd; J = 11.6, 9.1 Hz; 1 1H, 8 - 
CHH), 2.51 (s, 3 1H, NCH3), 1.39 (t, J = 7.0 Hz, 3 1H, CH2CH3). 13C NMR [75 MHz, 5 (ppm), 
CDO3 ]: 173.0 (4-C), 158.7 (4'-C), 155.9 (2-C), 149.9 (2''-C), 142.3 (5''-C), 127.5 (2'-C + 6 '-C), 124.0 
(1'-C), 115.0 (3'-C + 5'-C), 110.7 (4''-C), 107.7 (3''-C), 69.9 (5-C), 64.1 (6 -C), 63.8 (CH2CH3), 58.2 (8 -
MeN
(±)
120
Synthesis o f H ydantoins and Thiohydantoins Spiro-Fused to Pyrrolidines
C), 50.3 (9-C), 41.7 (NCH3), 14.9 (CH2CH3). FTIR [ V (cm-1), neat]: 3284, 2930, 2849, 2791, 1776, 
1714, 826, 734. MS [APCI (m/z)] calcd for (C19H21N3O4 + H)+ = 356, found 356. Crude yield: 
94%. Purity: 91% (LC).
(±)-3-{(5R,9S)-9-(2-Furyl)-7-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}benzomtrile 43i.
CN (From (±)-28) MS [APCI (m/z)] calcd for (Ci8Hi6N4O3 + H)+ = 337, found
337. Crude yield: 89%. Purity: 70% (LC).
(±)
(±)-(5R,9S)-9-(2-Furyl)-7-methyl-3-(3-pyridyl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione 43j.
(From (±)-28) MS [APCI (m/z)] calcd for (C16H16N4O3 + H)+ = 313, found 313. 
Crude yield: 78%. Purity: 74% (LC).
MeN
(±)
(±)-(5R,9S)-3-Ethyl-7-methyl-9-(1-methyl-1H-mdol-3-yl)-1,3,7-triazaspiro[4.4]nonane-2,4-dione 
44a.
(From (±)-29) *H NMR [400 MHz, 5 (ppm), CDCI3 ]: 8.07 (bs, 1 1H, NH),
7.51 (d, J = 7.9 Hz, 1 1H, 4'-CH), 7.23 (d, J = 8.2 Hz, 1 1H, 7'-CH), 7.19-7.13 
(m, 1 1H, 6 '-CH), 7.08-7.02 (m, 1 1H, 5'-CH), 6.96 (s, 1 1H, 2'-CH), 4.06 (dd; J 
= 12.2, 6.3 Hz; 1 1H, 9-CH), 3.73 (s, 3 1H, 1 '-NCH3), 3.38 (dd; J = 9.2, 6.3 Hz;
1 1H, 8 -CHH), 3.30 (d, J = 10.7 Hz, 1 1H, 6 -CHH), 3.14-3.04 (m, 2 1H,
MeN
r
'N 4'
N'7'a 7' Me
(±)
CH2CH3), 3.05 (d, J = 10.7 Hz, 1 1H, 6 -CHH), 2.99 (dd; J = 12.2, 9.2 Hz; 1 1H, 8 -CHH), 2.58 (s, 3 1H,
7 -NCH3), 0.25 (t, J = 7.2 Hz, 3 1H, CH2CH3). 13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 174.5 (4-C),
156.8 (2-C), 136.8 (7'a-C), 127.8 (3'a-C), 127.2 (2'-C), 122.0 (6 '-C), 119.7 (5'-C), 118.6 (4'-C), 109.3 (7'- 
C), 107.8 (3'-C), 71.0 (5-C), 64.3 (6 -C), 60.2 (8 -C), 48.4 (9-C), 41.8 (7 -NCH3), 32.9 (1 '-NCH3 + 
CH2CH3), 12.1 (CH2CH3). FTIR [V (cm-1), neat]: 3298, 2934, 2841, 2794, 1770, 1705, 730. MS 
[APCI (m/z)] calcd for (C18H22N4O2 + H)+ = 327, found 327. Crude yield: 76%. Purity: 98% (LC).
(±)-(5R,9S)-3-£er£-Butyl-7-methyl-9-(1-methyl-1H-mdol-3-yl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 44b.
(From (±)-29) MS [APCI (m/z)] calcd for (C20H26N4O2 + H)+ = 355, found 
355. Crude yield: 84%. Purity: 77% (LC).
Me
(±)
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(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-3-phenethyl-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 44c.
(From (±)-29) MS [APCI (m/z)] calcd for (C24H26N4O2 + H)+ = 403, found 
403. Crude yield: 99%. Purity: 84% (LC).
Me
(±)
CO2Et
(±)-Ethyl 3-{(5R,9S)-7-methyl-9-(1-methyl-1H-indol-3-yl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-
3-yl}propanoate 44d.
(From (±)-29) MS [APCI (m/z)] calcd for (C21H26N4O4 + H)+ = 399, found
399. Crude yield: 58% (combined yield of (±)-44d and (±)-44k). Purity: 96% 
(LC; combined purity of (±)-44d and (±)-44k).MeN
N
Me
(±)
(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-3-phenyl-1,3,7-triazaspiro[4.4]nonane-2,4-di- 
one 44e.
(From (±)-29) MS [APCI (m/z)] calcd for (C22H22N 4O2 + H)+ = 375, found
375. Crude yield: 99%. Purity: 92% (LC).
Me
(±)
(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-3-[4-(trifluoromethyl)phenyl]-1,3,7-triaza- 
spiro[4.4]nonane-2,4-dione 44f.
(From (±)-29) *H NMR [400 MHz, 5 (ppm), CDCls]: 8.26 (bs, 1 1H, NH), 
7.59 (d, J = 7.9 Hz, 1 1H, 4'-CH), 7.45-7.38 (m, 2 1H, 3"-CH + 5"-CH), 7.28 (d, 
J = 8.2 Hz, 1 1H, 7'-CH), 7.24-7.18 (m, 1 1H, 6 '-CH), 7.12-7.06 (m, 1 1H, 5'- 
CH), 6.98 (s, 1 !H, 2'-CH), 6.63-6.57 (m, 2 !H, 2''-CH + 6 ''-CH), 4.17 (dd; J =
12.0, 6.4 Hz; 1 !H, 9-CH), 3.73 (s, 3 !H, 1'-NCHb), 3.46 (dd; J = 9.3, 6.4 Hz; 1 
!H, 8 -CHH), 3.43 (d, J = 10.7 Hz, 1 !H, 6 -CHH), 3.16 (d, J = 10.7 Hz, 1 !H, 6 - 
CHH), 3.01 (dd; J = 12.0, 9.3 Hz; 1 !H, 8 -CHH), 2.62 (s, 3 !H, 7 -NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDO3 ]: 173.1 (4-C), 155.1 (2-C), 137.0 (7'a-C), 134.5 (q, J = 1.4 Hz, 1''-C),
129.9 (q, J = 32.5 Hz, 4''-C), 127.5 (3'a-C), 127.3 (2'-C), 126.4 (2''-C + 6 ''-C), 125.9 (q, J = 3.7 Hz, 3''-C 
+ 5''-C), 123.8 (q, J = 270.5 Hz, CF3), 122.4 (6 '-C), 120.1 (5'-C), 118.5 (4'-C), 109.7 (7'-C), 107.7 (3'-C),
71.4 (5-C), 64.5 (6 -C), 60.0 (8 -C), 49.5 (9-C), 41.8 (7 -NCH3), 33.1 (1 '-NCH3). FTIR [ V (cm-1), neat]: 
3250, 2947, 2840, 2791, 1778, 1717, 1323, 839, 734. MS [APCI (m/z)] calcd for (C23H21F3N 4O2 + 
H)+ = 443, found 443. Crude yield: 98%. Purity: 91% (LC).
Me
(±)
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(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-3-(2-thienyl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 44g.
(From (±)-29) MS [APCI (m/z)] calcd for (C20H20N4O2S+ H)+ = 381, found
381. Crude yield: quantitative. Purity: 97% (LC).
Me
(±)
(±)-(5R,9S)-3-(4-Ethoxyphenyl)-7-methyl-9-(1-methyl-1H-indol-3-yl)-1,3,7-triazaspiro[4.4]non-
(From (±)-29) MS [APCI (m/z)] calcd for (C24H26N4O3 + H)+ = 419, found 
419. Crude yield: 97%. Purity: 8 8 % (LC).
Me
(±)
(±)-3-{(5R,9S)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}- 
l j " \ r—CN benzonitrile 44i.
Os
(From (±)-29) MS [APCI (m/z)] calcd for (C23H2iN 5O2 + H)+ = 400, found
400. Crude yield: 8 8 %. Purity: 69% (LC).
MeN
N
Me
(±)
(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-3-(3-pyridyl)-1,3,7-triazaspiro[4.4]nonane-2,4- 
dione 44j.
(From (±)-29) MS [APCI (m/z)] calcd for (C21H21N 5O2 + H)+ = 376, found
376. Crude yield: 82%. Purity: 60% (LC).
Me
(±)
General Procedure for Spiro Thiohydantoin Formation Using Parallel Synthesis. A
solution of isothiocyanate 45 (0.12 mmol for a, 0.10 mmol for b-h) from a 0.3 M stock solution in 
DMF was added to a solution of a-amino ester (0.10 mmol) in DMF (1.5 mL). The resulting 
reaction mixture was stirred at 40 °C for 40 h. After that time, the solvent was evaporated.
Washing step. Diethyl ether (2 mL) was added to the crude mixture of compounds (±)-50(a-h)- 
(±)-53(a-h) (for (±)-52a-h only 1.2 mL). The mixture was shaken until a white precipitate was 
formed. The sample was centrifuged, the solvent was carefully eliminated with a pipette, and 
the resulting white or off-white solid was analyzed. For compounds (±)-46(a-h)-(±)-49(a-h) the
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washing step was carried out with only 1 mL of Et2O and for compounds (±)-48a-c and (±)-48e 
there was no washing step, and they were analyzed immediately after evaporation of the 
solvent.
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-3-ethyl-7-methyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4- 
one 46a.
+
, , OMe 
(±)
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-phenethyl-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 46b.
(From (±)-22) MS [APCI (m/z)] calcd for (C23H27N3O3S + H)+ = 426, found 
426. Crude yield: 65%. Purity: 73% (LC).
, , OMe
(±)
(±)-Ethyl 3-{(5R,9R)-9-(3,5-dimethoxyphenyl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]- 
CO2Et nonan-3-yl}propanoate 46c. 
r ^  (From (±)-22) MS [APCI (m/z)] calcd for (C20H27N 3O5S + H)+ = 422,
O^  -N
MeN 1"'N
J', „OMe
\_g found 422. Crude yield: 73%. Purity: 75% (LC).
rOMe
(±)
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-phenyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan- 
4-one 46d.
(From (±)-22) MS [APCI (m/z)] calcd for (C21H23N 3O3S + H)+ = 398, 
found 398. Crude yield: 95%. Purity: 83% (LC).
, , OMe 
(±)
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1,3,7- 
triazaspiro[4.4]nonan-4-one 46e.
(From (±)-22) MS [APCI (m/z)] calcd for (C22H22F3N3O3S + H)+ = 466, 
found 466. Crude yield: 85%. Purity: 96% (LC).
, , OMe 
(±)
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(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-3-(4-ethoxyphenyl)-7-methyl-2-thioxo-1,3,7-triazaspiro-
[4.4]nonan-4-one 46f.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3 ]: 7.46 (bs, 1 !H, NH),
7.10-7.04 (m, 2 ^ ,  2"-CH + 6 "-CH), 6.97-6.91 (m, 2 ^ ,  3"-CH + 5"-CH), 
6.40 (t, J = 2.1 Hz, 1 1H, 4'-CH), 6.38 (d, J = 2.1 Hz, 2 ^ ,  2'-CH + 6 '-CH),
4.05 (q, J = 6.9 Hz, 2 !H, CH2CH3), 3.93 (dd; J = 9.0, 5.7 Hz; 1 !H, 9-CH), 
3.77 (s, 6  !H, 2 x OCH3), 3.34 (dd; J = 9.9, 5.7 Hz; 1 ^ ,  8 -CHH), 3.13 (d, J =
9.9 Hz, 1 !H, 6 -CHH), 3.06 (d, J = 9.9 Hz, 1 ^ ,  6 -CHH), 2.95 (dd(3), J = 9.6 
Hz, 1 !H, 8 -CHH), 2.49 (s, 3 !H, NCH3), 1.42 (t, J = 6.9 Hz, 3 !H, CH2CH3). 
13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 182.5 (2-C), 174.5 (4-C), 161.5 (3'-C + 5'-C), 159.5 (4"-C),
138.7 (1'-C), 129.4 (2"-C + 6 "-C), 125.2 (1"-C), 115.0 (3"-C + 5"-C), 106.3 (2'-C + 6 '-C), 99.7 (4'-C),
72.8 (5-C), 64.7 (6 -C), 63.8 (CH2CH3), 59.6 (8 -C), 55.6 (2 x OCH3), 54.0 (9-C), 41.8 (NCH3 ), 14.9 
(CH2CH3). FTIR [ V (cm-1), neat]: 3142, 2936, 2839, 2790, 1748, 1596, 1203, 1155, 837. MS [APCI 
(m/z)] calcd for (C23H27N3O4S + H)+ = 442, found 442. Crude yield: 92%. Purity: 90% (LC).
OEt
(±)-3-{(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-
(From (±)-22) MS [APCI (m/z)] calcd for (C22H22N4O3S + H)+ = 423, found 
423. Crude yield: 98%. Purity: 87% (LC).
(±)
OMe
(±)-(5R,9R)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-(3-pyridyl)-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 46h.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3 ]: 8.65 (dd; J = 4.8, 1.2 
Hz; 1 !H, 6 "-CH), 8.49 (d, J = 2.4 Hz, 1 !H, 2"-CH), 7.57 (ddd(6 ); J = 8.1, 1.8,
1.8 Hz; 1 !H, 4"-CH), 7.41 (dd; J = 8.1, 4.8 Hz; 1 !H, 5"-CH), 6.41 (t, J = 2.1 
Hz, 1 !H, 4'-CH), 6.37 (d, J = 2.1 Hz, 2 !H, 2'-CH + 6 '-CH), 3.94 (dd; J = 9.0,
6.2 Hz; 1 !H, 9-CH), 3.77 (s, 6  !H, 2 x OCH3), 3.37 (dd; J = 9.9, 6.2 Hz; 1 iH, 
8 -CHH), 3.17 (d, J = 9.9 Hz, 1 1H, 6 -CHH), 3.10 (d, J = 9.9 Hz, 1 1H, 6 - 
CHH), 2.97 (dd(3), J = 9.6 Hz, 1 1H, 8 -CHH), 2.51 (s, 3 1H, NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDCI3 ]: 181.1 (2-C), 174.0 (4-C), 161.5 (3'-C + 5'-C), 150.0 (6 ''-C), 149.2 
(2''-C), 138.2 (1'-C), 135.9 (4''-C), 129.8 (3''-C), 123.7 (5''-C), 106.3 (2'-C + 6 '-C), 99.7 (4'-C), 73.2 (5- 
C), 64.4 (6 -C), 59.4 (8 -C), 55.6 (2 x OCH3), 54.2 (9-C), 41.8 (NCH3). MS [APCI (m/z)] calcd for 
(C20H22N 4O3S + H)+ = 399, found 399. Crude yield: 95%. Purity: 96% (LC).
(±)
OMe
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-3-ethyl-7-methyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4- 
one 47a.
' ^ s (From (±)-23) MS [APCI (m/z)] calcd for (C16H19N 3O3S + H)+ = 334, found 
334. Crude yield: 70%. Purity: 78% (LC).
O
MeN 1"'N
(±)
O
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(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-phenethyl-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 47b.
(From (±)-23) MS [APCI (m/z)] calcd for (C22H23N3O3S + H)+ = 410, found 
410. Crude yield: 6 8 %. Purity: 76% (LC).
(±)
(±)-Ethyl 3-{(5R,9R)-9-(1,3-benzodioxol-5-yl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-3-yl}propanoate 47c.
(From (±)-23) MS [APCI (m/z)] calcd for (Q 9H23N3O5S + H)+ = 406, found 
406. Crude yield: 71%. Purity: 8 6 % (LC).
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-phenyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4- 
one 47d.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDCI3]: 8.34 (bs, 1 1H, NH), 
7.51-7.36 (m, 3 1H, 3"-CH + 4"-CH + 5"-CH), 7.20-7.11 (m, 2 1H, 2"-CH + 
6 "-CH), 6.81 (d, J = 1.8 Hz, 1 1H, 4'-CH), 6.77 (d, J = 7.8 Hz, 1 1H, 7'-CH), 
6.67 (dd; J = 7.8, 1.8 Hz; 1 1H, 6 '-CH), 5.96 (s, 2 1H, 2 '-CH2), 3.94 (dd; J = 8.7,
6.9 Hz; 1 1H, 9-CH), 3.27 (dd; J = 9.6, 6.9 Hz; 1 1H, 8 -CHH), 3.17 (d, J = 10.2 
Hz, 1 1H, 6 -CHH), 3.11 (d, J = 10.2 Hz, 1 1H, 6 -CHH), 3.00 (dd(3), J = 9.3 
Hz, 1 1H, 8 -CHH), 2.49 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCls]: 181.9 (2-C), 174.4 
(4-C), 148.3 (3'a-C), 147.5 (7'a-C), 132.8 (1"-C), 129.5 (5'-C), 129.3 (4"-C), 129.2 (3"-C + 5"-C), 128.4 
(2"-C + 6 ''-C), 121.6 (6 '-C), 108.(3 (7'-C), 108.2 (4'-C), 101.3 (2'-C), 73.3 (5-C), 64.2 (6 -C), 57.7 (8 -C),
54.1 (9-C), 41.9 (NCH3). FTIR [V (cm-1), neat]: 3156, 2940, 2846, 2789, 1746, 1253, 1236, 1036, 931, 
756, 694. MS [APCI (m/z)] calcd for (C20H19N3O3S + H)+ = 382, found 382. Crude yield: 90%. 
Purity: 92% (LC).
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1,3,7-tri- 
azaspiro[4.4]nonan-4-one 47e.
(From (±)-23) MS [APCI (m/z)] calcd for (C21H18F3N 3O3S + H)+ = 450, 
found 450. Crude yield: 83%. Purity: 96% (LC).
(±)
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(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-3-(4-ethoxyphenyl)-7-methyl-2-thioxo-1,3,7-triazaspiro- 
OEt [4.4]nonan-4-one 47f.
(From (±)-23) MS [APCI (m/z)] calcd for (C22H23N 3O4S + H)+ = 426, found 
426. Crude yield: 98%. Purity: 95% (LC).
(±)
(±)-3-{(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-3- 
CN yl}benzonitrile 47g.
(From (±)-23) MS [APCI (m/z)] calcd for (C21H18N4O3S + H)+ = 407, found 
407. Crude yield: 97%. Purity: 96% (LC).
O
>
O
(±)
(±)-(5R,9R)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-(3-pyridyl)-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 47h.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDCI3]: 8.65 (dd; J = 4.8, 1.5 
Hz; 1 1H, 6 "-CH), 8.47 (d, J = 2.4 Hz, 1 1H, 2"-CH), 7.57 (ddd; J = 8.1, 2.4, 
1.5 Hz; 1 1H, 4"-CH), 7.41 (ddd; J = 8.1, 4.8, 0.6 Hz; 1 1H, 5"-CH), 6.78 (d, J 
= 7.8 Hz, 1 !H, 7'-CH), 6.77 (d, J = 1.8 Hz, 1 !H, 4'-CH), 6 . 6 6  (dd; J = 7.8, 1.8 
Hz; 1 !H, 6 '-CH), 5.98 (s, 2 !H, 2 '-CH2), 3.95 (dd; J = 9.0, 5.7 Hz; 1 !H, 9-CH), 
3.30 (dd; J = 9.6, 5.7 Hz; 1 !H, 8 -CHH), 3.18 (d, J = 9.9 Hz, 1 !H, 6 -CHH), 
3.08 (d, J = 9.9 Hz, 1 !H, 6 -CHH), 2.97 (dd(3), J = 9.6 Hz, 1 !H, 8 -CHH), 2.50 (s, 3 !H, NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDCI3]: 181.5 (2-C), 174.3 (4-C), 150.4 (6 ''-C), 149.7 (2''-C), 149.0 (3'a-C), 
148.1 (7'a-C), 136.3 (4''-C), 130.2 (3''-C), 130.1 (5'-C), 124.1 (5''-C), 121.9 (6 '-C), 109.3 (7'-C), 108.5 
(4'-C), 101.9 (2'-C), 73.8 (5-C), 64.8 (6 -C), 60.3 (8 -C), 54.6 (9-C), 42.2 (NCH3). FTIR [ V (cm-1), neat]: 
3069, 2940, 2848, 2787, 1748, 1253, 1236, 1036, 930, 707. MS [APCI (m/z)] calcd for (C19H18N4O3S 
+ H)+ = 383, found 383. Crude yield: 97%. Purity: 93% (LC).
(±)-(5R,9R)-3-Ethyl-9-(2-furyl)-7-methyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 48a.
(From (±)-24) MS [APCI (m/z)] calcd for (C13H17N 3O2S + H)+ = 280, found 280. 
Crude yield: quantitative. Purity: 85% (LC).
MeN
(±)
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(±)-(5R,9R)-9-(2-Furyl)-7-methyl-3-phenethyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 48b.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3 ]: 7.76 (bs, 1 !H, NH),
7.36-7.18 (m, 6  !H, 5'-CH + Ph), 6.29 (dd; J = 3.3, 1.8 Hz; 1 !H, 4'-CH), 6.10 
(d, J = 3.3 Hz, 1 !H, 3'-CH), 4.07-3.97 (m, 2 ^ ,  NCH2CH2), 3.94 (dd; J = 9.3,
6.9 Hz; 1 !H, 9-CH), 3.25 (dd; J = 9.6, 6.9 Hz; 1 ^ ,  8 -CHH), 3.02-2.85 (m, 5 
!H, 6 -CH2 + 8 -CHH + NCH2CH2), 2.43 (s, 3 !H, NCH3). 13C NMR [75 MHz,
5 (ppm), CDCI3]: 182.5 (2-C), 174.2 (4-C), 150.2 (2'-C), 143.0 (5'-C), 137.9 (1''- 
C), 129.1 (2''-C + 6 ''-C), 128.6 (3''-C + 5''-C), 126.7 (4''-C), 110.5 (4'-C), 108.0 
(3'-C), 71.6 (5-C), 64.4 (6 -C), 58.0 (8 -C), 46.7 (9-C), 42.4 (NCH2CH2), 41.8 
(NCH3), 33.6 (NCH2CH2). FTIR [V (cm-1), neat]: 3283, 2941, 2846, 2793, 1740, 743, 700. MS 
[APCI (m/z)] calcd for (Ci9H2iN 3O2S + H)+ = 356, found 356. Crude yield: quantitative. Purity: 
94% (LC).
(±)
(±)-Ethyl 3-{(5R,9R)-9-(2-furyl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}pro- 
(X^ Et panoate 48c.
(From (±)-24) MS [APCI (m/z)] calcd for (C16H21N3O4S + H)+ = 352, foundO.v
^=S 352. Crude yield: quantitative. Purity: 92% (LC).
II
O
(±)
(±)-(5R,9R)-9-(2-Furyl)-7-methyl-3-phenyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 48d.
i f \  (From (±)-24) MS [APCI (m/z)] calcd for (C17H17N 3O2S + H)+ = 328, found 328.
O.v
Crude yield: 76%. Purity: 98% (LC).
MeN 1 "N
o O
(±)
CF3
4''
f  V '
MeN
(±)-(5R,9R)-9-(2-Furyl)-7-methyl-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1,3,7-triazaspiro[4.4]- 
nonan-4-one 48e.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3 ]: 8.52 (bs, 1 1H, NH), 7.79­
7.71 (m, 2 1H, 3''-CH + 5''-CH), 7.51-7.43 (m, 2 1H, 2''-CH + 6 ''-CH), 7.40 (d, J =
1.8 Hz, 1 1H, 5'-CH), 6.35 (dd; J = 3.3, 1.8 Hz; 1 1H, 4'-CH), 6.23 (d, J = 3.3 Hz, 1 
1H, 3'-CH), 4.12 (dd; J = 9.0, 7.8 Hz; 1 1H, 9-CH), 3.35 (dd; J = 9.6, 7.8 Hz; 1 1H,
8 -CHH), 3.17 (2d(3), J = 10.6 Hz, 2 1H, 6 -CH2), 3.05 (dd(3), J = 9.6 Hz, 1 1H, 8 - 
CHH), 2.49 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 181.6 (2-C),
173.6 (4-C), 149.9 (2'-C), 143.2 (5'-C), 136.1 (q, J = 1.4 Hz, 1''-C), 131.1 (q, J = 32.7 Hz, 4''-C), 128.9 
(2''-C + 6 ''-C), 126.3 (q, J = 3.7 Hz, 3''-C + 5''-C), 123.8 (q, J = 270.8 Hz, CF3), 110.6 (4'-C), 108.2 (3'- 
C), 72.4 (5-C), 64.0 (6 -C), 57.4 (8 -C), 47.6 (9-C), 41.9 (NCH3). MS [APCI (m/z)] calcd for 
(C18H16F3N3O2S + H)+ = 396, found 396. Crude yield: quantitative. Purity: 98% (LC).
(±)
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(±)-(5R,9R)-3-(4-Ethoxyphenyl)-9-(2-furyl)-7-methyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4- 
one 48f.
(From (±)-24) MS [APCI (m/z)] calcd for (C19H21N 3O3S + H)+ = 372, found 
372. Crude yield: 90%. Purity: 97% (LC).
O_s
MeN
N
"N
-, H
;o
CN
(±)
(±)-3-{(5R,9R)-9-(2-Furyl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}benzoni- 
trile 48g.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3 ]: 8.30 (bs, 1 1H, NH), 
7.76-7.70 (m, 1 1H, 6 -CH), 7.64 (t, J = 1.5 Hz, 1 1H, 2-CH), 7.62-7.55 (m, 2 1H,
4-CH + 5-CH), 7.41 (d, J = 1.8 Hz, 1 1H, 5"-CH), 6.36 (dd; J = 3.3, 1.8 Hz; 1 
1H, 4"-CH), 6.24 (d, J = 3.3 Hz, 1 !H, 3"-CH), 4.12 (dd; J = 9.0, 7.5 Hz; 1 !H,
9-CH), 3.35 (dd; J = 9.6, 7.5 Hz; 1 !H, 8 '-CHH), 3.15 (2d(3), J = 10.5 Hz, 2 !H, 
6 '-CH2), 3.04 (dd(3), J = 9.6 Hz, 1 !H, 8 '-CHH), 2.50 (s, 3 !H, NCH3). 13C 
NMR [75 MHz, 5 (ppm), CDCI3]: 181.3 (2'-C), 173.4 (4'-C), 149.9 (2"-C), 143.3 (5"-C), 133.8 (3-C),
133.0 (4-C), 132.6 (6 -C), 132.1 (2-C), 130.1 (5-C), 117.8 (CN), 113.4 (1-C), 110.7 (4"-C), 108.2 (3"-C),
72.4 (5'-C), 64.0 (6 '-C), 57.4 (8 '-C), 47.7 (9'-C), 41.8 (NCH3). FTIR [ V (cm-1), neat]: 3256, 2940, 2844, 
2795, 2231, 1751, 733. MS [APCI (m/z)] calcd for (C18H16N 4O2S + H)+ = 353, found 353. Crude 
yield: quantitative. Purity: 93% (LC).
(±)
(±)-(5R,9R)-9-(2-Furyl)-7-methyl-3-(3-pyridyl)-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 48h.
r ^ N (From (±)-24) MS [APCI (m/z)] calcd for (C16H16N 4O2S + H)+ = 329, found 329. 
Crude yield: 98%. Purity: >99% (LC).
O-  N
^ S
MeN I "N
; o
(±)
(±)-(5R,9R)-3-Ethyl-7-methyl-9-(1-methyl-1H-mdol-3-yl)-2-thioxo-1,3,7-triazaspiro[4.4]nonan-
4-one 49a.
(From (±)-25) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.46 (d, J = 7.8 Hz, 1 
!H, 4'-CH), 7.29 (d, J = 8.1 Hz, 1 !H, 7'-CH), 7.20 (ddd(7); J = 8.1, 6.9, 0.9 Hz;
1 !H, 6 '-CH), 7.07 (ddd(7); J = 7.8, 6.9, 1.2 Hz; 1 !H, 5'-CH), 6.98 (s, 1 !H, 2'- 
CH), 4.24 (dd; J = 9.0, 6 . 6  Hz; 1 !H, 9-CH), 3.75 (s, 3 !H, 1 '-NCH3), 3.76-3.68 
(m, 2 !H, CH2CH3), 3.32 (dd; J = 9.3, 6 . 6  Hz; 1 !H, 8 -CHH), 3.09 (d, J = 10.2 
Hz, 1 !H, 6 -CHH), 3.07 (dd(3), J = 9.3 Hz, 1 !H, 8 -CHH), 3.04 (d, J = 10.2 Hz, 1 !H, 6 -CHH), 2.52 
(s, 3 !H, 7 -NCH3), 1.03 (t, J = 7.2 Hz, 3 !H, CH2CH3). 13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 182.4 
(2-C), 175.1 (4-C), 137.2 (7'a-C), 127.3 (3'a-C), 127.2 (2'-C), 122.4 (6 '-C), 119.9 (5'-C), 118.6 (4'-C),
109.7 (3'-C + 7'-C), 72.2 (5-C), 64.7 (6 -C), 60.5 (8 -C), 45.4 (9-C), 41.9 (7-NCH3), 36.4 (CH2CH3), 33.0
Me
(±)
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(r-NCHa), 12.8 (CH2CH3). FTIR [ V (cm-1), neat]: 3171, 2937, 2841, 2787, 1735, 739. MS [APCI 
(m/z)] calcd for (C18H22N4OS + H)+ = 343, found 343. Crude yield: 79%. Purity: 82% (LC).
(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-3-phenethyl-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 49b.
(From (±)-25) MS [APCI (m/z)] calcd for (C24H26N 4OS + H)+ = 419, found 
419. Crude yield: 8 6 %. Purity: 93% (LC).
Me
(±)
(±)-Ethyl 3-{(5R,9R)-7-methyl-9-(1-methyl-1H-indol-3-yl)-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-3-yl}propanoate 49c.
(From (±)-25) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.46 (d, J = 8.1 Hz, 1 
!H, 4"-CH), 7.28 (d, J = 8.1 Hz, 1 !H, 7"-CH), 7.22 (ddd(7); J = 8.1, 6.9, 0.9 
Hz; 1 !H, 6 '-CH), 7.09 (ddd(7); J = 8.1, 6.9, 1.2 Hz; 1 !H, 5'-CH), 7.08 (s, 1 !H, 
2"-CH), 4.30 (dd; J = 9.0, 6.9 Hz; 1 !H, 9'-CH), 4.09 (q, J = 7.2 Hz, 2 !H, 
Me CH2CH3), 3.98-3.87 (m, 2 !H, 3 -CH2), 3.76 (s, 3 !H, 1 ''-NCH3), 3.53 (dd; J =
(±) 9.6, 6.9 Hz; 1 !H, 8 '-CHH), 3.27 (d, J = 10.2 Hz, 1 !H, 6 '-CHH), 3.17 (d, J =
10.2 Hz, 1 !H, 6 '-CHH), 3.15 (dd(3), J = 9.4 Hz, 1 !H, 8 '-CHH), 2.63 (s, 3 !H, 7'-NCHs), 2.48-2.35 
(m, 2 !H, 2 -CH2), 1.24 (t, J = 7.2 Hz, 3 XH, CH2CH3). 13C NMR [75 MHz, 5 (ppm), CDCI3 ]: 182.2 
(2'-C), 174.9 (4'-C), 171.2 (CO2), 137.6 (7''a-C), 128.1 (2''-C), 127.6 (3''a-C), 122.9 (6 ''-C), 120.4 (5''-C),
118.8 (4''-C), 110.3 (7''-C), 109.0 (3''-C), 72.5 (5'-C), 64.6 (6 '-C), 61.3 (CH2CH3), 60.6 (8 '-C), 45.7 (9'- 
C), 42.3 (7 '-NCH3), 37.3 (3-C), 33.5 (1 ''-NCH3), 32.3 (2-C), 14.7 (CH2CH3). FTIR [V (cm-1), neat]: 
3278, 2937, 2840, 2789, 1734, 738. MS [APCI (m/z)] calcd for (C21H26N 4O3S + H)+ = 415, found
415. Crude yield: 81%. Purity: 94% (LC).
(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-3-phenyl-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 49d.
(From (±)-25) MS [APCI (m/z)] calcd for (C22H22N 4OS + H)+ = 391, found
391. Crude yield: 82%. Purity: 97% (LC).
Me
(±)
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(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1,3,7-
(From (±)-25) MS [APCI (m/z)] calcd for (C23H21F3N 4OS + H)+ = 459, found 
459. Crude yield: 84%. Purity: 97% (LC).
Me
(±)
(±)-(5R,9R)-3-(4-Ethoxyphenyl)-7-methyl-9-(1-methyl-1H-mdol-3-yl)-2-thioxo-1,3,7-triaza- 
OEt spiro[4.4]nonan-4-one 49f.
(From (±)-25) MS [APCI (m/z)] calcd for (C24H26N4O2S + H)+ = 435, found
435. Crude yield: 90%. Purity: 93% (LC).
Me
(±)
(±)-3-{(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-
3-yl}benzonitrile 49g.
(From (±)-25) MS [APCI (m/z)] calcd for (C23H21N5OS + H)+ = 416, found
416. Crude yield: 82%. Purity: 93% (LC).
Me
(±)
(±)-(5R,9R)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-3-(3-pyridyl)-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 49h.
(From (±)-25) MS [APCI (m/z)] calcd for (C21H21N 5OS + H)+ = 392, found
392. Crude yield: 95%. Purity: 96% (LC).
Me
(±)
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-3-ethyl-7-methyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4- 
one 50a.
(From (±)-26) *H NMR [400 MHz, 5 (ppm), CDCI3 ]: 9.29 (bs, 1 1H, NH),
6.33 (t, J = 2.2 Hz, 1 1H, 4'-CH), 6.29 (d, J = 2.2 Hz, 2 1H, 2'-CH + 6 '-CH),
3.73 (s, 6  1H, 2  x OCH3), 3.64 (dd; J = 12.2, 6.2 Hz; 1 1H, 9-CH), 3.63 
(dddd(6 ); J = 13.5, 7.0, 7.0, 7.0 Hz; 1 1H, CHHCH3), 3.48 (dddd(6 ); J = 13.5,
7.0, 7.0, 7.0 Hz; 1 1H, CHHCH3), 3.38 (dd; J = 9.4, 6.2 Hz; 1 1H, 8 -CHH),(±)
OMe
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3.33 (d, J = 11.1 Hz, 1 iH, 6 -CHH), 3.08 (dd; J = 12.2, 9.4 Hz; 1 IH, 8 -CHH), 2.99 (d, J = 11.1 Hz, 1 
!H, 6 -CHH), 2.63 (s, 3 1H, NCH3), 0.70 (t, J = 7.0 Hz, 1 1H, CH2CH3). 13C NMR [75 MHz, 5 (ppm), 
CDCI3 ]: 183.1 (2-C), 174.1 (4-C), 160.9 (3'-C + 5'-C), 135.9 (1'-C), 105.5 (2'-C + 6 '-C), 100.4 (4'-C),
72.4 (5-C), 63.5 (6 -C), 58.1 (8 -C), 55.5 (2 x OCH3), 55.4 (9-C), 42.1 (NCH3 ), 36.0 (CH2CH3), 12.3 
(CH2CH3). FTIR [ V (cm-1), neat]: 3186, 2938, 2837, 2792, 1737, 1595, 1203, 1153, 846. HRMS [ESI 
(m/z)] calcd for (C17H23N 3O3S + H)+ = 350.15384, found 350.15322 ( |A|  = 1.8 ppm). Crude 
yield: 89%. Purity: 94% (LC).
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-phenethyl-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 50b.
(From (±)-26) 1H NMR [400 MHz, 5 (ppm), CDCI3 ]: 9.39 (bs, 1 1H, NH),
7.29-7.23 (m, 2 1H, 3"-CH + 5"-CH), 7.22-7.16 (m, 1 1H, 4"-CH), 7.16-7.10 
(m, 2 1H, 2"-CH + 6 "-CH), 6.32 (s, 3 1H, 2'-CH + 4'-CH + 6 '-CH), 3.81-3.73 
(m, 1 1H, NCHHCH2), 3.73 (s, 6  1H, 2 x OCH3), 3.69-3.59 (m, 2 1H, 9-CH + 
NCHHCH2), 3.40 (dd; J = 9.3, 6.1 Hz; 1 1H, 8 -CHH), 3.33 (d, J = 11.2 Hz, 1 
1H, 6 -CHH), 3.09 (dd; J = 12.2, 9.3 Hz; 1 1H, 8 -CHH), 2.94 (d, J = 11.2 Hz, 1 
1H, 6 -CHH), 2.63 (s, 3 1H, NCH3), 2.55 (ddd; J = 12.8, 11.4, 5.8 Hz; 1 1H, 
NCH2CHH), 2.14 (ddd; J = 12.8, 11.6, 5.0 Hz; 1 1H, NCH2CHH). 13C NMR [75 MHz, 5 (ppm), 
CDCI3 ]: 183.0 (2-C), 174.1 (4-C), 161.0 (3'-C + 5'-C), 138.1 (1"-C), 136.0 (1'-C), 128.9 (2"-C + 6 "-C),
128.6 (3"-C + 5"-C), 126.7 (4"-C), 105.7 (2'-C + 6 '-C), 100.3 (4'-C), 72.5 (5-C), 63.6 (6 -C), 58.1 (8 -C),
55.6 (2 x OCH3), 55.3 (9-C), 42.1 (NCH2CH2), 42.0 (NCH3), 33.2 (NCH2CH2). FTIR [ V (cm-1), 
neat]: 3192, 2940, 2837, 2794, 1740, 1595, 1202, 1152, 846, 697. HRMS [ESI (m/z)] calcd for 
(C23H27N 3O3S + H)+ = 426.18514, found 426.18460 ( |A|  = 1.3 ppm). Crude yield: 84%. Purity: 
>99% (LC).
(±)-Ethyl 3-{(5R,9S)-9-(3,5-dimethoxyphenyl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]-
(From (±)-26) MS [APCI (m/z)] calcd for (C20H27N 3O5S + H)+ = 422, 
found 422. Crude yield: 94%. Purity: 95% (LC).
(±)
OMe
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-phenyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-
4-one 50d.
(From (±)-26) MS [APCI (m/z)] calcd for (C21H23N 3O3S + H)+ = 398, 
found 398. Crude yield: 93%. Purity: 98% (LC).
(±)
OMe
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(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1,3,7- 
triazaspiro[4.4]nonan-4-one 50e.
(From (±)-26) MS [APCI (m/z)] calcd for (C22H22F3N3O3S + H)+ = 466, 
found 466. Crude yield: 73%. Purity: >99% (LC).
(±)
OMe
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-3-(4-ethoxyphenyl)-7-methyl-2-thioxo-1,3,7-triazaspiro-
(From (±)-26) MS [APCI (m/z)] calcd for (C23H27N3O4S + H)+ = 442, found 
442. Crude yield: 90%. Purity: >99% (LC).
(±)
OMe
(±)-3-{(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-3- 
yl}benzonitrile 50g.
CN
CN (From (±)-26) MS [APCI (m/z)] calcd for (C22H22N4O3S + H)+ = 423, found
423. Crude yield: quantitative. Purity: >99% (LC).
MeN "NJH^^„OMe
(±) OMe
(±)-(5R,9S)-9-(3,5-Dimethoxyphenyl)-7-methyl-3-(3-pyridyl)-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 50h.
(From (±)-26) MS [APCI (m/z)] calcd for (C20H22N4O3S + H)+ = 399, found 
399. Crude yield: 97%. Purity: 94% (LC).
(±)
OMe
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-3-ethyl-7-methyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4- 
one 51a.
O -N S (From (±)-27) MS [APCI (m/z)] calcd for (C16H19N3O3S + H)+ = 334, found
MeN T N 334. Crude yield: 85%. Purity: 85% (LC).
-H^  ,O
O
(±)
133
Chapter 4
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-phenethyl-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 51b.
(From (±)-27) MS [APCI (m/z)] calcd for (C22H23N3O3S + H)+ = 410, found 
410. Crude yield: 8 6 %. Purity: 97% (LC).
(±)
(±)-Ethyl 3-{(5R,9S)-9-(1,3-benzodioxol-5-yl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]-
CO2Et
3 2
O
MeN
N\?_
5' r  > O
(±) 7"
7''a
nonan-3-yl}propanoate 51c.
(From (±)-27) *H NMR [400 MHz, 5 (ppm), CDCI3]: 8.58 (bs, 1 !H, NH),
6.72 (d, J = 8.0 Hz, 1 !H, 7"-CH), 6 .66 (d, J = 1.4 Hz, 1 !H, 4"-CH), 6.62 (dd; J 
= 8.0, 1.4 Hz; 1 !H, 6 "-CH), 5.94 (s, 2 !H, 2 "-CH2), 4.09 (q, J = 7.1 Hz, 2 !H, 
CH2CH3), 3.87 (ddd; J = 13.6, 10.3, 5.8 Hz; 1 !H, 3-CHH), 3.74 (ddd; J =
13.6, 10.3, 5.3 Hz; 1 !H, 3-CHH), 3.65 (dd; J = 12.0, 6.0 Hz; 1 !H, 9'-CH),
3.35 (d, J = 11.2 Hz, 1 !H, 6 '-CHH), 3.36-3.32 (m, 1 !H, 8 '-CHH), 3.03 (dd; J = 12.0, 9.8 Hz; 1 !H, 8 '- 
CHH), 2.99 (d, J = 11.2 Hz, 1 !H, 6 '-CHH), 2.60 (s, 3 !H, NCH3), 2.27 (ddd; J = 16.3, 10.3, 5.8 Hz; 1 
!H, 2-CHH), 1.92 (ddd; J = 16.3, 10.3, 5.3 Hz; 1 !H, 2-CHH), 1.23 (t, J = 7.1 Hz, 3 !H, CH2CH3). 13C 
NMR [75 MHz, 5 (ppm), CDCI3]: 182.3 (2'-C), 173.9 (4'-C), 170.5 (CO2), 148.0 (3''a-C), 147.8 (7''a- 
C), 126.9 (5''-C), 121.5 (6 ''-C), 108.5 (7''-C), 108.3 (4''-C), 101.4 (2''-C), 72.6 (5'-C), 63.1 (6 '-C), 60.8 
(CH2CH3), 58.6 (8 '-C), 55.4 (9'-C), 41.9 (NCH3), 36.3 (3-C), 31.6 (2-C), 14.3 (CH2CH3). FTIR [V 
(cm-1), neat]: 3282, 2948, 2842, 2784, 1741, 1731, 1252, 1236, 1036, 928. HRMS [ESI (m/z)] calcd 
for (C19H23N3O5S + H)+ = 406.14367, found 406.14128 (| A | = 5.9 ppm). Crude yield: 98%. Purity: 
97% (LC).
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-phenyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4- 
one 51d.
(From (±)-27) MS [APCI (m/z)] calcd for (C20H19N3O3S + H)+ = 382, found
382. Crude yield: 98%. Purity: >99% (LC).
(±)
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1,3,7-tri-
(From (±)-27) MS [APCI (m/z)] calcd for (C21H18F3N3O3S + H)+ = 450, 
found 450. Crude yield: 95%. Purity: >99% (LC).
O
O
(±)
134
Synthesis o f H ydantoins and Thiohydantoins Spiro-Fused to Pyrrolidines
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-3-(4-ethoxyphenyl)-7-methyl-2-thioxo-1,3,7-triazaspiro- 
OEt [4.4]nonan-4-one 51f.
(From (±)-27) MS [APCI (m/z)] calcd for (C22H23N3O4S + H)+ = 426, found 
426. Crude yield: 99%. Purity: 99% (LC).
MeN 1 "N
(±)
O
MeN
(±)
(±)-3-{(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-3- 
yl}benzonitrile 51g.
(From (±)-27) *H NMR [400 MHz, 5 (ppm), CD3SOCD3]: 11.17 (bs, 1 !H, 
NH), 7.86 (dt; J = 7.8, 1.4 Hz; 1 iH, 6-CH), 7.63 (dd(3), J = 8.0 Hz, 1 iH, 5- 
CH), 7.07 (dt; J = 8.0, 1.4 Hz; 1 1H, 4-CH), 7.00 (t, J = 1.4 Hz, 1 1H, 2-CH), 
6.91 (d, J = 8.0 Hz, 1 1H, 7"-CH), 6.72 (d, J = 1.4 Hz, 1 1H, 4"-CH), 6 .66  (dd; J 
= 8.0, 1.4 Hz; 1 1H, 6"-CH), 6.02-6.00 (m, 2 1H, 2 "-CH2), 3.71 (dd; J = 11.7,
6.2 Hz; 1 1H, 9'-CH), 3.27 (d, J = 11.2 Hz, 1 1H, 6 '-CHH), 3.12 (dd; J = 9.2,
6.2 Hz; 1 1H, 8 '-CHH), 2.92 (dd; J = 11.7, 9.2 Hz; 1 1H, 8 '-CHH), 2.88 (d, J = 11.2 Hz, 1 1H, 6 '- 
CHH), 2.38 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CD3SOCD3]: 180.5 (2'-C), 173.9 (4'-C),
147.1 (3''a-C), 146.7 (7''a-C), 133.7 (3-C), 133.4 (4-C), 132.4 (6-C), 131.7 (2-C), 130.2 (5-C), 128.3 (5''- 
C), 121.2 (6 ''-C), 117.7 (CN), 111.6 (1-C), 108.1 (7''-C), 107.9 (4''-C), 101.1 (2''-C), 73.5 (5'-C), 61.7 (6 '- 
C), 57.1 (8 '-C), 53.7 (9'-C), 41.7 (NCH3). FTIR [V (cm-1), neat]: 3240, 2951, 2840, 2781, 2229, 1752, 
1252, 1236, 1036, 930. HRMS [ESI (m/z)] calcd for (C21H18N4O3S + H)+ = 407.11779, found 
407.11531 (| A | = 6.1 ppm). Crude yield: quantitative. Purity: 97% (LC).
(±)-(5R,9S)-9-(1,3-Benzodioxol-5-yl)-7-methyl-3-(3-pyridyl)-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 51h.
(From (±)-27) MS [APCI (m/z)] calcd for (C19H18N4O3S + H)+ = 383, found
383. Crude yield: quantitative. Purity: >99% (LC).
(±)
(±)-(5R,9S)-3-Ethyl-9-(2-furyl)-7-methyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 52a.
O
MeN
(From (±)-28) MS [APCI (m/z)] calcd for (C13H17N3O2S + H)+ = 280, found 280. 
N—g Crude yield: 91%. Purity: 95% (LC).
(±)
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(±)-(5R,9S)-9-(2-Furyl)-7-methyl-3-phenethyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 52b.
(From (±)-28) MS [APCI (m/z)] calcd for (C19H21N3O2S + H)+ = 356, found 
356. Crude yield: 8 8 %. Purity: 98% (LC).
(±)
(±)-Ethyl 3-{(5R,9S)-9-(2-furyl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}pro-
(From (±)-28) MS [APCI (m/z)] calcd for (C16H21N3O4S + H)+ = 352, found
352. Crude yield: 89%. Purity: 96% (LC).
(±)
(±)-(5R,9S)-9-(2-Furyl)-7-methyl-3-phenyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 52d.
(From (±)-28) *H NMR [400 MHz, 5 (ppm), CDCI3]: 9.17 (bs, 1 1H, NH), 7.46­
7.35 (m, 4 1H, 5'-CH + 3"-CH + 4"-CH + 5"-CH), 7.06-6.99 (m, 2 1H, 2"-CH + 6 "- 
CH), 6.36 (dd; J  = 3.3, 2.0 Hz; 1 1H, 4'-CH), 6.23 (d, J  = 3.3 Hz, 1 1H, 3'-CH), 3.91 
(dd; J  = 11.6, 6.6 Hz; 1 1H, 9-CH), 3.50 (dd; J  = 9.4, 6 .6  Hz; 1 1H, 8-CHH), 3.43 
(d, J  = 10.8 Hz, 1 1H, 6-CHH), 3.06 (d, J  = 10.8 Hz, 1 1H, 6-CHH), 2.94 (dd; J  =
11.6, 9.4 Hz; 1 1H, 8-CHH), 2.59 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), 
CDCI3]: 183.0 (2-C), 173.3 (4-C), 149.1 (2'-C), 142.5 (5'-C), 132.8 (1"-C), 129.2 (4"- 
C), 129.1 (3"-C + 5"-C), 128.3 (2"-C + 6 "-C), 110.9 (4'-C), 108.2 (3'-C), 72.2 (5-C), 63.9 (6-C), 57.9 (8- 
C), 50.2 (9-C), 41.8 (NCH3). FTIR [V (cm-1), neat]: 3110, 2948, 2847, 2794, 1753, 760, 732, 691. 
HRMS [ESI (m/z)] calcd for (C17H17N3O2S + H)+ = 328.11197, found 328.11137 (| A | = 1.8 ppm). 
Crude yield: 95%. Purity: 99% (LC).
O
MeN
4 V
"NH 3'
(±)
o 5'
(±)-(5R,9S)-9-(2-Furyl)-7-methyl-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1,3,7-triazaspiro[4.4]- 
CF3 nonan-4-one 52e.
(From (±)-28) MS [APCI (m/z)] calcd for (C18H16F3N3O2S + H)+ = 396, found 
396. Crude yield: 79%. Purity: 96% (LC).
MeN
(±)
(±)-(5R,9S)-3-(4-Ethoxyphenyl)-9-(2-furyl)-7-methyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 
OEt 52f.
(From (±)-28) *H NMR [400 MHz, 5 (ppm), CDQ3]: 9.46 (bs, 1 1H, NH), 7.38 
(dd; J  = 1.8, 0.6 Hz; 1 1H, 5"-CH), 6.94-6.86 (m, 4 1H, 2'-CH + 3'-CH + 5'-CH + 
6 '-CH), 6.35 (dd; J  = 3.2, 1.8 Hz; 1 1H, 4"-CH), 6.23 (d, J  = 3.2 Hz, 1 1H, 3"-CH), 
MeN 1 'H 4 .0 2  (q, J  = 7.0 Hz, 2 1H, CH2CH3), 3.88 (dd; J  = 11.7, 6.6  Hz; 1 1H, 9-CH), 3.49
(dd; J  = 9.3, 6.6 Hz; 1 1H, 8-CHH), 3.41 (d, J  = 10.8 Hz, 1 1H, 6-CHH), 3.05 (d, J
(±)
5
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= 10.8 Hz, 1 !H, 6-CHH), 2.93 (dd; J = 11.7, 9.3 Hz; 1 !H, 8-CHH), 2.59 (s, 3 !H, NCH3), 1.40 (t, J =
7.0 Hz, 3 !H, CH2CH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 183.5 (2-C), 173.5 (4-C), 159.4 (4'-C),
149.2 (2"-C), 142.4 (5"-C), 129.3 (2'-C + 6 '-C), 125.2 (1'-C), 114.9 (3'-C + 5'-C), 110.8 (4"-C), 108.1 
(3"-C), 72.1 (5-C), 64.0 (6-C), 63.8 (CH2CH3), 58.0 (8-C), 50.2 (9-C), 41.9 (NCH3), 14.9 (CH2CH3). 
FTIR [V (cm-1), neat]: 3278, 2937, 2841, 2795, 1750, 821, 732. HRMS [ESI (m/z)] calcd for 
(C19H21N3O3S + H)+ = 372.13819, found 372.13606 ( |A|  = 5.7 ppm). Crude yield: 93%. Purity: 
99% (LC).
(±)-3-{(5R,9S)-9-(2-Furyl)-7-methyl-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-3-yl}benzoni-
f \ ^ - C N  trile 5 2 g.
(From (±)-28) MS [APCI (m/z)] calcd for (C18H16N4O2S + H)+ = 353, found
-N
MeN l'"HII
o ~ y
353. Crude yield: 93%. Purity: 99% (LC).
(±)
(±)-(5R,9S)-9-(2-Furyl)-7-methyl-3-(3-pyridyl)-2-thioxo-1,3,7-triazaspiro[4.4]nonan-4-one 52h.
l f " ^ N (From (±)-28) MS [APCI (m/z)] calcd for (C16H16N4O2S + H)+ = 329, found 
329. Crude yield: quantitative. Purity: >99% (LC).
MeN "'H
V
N
, ^ S
o~ -/
(±)
(±)-(5R,9S)-3-Ethyl-7-methyl-9-(1-methyl-1H-indol-3-yl)-2-thioxo-1,3,7-triazaspiro[4.4]nonan-
I—  4-one 53a.
N
> = S
o
N (From (±)-29) MS [APCI (m/z)] calcd for (C18H22N4OS + H)+ = 343, found
MeN |"'H 343. Crude yield: 8 8 %. Purity: 90% (LC).
N
Me
(±)
(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-3-phenethyl-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 53b.
(From (±)-29) MS [APCI (m/z)] calcd for (C24H26N4OS + H)+ = 419, found
419. Crude yield: 8 8 %. Purity: 83% (LC).
Me
(±)
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(±)-Ethyl 3-{(5R,9S)-7-methyl-9-(1-methyl-1H-indol-3-yl)-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]-
(From (±)-29) MS [APCI (m/z)] calcd for (C21H26N4O3S + H)+ = 415, found
Me
(±)
(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-3-phenyl-2-thioxo-1,3,7-triazaspiro[4.4]nonan 
-4-one 53d.
(From (±)-29) MS [APCI (m/z)] calcd for (C22H22N4OS + H)+ = 391, found 
391. Crude yield: 85%. Purity: 96% (LC).
Me
(±)
(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1,3,7- 
triazaspiro[4.4]nonan-4-one 53e.
(From (±)-29) *H NMR [400 MHz, 5 (ppm), CDCI3]: 7.60 (d, J = 7.9 Hz, 1 
1H, 4'-CH), 7.44-7.38 (m, 2 1H, 3"-CH + 5"-CH), 7.32 (d, J = 8.2 Hz, 1 1H, 7'- 
CH), 7.29-7.23 (m, 1 1H, 6 '-CH), 7.18-7.11 (m, 1 1H, 5'-CH), 6.97 (s, 1 1H, 2'- 
CH), 6.37-6.29 (m, 2 !H, 2''-CH + 6 ''-CH), 4.33 (dd; J = 12.2, 6.4 Hz; 1 !H, 9- 
CH), 3.73 (s, 3 !H, 1'-NCHs), 3.65 (dd; J = 9.4, 6.4 Hz; 1 !H, 8-CHH), 3.60 (d, 
J = 11.0 Hz, 1 !H, 6-CHH), 3.19 (d, J = 11.0 Hz, 1 !H, 6-CHH), 3.08 (dd; J =
12.2, 9.4 Hz; 1 !H, 8-CHH), 2.75 (s, 3 !H, 7-NCHs). 13C NMR [75 MHz, 5 
(ppm), CDCls]: 182.2 (2-C), 173.4 (4-C), 137.0 (7'a-C), 135.8 (q, J = 1.4 Hz, 1''-C), 130.9 (q, J = 32.5 
Hz, 4''-C), 128.6 (2''-C + 6 ''-C), 127.5 (2'-C), 127.1 (3'a-C), 126.0 (q, J = 3.7 Hz, 3''-C + 5''-C), 123.7 (q, 
J = 270.5 Hz, CF3), 122.6 (6 '-C), 120.4 (5'-C), 118.7 (4'-C), 109.6 (7'-C), 107.0 (3'-C), 73.5 (5-C), 64.0 
(6-C), 59.4 (8-C), 49.3 (9-C), 42.2 (7 -NCH3), 33.1 (1 '-NCH3). FTIR [ V (cm-1), neat]: 3289, 2948, 
2829, 2795, 1751, 1321, 840, 737. HRMS [ESI (m/z)] calcd for (C23H21F3N4OS + H)+ = 459.14664, 
found 459.14440 (| A | = 4.9 ppm). Crude yield: 75%. Purity: 99% (LC).
Me
(±)
(±)-(5R,9S)-3-(4-Ethoxyphenyl)-7-methyl-9-(1-methyl-1H-mdol-3-yl)-2-thioxo-1,3,7-triazaspiro- 
OEt [4.4]nonan-4-one 53f.
(From (±)-29) MS [APCI (m/z)] calcd for (C24H26N4O2S + H)+ = 435, found 
435. Crude yield: 97%. Purity: 96% (LC).
Me
(±)
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(±)-3-{(5R,9S)-7-Methyl-9-(1-methyl-1H-mdol-3-yl)-4-oxo-2-thioxo-1,3,7-triazaspiro[4.4]nonan-
3-yl}benzonitrile 53g.
(From (±)-29) MS [APCI (m/z)] calcd for (C23H21N5OS + H)+ = 416, found
416. Crude yield: 99%. Purity: 97% (LC).
Me
(±)
(±)-(5R,9S)-7-Methyl-9-(1-methyl-1H-indol-3-yl)-3-(3-pyridyl)-2-thioxo-1,3,7-triazaspiro[4.4]- 
nonan-4-one 53h.
(From (±)-29) iH NMR [400 MHz, 5 (ppm), CDCI3]: 8.44 (dd; J = 4.8, 1.5 Hz;
1 1H, 6 "-CH), 7.58 (d, J = 7.9 Hz, 1 1H, 4'-CH), 7.44 (d, J = 2.0 Hz, 1 1H, 2''- 
CH), 7.32 (d, J = 8.2 Hz, 1 1H, 7'-CH), 7.29-7.23 (m, 1 1H, 6 '-CH), 7.17-7.11 
(m, 1 !H, 5'-CH), 7.11 (dd; J = 8.2, 4.8 Hz; 1 !H, 5"-CH), 6.98 (s, 1 !H, 2'-CH),
6.61 (ddd(6); J = 8.2, 1.8, 1.8 Hz; 1 !H, 4''-CH), 4.29 (dd; J = 12.0, 6.3 Hz; 1 
!H, 9-CH), 3.73 (s, 3 !H, 1 '-NCH3), 3.61 (dd; J = 9.2, 6.3 Hz; 1 !H, 8-CHH), 
3.55 (d, J = 11.0 Hz, 1 !H, 6-CHH), 3.16 (d, J = 11.0 Hz, 1 !H, 6-CHH), 3.03
Me
(±)
(dd; J = 12.0, 9.2 Hz; 1 !H, 8-CHH), 2.72 (s, 3 !H, 7-NCHs). 13C NMR [75 MHz, 5 (ppm), CDCI3]:
182.4 (2-C), 173.5 (4-C), 149.6 (6 ''-C), 149.0 (2''-C), 136.9 (7'a-C), 135.8 (4''-C), 129.6 (3''-C), 127.4 (2'- 
C), 127.1 (3'a-C), 123.4 (5''-C), 122.6 (6 '-C), 120.4 (5'-C), 118.5 (4'-C), 109.7 (7'-C), 107.2 (3'-C), 73.7 
(5-C), 64.3 (6-C), 59.6 (8-C), 49.5 (9-C), 42.3 (7-NCHs), 33.1 (1'-NCH3). FTIR [ V (cm-1), neat]: 3312, 
2948, 2842, 2794, 1751, 731, 708. HRMS [ESI (m/z)] calcd for (C21H21N5OS + H)+ = 392.15451, 
found 392.15151 (| A | = 7.6 ppm). Crude yield: quantitative. Purity: 96% (LC).
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CHAPTER 5
Synthesis of Dihydrouracils, 
Dihydrothiouracils, and ß-Lactams Spiro- 
Fused to Pyrrolidines
Ri
(±)
Abstract
In  th is  ch a p te r, th e  so lu tio n -p h ase  sy n th es is  of a lib ra ry  of d ih y d ro u ra c ils  sp iro - 
fu se d  to  p y rro lid in e s  is d esc rib ed . U n d e r  th e  sam e co n d itio n s , a lib ra ry  o f a -  
u re id o m e th y l ac ids w a s  sy n th e s iz e d  b y  h y d ro ly s is  of th e  c o r re sp o n d in g  sp iro  
d ih y d ro u ra c ils . T he o p tim iz a tio n  fo r a lib ra ry  sy n th es is  of d ih y d ro th io u ra c ils  sp iro - 
fu se d  to  p y rro lid in e s  is a lso  d esc rib ed . F inally , th e  sy n th es is  of n e w  scaffo lds su itab le  
fo r lib ra ry  sy n th esis , su ch  as sp iro  ß -lac tam s a n d  te tra h y d ro m e th a n o b e n z a z e p in e s , is 
ex p lo red .
Chapter 5
5.1 Introduction
Pyrimidine-2/4-diones are a class of bioactive heterocyclic m olecules, the m ost 
fam ous exam ples are uracil 1 and thymine 2 (Figure 5.1), which form part of the 
nucleotides of RNA and DN A, respectively .1 Pyrimidine-2,4-diones have attracted 
considerable attention in the pharmaceutical industry as anti-inflammatory agents,2 
dopam ine receptor agonists,3 serotonin uptake inhibitors,4 and antiepileptic agents .5 A  
good exam ple of a pyrimidine-2,4-dione derivative w ith a m edicinal application is 
zidovudine (AZT) 3, used as an anti-AIDS agent.6 This m oiety is also the core 
structural elem ent of som e fungicides7 and herbicides.8
2-Thiouracil (2-thioxopyrimidin-4-one) derivatives are less com m on and less studied  
than the pyrimidine-2,4-diones. Some of the 2-thiouracil derivatives have been used for 
treating coronary heart diseases9 and have been found to have hypoglycem ic activity .10 
6-Propyl-2-thiouracil (PTU) 4 has been used for more than 50 years to treat 
hyperthyroidism  (Figure 5.1) .11
1 2  3 4
Figure 5.1 Uracil 1, Thym ine  2, Z idovudine (A Z T ) 3, and 6-Propyl-2-thiouracil (PTU) 4.
This chapter deals w ith the solution-phase synthesis of libraries of com pounds that 
combine two privileged structures, that is, the dihydro(2 -thio)uracil ring and the 2-  
arylethyl am ine moiety, which m ay have pharmacological relevance. These new  
com pounds present the same spiranic framework as the com pounds from Chapter 4 
and could therefore be considered as their "homo" derivatives.
5.2 R esults and D iscussion
5.2.1 Synthesis o f Spiro D ihydro(thio)uracils
The substrates utilized for the library synthesis in this chapter are depicted in Figure
5.2. The synthesis of these a-am inom ethyl esters (±)-5-(±)-10 has been described in 
Chapter 2.
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GO2M© GO2M© GO2M©
M.N l " - 1NH2 M © ^ - ^  M e N ^ ' " - ^  om©
'OM©
C t
OM©
(±)-5 (±)-6 (±)-7
GO2M© GO2M© GO2M©
M © ^ , - NH2 Me^ - NH2 m© ^ ; - NH^
X >  Y v
0 M© ^N
M©
(±)-8 (±)-9 (±)-10
Figure 5.2 Substrates (±)-5-(±)-10 fo r  the Library Synthesis.
The procedure follow ed for the formation of the spiro dihydrouracils w as the same 
as the one for the formation of the spiro hydantoins (Chapter 4), that is, formation of a 
urea by addition of an isocyanate and subsequent cyclization by reaction w ith  a base. 
The conversion of substrates (±)-5-(±)-10 into chemsets (±)-12-(±)-17 w as accomplished  
using reagent chem set 11. Eight isocyanates 11a-h (alkyl, electron-rich aryl, electron- 
poor aryl, and heteroaryl isocyanates; Figure 5.3) were selected for the generation of a 
48-com pound library.
a b c d
e f g h
Figure 5.3 Isocyanates 1 1 a -h  Used fo r  the Reaction o f  Substrates (±)-5-(±)-10.
The reactions for the formation of the a-ureidom ethyl esters were run in either 
CH2Q 2 or DMF depending on reagent solubility and reactivity, as w as the case for the 
a-ureido esters in Chapter 4. Thus, the reactions of (±)-5-(±)-10 w ith 11a,c-e in CH2Q 2 
for 15 h at room  temperature afforded the corresponding a-ureidom ethyl esters. In 
order to reach full conversion to the a-ureidom ethyl esters using isocyanates 1 1 b,f-h , 
DMF at 80 °C for 15 h had to be used. After evaporation of the solvent, the crude 
mixture w as dissolved in THF and 1 M KOBuf in THF (1 equiv) w as added .12 The 
reactions were stirred at room  temperature for 15 h and the solvent was evaporated. 
Liquid-liquid extraction afforded two different types of com pounds depending on the 
isocyanate used: (1) the alkyl isocyanates 11a-c gave the expected 4-arylspiro- 
[dihydrouracil-5,3'-pyrrolidines] (±)-12(a-c)-(±)-17(a-c) w ith yields ranging from 49 to 
80% (61% average) and w ith purities ranging from 60 to 99% (83% average; Scheme 5.1
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and Table 5.1) according to LC-MS analysis (also confirmed by 1H NMR spectroscopy) 
and (2 ) the aryl isocyanates 1 1 d -h  gave m ostly the unexpected a-ureidom ethyl acids 
(±)-18(d-h)-(±)-23(d-h) w ith yields ranging from 45 to 79% (64% average) and with  
purities ranging from 0 to >99% (82% average; Scheme 5.2 and Table 5.2) according to 
LC-MS analysis (also confirmed by 1H NMR spectroscopy).
Scheme 5.1 Spiro D ihydrouracil Formation fro m  Substrates (±)-5-(±)-10.
CO2 M©
M © N ^ ' - NH2
'Ar
(±)-5-(±)-10
1. RNCO 11a,c, CH2Cl2
21 °C, 15 h or 
RNCO 11b, DMF 
80 °G, 15 h
2. KOBu', THF, 21 °G, 15 h
R
oY Ny °
m©nH " - NH
"Ar
(±)-12(a-c)-(±)-17(a-c)
R = Et a, PhCH2CH2 b, E t02GGH2GH2 c
Scheme 5.2 a-U reidom ethyl A cid  Formation fro m  Substrates (±)-5-(±)-10.
CO2 M©
M © N ^ " - NH2
'Ar
(±)-5-(±)-10
1. RNCO 11d,e, GH2Gl2
21 °G, 15 h or 
RNCO 11 f—h , DMF 
80 °G, 15 h
2. KOBu', THF, 21 °G, 15 h
O
M © ^ " '  'H
C ° 2H i.
'Ar
(±)-18(d-h)-(±)-23(d-h)
R = Ph d, 4-GF3G6H4 e, 4-Et0G6H4 f, 3-NGG6H4 g, 3-Py h
The reactions carried out w ith reagent 11a resulted in high purities (89% average) for 
the formation of the spiro dihydrouracils, due to lack of com peting reactions. The 
purities of the products from the reactions run in DMF (reagent 11b) were in the range 
60 to 92% (70% average). These lower purities could be due to partial decom position of 
the isocyanates at the temperature used for the reactions in DMF. The reactions carried 
out w ith reagent 11c gave a mixture of the expected ethyl esters (±)-12c-(±)-17c, the 
m ethyl esters (±)-12i-(±)-17i (from transesterification of the ethyl ester on the R group 
by m ethoxide, formed in the cyclization), the acids (±)-12j-(±)-17j (from hydrolysis of 
the esters), and the deorganylated com pounds (±)-12k-(±)-17k (Figure 5.4 and Table
5.1) .13 The overall cyclization reaction worked w ell, since products (±)-12i-(±)-17i, 
(±)-12j-(±)-17j, and (±)-12k-(±)-17k were formed from (±)-12c-(±)-17c. Shorter reaction 
tim es should be used to avoid these side reactions.
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(±)-12c-(±)-17c (±)-12i-(±)-17i (±)-12j-(±)-17j (±)-12k-(±)-17k
Figure 5.4 Products Formed fro m  the Reaction w ith  Reagent 11c.
The above-m entioned deorganylation side reaction could have taken place through 
an E1cB m echanism  (Scheme 5.3). The substrate (±)-12c-(±)-17c (or (±)-12i-(±)-17i) is 
dehydronated to form the enolate (±)-12l-(±)-17l, w hich undergoes an elimination 
reaction to afford (±)-12k-(±)-17k after work-up.
Scheme 5.3 Formation o f  Com pounds (±)-12k-(±)-17k.
C°2Et C°2Et
C e  N
^ V °  bas© e f V °  W °  work-up V T 0
m© 0 - NH ------- "  m© 0 - NH m©n^ ' - NH -----------"  m©nH ' - NH
"Ar "Ar '"Ar ""Ar
(±)-12c-(±)-17c (±)-12l-(±)-17l (±) (±)-12k-(±)-17k
The aryl-substituted dihydrouracils underwent hydrolysis (and not the alkyl- 
substituted dihydrouracils) because the electrophilicity of the ureide carbonyls is 
enhanced (with respect to the alkyl group) due to the conjugation of the imide-type 
nitrogen with the aryl group. Thus, residual H 2O from KOBuf could have hydrolyzed  
the ureide to the ureido acid .14
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Table 5.1 S o lu tio n -P h a se  S y n th e s is  o f  S p iro  D ih y d ro u ra c il  L ib ra ry  ( ± ) - 1 2 ( a - c , i - k ) - ( ± ) - 1 7 ( a - c , i - k ) a'b
° ^ n Y °  
„ nh
(±)-12a 
51% (89%)
o ^ „ - Y °
„ n h
(±)-12b 
63% (70%)
R
°y Ny °
, ,  — 1". „ - H  M©N I
(±)-12c,i-k 
80% (91%)c
o ^ n ^ o
1-, „ - h
OM©
(±)-13a 
60% (93%)
° ^ „ - y °
„ - h
OM©
(±)-13b 
64% (60%)
° ^ n Y °
.n h
OM©
(±)-13c,i-k 
49% (88%)c
o ^ - Y °
„ n h
OM©
(±)-14a 
66% (90%)
° Y - y o
kH - „ „ nh
M©N I ^  ,
OM©
(±)-14b 
60% (68%)
O ^ - y O  
-k ,nh
OM©
(±)-14c,i-k 
54% (95%)c
o ^ n ^ o  
. n h
>
(±)-15a 
63% (95%)
oY -y °
m© 0 - NH
C O
(±)-15b 
64% (68%)
R
°y Ny °
M©N J
>
(±)-15c,i-k 
61% (98%)c
r
5-y °,nh
, 0
M©
(±)-16a 
61% (99%)
o^ „ - Y °
„ n h
M©
(±)-16b 
54% (92%)
Ph
R
° Y - Y °
m ©n
" O
M©
(±)-16c,i-k 
66% (79%)c
°Y -y °
M©N ,
t p
M©
(±)-17a 
69% (69%)
° Y - y °
m ©n  ,
- Q
-
M©
(±)-17b 
68% (62%)
■k „ nh
m ©n
M©
(±)-17c,i-k 
62% (86%)c
a % = C rude yield based on m ass recovery. b (%) = Purity determ ined by LC-MS at 215 nm. c M ixture of 
com pounds, R = CH2CH 2CO2Et c, CH 2CH 2CO2Me i, CH 2CH 2CO2H j, and  H k.
R
R
R
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Table 5.2 S o lu tio n -P h a se  S y n th e s is  o f  a -U r e id o m e th y l  A c id  L ib ra ry  ( ± ) - 1 8 ( d - h ) - ( ± ) - 2 3 ( d - h ) a'h
h
. . i '-  -
m ©n  I h h
C°2H
(±)-18d 
49% (>99%)
d
C 0 2H II 
" " " -  -  
H
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d
C 0 2H II 
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(±)-18f 
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C° 2 H II
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O O OO
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I h  h  m ©n  h
,0M ©  V -J ', .  ^
OM© 
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'2H a
n  n
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(±)-20f 
52% (99%)
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CO2H 
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-
n
O O
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o>
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-
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. -O
M©
(±)-22d 
58% (14%)d
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©-O
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a % = C rude yield based on m ass recovery. b (%) = Purity determ ined by LC-MS at 215 nm. c Plus (±)-15f 
(21%). d Plus (±)-16d (77%). e Plus (±)-16e (18%). f Plus (±)-16f (81%). g Plus (±)-16h (54%). h Plus (±)-17d (2%). 
i Plus (±)-17f (5%).
n
-
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In order to find conditions for the exclusive formation of the spiro dihydrouracils 
using aryl isocyanates, the a-ureidom ethyl ester (±)-24d w as synthesized, isolated, and 
reacted w ith several bases under different conditions for the formation of spiro 
dihydrouracil (±)-12d (Table 5.3).
Table 5.3 O ptim ization  o f  the Formation o f Spiro D ihydrouracil (±)-12d
GO;
M © - ^ j
M© °
-N X N -Ph
h h
Ph
(±)-24d
Ph
° y - y °
m © - H " - -H
"Ph
(±)-12d
C ° 2H 
M©- I H
O
A „ „ P h
-  -  
H
Ph 
(±)-18d
Entry Conditions
Products3
(±)-24d/(±)-12d/(±)-18d
1 EtsN (1.1 equiv), THF, Ar, reflux, 22 h 1:0:0
2 Proton sponge (0.2 equiv), THF, 21 °C, 5 h 1:0:0
3 Proton sponge (1 equiv), THF, 21 °C, 17 h 1:0:0
4 Proton sponge (1 equiv), THF, reflux, 7 h 1:0:0
5 DIPEA (1 equiv), DMF, 90 °C, 6 h15 1:0:0
6 DBU (1 equiv), THF, Ar, 26 °C, 5 h16 1:0:0
7 DBU (1 equiv), THF, Ar, reflux, 17 h 5:1:0
8 DBU (1 equiv), ButNBr, 4 À MS, PhMe, Ar, reflux, 27 h17 1:9:0
9 KOBut (1 equiv), THF, 29 °C, 30 min 1:3:1
10 KOBut (1  equiv), THF, 31 °C, 55 min 0:2:1
11 KOBut (1  equiv), THF, Ar, 21 °C, 2 h 0:1:2
12 KOBut (0.1  equiv), THF, Ar, 21 °C, 17 h 3:6:1
13 Phosphazene P2-t-Bu (0.1 equiv), THF, Ar, 21 °C, 5 h 1:3:0
14 Phosphazene P2-t-Bu (1 equiv), THF, Ar, 21 °C, 18 h 1:0:4
15 DMSO, 165 °C, 15 h decomposition
a Ratio calculated by integration of the 1H NMR signals of the crude reaction mixture.
+
Firstly, the reaction w as attempted w ith an easy-to-handle base because, if 
successful, it w ou ld  make the work-up of the reactions ea sy —an important factor in 
parallel synthesis. A ll the amines used were found to have insufficient basicity for this 
transformation to take place (entries 1-5 ) . 18 The am idine DBU gave prom ising results, 
but the separation of the product (±)-12d from DBU (and especially from the coreagent 
Bu4NBr, entry 8 ) w as difficult and tedious, making these reaction conditions unsuitable 
for parallel synthesis. Potassium  tert-butoxide w as the only base that caused >99% of 
the starting material to react,19 but it w as the base that gave the largest am ount of 
hydrolyzed product (±)-18d (entries 9-12). H eating only (entry 15) resulted in 
decom position of the starting material. To the best of our know ledge, there is no 
exam ple in the literature of a dihydrouracil ring w ith such a tendency toward 
hydrolysis under basic conditions. This cyclization can also take place using acid 
catalysis,20 but this has not yet been attempted.
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In an advanced period of the present research, the optim ization for the formation of 
spiro dihydrothiouracils for library synthesis w as attempted. Thus, a-am inom ethyl 
ester (±)-7 w as reacted w ith ethyl and phenyl isothiocyanate under different conditions 
(Table 5.4).
Table 5.4 Formation o f Spiro D ihydrothiouracils
Et
(±)-26 (±)-29 (±)-30
Entry Conditions Products Ratioa
1 EtNCS, CH2Cl2, 21 °C, 15 h (±)-25 + (±)-27 + (±)-28 1:0:0
2 PhNCS, CH 2O 2, 21 °C, 15 h (±)-26 + (±)-29 + (±)-30 1:0:0
3 EtNCS, DMF, 21 °C, 15 h (±)-25 + (±)-27 + (±)-28 1:0:0
4 PhNCS, DMF, 21 °C, 15 h (±)-26 + (±)-29 + (±)-30 1:0:0
5 EtNCS, CHCls/EtsN (10:1), 50 °C, 15 h (±)-25 + (±)-27 + (±)-28 1:0:0
6 PhNCS, CHCls/EtsN (10:1), 50 °C, 15 h (±)-26 + (±)-29 + (±)-30 1:0:0
7 PhNCS, DMF, 80 °C, 15 h (±)-26 + (±)-29 + (±)-30 3:1:0
8 1. EtNCS, CH 2O 2, 21 °C, 15 h (±)-25 + (±)-27 + (±)-28 6:1:02. KOBut (5 mol%), THF, 21 °C, 15 h
9 1. PhNCS, CH 2O 2, 21 °C, 15 h (±)-26 + (±)-29 + (±)-30 1:0:02. KOBut (5 mol%), THF, 21 °C, 15 h
10
1. EtNCS, DMF, 21 °C, 15 h
(±)-25 + (±)-27 + (±)-28 0:1:02. KOBut (1 equiv), THF, 21 °C, 3 h
11 1. PhNCS, DMF, 21 °C, 15 h (±)-26 + (±)-29 + (±)-30 0:2:12. K O Bu (1 equiv), THF, 21 °C, 3 h
1. PhNCS, CH 2O 2, 21 °C, 15 h
(±)-26 + (±)-29 + (±)-3012 2. KOBut (1 equiv), THF, 21 °C, 15 h 0:0:1
a Ratio calculated by integration of the aH NMR signals of the crude reaction mixture.
The reactions in CH2Q 2 at room  temperature for 15 h quantitatively formed a- 
thioureidom ethyl esters (±)-25 and (±)-26 (entries 1 and 2). In neither case w as a trace of 
the spiro dihydrothiouracil observed. The reactions w ere then run in DMF w ith similar 
results (entries 3 and 4). One reason w h y  this cyclization did not occur spontaneously 
unlike the analogous reaction for m aking spiro thiohydantoins (Chapter 4) is that the 
entropy of activation is lower in the latter case. The reactions were also run in
151
Chapter 5
CHCl3 /E t3N  (10:1) at 50 °C for 15 h, but the spiro dihydrothiouracils w ere not observed  
in these cases either (entries 5 and 6 ). Com pound (±)-7 w as then reacted w ith phenyl 
isothiocyanate in DMF at 80 °C for 15 h to yield a 3:1 mixture of the a-thioureido- 
m ethyl ester (±)-26 and the spiro dihydrothiouracil (±)-29 (entry 7). On obtaining these 
results, com pound (±)-7 w as again reacted w ith ethyl and phenyl isothiocyanates in 
CH2Q 2. After evaporation of the solvent, the crude mixture w as dissolved in THF and
1 M KOBuf in THF (5 mol%) w as added. The reactions w ere stirred at room  
temperature for 15 h and the solvent evaporated. Liquid-liquid extraction afforded a 
6:1 mixture of the a-thioureidom ethyl ester (±)-25 and spiro dihydrothiouracil (±)-27 
for one reaction (entry 8 ), and only the a-thioureidom ethyl ester (±)-26 for the other 
reaction (entry 9). The same procedure w as follow ed using DMF instead of CH 2Q 2 for 
the first step and 1 equiv of KOBuf over 3 h for the second step (entries 10 and 11). 
Follow ing this m ethod, spiro dihydrothiouracil (±)-27 w as formed as a single product 
in quantitative yield (based on m ass recovery) and 89% purity (a-thioureidom ethyl 
acid (±)-28 w as not observed), and spiro dihydrothiouracil (±)-29 w as formed in a 2:1 
ratio alongside the a-thioureidom ethyl acid (±)-30 in quantitative yield (based on mass 
recovery). Finally, com pound (±)-7 w as reacted w ith phenyl isothiocyanate in CH 2Q 2 
for 15 h, the solvent w as evaporated, and reaction of the crude w ith KOBuf in THF for 
15 h yielded, as in the case of their oxygen counterparts, the a-thioureidom ethyl acid 
(±)-30 (entry 12).
5.2.2 Synthesis o f Spiro ß-Lactams
Throughout the present research, the synthesis of different scaffolds (always 
containing the 2 -arylethyl amine and suitable for combinatorial chemistry) was 
investigated. Thus, potentially relevant spiro ß-lactams were synthesized am ong other 
structures. The ß-lactam ring is present in the structure of several antibiotic families, 
principally penicillins, cephalosporins, and carbapenems.21 Over the years, there has 
been significant interest in spiro ß-lactams because of their antiviral22 and 
antibacterial23 properties, and also because spiro ß-lactams have been reported to 
behave as ß-turn m im etics .24
One of the m ost used bases in the literature for the cyclization of ß-amino esters to ß- 
lactams is MeMgBr.25 This base had been used in our group on 1- 
(aminomethyl)cyclohex-3-ene-1-carboxylates w ith good results.26 Thus, com pound  
( ± ) - 6  w as reacted w ith different ratios of MeMgBr in THF at room  temperature to form  
a mixture of the substrate (±)-6 , the spiro ß-lactam (±)-31, and the tertiary alcohol (±)-32 
in every case (Table 5.5).
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Table 5.5 Product Ratio U sing M eM gB r w ith  Substrate (±)-6
Me
CO2Me
d :MeN |, ' " ' NH2 MeM0Br
(±)-6
T H F , 21 °C, 5 h 
OMe
Entry MeMgBr (equiv)
Products3
(±)-6/(±)-31/(±)-32
1 1 .0 3:1:1
2 1.3 1:1.85:1.75
3 2.0 1:1.15:1
a Ratio calculated by integration of the 1H NMR signals 
of the crude reaction mixture.
Use of a more hindered base, such as BufMgCl,27 prevented the addition of the base 
to the lactam so that only dehydronation took place. It w as found that 2 equiv of base 
in THF at room  temperature worked best for achieving this cyclization. These 
conditions w ere successfully performed on the a-am inom ethyl esters (±)-5 and ( ± ) - 6  to 
afford spiro ß-lactams (±)-33 and (±)-31, respectively (Table 5.6).
Table 5.6 Formation o f Spiro ßß-Lactams (±)-31 and (±)-33
O
CO2Me
, — N H  B u 'M gC ! (2 equ iv )
MeN^J
'Ar 
(±)-5,(±)-6
T H F , 21 °C, 45  m in
NH
MeN 1 1,1 
'^"Ar 
(±)-33,(±)-31
Entry Ar Product Yield (%)
phenyl
'N H
(±)-33
2 4-m ethoxyphenyl MeN
f.,/
(±)-31 90
O
1
O
5.2.3 Synthesis o f Tetrahydrom ethanobenzazepines
In an attempt to synthesize bridged com pounds, the 2-cyanoacrylates 34 and 35 
(synthesized in Chapter 2) were reacted w ith glycine (instead of N-m ethylglycine, see 
Chapter 2) and paraformaldehyde in refluxing toluene. Follow ing this procedure, 
either pyrrolidines w ith a secondary amine28 an d /or  m ethylene-linked cycloadduct 
dimers29 are obtained. In our case, an inseparable 1:1 mixture of the meso com pounds 
36 and 39, and the corresponding racemates (±)-37 and (±)-40 of the m ethylene-linked  
dimers were obtained alongside <10% of the m ethylated pyrrolidines (±)-38 and (±)-41
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(Table 5.7) .30 M ost notably, this cycloaddition is m uch slower and less clean than the 
one using N-m ethylglycine.
Table 5.7 1,3-Dipolar Cycloaddition Reaction o f  Com pounds 34 and 35 
N C ^ ^C Ü 2M e h2NCH2C 02H
Ar
MeO2C
-  NC'V'X
(CH2O)n, PhMe, A
Ar
CO2Me MeO2C 
„N f ' 'CN + NC1
Ar Ar» N N
CO2Me
■CN
CO2Me
CN
CN + M e r t ' CN
'"Ar '"Ar
34 Ar = 3,5-dimethoxyphenyl
35 Ar =1,3-benzodioxol-5-yl
36
39
(±)-37
(±)-40
(±)-38
(±)-41
Entry Ar Products Time (h) Yield (%)a
1 3,5-dimethoxyphenyl 36 + (±)-37 4 58
2 1,3-benzodioxol-5-yl 39 + (±)-40 6 88
a Com bined isolated yield.
The formation of the m ethylene-linked dimers could be rationalized as follow s  
(Scheme 5.4; show n for com pound 34): once the cycloaddition reaction has taken place, 
the secondary amine of the cycloadduct (±)-42 condenses w ith form aldehyde to form  
the im inium  ion (±)-43 that, on addition of another cycloadduct, gives the products 36 
and (±)-37. The m ethylated com pound (±)-38 could be formed by a hydride transfer 
either from formate 44 or form aldehyde hydrate 45 to the im inium  ion (±)-43 (the 
Eschweiler-Clarke reaction31 or the crossed-Cannizzaro reaction ,32 respectively). 
Formate 44 is formed by a Cannizzaro reaction between the H 2O formed by the 
condensation reactions and form aldehyde or by the crossed-Cannizzaro reaction, 
follow ed by dehydronation of formic acid by any amine.
Scheme 5.4 Plausible Explanation fo r  the Formation o f  Compounds 36, (±)-37, and (±)-38.
CO
c th n
2Me
*"C N
N C ^ .C O 2 M e  H2NCH2C 0 2H
Ar
(CH2O)n, PhMe, A
34 Ar = 3,5-dimethoxyphenyl
CO2Me
H N ^ f" CN
"Ar
(±)-42
r
CO2Me
H cH 0  ©A^f"CN
H2C=N I
"Ar
(±)-43
'Ar 
(±)-42
O
q o A h
44
(-CO2)
36 + (±)-37
H O ^ O H
X 
H h
45
(-H C 0 2H)
MeN
CO2Me
CN
""Ar 
(±)-38
Treatment of the mixture 3 6 / (±)-37 w ith Eschenmoser's salt in M eCN at 40 °C for 17 
h afforded the bridged com pound (±)-46 in good yield (Scheme 5.5) ,33 via a Pictet- 
Spengler reaction (see Chapter 6 ).The reaction w ith the less reactive substrates 3 9 /
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(±)-40 d id  n o t  g iv e  th e  ex p ec ted  p ro d u c t, so th is  ro u te  w a s  a b a n d o n e d  as th e  ta rg e te d  
a r ra y  of sca ffo lds w o u ld  n o t  b e  accessible.
Scheme 5.5 Formation o f  the Bridged Com pound (±)-46.
MeO2C
NC
MeO.
OMe
MeO2C
NC-'
CO2Me
N ' N ^ f ' ,CN nuV-A,, .OMe
36
OMe
MeO.
CO2Me
. /"■■/"CN N NV^'<, _,OMe
OMe OMe
(±)-37
[Me2NCH2]I, MeCN 
40 °C, 17 h
80%
MeO.
CO2Me 
' CN
OMe
(±)-46
+
5.3 C onclusion
Firstly , w e  h a v e  d e v e lo p e d  a m e th o d  fo r th e  sy n th es is  of a sm all l ib ra ry  of 7- 
a lk y ld ih y d ro u ra c ils  sp iro -fu se d  to  p y rro lid in e s  to  th e  3 -position . T he c o rre sp o n d in g  7- 
a ry l d e riv a tiv e s  h y d ro ly z e d  u n d e r  th e  co n d itio n s  u tiliz e d  fo r th e  cy c liza tio n  a n d  
y ie ld e d  a -u re id o m e th y l acids. T he o p tim iz a tio n  of th is  cy c liza tio n  sh o u ld  b e  fu r th e r  
d ev e lo p e d . S econd ly , d ih y d ro th io u ra c ils  sp iro -fu se d  to  p y rro lid in e s  can  also  b e  
fo rm e d  u s in g  e th y l a n d  p h e n y l iso th io cy an a tes  b y  fo llo w in g  th e  sam e p ro c e d u re  as fo r 
th e ir  o x y g en a te d  d eriv a tiv e s . T h ird ly , th e  cy c liza tio n  of a -a m in o m e th y l e s te rs  to  ß- 
lac tam s w a s  ach iev ed  a n d  w e  an tic ip a te  th a t  th is  re ac tio n  c o u ld  b e  a p p lie d  
in d e p e n d e n tly  to  th e  a ry l g ro u p  o n  th e  p y rro lid in e . F inally , te tra h y d ro m e th a n o - 
b e n z a z e p in e s  c o u ld  o n ly  b e  sy n th e s iz e d  w h e n  th e  a ry l g ro u p  of th e  su b s tra te s  w a s  
v e ry  reac tiv e  to w a rd  e lec tro p h ile s .
5.4 A cknow ledgem ents
D r. R ich a rd  H . B laauw  a n d  C h ira lix  B.V. (N ijm egen , T he N e th e rlan d s) a re  
a c k n o w le d g e d  fo r th e  u se  of th e ir  p a ra lle l-sy n th es is  facilities.
5.5 Experimental Section
For general experim ental details, see Sections 2.5 (p 33) and 4.5 (p 104).
G eneral Procedure 1 for Spiro D ihydrouracil/a-U reidom ethyl Acid Form ation U sing 
Parallel Synthesis. A solution of isocyanate 11 (0.12 m mol for a, 0.10 m mol for c-e) from a 0.3 
M stock solution in  CH 2Cl2 was added  to a solution of a-am inom ethyl ester (0.10 mmol) in 
CH 2Cl2 (1.5 mL). The resulting reaction m ixture was stirred at room  tem perature for 15 h. After
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that time, the solvent was evaporated and THF (1.5 mL) and 1 M KOBuf in THF (0.10 mmol) 
were added. The reaction m ixture was then stirred at room  tem perature for 15 h. A saturated 
solution of N H 4Cl (1.0 mL) was added  and the layers were separated (centrifugation was 
needed for the separation w hen aryl isocyanate was used). The aqueous layer was extracted 
w ith  CH 2Cl2 (2 x 1 .5  mL) and the combined organic layers were evaporated to dryness under 
vacuum.
G eneral Procedure 2 for Spiro D ihydrouracil/a-U reidom ethyl Acid Form ation U sing 
Parallel Synthesis. A solution of isocyanate 11b,f-h (0.10 mmol) from a 0.3 M stock solution in 
DMF was added  to a solution of a-am inom ethyl ester (0.10 mmol) in DMF (1.5 mL). The 
resulting reaction m ixture was stirred at 80 °C for 15 h. After that time, the solvent was 
evaporated and THF (1.5 mL) and 1 M KOBuf in  THF (0.10 mmol) were added. The reaction 
m ixture w as then stirred at room tem perature for 15 h. A saturated solution of N H 4Cl (1.0 mL) 
w as added  and the layers were separated (centrifugation was needed for the separation w hen 
aryl isocyanate w as used). The aqueous layer w as extracted w ith  CH 2Cl2 (2 x 1.5 mL) and the 
combined organic layers were evaporated to dryness under vacuum.
(±)-(4R,5S)-7-Ethyl-2-methyl-4-phenyl-2,7,9-triazaspiro[4.5]decane-6,8-dione 12a.
^  (From (±)-5) iH  NM R [400 MHz, 5 (ppm), CDCls]: 7.30-7.19 (m, 5 iH, Ph),
O ^ N ^ O  5.60 (bd, J = 2.1 Hz, 1 1H, NH), 4.20 (dd; J = 8.1, 5.4 Hz; 1 1H, 4-CH), 3.85 (dq; J
^ N h  = 12.9, 7.2 Hz; 1 1H, CHHCH 3), 3.80 (dq; J = 12.9, 7.2 Hz; 1 1H, CHHCH 3), 3.06 
MeN 2'
^ - ,3' (dd; J = 9.6, 5.4 Hz; 1 1H, 3-CHH), 2.99 (dd; J = 9.6, 8.1 Hz; 1 1H, 3-CHH), 2.95 
4' (d, J = 9.3 Hz, 1 1H, 1-CHH), 2.94 (dd; J = 12.6, 4.2 Hz; 1 1H, 10-CHH), 2.68 (d, J 
(±) = 9.3 Hz, 1 1H, 1-CHH), 2.66 (d, J = 12.6 Hz, 1 1H, 10-CHH), 2.41 (s, 3 1H,
NCH 3), 1.16 (t, J = 7.2 Hz, 3 1H, CH 2CH3). 13C NM R [75 MHz, 5 (ppm), CDCla]: 173.1 (6-C), 154.1 
(8 -C), 139.4 (1'-C), 128.7 (2'-C + 6 '-C), 128.6 (3'-C + 5'-C), 127.3 (4'-C), 64.0 (1-C), 62.0 (3-C), 52.0 (5- 
C), 48.3 (4-C), 43.4 (10-C), 42.0 (NCH3), 36.4 (CH2CHb), 13.8 (CH2CHb). FTIR [ V (cm-1), neat]: 
3240, 2937, 2841, 2784, 1716, 1673, 763, 703. MS [APCI (m /z)] calcd for (C16H 21N 3O 2 + H)+ = 288, 
found 288. C rude yield: 51%. Purity: 89% (LC).
(±)-(4R,5S)-2-M ethyl-7-phenethyl-4-phenyl-2,7,9-triazaspiro[4.5]decane-6,8-dione 12b.
' (From (±)-5) ^  NM R [400 MHz, 5 (ppm), CDCb]: 7.33-7.15 (m, 10 1H, 2 x 
Ph), 5.66 (bd, J = 3.4 Hz, 1 1H, NH), 4.16 (dd; J = 8.0, 5.4 Hz; 1 1H, 4-CH), 4.04 
(dt; J = 13.0, 7.6 Hz; 1 1H, NCHHCH2), 3.98 (dt; J = 13.0, 7.6 Hz; 1 1H, 
NCHHCH2), 3.05 (dd; J = 9.3, 5.4 Hz; 1 1H, 3-CHH), 2.98-2.83 (m, 5 1H, 1-CHH 
+ 3-CHH + 10-CHH + N CH 2CH2), 2.56 (d, J = 9.5 Hz, 1 1H, 1-CHH), 2.55 (d, J =
13.2 Hz, 1 1H, 10-CHH), 2.39 (s, 3 1H, NCH3). 13C NM R [75 M Hz, 5 (ppm), 
CDCla]: 173.2 (6-C), 154.0 (8 -C), 139.3 (1"-C), 138.6 (1'-C), 129.2 (2'-C + 6 '-C),
128.8 (2"-C + 6 "-C), 128.6 (3"-C + 5"-C), 128.5 (3'-C + 5'-C), 127.3 (4"-C), 126.5 
(4'-C), 64.0 (1-C), 61.9 (3-C), 52.1 (5-C), 48.2 (4-C), 43.4 (10-C), 42.2 (NCH2CH2), 41.9 (NCH3), 34.5 
(NCH2CH2). FTIR [ V (cm-1), neat]: 3254, 2938, 2841, 2784, 1717, 1673, 758, 701. MS [APCI (m /z)] 
calcd for (C22H 25N 3O2 + H)+ = 364, found 364. C rude yield: 63%. Purity: 70% (LC).
MeN
(±)
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(±)-Ethyl 3-{(4R,5S)-2-methyl-6,8-dioxo-4-phenyl-2,7,9-triazaspiro[4.5]decan-7-yl}propanoate 
CO2Et 12c.
^  (From (±)-5) MS [APCI (m /z)] calcd for (C19H 25N 3O4 + H)+ = 360, found 360.
° ^ ^ n ^ °  C rude yield: 80% (combined yield of (±)-12c, (±)-12i, (±)-12j, and (±)-12k). 
MeN ^ d >v'''NH Purity: 91% (LC; combined purity  of (±)-12c, (±)-12i, (±)-12j, and (±)-12k).
(±)
(±)-(4R,5S)-7-Ethyl-4-(4-methoxyphenyl)-2-methyl-2,7,9-triazaspiro[4.5]decane-6,8-dione 13a.
(From (±)-6) MS [APCI (m /z)] calcd for (C17H 23N3O3 + H)+ = 318, found 
318. C rude yield: 60%. Purity: 93% (LC).
(±)
(±)-(4R,5S)-4-(4-M ethoxyphenyl)-2-methyl-7-phenethyl-2,7,9-triazaspiro[4.5]decane-6,8-dione 
13b.
(From (±)-6) MS [APCI (m /z)] calcd for (C23H27N3O3 + H)+ = 394, found 
394. C rude yield: 64%. Purity: 60% (LC).
(±)
(±)-Ethyl 3-{(4R,5S)-4-(4-methoxyphenyl)-2-methyl-6,8-dioxo-2,7,9-triazaspiro[4.5]decan-7- 
CO2Et yl}propanoate 13c.
^  (From (±)-6) FTIR [V (cm-1), neat]: 3245, 2935, 2837, 2784, 1719, 1674,
o^ n Y °  1247, 835. MS [APCI (m /z)] calcd for (C20H 27N 3O5 + H)+ = 390, found 390.
MeN d ' V ' ' NH C rude yield: 49% (combined yield of (±)-13c, (±)-13i, (±)-13j, and (±)-13k).
Purity: 88% (LC; combined purity  of (±)-13c, (±)-13i, (±)-13j, and (±)-13k).
'O M e  
(±)
(±)-(4R,5S)-4-(3,5-Dimethoxyphenyl)-7-ethyl-2-methyl-2,7,9-triazaspiro[4.5]decane-6,8-dione 
14a.
(From (±)-7) MS [APCI (m /z)] calcd for (C18H 25N 3O4 + H)+ = 348, found 
348. C rude yield: 66%. Purity: 90% (LC).
(±) OMe
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(±)-(4R,5S)-4-(3,5-Dimethoxyphenyl)-2-methyl-7-phenethyl-2,7,9-triazaspiro[4.5]decane-6,8- 
d ione 14b.
(From (±)-7) MS [APCI (m /z)] calcd for (C24H29N3O4 + H)+ = 424, found
424. C rude yield: 60%. Purity: 68% (LC).
(±) OMe
(±)-Ethyl 3-{(4R,5S)-4-(3,5-dimethoxyphenyl)-2-methyl-6,8-dioxo-2,7,9-triazaspiro[4.5]decan-7- 
yl}propanoate 14c.
(From (±)-7) MS [APCI (m /z)] calcd for (C21H 29N3O6 + H)+ = 420, found
420. C rude yield: 54% (combined yield of (±)-14c, (±)-14i, (±)-14j, and 
(±)-14k). Purity: 95% (LC; combined purity  of (±)-14c, (±)-14i, (±)-14j, and 
(±)-14k).
(±) OMe
(±)-(4R,5S)-4-(1,3-Benzodioxol-5-yl)-7-ethyl-2-methyl-2,7,9-triazaspiro[4.5]decane-6,8-dione 
15a.
(From (±)-8) MS [APCI (m /z)] calcd for (C17H 21N 3O4 + H)+ = 332, found 
332. C rude yield: 63%. Purity: 95% (LC).
(±)
(±)-(4R,5S)-4-(1,3-Benzodioxol-5-yl)-2-methyl-7-phenethyl-2,7,9-triazaspiro[4.5]decane-6,8-di- 
one 15b.
(From (±)-8) MS [APCI (m /z)] calcd for (C23H 25N 3O4 + H)+ = 408, found 
408. C rude yield: 64%. Purity: 68% (LC).
(±)
(±)-Ethyl 3-{(4R,5S)-4-(1,3-benzodioxol-5-yl)-2-methyl-6,8-dioxo-2,7,9-triazaspiro[4.5]decan-7- 
yl}propanoate 15c.
(From (±)-8) MS [APCI (m /z)] calcd for (C20H 25N 3O 6 + H)+ = 404, found 
404. C rude yield: 61% (combined yield of (±)-15c, (±)-15i, (±)-15j, and 
(±)-15k). Purity: 98% (LC; combined purity  of (±)-15c, (±)-15i, (±)-15j, and
(±)
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MeN
.N~-y Me 5'
(±)
(±)-(4R,5S)-7-Ethyl-2-methyl-4-(1-methyl-1H-pyrrol-2-yl)-2,7,9-triazaspiro[4.5]decane-6,8-di- 
one 16a.
(From (±)-9) ^  NM R [400 MHz, 5 (ppm), CDCI3]: 6.52 (dd; J = 2.8, 1.6 Hz; 1 
1H, 5'-CH), 6.05 (dd; J = 3.5, 2.8 Hz; 1 !H, 4'-CH), 6.03 (dd; J = 3.5, 1.6 Hz; 1 !H, 
3'-CH), 5.84 (bd, J = 3.5 Hz, 1 1H, NH), 4.35 (dd(3), J = 8.0 Hz, 1 1H, 4-CH), 3.85 
(dq; J = 13.1, 7.0 Hz; 1 !H, CHHCH 3), 3.79 (dq; J = 13.1, 7.0 Hz; 1 !H, CHHCH3), 
3.44 (s, 3 !H, 1 '-NCH3), 3.15 (dd(3), J = 8.6  Hz, 1 ^ ,  3-CHH), 2.96 (dd; J = 13.0,
4.6 Hz; 1 !H, 10-CHH), 2.92 (d, J = 9.8 Hz, 1 !H, 1-CHH), 2.78 (dd(3), J = 8.8 Hz, 1 !H, 3-CHH), 
2.65 (d, J = 9.8 Hz, 1 !H, 1-CHH), 2.62 (d, J = 13.0 Hz, 1 !H, 10-CHH), 2.37 (s, 3 !H, 2-NCH3), 1.15 
(t, J = 7.0 Hz, 3 !H, CH 2CH3). 13C NM R [75 MHz, 5 (ppm), CDCI3]: 173.5 (6-C), 154.2 (8-C), 129.9 
(2'-C), 122.4 (5'-C), 107.5 (3'-C), 107.2 (4'-C), 66.0 (1-C), 62.0 (3-C), 51.0 (5-C), 43.9 (10-C), 41.9 (2- 
NCH3), 39.5 (4-C), 36.4 (CH2CH3), 34.1 (1'-NCH3), 13.7 (CH2CH3). FTIR [ V (cm-1), neat]: 3329, 
2937, 2842, 2784, 1716, 1671, 727. MS [APCI (m /z)] calcd for (C15H 22N 4O 2 + H)+ = 291, found 
291. C rude yield: 61%. Purity: 99% (LC).
MeN
O ^ N ^ O  
k^NH
3'
(±)-(4R,5S)-2-M ethyl-4-(1-methyl-1H-pyrrol-2-yl)-7-phenethyl-2,7,9-triazaspiro[4.5]decane-6,8- 
4'' dione 16b.
(From (±)-9) ^  NM R [400 MHz, 5 (ppm), CDCI3]: 7.32-7.15 (m, 5 iH, Ph), 6.51 
(dd; J = 2.8, 1.6 Hz; 1 1H, 5'-CH), 6.05 (dd; J = 3.5, 2.8 Hz; 1 1H, 4'-CH), 6.02 (dd; 
J = 3.5, 1.6 Hz; 1 1H, 3'-CH), 5.96 (bd, J = 4.0 Hz, 1 1H, NH), 4.31 (dd(3), J = 8.1 
Hz, 1 1H, 4-CH), 4.08-3.95 (m, 2 1H, NCH 2CH 2), 3.34 (s, 3 1H, 1'-NCH3), 3.13 
(dd(3), J = 8.6 Hz, 1 1H, 3-CHH), 2.92 (dd; J = 12.9, 4.7 Hz; 1 1H, 10-CHH), 
2.91-2.83 (m, 2 1H, N CH 2CH2), 2.80 (d, J = 9.8 Hz, 1 1H, 1-CHH), 2.76 (dd(3), J 
= 8.8 Hz, 1 1H, 3-CHH), 2.62 (d, J = 9.8 Hz, 1 1H, 1-CHH), 2.55 (d, J = 12.9 Hz, 1 
1H, 10-CHH), 2.35 (s, 3 1H, 2-NCH3). 13C N M R [75 MHz, 5 (ppm), CDCI3]:
173.6 (6-C), 154.2 (8-C), 138.6 (1''-C), 129.8 (2'-C), 129.2 (2''-C + 6''-C), 128.5 (3''-C + 5''-C), 126.5 
(4''-C), 122.4 (5'-C), 107.5 (3'-C), 107.2 (4'-C), 65.9 (1-C), 62.0 (3-C), 51.0 (5-C), 43.8 (10-C), 42.2 
(NCH2C H 2), 41.9 (2 -NCH3), 39.3 (4-C), 34.4 (NCH2CH2), 34.1 (1'-NCH3). FTIR [ V (cm-1), neat]: 
3251, 2941, 2843, 2785, 1716, 1671, 761, 728, 699. MS [APCI (m /z)] calcd for (C21H 26N 4O 2 + H)+ = 
367, found 367. C rude yield: 54%. Purity: 92% (LC).
Me
(±)
" n
(±)-Ethyl 3-{(4R,5S)-2-methyl-4-(1-methyl-1H-pyrrol-2-yl)-6,8-dioxo-2,7,9-triazaspiro[4.5]- 
C°2Et decan-7-yl}propanoate 16c.
(From (±)-9) MS [APCI (m /z)] calcd for (C18H 26N 4O4 + H)+ = 363, found 363. 
C rude yield: 66% (combined yield of (±)-16c, (±)-16i, (±)-16j, and (±)-16k). 
Purity: 79% (LC; combined purity  of (±)-16c, (±)-16i, (±)-16j, and (±)-16k).MeN
Ny °
NH
Me
(±)
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(±)-(4R,5S)-7-Ethyl-2-methyl-4-(1-methyl-1H-indol-3-yl)-2,7,9-triazaspiro[4.5]decane-6,8-dione 
^  17a.
° ^ ' ' NY °  (From (±)-10) MS [APCI (m /z)] calcd for (Q 9H 24N 4O2 + H)+ = 341, found 
Me^^N K -N H  3 4 1 . C rude yield: 69%. Purity: 69% (LC).
N 
(±) Me
(±)-(4R,5S)-2-M ethyl-4-(1-methyl-1H-indol-3-yl)-7-phenethyl-2,7,9-triazaspiro[4.5]decane-6,8- 
d ione 17b.
(From (±)-10) MS [APCI (m /z)] calcd for (C25H 2&N4O2 + H)+ = 417, found
417. C rude yield: 6 8 %. Purity: 62% (LC).
(±) Me
(±)-Ethyl 3-{(4R,5S)-2-methyl-4-(1-methyl-1H-indol-3-yl)-6,8-dioxo-2,7,9-triazaspiro[4.5]decan- 
C ° 2Et 7-yl}propanoate 17c. 
p (From (±)-10) MS [APCI (m /z)] calcd for (C22H 28N 4O4 + H)+ = 413, found
° ^ ^ NY °  413. C rude yield: 62% (combined yield of (±)-17c, (±)-17i, (±)-17j, and 
MelN j ' ' v - 'NH (±)-17k). Purity: 8 6 % (LC; combined purity  of (±)-17c, (±)-17i, (±)-17j, and
] p O  (±)-17k).
N
(±) Me
(±)-(3R,4S)-1-M ethyl-4-phenyl-3-[(3-phenylureido)m ethyl]pyrrolidine-3-carboxylic acid 18d.
O (From (±)-5) MS [APCI (m /z)] calcd for (C20H 23N 3O3 + H)+ = 354,
'NA N ^ ^ ''' ’^  found 354. C rude yield: 49%. Purity: >99% (LC).
CO2H II
^ J , - X
(±)
(±)-(3R,4S)-1-M ethyl-4-phenyl-3-({3-[4-(trifluoromethyl)phenyl]ureido}methyl)pyrrolidine-3- 
O ^ v ^ C F 3 carboxylic acid 18e.
'N N
/ J - N ^ N ^ 1 (From (±)-5) MS [APCI (m /z)] calcd for (C21H 22F3N 3O3 + H)+ =
MeN. I H H 422, found 422. C rude yield: 75%. Purity: 97% (LC).
(±)
(±)-(3R,4S)-3-{[3-(4-Ethoxyphenyl)ureido]methyl}-1-methyl-4-phenylpyrrolidine-3-carboxylic
O ^ '" v -'OEt acid 18f.
CO2H O I II
(From (±)-5) MS [APCI (m /z)] calcd for (C22H 27N 3O4 + H)+ = 398, 
MeNJ , „ .  H found 398. C rude yield: 48%. Purity: >99% (LC).
(±)
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(±)-(3R,4S)-3-{[3-(3-Cyanophenyl)ureido]methyl}-1-methyl-4-phenylpyrrolidine-3-carboxylic 
O acid 18g.
(From (±)-5) MS [APCI (m /z)] calcd for (C21H 22N 4O3 + H)+ = 379,
found 379. C rude yield: 54%. Purity: >99% (LC).
(±)
(±)-(3R,4S)-1-M ethyl-4-phenyl-3-{[3-(3-pyridyl)ureido]methyl}pyrrolidine-3-carboxylic acid
COH o  l ^ i l  18h.
(From (±)-5) MS [APCI (m /z)] calcd for (C19H 22N 4O3 + H)+ = 355, 
found 355. C rude yield: 49%. Purity: 79% (LC).MeN H H
(±)
(±)-(3R,4S)-4-(4-M ethoxyphenyl)-1-methyl-3-[(3-phenylureido)m ethyl]pyrrolidine-3-carbox- 
O ylic acid 19d.
C° 2HNA N^  (From (±)-6) MS [APCI (m /z)] calcd for (C21H 25N 3O4 + H)+ = 384,
M eN ^^ H H found 384. C rude yield: 60%. Purity: 99% (LC).
OMe
(±)
(±)-(3R,4S)-4-(4-M ethoxyphenyl)-1-methyl-3-({3-[4-(trifluoromethyl)phenyl]ureido}methyl)-
CF3 pyrrolidine-3-carboxylic acid 19e.
C°2h 0  if T  (From (±)-6) MS [APCI (m /z)] calcd for (C22H 24F3N 3O4 + H)+ = 
MeN I H H 452, found 452. C rude yield: 65%. Purity: 98% (LC).
OMe
(±)
(±)-(3R,4S)-3-{[3-(4-Ethoxyphenyl)ureido]methyl}-4-(4-methoxyphenyl)-1-methylpyrrolidine-
n  ,íí::\ ' ' '0 E t  3-carboxylic acid 19f. 
co2h 0  | Il
/ - 4 " ' ^ N^ N^ ^  (From (±)-6) MS [APCI (m /z)] calcd for (C23H 29N 3O5 + H)+ = 428,
MeNw l „  .Ä  H found 428. C rude yield: 70%. Purity: >99% (LC).
OMe
(±)
ni-i u O f^^ìi 3-carboxylic acid 19g.CO2H "
A '4 '' ' ' ' 'NA ' N^ ' ' ' ; v CN (From (±)-6) MS [APCI (m /z)] calcd for (C22H 24N 4O4 + H)+ = 409, 
MeN^I^ H H
(±)-(3R,4S)-3-{[3-(3-Cyanophenyl)ureido]methyl}-4-(4-methoxyphenyl)-1-methylpyrrolidine-
A
N ~ CN 
found 409. C rude yield: 60%. Purity: 96% (LC).
'OMe 
(±)
(±)-(3R,4S)-4-(4-M ethoxyphenyl)-1-methyl-3-{[3-(3-pyridyl)ureido]methyl}pyrrolidine-3-car-
n  ^ N ^  boxylic acid 19h.
co2h 0  I 1
SA NX |N^ J J (From (±)-6) MS [APCI (m /z)] calcd for (C20H 24N 4O4 + H)+ = 385,
MeN I H H found 385. C rude yield: 45%. Purity: 76% (LC).
OMe
(±)
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(±)-(3R,4S)-4-(3,5-Dim ethoxyphenyl)-1-m ethyl-3-[(3-phenylureido)m ethyl]pyrrolidm e-3-car-
O boxylic acid 20d.
c° 2h II
/ " 4 " '^ N N^ ^  (From (±)-7) MS [APCI (m /z)] calcd for (C22H 27N 3O5 + H)+ = 414,
MeN H H
(±)
OMe found 414. C rude yield: 76%. Purity: 97% (LC).
(±)-(3R,4S)-4-(3,5-Dimethoxyphenyl)-1-methyl-3-({3-[4-(trifluoromethyl)phenyl]ureido}meth-
Aj ° 2HNX N^ ^  (From (±)-7) MS [APCI (m /z)] calcd for (C23H 26F3N 3O5 + H)+ =
MeN^ , ,  H  .0 Me 482, found 482. C rude yield: 63%. Purity: 99% (LC).
O CF3 yl)pyrrolidine-3-carboxylic acid 20e.
(±)
(±)-(3R,4S)-4-(3,5-Dimethoxyphenyl)-3-{[3-(4-ethoxyphenyl)ureido]methyl}-1-methylpyrroli-
dine-3-carboxylic acid 20f.
(From (±)-7) *H NM R [300 MHz, 5 (ppm), CD3SOCD3]: 8.83 (bs, 1
!H, NHAr), 7.30-7.21 (m, 2 IH, 2"-CH + 6"-CH), 6.79-6.70 (m, 2
!H, 3"-CH + 5"-CH), 6.47 (d, J = 2.1 Hz, 2 IH, 2'-CH + 6’-CH), 6.41
(t, J = 2.1 Hz, 1 !H, 4'-CH), 6.12 (bs, 1 !H, CH 2NH), 3.92 (q, J = 6.9 
OMe
(±) Hz, 2 iH, CH2CH3), 3.72 (s, 6 IH, 2 x OCH3), 3.74-3.68 (m, 1 IH, 4-
CH), 3.45 (d, J = 10.2 Hz, 1 1H, 2-CHH), 3.39 (dd; J = 9.6, 7.5 Hz; 1 1H, 5-CHH), 3.24-3.18 (m, 1 1H, 
5-CHH), 3.17 (dd; J = 12.9, 8.1 Hz; 1 1H, CHHNH), 2.86 (d, J = 10.2 Hz, 1 1H, 2-CHH), 2.64 (s, 3 
1H, NCH3), 2.59 (dd; J = 12.9, 2.1 Hz; 1 1H, CHHNH), 1.28 (t, J = 6.9 Hz, 1 1H, CH 2CH3). 13C NM R 
[75 MHz, 5 (ppm), CDCI3]: 176.7 (CO2), 160.2 (3'-C + 5'-C), 155.6 (NCON), 152.9 (4"-C), 139.9 (1'- 
C), 133.9 (1''-C), 119.0 (2''-C + 6''-C), 114.4 (3''-C + 5''-C), 107.1 (2'-C + 6'-C), 98.3 (4'-C), 63.0 
(CH2CH3), 62.2 (2-C), 59.1 (5-C), 55.8 (3-C), 55.1 (2 x OCH3), 49.8 (4-C), 42.6 (NCH3), 40.8 
(CH2NH), 14.7 (CH2CH3). FTIR [ V (cm-1), neat]: 3354, 3250, 2947, 2836, 1671, 1594, 1542, 1204, 
1153, 824. MS [APCI (m /z)] calcd for (C24H 31N 3O 6 + H)+ = 458, found 458. C rude yield: 52%. 
Purity: 99% (LC).
(±)-(3R,4S)-3-{[3-(3-Cyanophenyl)ureido]methyl}-4-(3,5-dimethoxyphenyl)-1-methylpyrroli-
dine-3-carboxylic acid 20g.
(From (±)-7) !H NM R [300 MHz, 5 (ppm), CD3SOCD3]: 9.88 (bs, 1
CN
1H, NHAr), 7.99 (s, 1 1H, 2'-CH), 7.63 (d, J = 8.4 Hz, 1 1H, 6'-CH), 
7.38 (dd(3), J = 7.8 Hz, 1 1H, 5'-CH), 7.28 (d, J = 7.5 Hz, 1 1H, 4'- 
CH), 6.66 (bs, 1 1H, CH 2NH), 6.47 (d, J = 2.1 Hz, 2 1H, 2''-CH + 6''- 
CH), 6.40 (t, J = 2.1 Hz, 1 1H, 4''-CH), 3.77 (dd(3), J = 8.7 Hz, 1 1H,
4-CH), 3.71 (s, 6 1H, 2 x OCH3), 3.59 (d, J = 10.5 Hz, 1 1H, 2-CHH), 3.54 (dd; J = 9.9, 7.5 Hz; 1 1H,
5-CHH), 3.37 (dd(3), J = 9.0 Hz, 1 1H, 5-CHH), 3.23 (dd; J = 12.8, 8.4 Hz; 1 1H, CHHNH), 2.97 (d, J 
= 10.5 Hz, 1 1H, 2-CHH), 2.75 (s, 3 1H, NCH3), 2.63 (dd; J = 12.8, 1.8 Hz; 1 1H, CHHNH). 13C 
NM R [75 M Hz, 5 (ppm), CD3SOCD3]: 176.7 (CO2), 160.2 (3''-C + 5''-C), 155.4 (NCON), 141.8 (1'- 
C), 139.3 (1''-C), 129.9 (5'-C), 124.0 (4'-C), 122.0 (6'-C), 119.8 (2'-C), 119.1 (CN), 111.3 (3'-C), 107.0 
(2''-C + 6''-C), 98.4 (4''-C), 62.3 (2-C), 58.6 (5-C), 55.9 (3-C), 55.1 (2 x OCH3), 49.8 (4-C), 42.4
(±) OMe
5
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(NCH3), 40.7 (CH2NH). FTIR [ V (cm-1), neat]: 3377, 3184, 2942, 2838, 2790, 2234, 1679, 1594, 
1543, 1203, 1150, 830. MS [APCI (m /z)] calcd for (C23H 26N 4O5 + H)+ = 439, found 439. Crude 
yield: 58%. Purity: >99% (LC).
(±)-(3R,4S)-4-(3,5-Dimethoxyphenyl)-1-methyl-3-{[3-(3-pyridyl)ureido]methyl}pyrrolidme-3- 
~ ^N. carboxylic acid 2 0h.
co2h O [ ll
/ - U 1A nX n^ J J (From (±)-7) MS [APCI (m /z)] calcd for (C21H 26N 4O5 + H)+ = 415, 
MeN ' H o^Me found 415. C rude yield: 48%. Purity: 43% (LC).
(±) OMe
MeN
sC02h X . .
n n 1-
H H
>2 
7'a O 7'
(±)
(±)-(3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-methyl-3-[(3-phenylureido)methyl]pyrrolidme-3-car-
boxylic acid 2 1 d.
(From (±)-8) *H NM R [300 MHz, 5 (ppm), CD3SOCD3] : 9.01 (bs, 1 1H, 
NHPh), 7.42-7.34 (m, 2 1H, 2"-CH + 6 "-CH), 7.22-7.12 (m, 2 1H, 3''- 
CH + 5"-CH), 6.96 (d, J = 1.2 Hz, 1 1H, 4'-CH), 6.86  (d, J = 8.1 Hz, 1 
1H, 7'-CH), 6.87-6.80 (m, 1 1H, 4"-CH), 6.76 (dd; J = 8.1, 1.2 Hz; 1 1H, 
6 '-CH), 6.26 (bd, J = 6.0 Hz, 1 1H, CH 2NH), 6.01-5.97 (m, 2 1H, 2'- 
CH2), 3.72 (dd(3), J = 8.2 Hz, 1 1H, 4-CH), 3.46 (d, J = 10.5 Hz, 1 1H, 2-CHH), 3.42 (dd; J = 9.9, 7.5 
Hz; 1 1H, 5-CHH), 3.25-3.17 (m, 1 1H, 5-CHH), 3.16 (dd; J = 12.9, 8.4 Hz; 1 1H, CHHNH), 2.88 (d, 
J = 10.5 Hz, 1 1H, 2-CHH), 2.65 (s, 3 1H, NCH3), 2.58 (dd; J = 12.9, 2.4 Hz; 1 1H, CHHNH). 13C 
NM R [75 MHz, 5 (ppm), CD3SOCD3]: 176.7 (CO2), 155.4 (NCON), 147.1 (3'a-C), 146.1 (7'a-C),
140.8 (1''-C), 131.3 (5'-C), 128.5 (3''-C + 5''-C), 121.9 (6'-C), 120.7 (4''-C), 117.4 (2''-C + 6''-C), 108.9 
(7'-C), 107.9 (4'-C), 100.9 (2'-C), 62.2 (2-C), 59.4 (5-C), 55.9 (3-C), 49.5 (4-C), 42.8 (NCH3), 40.5 
(CH2NH). FTIR [ V (cm-1), neat]: 3359, 3254, 2954, 2898, 2780, 1671, 1597, 1549, 1495, 1228, 1035, 
931, 756, 694. MS [APCI (m /z)] calcd for (C21H 23N 3O5 + H)+ = 398, found 398. Crude yield: 74%. 
Purity: >99% (LC).
(±)-(3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-methyl-3-({3-[4-(trifluoromethyl)phenyl]ureido}methyl)
C 02H 0
/ " 4 " ' ^ N  N 
MeN H H
O
(±)
CPs pyrrolidine-3-carboxylic acid 21e.
(From (±)-8) FTIR [V (cm-1), neat]: 3358, 3254, 2958, 2904, 1675, 
1601, 1546, 1504, 1489, 1321, 1231, 1035, 931. MS [APCI (m /z)] 
calcd for (C22H 22F3N 3O5 + H)+ = 466, found 466. C rude yield: 
6 8 %. Purity: >99% (LC).
(±)-(3R,4S)-4-(1,3-Benzodioxol-5-yl)-3-{[3-(4-ethoxyphenyl)ureido]methyl}-1-methylpyrroli-
co2h
M e N ^ j
(±)
O
N ^ N  
H H 
O
O
OEt dine-3-carboxylic acid 21f.
(From (±)-8) MS [APCI (m /z)] calcd for (C23H 27N 3O 6 + H)+ = 442, 
found 442. C rude yield: 61%. Purity: 77% (LC).
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(±)-(3R,4S)-4-(1,3-Benzodioxol-5-yl)-3-{[3-(3-cyanophenyl)ureido]methyl}-1-methylpyrroli-
nr\ u O dine-3-carboxylic acid 21g.CO2H " 1 1
(From (±)-8) MS [APCI (m /z)] calcd for (C22H 22N 4O5 + H)+ = 423,
MeN N H
c o 2h n
H - " n A ..
MeN I H H
^ .^ O  found 423. C rude yield: 62%. Purity: 99% (LC).
O
(±)
(±)-(3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-methyl-3-{[3-(3-pyridyl)ureido]methyl}pyrrolidine-3- 
~ .^ N. carboxylic acid 2 1 h.
c o 2h O I I
(From (±)-8 ) MS [APCI (m /z)] calcd for (C20H 22N 4O5 + H)+ = 399, 
MeN. 1 H O found 399. C rude yield: 54%. Purity: 71% (LC).
' )O
(±)
(±)-(3R,4S)-1-M ethyl-4-(1-methyl-1H-pyrrol-2-yl)-3-[(3-phenylureido)methyl]pyrrolidine-3-
O f^^ii carboxylic acid 2 2 d.
N ' - N'  ^  (From (±)-9) MS [APCI (m /z)] calcd for (C19H 24N 4O3 + H)+ = 357, 
found 357. C rude yield: 58%. Purity: 14% (LC).
. uMe
(±)
(±)-(3R,4S)-1-Methyl-4-(1-methyl-1H-pyrrol-2-yl)-3-({3-[4-(trifluoromethyl)phenyl]ureido}-
n  ^ -^ /C P s m ethyl)pyrrolidine-3-carboxylic acid 22e.
CO H O I I I
/ ' 4 " ' 2" NA N^ ^  (From (±)-9) MS [APCI (m /z)] calcd for (C20H 23F3N 4O3 + H)+ =
MeN^ ' , ,  H H 425, found 425. C rude yield: 65%. Purity: 79% (LC).
, | QMe
(±)
(±)-(3R,4S)-3-{[3-(4-Ethoxyphenyl)ureido]methyl}-1-methyl-4-(1-methyl-1H-pyrrol-2-yl)pyrro-
O ^''-'Y'-OEt lidine-3-carboxylic acid 22f.
(From (±)-9) MS [APCI (m /z)] calcd for (C21H 28N 4O4 + H)+ = 401, 
MeN^ ^ -,, H H found 401. C rude yield: 62%. Purity: 16% (LC).
, N ^
Me
(±)
(±)-(3R,4S)-3-{[3-(3-Cyanophenyl)ureido]methyl}-1-methyl-4-(1-methyl-1H-pyrrol-2-yl)pyrro-
n n  u O ^ ^ > 1  lidine-3-carboxylic acid 22g.CO2H " 1 1
' 'N" ^ " ' " ' V CN (From (±)-9) MS [APCI (m /z)] calcd for (C20H 23N 5O3 + H)+ = 382, 
MeN I N H
V-'-'k ^  found 382. C rude yield: 61%. Purity: 99% (LC).
Me
(±)
(±)-(3R,4S)-1-M ethyl-4-(1-methyl-1H-indol-3-yl)-3-[(3-phenylureido)methyl]pyrrolidine-3-car-
boxylic acid 23d.
(From (±)-10) MS [APCI (m /z)] calcd for (C23H 26N 4O3 + H)+ = 407, 
found 407. C rude yield: 79%. Purity: 97% (LC).
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(±)-(3R,4S)-1-Methyl-4-(1-methyl-1H-mdol-3-yl)-3-({3-[4-(trifluoromethyl)phenyl]ureido}-
CF3 m ethyl)pyrrolidine-3-carboxylic acid 23e.
(From (±)-10) MS [APCI (m /z)] calcd for (C24H 25F3N 4O3 + H)+ 
475, found 475. C rude yield: 76%. Purity: >99% (LC).MeN
CO2H
(±)
r \ j
' n'
Me
co2h 0  2 
m'2'4 " " ''N ' 'N 'i' 6'MeN H a- H 6
3"^^=\5'
5 : : ' r y J >
2 N 7''a 7''
(±) Mo
(±)-(3R,4S)-3-{[3-(4-Ethoxyphenyl)ureido]methyl}-1-methyl-4-(1-methyl-1H-indol-3-yl)pyrro-
OEt lidine-3-carboxylic acid 23f.
II I J s (From (±)-10) *H NM R [400 MHz, 5 (ppm), CD3SOCD3]: 8.92 (bs,
1 !H, NHAr), 7.62 (d, J = 7.8 Hz, 1 !H, 4"-CH), 7.38 (d, J = 8.4 Hz, 1 
1H, 7"-CH), 7.34 (s, 1 !H, 2"-CH), 7.29-7.21 (m, 2 !H, 2'-CH + 6'- 
CH), 7.12 (dd(3), J = 7.5 Hz, 1 1H, 6''-CH), 6.96 (dd(3), J = 7.5 Hz, 1 
1H, 5''-CH), 6.77-6.69 (m, 2 !H, 3'-CH + 5'-CH), 6.18 (bd, J = 6.9 
Hz, 1 !H, CH 2NH), 4.11 (dd; J = 9.6, 7.5 Hz; 1 !H, 4-CH), 3.91 (q, J = 6.9 Hz, 2 !H, CH2CH3), 3.77 
(s, 3 !H, 1''-NCH3), 3.54 (d, J = 10.2 Hz, 1 !H, 2-CHH), 3.53-3.49 (m, 1 !H, 5-CHH), 3.21 (dd; J =
13.2, 8.4 Hz; 1 !H, CHHNH), 3.22-3.16 (m, 1 !H, 5-CHH), 2.86 (d, J = 10.2 Hz, 1 !H, 2-CHH), 2.68 
(s, 3 !H, 1 -NCH3), 2.66 (dd; J = 13.2, 2.1 Hz; 1 !H, CHHNH), 1.27 (t, J = 6.9 Hz, 3 !H, CH 2CH3). 
FTIR [ V (cm-1), neat]: 3330, 2938, 2880, 1664, 1595, 1540, 827, 733. MS [APCI (m /z)] calcd for 
(C25H 30N 4O4 + H)+ = 451, found 451. C rude yield: 70%. Purity: 94% (LC).
(±)-(3R,4S)-3-{[3-(3-Cyanophenyl)ureido]methyl}-1-methyl-4-(1-methyl-1H-indol-3-yl)pyrro-
lidine-3-carboxylic acid 23g.
(From (±)-10) *H NM R [400 MHz, 5 (ppm), CD3SOCD3]: 10.07 (bs,
1 !H, NHAr), 8.02 (s, 1 !H, 2'-CH), 7.67 (d, J = 8.1 Hz, 1 !H, 6'-CH),
7.61 (d, J = 7.8 Hz, 1 !H, 4''-CH), 7.39-7.36 (m, 1 !H, 7''-CH), 7.37 
(dd(3), J = 7.8 Hz, 1 !H, 5'-CH), 7.36 (s, 1 !H, 2''-CH), 7.27 (d, J = 7.5 
Hz, 1 !H, 4'-CH), 7.10 (dd(3), J = 7.5 Hz, 1 !H, 6''-CH), 6.88 (dd(3), J 
= 7.5 Hz, 1 !H, 5''-CH), 6.74 (bs, 1 !H, CH 2NH), 4.17 (dd; J = 9.9, 7.8 Hz; 1 !H, 4-CH), 3.77 (s, 3 !H, 
1''-NCH3), 3.73-3.63 (m, 2 !H, 2-CHH + 5-CHH), 3.36 (dd(3), J = 9.9 Hz, 1 !H, 5-CHH), 3.29 (dd; J 
= 13.4, 9.0 Hz; 1 !H, CHHNH), 2.99 (d, J = 9.9 Hz, 1 !H, 2-CHH), 2.80 (s, 3 !H, 1 -NCH3), 2.68 (dd; 
J = 13.4, 2.1 Hz; 1 !H, CHHNH). 13C NM R [75 MHz, 5 (ppm), CD3SOCD3]: 177.3 (CO2), 155.5 
(NCON), 142.0 (1'-C), 136.6 (7''a-C), 129.8 (5'-C), 127.7 (3''a-C), 127.6 (2''-C), 123.9 (4'-C), 122.0 (6'- 
C), 121.3 (6''-C), 119.8 (2'-C), 119.4 (5''-C), 119.1 (CN), 118.6 (4''-C), 111.3 (3'-C), 109.6 (3''-C), 109.3 
(7''-C), 62.6 (2-C), 59.1 (5-C), 55.4 (3-C), 42.4 (1 -NCH3), 41.9 (4-C), 41.0 (CH2NH), 32.5 (1''-NCH3). 
FTIR [V (cm-1), neat]: 3361, 2940, 2226, 1685, 1583, 1564, 742. MS [APCI (m /z)] calcd for 
(C24H 25N 5O3 + H)+ = 432, found 432. C rude yield: 67%. Purity: 99% (LC).
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(±)-(3R,4S)-1-M ethyl-4-(1-methyl-1H-mdol-3-yl)-3-{[3-(3-pyridyl)ureido]methyl}pyrrolidme-3-
carboxylic acid 23h.
(From (±)-10) MS [APCI (m /z)] calcd for (C22H 25N 5O3 + H)+ = 408, 
MeN I H - H found 408. C rude yield: 71%. Purity: 36% (LC).
(±)
'N'
Me
MeN H H
3'
3''
N"^
(±)
6' \--ji^4' 
5'
(±)-M ethyl (3R,4S)-1-m ethyl-4-phenyl-3-[(3-phenylureido)m ethyl]pyrrolidine-3-carboxylate
24d.
Phenyl isocyanate (2.563 g, 21.52 mmol) was added  to a solution of 
a-am inom ethyl ester (±)-7 (4.858 g, 19.56 mmol) in dry CH2Cl2 (40 
mL). The resulting reaction m ixture was stirred at room  tem perature 
for 2.5 h  and the solvent was then evaporated to afford (±)-24d 
(6.895 g, 96%) as a white foam, after colum n chrom atography (CH2Cl2/M eO H , 14:1). *H NM R 
[300 MHz, 5 (ppm), CDCls]: 7.47 (bs, 1 !H, NHPh), 7.28-7.15 (m, 9 !H, Ph' + 2"-CH + 3"-CH + 5''- 
CH + 6''-CH), 7.03-6.96 (m, 1 !H, 4''-CH), 5.35 (bdd; J = 7.8, 3.6 Hz; 1 !H, CH 2NH), 3.91 (dd(3), J =
8.2 Hz, 1 !H, 4-CH), 3.70 (s, 3 !H, OCH3), 3.44 (dd; J = 14.1, 8.4 Hz; 1 !H, CHHNH), 3.20 (d, J = 9.6 
Hz, 1 !H, 2-CHH), 3.05 (dd(3), J = 8.6 Hz, 1 !H, 5-CHH), 2.96 (dd(3), J = 9.0 Hz, 1 !H, 5-CHH), 
2.80 (dd; J = 14.1, 3.9 Hz; 1 !H, CHHNH), 2.72 (d, J = 9.6 Hz, 1 !H, 2-CHH), 2.39 (s, 3 !H, NCH3). 
13C NM R [75 MHz, 5 (ppm), C D O 3]: 176.0 (CO2), 156.1 (NCON), 138.8 (1''-C), 137.3 (1'-C), 129.0 
(2'-C + 6'-C)*, 128.5 (3'-C + 5'-C)*, 128.4 (3''-C + 5''-C)*, 127.2 (4'-C), 123.2 (4''-C), 120.5 (2''-C + 6''- 
C), 63.3 (2-C), 60.4 (5-C), 57.0 (3-C), 52.8 (OCH3), 50.8 (4-C), 44.0 (CH2NH), 42.3 (NCH3). FTIR [ V 
(cm-1), neat]: 3323, 2952, 2836, 2790, 1725, 1656, 1597, 1554, 751, 701. HRM S [ESI (m /z)] calcd for 
(C21H 2sN3O3 + H)+ = 368.19687, found 368.19803 (| A | = 1.7 ppm). Rf: 0.40 (CH2Cl2/M eO H , 8:1). 
Mp: 160.6 °C.
.. .. , i^^NHMeN I ^ 2'
^ 3 '
(±)
(±)-(4R,5S)-2-Methyl-4,7-diphenyl-2,7,9-triazaspiro[4.5]decane-6,8-dione 12d.
A 1 M solution of KOBuf in THF (120 |xL, 120 jamol) w as added  to a solution 
of a-ureido ester (±)-24d (44 mg, 120 |j,mol) in THF (4 mL). The resulting 
reaction m ixture w as stirred for 55 m in at 31 °C. Brine (1 mL) was then added. 
The layers were separated and the aqueous phase was extracted w ith  CH2Cl2 
(2 x 1.5 mL). The com bined organic layers were dried over N a2SO4 and 
concentrated in  vacuo. The residue afforded (±)-12d (23 mg, 57%) as a white 
solid, after colum n chrom atography (CH2Cl2/M eO H , 19:1). *H NM R [300 
MHz, 5 (ppm), CD3SOCD3]: 7.79 (bd, J = 3.0 Hz, 1 !H, NH), 7.43-7.20 (m, 8 !H, Ph' + 3''-CH + 4''- 
CH + 5''-CH), 7.16-7.11 (m, 2 !H, 2''-CH + 6''-CH), 4.05 (dd(3), J = 6.9 Hz, 1 !H, 4-CH), 2.98 (dd; J 
= 9.0, 6.6 Hz; 1 !H, 3-CHH), 2.95-2.84 (m, 4 !H, 1-CH2 + 3-CHH + 10-CHH), 2.67 (dd; J = 12.6, 1.5 
Hz; 1 !H, 10-CHH), 2.36 (s, 3 !H, NCH3). 13C NM R [75 MHz, 5 (ppm), C D O 3]: 173.3 (6-C), 153.9 
(8-C), 139.0 (1'-C), 135.4 (1''-C), 129.1 (3''-C + 5''-C), 128.63 (3'-C + 5'-C)*, 128.58 (2''-C + 6''-C)*,
128.5 (2'-C + 6'-C)*, 128.4 (4''-C), 127.2 (4'-C), 64.0 (1-C), 62.0 (3-C), 52.5 (5-C), 48.3 (4-C), 43.7 (10- 
C), 42.1 (NCH3). FTIR [V (cm-1), neat]: 3254, 2945, 2835, 2792, 1725, 1684, 767, 753, 707, 693. 
Elem. anal. calcd for C2qH21N 3 0 2: C 71.62%, H 6.31%, N 12.53%; found C 71.70%, H 6.17%, N
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12.48%. Rf: 0.44 (CH2Cl2/M eO H , 8:1). Mp: 231.5 °C (from MeOH, colorless crystals). Purity: 
>99.5% (GC).
G eneral Procedure for a-T hioureidom ethyl Ester Form ation. The isothiocyanate (1 equiv) 
w as added  to a solution of the a-am inom ethyl ester (±)-7 in CH 2Cl2 or DMF (0.15 M). The 
resulting reaction m ixture w as stirred for 15 h  and the solvent was then evaporated.
(±)-M ethyl (3R,4S)-4-(3,5-dim ethoxyphenyl)-3-[(3-ethylthioureido)methyl]-1-m ethylpyrroli-
2 C02M e^  Et dine-3-carboxylate 25.
MeN ^ l H H According to the general procedure using ethyl isocyanate, the reaction of
5 a-am inom ethyl ester (±)-7 (16.0 mg, 51.9 |j,mol) afforded (±)-25 (20.5 mg,
6' ^ Y 4' 99%) as a yellow oil. *H NM R [400 MHz, 5 (ppm), CDCb]: 6.38 (bs, 2 !H, 
(±) 0Me 2'-CH + 6 '-CH), 6.35 (t, J = 2.0 Hz, 1 !H, 4'-CH), 6.27 (bdd; J = 7.4, 4.3 Hz; 1 
!H, NH), 4.00 (t, J = 8.6 Hz, 1 !H, 4-CH), 3.78 (s, 3 !H, COÆ H3), 3.77 (s, 6 !H, 2 x OCH3), 3.65-2.81 
(m, 8 !H, 2 -C H 2 + 5-CH2 + 2 x CH2NH), 2.44 (s, 3 !H, NCH3), 1.19 (t, J = 7.2 Hz, 3 !H, CH 2CH3). 
MS [ESI (m /z)] calcd for (C19H 29N 3O4S + H)+ = 396, found 396.
(±)-M ethyl (3R,4S)-4-(3,5-dim ethoxyphenyl)-1-methyl-3-[(3-phenylthioureido)m ethyl]pyrro-
3'' lidine-3-carboxylate 26.
S 2' '^ y ' '  J
1 JJ5' According to the general procedure using phenyl isocyanate, theC02Me
'N  n 1' 6'
Mel\ d  H 0Me reaction of a-am inom ethyl ester (±)-7 (17.3 mg, 56.1 |j,mol) afforded
(±)-26 (26.6 mg, 99%) as a yellow oil. *H NM R [400 MHz, 5 (ppm), 
C D O 3]: 7.92 (bs, 1 !H, NH), 7.43-7.38 (m, 2 !H, 3''-CH +5''-CH), 7.22-
,,, 0Me
(±) 7.08 (m, 3 !H, 2''-CH +4''-CH + 6 ''-CH), 6.33 (d, J = 2.2 Hz, 2 !H, 2'-CH
+ 6 '-CH), 6.30 (t, J = 2.2 Hz, 1 iH, 4'-CH), 4.08-3.88 (m, 2 iH, 4-CH + CHHNH), 3.75 (s, 6 iH, 2 x 
OCH3), 3.70 (s, 3 1H, CO2CH3), 3.32 (bd, J = 13.1 Hz, 1 1H, CHHNH), 3.06 (d, J = 9.5 Hz, 1 1H, 2- 
CHH), 2.92 (t, J = 8.8 Hz, 1 1H, 5-CHH), 2.92-2.74 (bm, 2 1H, 2-CHH + 5-CHH), 2.27 (bs, 3 1H, 
NCH3). MS [ESI (m /z)] calcd for (C23H 29N 3O4S + H)+ = 444, found 444.
G eneral Procedure for Spiro Thiouracil Form ation. A 1 M solution of KOBut in THF (1 
equiv) was added  to a solution of a-thioureidom ethyl ester in THF (0.15 M). The resulting 
reaction m ixture w as stirred for 3 h. A saturated solution of NaHCO 3 (1 mL per mmol) was then 
added. The layers w ere separated and the organic phase was dried over MgSO4, filtered, and 
concentrated in  vacuo.
5
(±)-(4R,5S)-4-(3,5-Dimethoxyphenyl)-7-ethyl-2-methyl-8-thioxo-2,7,9-triazaspiro[4.5]decan-6- 
one 27.
According to the general procedure, the reaction of a-thioureidom ethyl 
ester (±)-25 (20.5 mg, 51.9 |j,mol) afforded (±)-27 (19.9 mg, 99% crude
0Me
yield) as an  orange oil. *H NM R [400 MHz, 5 (ppm), CDCls] : 7.37 (bs, 1 
1H, NH), 6.43 (d, J = 2.2 Hz, 2 1H, 2'-CH + 6 '-CH), 6.34 (t, J = 2.2 Hz, 1 1H, 
(±) 0Me 4'-CH), 4.30 (dq; J = 13.2, 6.9 Hz; 1 1H, CHHCH3), 4.26 (dq; J = 13.2, 6.9 Hz;
1 1H, CHHCH 3), 4.10 (dd; J = 8.0, 5.7 Hz; 1 1H, 4-CH), 3.77 (s, 6 1H, 2 x OCH3), 3.10 (dd; J = 13.5,
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3.2 Hz; 1 iH, 10-CHH), 3.02 (dd; J = 9.5, 5.7 Hz; 1 IH, 3-CHH), 2.95 (dd; J = 9.5, 8.0 Hz; 1 IH, 3- 
CHH), 2.85 (d, J = 9.5 Hz, 1 IH, 1-CHH), 2.84 (d, J = 13.5 Hz, 1 IH, 10-CHH), 2.70 (d, J = 9.5 Hz, 1 
!H, 1-CHH), 2.39 (s, 3 ^ ,  NCH3), 1.24 (t, J = 6.9 Hz, 3 ^ ,  CH 2CH3). 13C NM R [75 MHz, 5 (ppm), 
CDCI3]: 181.6 (8 -C), 169.9 (6-C), 160.7 (3'-C + 5'-C), 140.9 (1'-C), 107.0 (2'-C + 6 '-C), 99.2 (4'-C), 63.8 
(1-C), 61.3 (3-C), 55.5 (2 x OCH3), 51.1 (5-C), 48.4 (4-C), 45.4 (10-C), 42.3 (CH2CH3), 41.7 (NCH3),
13.3 (CH2CH3). FTIR [ V (cm-1), neat]: 3210, 2937, 2838, 2786, 1691, 1605, 1594, 1205, 1154, 1065, 
840. MS [ESI (m /z)] calcd for (C18H 25N 3O3S + H)+ = 364, found 364. Purity: 89% (LC).
(±)-(4R,5S)-4-(3,5-Dimethoxyphenyl)-2-methyl-7-phenyl-8-thioxo-2,7,9-triazaspiro[4.5]decan-
6-one 29.
According to the general procedure, the reaction of a-thioureidom ethyl 
ester (±)-26 (26.6 mg, 56.1 |j,mol) afforded (±)-29 (21.2 mg, 99% crude 
yield) as an  orange oil. *H NM R [300 M Hz, 5 (ppm), CDCI3 ]: 7.99 (bs, 1 
!H, NH), 7.49-7.39 (m, 3 ^ ,  3"-CH + 4"-CH +5"-CH), 7.16-7.12 (m, 2 ^ ,  
2"-CH + 6"-CH), 6.47 (d, J = 2.1 Hz, 2 iH, 2'-CH + 6'-CH), 6.35 (t, J = 2.1 
Hz, 1 1H, 4'-CH), 4.14 (dd; J = 8.1, 5.1 Hz; 1 1H, 4-CH), 3.76 (s, 6 1H, 2 x 
OCH3), 3.70 (dd; J = 7.5, 6.0 Hz; 1 1H, 3-CHH), 3.22 (d, J = 13.5 Hz, 1 1H, 
10-CHH), 3.09-2.92 (m, 3 1H, 1-CHH + 3-CHH + 10-CHH), 2.82 (d, J = 9.6 Hz, 1 1H, 1-CHH), 2.41 
(s, 3 1H, NCH3). MS [ESI (m /z)] calcd for (C22H 25N 3O3S + H)+ = 412, found 412. Purity: 57% 
(LC).
G eneral Procedure for Spiro ß-Lactam Form ation. tert-Butylmagnesium chloride (2 equiv; 
from a 2.0 M solution in Et2O) w as added  to a solution of a-am inom ethyl ester in dry  THF (0.1 
M). The resulting reaction m ixture was stirred at room  tem perature for 45 min. Brine was added 
and the layers were separated. The aqueous phase was extracted w ith  CH 2Cl2 and the combined 
organic extracts were dried over MgSO4. Removal of the solvent under reduced pressure left a 
residue, w hich w as purified by colum n chrom atography on silica gel (CH2Cl2/M eO H , 
19:1^9:1).
(±)
(±)-(4R,8S)-8-(4-M ethoxyphenyl)-6-methyl-2,6-diazaspiro[3.4]octan-1-one 31.
According to the general procedure, the reaction of a-am inom ethyl ester 
(±)-6 (49 mg, 176 |amol) afforded (±)-31 (39 mg, 90%) as a white solid. 1H 
NM R [400 MHz, 5 (ppm), CDCfe]: 7.20-7.15 (m, 2 1H, 2'-CH + 6'-CH), 
6.87-6.82 (m, 2 1H, 3'-CH + 5'-CH), 5.68 (bs, 1 1H, NH), 3.80 (s, 3 1H, 
OCH3), 3.70 (dd; J = 8.0, 6.4 Hz; 1 1H, 8-CH), 3.07 (d, J = 9.8 Hz, 1 1H, 5- 
CHH), 3.04 (d, J = 9.8 Hz, 1 1H, 5-CHH), 3.03 (d, J = 5.8 Hz, 1 1H, 3-CHH), 2.96 (dd; J = 9.5, 8.0 
Hz; 1 1H, 7-CHH), 2.91 (dd; J = 9.5, 6.4 Hz; 1 1H, 7-CHH), 2.87 (d, J = 5.8 Hz, 1 1H, 3-CHH), 2.42 
(s, 3 1H, NCH3). 13C NM R [75 MHz, 5 (ppm), CDCfe]: 172.5 (1-C), 158.3 (4'-C), 132.3 (1'-C), 129.1 
(2'-C + 6'-C), 113.9 (3'-C + 5'-C), 66.3 (4-C), 62.8 (5-C), 62.7 (7-C), 55.5 (OCH3), 47.3 (8-C), 47.2 (3- 
C), 42.4 (NCH3). FTIR [ V (cm-1), neat]: 3235, 2948, 2840, 2792, 1745, 1247, 832. MS [ESI (m /z)] 
calcd for (C14H 18N 2O 2 + H)+ = 247, found 247. Rf: 0.36 (CH2O 2/M eO H , 8:1). Purity: >99.5% 
(GC).
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(±)-(4R,8S)-6-M ethyl-8-phenyl-2,6-diazaspiro[3.4]octan-1-one 33.
O. 1 According to the general procedure, the reaction of a-am inom ethyl ester (±)-5
'-MU
/ (215 mg, 865 |j,mol) afforded (±)-33 (164 mg, 8 8 %) as a w hite solid. 1H NM R
MeN I ' 3 2 '
^ 3' [400 MHz, 5 (ppm), CDCfe]: 7.32-7.26 (m, 2 1H, 3'-CH + 5'-CH), 7.25-7.19 (m, 3
^ 4  1H, 2'-CH + 4'-CH + 6 '-CH), 6.36 (bs, 1 1H, NH), 3.70 (dd(3), J = 7.2 Hz, 1 1H, 8­
5'
(±) CH), 3.05 (d, J = 10.0 Hz, 1 1H, 5-CHH), 3.02 (d, J = 10.0 Hz, 1 1H, 5-CHH), 3.01
(d, J = 5.9 Hz, 1 1H, 3-CHH), 2.96 (dd; J = 9.5, 7.8 Hz; 1 1H, 7-CHH), 2.92 (dd; J = 9.5, 6 .6  Hz; 1 1H,
7-CHH), 2.81 (d, J = 5.9 Hz, 1 1H, 3-CHH), 2.40 (s, 3 1H, NCH3). 13C NM R [75 MHz, 5 (ppm), 
C D O 3]: 172.6 (1-C), 140.2 (1'-C), 128.4 (3'-C + 5'-C), 128.0 (2'-C + 6 '-C), 126.7 (4'-C), 65.8 (4-C), 
62.64 (5-C), 62.62 (7-C), 47.8 (8 -C), 47.1 (3-C), 42.2 (NCH3). FTIR [ V (cm-1), neat]: 3227, 2948, 
2834, 2793, 1746, 763, 702. MS [ESI (m /z)] calcd for (C13H 16N 2O + H)+ = 217, found 217. Rf: 0.35 
(CH2Cl2/M eO H , 8:1). Purity: 99.4% (GC).
(±)-2-[(3R,4S)-3-(Aminomethyl)-4-(4-methoxyphenyl)-1-methylpyrrolidin-3-yl]propan-2-ol 32.
Mei ou M ethylm agnesium  brom ide (220 |j,l, 661 |j,mol) was added  to a solution of
a-am inom ethyl ester (± )-6  (92 mg, 330 |j,mol) in  dry THF (2 mL). The 
resulting reaction m ixture was stirred at room  tem perature for 3 h. Brine 
was added  and the layers were separated. The aqueous phase was 
extracted w ith  CH 2Cl2 and the combined organic extracts were dried over 
MgSO4. Removal of the solvent under reduced pressure left a residue, w hich w as purified by 
colum n chrom atography on silica gel (CH2C h/M eO H , 19:1^9:1) to afford (±)-32 (14 mg, 15%) 
as a yellow oil. 1H NM R [300 MHz, 5 (ppm), C D O 3]: 7.41-7.33 (m, 2 1H, 2''-CH + 6 ''-CH), 6 .8 6­
6.78 (m, 2 1H, 3''-CH + 5''-CH), 3.78 (s, 3 1H, OCH3), 3.67 (t, J = 7.5 Hz, 1 1H, 4'-CH), 2.95 (s, 2 1H, 
2 '-CH2), 2.92 (d, J = 7.5 Hz, 2 1H, 5 '-CH2), 2.71 (d, J = 10.2 Hz, 1 1H, CHH N H 2), 2.42 (d, J = 10.2 
Hz, 1 1H, CH H N H 2), 2.41 (s, 3 1H, NCH 3), 1.31 (s, 3 1H, 1 -CH3), 1.28 (s, 3 1H, 3 -CH3). 13C NM R 
[75 MHz, 5 (ppm), C D Q 3]: 158.2 (4''-C), 130.5 (2''-C + 6''-C), 130.1 (1''-C), 113.7 (3''-C + 5''-C), 76.3 
(2-C), 64.3 (2'-C), 64.1 (5'-C), 55.5 (OCH3), 55.1 (3'-C), 47.3 (4'-C), 45.9 (CH2N H 2), 42.7 (NCH3), 27.7 
(3-C), 27.0 (1-C). MS [ESI (m /z)] calcd for (C16H 26N 2O 2 + H)+ = 279, found 279. Rf: 0.10 
(CH2Cl2/MeOH, 8:1).
G eneral Procedure for 1,3-Dipolar C ycloaddition Reaction of 34 and  35. A round-bottom ed 
flask fitted w ith  a D ean-Stark apparatus, a reflux condenser, and a drying tube containing 
calcium chloride was charged w ith  2-cyanoacrylate and toluene (0.20-0.25 M). W hen the 
m ixture was under reflux, glycine (1.2 equiv) and paraform aldehyde (3.6 equiv) were added. 
This addition was repeated every 50 m in until the substrate had completely reacted. W ater (20 
mL) was then added  and the layers were separated. The aqueous layer w as extracted w ith  Et2O 
(3 x 30 mL) and the combined organic layers were dried (MgSO4), filtered, and concentrated in  
vacuo.
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D im ethyl (3R,3'S,4R,4,S)-3,3,-dicyano-4,4,-bis(3,5-dim ethoxyphenyl)-1,1 '-m ethylenedipyrroli-
dine-3-carboxylate 36 and  (±)-dim ethyl (3R,3'R,4R,4'R)- 
3,3,-dicyano-4,4'-bis(3,5-dimethoxyphenyl)-1,1'-m ethyl- 
enedipyrrolidine-3-carboxylate 37.
According to the general procedure, 2-cyanoacrylate 34 
(700 mg, 2.83 mmol) afforded a 1:1 m ixture of 36 and 
(±)-37 (490 mg, 58%) as a w hite solid, after colum n 
chrom atography (heptane/A cO Et, 3:1^2:1). *H NM R 
[400 MHz, 5 (ppm), CDCls]: 6.51 (d, J = 2.2 Hz, 8 !H, 4 x 
2'-CH + 4 x 6 '-CH), 6.42 (t, J = 2.2 Hz, 4 !H, 4 x 4'-CH), 
3.96 (t, J = 8.0 Hz, 2 iH, 2 x 4-CH), 3.95 (t, J = 8.0 Hz, 2 
!H, 2 x 4-CH), 3.84 (s, 12 iH, 4 x CO2CH3), 3.78 (s, 24 iH, 8 x OCH3), 3.61 (s, 4 iH, 2 x NCH2N), 
3.53 (d, J = 10.5 Hz, 2 1H, 2 x 2-CHH), 3.52 (d, J = 10.2 Hz, 2 1H, 2 x 2-CHH), 3.45 (d, J = 10.2 Hz,
2 1H, 2 x 2-CHH), 3.44 (d, J = 10.5 Hz, 2 1H, 2 x 2-CHH), 3.32-3.24 (m, 8 1H, 4 x 5 -CH2). 13C NM R 
[75 MHz, 5 (ppm), CDCla]: 168.3 (4 x CO2), 160.9 (4 x 3'-C + 4 x 5'-C), 138.5 (2 x 1'-C), 138.4 (2 x 
1'-C), 117.81 (2 x CN), 117.79 (2 x CN), 106.61 (2 x 2'-C + 2 x 6'-C), 106.58 (2 x 2'-C + 2 x 6'-C), 
100.10 (2 x 4'-C), 100.07 (2 x 4'-C), 74.6 (2 x NCH 2N), 61.70 (2 x 2-C), 61.65 (2 x 2-C), 56.13 (2 x 5- 
C), 56.07 (2 x 5-C), 55.37 (4 x OCH3), 55.36 (4 x OCH3), 54.1 (2 x 3-C), 54.0 (2 x 3-C), 53.98 (2 x 
CO2CH3), 53.96 (2 x CO2CH3), 51.94 (2 x 4-C), 51.93 (2 x 4-C). Rf: 0.31 (heptane/A cO Et, 1:3). Mp:
160.7 °C.
D im ethyl (3R,3,S,4R,4,S)-4,4,-bis(1,3-benzodioxol-5-yl)-3,3,-dicyano-1,1,-m ethylenedipyrroli-
dine-3-carboxylate 39 and  (±)-dimethyl (3R,3'R,4R,4'R)- 
4,4'-bis(1,3-benzodioxol-5-yl)-3,3'-dicyano-1,1'-methyl- 
enedipyrrolidine-3-carboxylate 40.
According to the general procedure, 2-cyanoacrylate 35 
(4.657 g, 20.14 mmol) afforded a 1:1 m ixture of 39 and 
(±)-40 (4.957 g, 88%) as a white solid, after colum n 
chrom atography (heptane/A cO Et, 3:1^2:1). *H NM R 
[400 MHz, 5 (ppm), CDCla]: 6.87 (s, 4 1H, 4 x 4'-CH), 6.82 
(dd; J = 8.0, 1.7 Hz; 4 1H, 4 x 6'-CH), 6.78 (d, J = 8.0 Hz, 4 
1H, 4 x 7'-CH), 5.97 (s, 8 1H, 4 x 2'-CH2), 3.96 (t, J = 8.1 Hz, 4 1H, 4 x 4-CH), 3.84 (s, 12 1H, 4 x 
O C H ), 3.58 (s, 4 1H, 2 x NCH2N), 3.52 (d, J = 10.5 Hz, 2 1H, 2 x 2-CHH), 3.51 (d, J = 10.2 Hz, 2 
1H, 2 x 2-CHH), 3.42 (d, J = 10.2 Hz, 2 1H, 2 x 2-CHH), 3.41 (d, J = 10.5 Hz, 2 1H, 2 x 2-CHH), 
3.28-3.20 (m, 8 1H, 4 x 5 -CH2). 13C NM R [75 MHz, 5 (ppm), CDCb]: 168.4 (4 x CO2), 148.1 (4 x 
3'a-C), 147.7 (4 x 7'a-C), 130.1 (2 x 5'-C), 130.0 (2 x 5'-C), 122.03 (2 x 6'-C), 122.02 (2 x 6'-C), 117.91 
(2 x CN), 117.89 (2 x CN), 108.7 (4 x 4'-C), 108.51 (2 x 7'-C), 108.50 (2 x 7'-C), 101.4 (4 x 2'-C), 74.8 
(NCH2N), 74.7 (NCH2N), 61.61 (2 x 2-C), 61.56 (2 x 2-C), 56.50 (2 x 5-C), 56.47 (2 x 5-C), 54.40 (2 
x 3-C), 54.38 (2 x 3-C), 54.07 (2 x OCHî), 54.06 (2 x O C H ), 51.8 (4 x 4-C).
> 2'
(±)
2 2
2
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(±)-M ethyl (2R,4S,5S)-4-cyano-7,9-dimethoxy-1,3,4,5-tetrahydro-2,5-methano-2-benzazepine-4- 
carboxylate 46.
n GOpMe6 'M eO^^jv-^^^^-CN Eschenmoser's salt ([Me2N =CH2]I; 191 mg, 1.03 mmol) w as added  to a
0 \
-N
-.1 ) 3
s solution of am inals 36 and (±)-37 (200 mg, 337 |j,mol) in MeCN (30 mL).
OMe The resulting reaction m ixture w as stirred at 40 °C for 17 h. The solvent
(±) was evaporated, AcOEt (30 mL) w as then added, and the mixture was
w ashed w ith H 2O (10 mL). The layers were separated and the organic phase was dried 
(MgSO4), filtered, and concentrated in  vacuo. The residue was purified by colum n 
chrom atography on silica gel (heptane/A cO Et, 1:3) to afford (±)-46 (163 mg, 80%) as a light 
yellow foam. iH  NM R [400 MHz, 5 (ppm), CDCb]: 6.37 (d, J = 2.4 Hz, 1 1H, 6-CH), 6.29 (d, J = 
2.4 Hz, 1 1H, 8-CH), 4.21 (d, J = 17.8 Hz, 1 1H, 1-CHH), 3.86 (s, 3 1H, 7 -OCH3)*, 3.80 (s, 3 1H, 9- 
OCH3)*, 3.79 (m, 1 1H, 3-CHH), 3.76 (s, 3 1H, CO2CH 3)*, 3.75 (d, J = 17.8 Hz, 1 1H, 1-CHH), 3.48 
(d, J = 13.2 Hz, 1 1H, 3-CHH), 3.47 (dd(3), J = 2.1 Hz, 1 1H, 5-CH), 3.24 (dd; J = 11.7, 2.0 Hz; 1 1H, 
10-CHH), 3.21 (dd; J = 11.7, 2.4 Hz; 1 1H, 10-CHH). 13C NM R [75 MHz, 5 (ppm), CDCb]: 168.6 
(CO2), 159.7 (7-C), 157.7 (9-C), 138.7 (5a-C), 118.9 (CN), 112.5 (9a-C), 104.3 (6-C), 98.4 (8-C), 66.5 
(3-C), 57.2 (4-C), 56.5 (10-C), 56.0 (5-C), 55.6 (7 -OCH3)*, 55.2 (9-OCH3)*, 53.9 (CO2C H ), 48.5 (1-C). 
FTIR [ V (cm-1), neat]: 2954, 2838, 2790, 2238, 1739, 1608, 1594, 1248, 1155. HRM S [EI (m /z)] 
calcd for Gl6H18N 2O4 = 302.1267, found for [M+^] = 302.1280 (| A | = 4.4 ppm), peaks at (relative 
intensity): 302 (100), 260 (77), 243 (31), 175 (24), 42 (25). Rf: 0.28 (heptane/A cO Et, 1:1). Mp: 132.7 
°C.
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CHAPTER 6
Synthesis of (Hetero)areno[d]pyrrolo[3,4-b]- 
pyridines and (Hetero)areno[c]pyrrolo[3,4-e]- 
azepines and Their Derivatization
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Abstract
The formation of tri- and tetracyclic scaffolds com bining two privileged structures, 
the 2-arylethyl am ine m oiety and a tetrahydro(hetero)areno[c]pyridine/tetrahydro- 
(hetero)areno[c]azepine, is described. These scaffolds were obtained using the Pictet- 
Spengler reaction, resulting in hexahydropyrrolo[3,4-c]isoquinolines, a hexahydro- 
furo[2,3-d]pyrrolo[3,4-b]pyridine, an octahydropyrrolo[3',4':5,6]pyrido[3,4-b]indole, an 
octahydropyrrolo[3,4-d][2]benzazepine, and an octahydropyrrolo[3',4':5,6]azepino[3,4-
b]indole. The pyridinic scaffolds were further derivatized in parallel fashion to 
synthesize two libraries of potentially pharmacologically important com pounds.
Part of this chapter was published in: Blanco-Ania, D.; Hermkens, P. H. H.; Sliedregt, L. A. J. 
M.; Scheeren, H. W.; Rutjes, F. P. J. T. J. Comb. Chem. 2009, 11, 539-546, 11, 547-555.
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6.1 Introduction
Tetrahydroisoquinoline 1 and tetrahydro-ß-carboline 2 (Figure 6.1) are privileged  
core structures in naturally occurring alkaloids that often show  a w ide range of 
biological and pharmacological properties.1
Their structural features are included in sim ple com pounds, such as salsolinol 3, 
w hich is speculated to contribute to the etiology of Parkinson's disease and the 
neuropathology of chronic alcoholism .2 They are also seen in very com plex 
com pounds, like m anadom anzamine A 4, w hich exhibits activity against human  
im m unodeficiency virus (HIV-1) and AIDS opportunistic fungal infections (Figure
6.2)3
Figure 6.2 Salsolinol 3 and Manadomanzamine A 4.
The Pictet-Spengler reaction has been of vital importance in the synthesis of 
num erous pharmacologically important privileged core structures, including 
isoquinoline alkaloids (with the tetrahydroisoquinoline m oiety 1 ) and indole alkaloids 
(with the tetrahydro-ß-carboline m oiety 2 ) .4
The Pictet-Spengler reaction5 is a transformation in which the 2-arylethyl amine 5 
upon treatment w ith a carbonyl (aldehyde or ketone) com pound 6  forms the product 7 
containing a new  ring (Scheme 6.1). The reaction takes place through, firstly, a 
condensation reaction betw een the amine and the carbonyl to yield an im ine 8  (which  
is som etim es isolated) and, secondly, an intramolecular aromatic electrophilic 
substitution.
Figure 6.1 Tetrahydroisoquinoline 1 and Tetrahydro-ß-carboline 2.
3 H
4
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The reaction is carried out under neutral or acidic conditions. The best results are 
observed w hen the aryl group is electron-rich. To overcome this limitation, 
carboxamides, sulfonam ides, sulfinamides, sulfenamides, and aryl amines are used  
instead of am ines to form more reactive intermediates than the regular im inium  ions, 
proceeding via N-acyl,6 N -sulfonyl,7 N -sulfinyl,8 N-sulfenyl, 9 and N-aryl im inium 10 ions 
respectively. The carbonyl com pounds can be replaced by m asked aldehydes and 
ketones, such as acetals,11 aminals, 12 hem iam inal ethers,13 and a-am ino nitriles14 am ong  
others.
This reaction continues to be very important because of the growing interest in the 
synthesis of biologically active products having more com plex structures, such as 
m anzam ine ,15 the A lstonia alkaloids16, as w ell as the natural product ecteinascidin 743 
9 .17 Corey et al. show ed, w ith this last example, the great applicability of the Pictet- 
Spengler reaction in total synthesis using it three tim es for constructing this natural 
product (Scheme 6.2).
Scheme 6.2 Synthesis of Ecteinascidin 743 9. 
OBn O
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The Pictet-Spengler reaction has also been used for the synthesis of different 
tetrahydroheteroareno[c]pyridines. Clopidogrel 11 (Plavix®), the second best-selling  
prescription drug in 2007,18 is synthesized from the 2-(2-thienyl)ethyl amine 10 by  
treatment w ith paraformaldehyde and formic acid (Scheme 6.3) .19
Scheme 6.3 Synthesis of Clopidogrel 11.
(CH20 )„, h c o 2h 
50 °C, 20 min 
54%
The Pictet-Spengler reaction has not been greatly utilized in the formation of seven- 
m em bered rings, due to less favorable enthalpy and entropy for the cyclization. Several 
exam ples of cyclizations to tetrahydro-2 -benzazepines exist, but this area is m uch less 
developed than that of tetrahydroisoquinolines and tetrahydro-ß-carbolines. Most of 
these exam ples used activated im inium  ions, like the one used by H oshino et al.20 for 
the synthesis of the natural product m ontam ine 1 2  (Scheme 6.4).
Scheme 6.4 Synthesis of Montanine 12.
The 2-benzazepine skeleton is also a com m on structural feature in a variety of 
natural products, such as galantamine 1321 and ribasine 1422 (Figure 6.3), and synthetic 
bioactive com pounds .23
13 14
Figure 6.3 Natural Products with the 2-Benzazepine Feature: Galantamine 13 and Ribasine 14.
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In this chapter, the Pictet-Spengler reaction is utilized for the derivatization of a ­
amino esters (±)-15-(±)-19, synthesized in Chapter 3, to yield different polyhydro- 
(hetero)areno[d]pyrrolo[3,4-b]pyridines (±)-20-(±)-24 (Scheme 6.5).
Scheme 6.5 (Hetero)areno[d]pyrrolo[3,4-b]pyridines (±)-20-(±)-24.
CO2Me
M e N ^ f " NH2
^ " A r
(±)-15-(±)-19
Com pounds (±)-20-(±)-24 combine the 2-arylethyl amine scaffold, thoroughly  
described in Chapter 1, w ith a tetrahydro(hetero)areno[c]pyridine, such as 
tetrahydroisoquinoline or tetrahydro-ß-carboline.
Com pounds w ith the core structure 20, 21, or 22 could m odulate serotonin (5 -HT2) 
receptors for metabolic and central nervous system  disorders.24 Com pounds w ith  
formula 21 have the same core structure as the A m arillidaceae alkaloids plicamine and 
obliquine25 and derivatives of com pounds w ith structure 24 are reported to be tyrosine- 
kinase receptor inhibitors.26 Com pounds w ith structure 23 have not been previously  
synthesized nor have their properties been evaluated.
The Pictet-Spengler reaction of the a-am inom ethyl esters (±)-25 and (±)-26, 
synthesized in Chapter 2, to yield (hetero)areno[c]pyrrolo[3,4-e]azepines (±)-27 and 
(±)-28 is also described in this chapter (Scheme 6.6).
Scheme 6.6  (Hetero)areno[c]pyrrolo[3,4-e]azepines (±)-27 and (±)-28. 
CO2Me
M e N ^ f " '
NH2
Ar
(±)-25,(±)-26
(±)-27
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The derivatization of (hetero)areno[d]pyrrolo[3,4-b]pyridines (±)-21-(±)-24 using  
solution-phase parallel synthesis is also described. Two libraries, containing 32 and 68 
com pounds, are presented. Due to the pharmaceutical importance of am ides,27 the first 
library consists of the acylation of the scaffolds (±)-21-(±)-24 w ith eight acyl chlorides 
to form 32 am ides (±)-29 (Scheme 6.7). The second library consists of the annulation of 
a (thio)hydantoin ring to scaffolds (±)-21-(±)-24 using nine isocyanates and eight 
isothiocyanates to give com pounds (±)-30 and (±)-31, respectively (Scheme 6.7). The 
privileged structures hydantoin and 2-thiohydantoin w ere described in Chapter 4.
S chem e 6.7 Parallel D eriva tiza tion  o f  Scaffolds (± )-21 -(± )-24 .
MeO2C H 
MeN
H t
(±)-21-(±)-24
(±)-29 
32 compounds
(±)-30 
36 compounds
(±)-31 
32 compounds
6.2 R esults and D iscussion
6.2.1 Synthesis o f the Scaffolds. The Pictet-Spengler Reaction
Various conditions have been reported in the literature for performing Pictet- 
Spengler reactions: acidic or neutral conditions, protic or aprotic conditions, 
preform ing the imine, and so forth. In our case w e found that addition of TFA (2 equiv) 
to a CH 2Q 2 solution28 of com pounds (±)-15-(±)-19 and form aldehyde (37 wt% in H 2O 
solution) at room  temperature gave the desired products (±)-20-(±)-24 (Scheme 6.8). 
The reaction tim es were w hat could be expected according to the reactivity of the aryl 
groups. The work-up w as carried out by basifying the reaction mixture w ith saturated 
aqueous NaHCO3 and extracting w ith CH 2Q 2. It w as found that the reactions gave a 
higher yield if the reaction mixture w as im m ediately filtered through an ISOLUTE® 
SCX-2 colum n29 before purification. The excess reagents and by-products were w ashed  
aw ay w ith CH2Q 2 and MeOH. After this, the product w as collected from the column  
w ith a 1 M N H 3/M eO H  solution. In same cases, no further purification w as needed.
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Scheme 6 .8  P ic te t - S p e n g le r  R e a c t io n  o f  a - A m in o  E s te r s  ( ± ) - 1 5 - ( ± ) - 1 9 .
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The cyclization reaction of the phenyl-substituted pyrrolidine (±)-15 took place under 
m ild conditions (room temperature), but w ith a rather low  yield (28%). Introduction of 
electron-donating alkoxy groups on the phenyl ring (com pounds (±)-16 and (±)-17) or 
substitution of the phenyl group for electron-rich heteroaryl groups (furyl (±)-18 and 
indolyl (±)-19) resulted in faster and cleaner reactions and significantly higher yields, 
ranging from 65 to 91%. To the best of our know ledge, the cyclization of com pound  
(±)-18 is the first exam ple of a classical Pictet-Spengler reaction using a non-activated  
im inium  ion30 reacting w ith the 3-position of a furan ring.31 The reactivity of the 3- 
position of a furan ring is comparable to the 3-position of a thiophene ring32 and 
considering the successful thiophene cyclization in the synthesis of clopidogrel 11,19 w e  
were confident about the success of the cyclization of com pound (±)-18.
The cyclization of all substrates except for (±)-17 can result in only one regioisomer.33 
The reaction of com pound (±)-17, how ever, gave exclusively the regioisomer shown, 
whereas the corresponding isom er (±)-32 (Figure 6.4) w as not detected.34 35
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MeOpC N
MeN
H i y >
'O 
(±)-32
Figure 6.4 I s o m e r  (± ) - 3 2  n o t  F o u n d  in  th e  C y c l i z a t io n  o f  ( ± ) - 1 7.
W hen the same reaction conditions were applied to a-am inom ethyl esters (±)-25 and 
(±)-26 (Scheme 6.9), the reactions w ere significantly less clean than those of the a ­
amino esters (±)-15-(±)-19. A lthough the desired products w ere formed, the yields 
obtained for products (±)-27 and (±)-28 w ere lower than expected; there is at least one 
exam ple in the literature in which a less reactive aryl group on a substrate generated a 
product in 20% yield.36 Due to this result, the reaction w as not tried w ith the other a- 
am inom ethyl esters synthesized in Chapter 2, w hich are less reactive for this 
cyclization.
Scheme 6.9 P ic te t - S p e n g le r  R e a c t io n  o f  a - A m in o m e th y l  E s te r s  ( ± ) - 2 5 - ( ± ) - 2 6 .
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Remarkably, products (±)-33 and (±)-34 w ere also obtained from the cyclization 
reaction of (±)-25 and (±)-26, respectively, but only after filtration over the ISOLUTE® 
SCX-2 colum n and subsequent purification by colum n chromatography (silica gel). 
Their formation could only take place during the treatment of the ISOLUTE® SCX-2 
colum n w ith the 1 M N H 3/M eO H  solution, w hich serves as the nitrogen source, 
needed for formation of the amide. The aminal m ethylene should be present in the 
m olecule prior to the addition of NH 3 as there is no form aldehyde remaining (firstly, it 
w as evaporated and then w ashed away w ith  CH2Q 2 and MeOH). Based on these
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considerations, it w as postulated that (±)-33 and (±)-34 resulted from the reaction via 
the possible intermediates (±)-35, (±)-36, or (±)-37 (Figure 6.5).
MeN
MeO2C /  OH
MeN
(±)-35 (±)-36
Figure 6.5 Possible Intermediates for the Formation of Compounds (±)-33 and (±)-34.
An LC-MS analysis w as run during the cyclization reaction of (±)-25. A  mass 
corresponding to (±)-38, a structure like (±)-35, w as assigned to one of the peaks. The 
formation of (±)-38 could be explained as follows: once (±)-27 is formed, the secondary 
amine can add to form aldehyde and form the hem iam inal (±)-39, w hich can then 
undergo an acid-catalyzed intramolecular transesterification to yield (±)-38 (Scheme 
6 .1 0 ).
Scheme 6.10 Reaction Sequence for the Formation of Compound (±)-38.
-MeOH
(±)-27 (±)-39 (±)-38
The follow ing reaction sequence w as then proposed for the transformation of (±)-38 
into (±)-33 (Scheme 6.11). Com pound (±)-38 could react w ith NH 3 to give hydroxy  
am ide (±)-40. Elimination of hydroxide from the hem iam inal w ou ld  form the reactive 
im inium  ion (±)-41, w hich upon addition of the am ide (or maybe the amidate) w ou ld  
yield the tetracyclic com pound (±)-33.
Scheme 6.11 Reaction Sequence for the Formation of Compound (±)-33.
NH,
(±)-38 (±)-40 (±)-41 (±)-33
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A Pictet-Spengler cyclization reaction to convert com pound (±)-26 into (±)-28 was 
also attempted using Eschenmoser's salt37 [Me2N=CH 2]I (Scheme 6.12). The reaction 
gave a mixture of unidentified products, but product (±)-28 could not be identified by  
TLC, LC-MS, or NMR spectroscopy.
Scheme 6.12 Unsuccessful Pictet-Spengler Reaction with Eschenmoser's Salt.
Then, it w as decided to make the acetamide of a-am inom ethyl ester (±)-25 to see 
whether the cyclization w ou ld  take place using a more reactive N-acyl im inium  ion  
intermediate. Com pound (±)-25 w as reacted w ith Ac2O in pyridine at room  
temperature to give, almost quantitatively, am ide (±)-42. This com pound w as subjected 
to the same reaction conditions as before for the Pictet-Spengler reaction, but after two  
days the product (±)-43 w as not form ed and the substrate w as recovered (Scheme 6.13).
Scheme 6.13 Unsuccessful Pictet-Spengler Reaction with N-Acyl Iminium Ions.
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Another w ay of performing this type of cyclization proceeds via the Bischler- 
Napieralski reaction .38 This reaction originally consisted of the cyclization of an N- 
phenethyl amide 44 into a 3,4-dihydroisoquinoline 45 upon treatment w ith a 
dehydrating agent (Scheme 6.14).
Scheme 6.14 Bischler-Napieralski Reaction.
H
V
O
44
dehydrating
agent
R
45
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This reaction usually gives better results than the Pictet-Spengler reaction for the 
formation of seven-m em bered rings. Thus, com pound (±)-42 w as reacted w ith PO Q 3 in 
refluxing M eCN for 30 h. The substrate w as cleanly transformed into product (±)-46, 
but w ith only 55% conversion (Scheme 6.15). Am ide (±)-48 w as synthesized from the 
corresponding a-am inom ethyl ester (±)-47 (Chapter 2) and reacted under the same 
reaction conditions to give product (±)-49 in 71% yield (Scheme 6.15).39
Scheme 6.15 Bischler-Napieralski Reaction To Form Dihydrobenzazepines (±)-46 and (±)-49.
CO2Me
M e N ^ - NHA‘ V-A,, .,OMe POCI3, MeCN 
82 °C, 30 h 
conversion 55%
CO2Me
M e N ^ ' - NH2
OMe
(±)-42
OMe Ac2O, PyH 
OMe
MeN^f"'
CO2Me
NHAc
21 °C, 2 h 
95%
OMe
OMe
OMe
(±)-47
OMe
(±)-48
(±)-46
POCI3 , MeCN 
82 °C, 5 h 
71%
Hence, it w as concluded that the formation of seven-m em bered rings from our 
substrates w as lim ited to com pounds w ith aryl groups that are very reactive towards 
electrophiles. The idea of m aking large quantities of different scaffolds for the synthesis 
of libraries, as w as done for the six-membered rings, w as therefore forsaken.
6.2.2 Solution-Phase Parallel Synthesis
6.2.2.1 Synthesis of A m ide Library
Com pounds (±)-21-(±)-24 w ere derivatized using parallel synthesis by the acylation 
of the free amines to obtain a 32-membered am ide library (±)-51(a-h)-(±)-54(a-h). 
Com pound (±)-20 w as excluded from the parallel synthesis because a low  yield was 
obtained during its preparation and rerunning the reaction to obtain sufficient 
quantities of material w as deem ed unnecessary. Thus, conversion of com pounds 
(±)-21-(±)-24 to chemsets (±)-51-(±)-54 w as accom plished using acylation w ith reagent 
chem set 50 (Figure 6 .6 ).
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a b  c d
O O O O
e f g h
Figure 6 .6  Acyl Chlorides 5 0 a -h  Used for the Acylation of Substrates (±)-21-(±)-24.
The overnight reaction of substrates (±)-21-(±)-24 w ith the eight acyl chlorides 50a-h  
(1 equiv) in CH2CI2 at room  temperature, follow ed by NaHCO3 (sat.)/C H 2Cl2 
extraction and evaporation of CH 2Q 2, cleanly yielded 32 new  am ides (±)-51(a-h)- 
(±)-54(a-h) w ith yields ranging from 62 to >99% (90% average) and purities from 63 to 
>99% (93% average; Scheme 6.16 and Table 6.1). By using equimolar amounts of the 
acyl chlorides and without the addition of an external base (the substrate contains a 
tertiary amine), the work-up did not require the regular thorough repeated extraction 
or addition of scavengers for the elim ination of the residual acyl chlorides.40
Scheme 6.16 Acylation Library from Substrates (±)-21-(±)-24. 
MeO2C HN
MeN
(±)-21-(±)-24
RCOCl
50a-h, CH2Cl2
21 °C, 17 h
R = Me a, PhCH2 b, EtO2CCH2CH2 c, Ph d, 4-CF3C6H4 e, 
4-EtOC6H4 f, 3-NCC6H4 g, 4-ClC6H4 h
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Table 6.1 S o lu tio n -P h a se  S y n th e s is  o f  A m id e  L ib ra ry  ( ± ) - 5 1 ( a - h ) - ( ± ) - 5 4 ( a - h ) a'b
C r
OMe
(±)-51a 
80% (>99%)
OMe
(±)-51e 
>99% (98%)
O
MeO2C
OMe
(±)-51b 
8 % (8 8 %) 
^ OE’
OMe
(±)-51f 
94% (95%)
O ^ / - s s,,i,,,CO2Et 
MeO2C J
Hy
OMe
(±)-51c 
99% (97%)
OMe
(±)-51g 
90% (98%)
Ov Ph
>,C J
(±)-51d 
92% (96%)
(±)-51h 
6 % (91%)
C r
j
(±)-52a 
67% (>99%)
(±)-52e 
94% (96%)
O
(±)-52b 
92% (96%)
o^ T
MeOoC J,
(±)-52f 
94% (96%)
C I
H i 6o~J
(±)-52c 
95% (97%)
(±)-52g 
6 % (98%)
% - Ph 
>2C ,
O
(±)-52d 
6 % (8 8 %)
O ^
(±)-52h 
90% (81%)
Cl
O O O
MeO2C MeO2C M e O C
O
MeOoC
O
Cl
OO O
MeO2C MeO2C MeO9C
O O
O O O
O,
MeO2C 
MeN'
(±)-53a 
62% (8 8 %)
(±)-53b 
89% (96%)
O^ ^ /S,N,,,„,.«,CO2Et
)2C X
O -
(±)-53c 
8% (97%)
^ Ph)„C 1
(±)-53d 
95% (70%)
(±)-53e 
8% (8 8 %)
(±)-53f 
92% (92%)
(±)-53g 
91% (89%)
(±)-53h 
95% (63%)
(±)-54a 
62% (>99%)
(±)-54e 
95% (>99%)
O.
MeO2C
(±)-54b 
97% (>99%)
v y
(±)-54f 
95% (90%)
MeN,
H
W
(±)-54c 
94% (96%)
V /  
(±)-54g 
92% (>99%)
OV Ph
: .N .
(±)-54d 
81% (95%)
V /
(±)-54h 
99% (8 8 %)
1 % = Crude yield based on mass recovery. b (%) = Purity determined by LC-MS at 215 nm.
O
MeO2CN NN
Cl
O OO O
MeO2C M eO C MeO2C MeO2C
N N N N
Cl
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6.2.2.2 Synthesis of (Thio)hydantoin Library
The conversion of substrates (±)-21-(±)-24 into chemsets (±)-56-(±)-59 was 
accom plished using annulation of a hydantoin ring w ith reagent chem set 55. Nine 
isocyanates 55a-i (alkyl, electron-rich aryl, electron-poor aryl, and heteroaryl 
isocyanates; Figure 6.7) were selected for the generation of a 36-com pound sub-library.
'NCO Phk 'NCO NOO
NOO
F3O
NOO
NOO
NOO NO NOO NOO
E ta ^  ^  n
g h i
Figure 6.7 Isocyanates 55a-i Used for the Annulation of Substrates (±)-21-(±)-24.
The annulation of a hydantoin ring to tetrahydroisoquinolines has been w ell studied  
by Sergheraert and co-workers. They found that treatment of m ethyl 1,2,3,4- 
tetrahydroisoquinoline-3-carboxylate w ith an alkyl or an aryl isocyanate in CH2Q 2 at 
room  temperature using a large excess of DIPEA gave the desired isoquinoline- 
hydantoins .41 W e found for substrates (±)-21-(±)-24 that there w as no need for the 
addition of an external base (DIPEA), since all the scaffolds possess a tertiary amine 
within the structure, as for the acylation reaction. The conversion of these com pounds 
into chemsets (±)-56-(±)-59 took place w ithin 40 h (although m ost of the reactions w ith  
the more reactive aryl isocyanates w ere finished after 5-20 h) in CH2Q 2 at room  
temperature for the aromatic isocyanates42 and at reflux for the aliphatic isocyanates 
(Scheme 6.17).
Scheme 6.17 Hydantoin Annulation Sub-Library from Substrates (±)-21-(±)-24.
MeO2O N
MeN
(±)-21-(±)-24
RNOO
55a-i, OHjOlj 
21-40 °O, 40 h
R = Et a, PhOH2OH2 b, EtO2OOH2OH2 c, Ph d, 4-OF3O6H4 e, 
2-thienyl f, 4-EtOO6H4 g, 3-NOO6H4 h, 3-Py i
ba c
d fe
It w as observed that only one equivalent of isocyanate per equivalent of substrate 
w as needed for the reaction to proceed, except in the case of (±)-55a where 1.2 equiv  
w as used. The transformation consisted of two steps: the addition of the free amine to 
the isocyanate to form a urea and the cyclization betw een the urea and the ester to
188
Synthesis o f (Hetero)areno[d]pyrrolo[3,4-b]pyridines and (Hetero)areno[c]pyrrolo[3,4-e]azepines and Their Derivatization
form the hydantoin (see Chapter 4). The urea formation took place in 1-8 h hours in all 
cases, but the cyclization w as much slower (especially for the alkyl ureas because of 
their lower acidity) occurring in 3-30 h, although no base w as needed (see Chapter 4). 
Thus, com pounds (±)-56(a-i)-(±)-59(a-i) were obtained after evaporation of CH2Q 2, 
MeOH (the leaving group from the ester), and any excess reagents w ith purities 
ranging from 57 to >99% (90% average) according to LC-MS analysis (also confirmed 
by XH NMR spectroscopy) and w ith quantitative yields (based on m ass recovery, Table
6.2). All reactions using the aromatic isocyanates 55d-i were clean and resulted in 
products w ith purity >90%, except 55h. The aliphatic isocyanates 55a-c gave products 
w ith purities in the range 57-89%, probably due to partial isocyanate decom position  
under reflux conditions.43 Com pounds (±)-21-(±)-24 were also treated w ith te rt-b u ty l  
isocyanate, but the reaction stopped after carbamoylation of the substrates so that only 
the corresponding ureas w ere detected. Addition of DIPEA to aid the reaction was 
ineffective and KOBut44 (see Chapter 4) gave a mixture of the ureas, the hydantoins, 
and other unidentified com pounds.
Follow ing a similar procedure, conversion of the tri- and tetracyclic substrates 
(±)-21-(±)-24 to chemsets (±)-61-(±)-64 w as achieved using annulation of a 2- 
thiohydantoin ring w ith reagent chem set 60. In this case, eight isothiocyanates 60a-h  
(alkyl, electron-rich aryl, electron-poor aryl, and heteroaryl isothiocyanates; Figure 6.8) 
were selected for the generation of a 32-com pound sub-library.
a b c d
e f g h
Figure 6 .8  Isothiocyanates 6 0 a -h  Used for the Annulation of Substrates (±)-21-(±)-24.
The reactions w ere performed under the same reaction conditions as for the 
hydantoin formation, but using DMF as the solvent.45 One equivalent of the 
isothiocyanates w as used, except in the case of 60a where 1.2 equiv w as used. The 
corresponding thioureas were not observed and com pounds (±)-61(a-h)-(±)-64(a-h) 
were cleanly obtained after evaporation of DMF, MeOH, and any excess reagents with  
purities ranging from 73 to >99% (94% average) according to LC-MS analysis (also 
confirmed by XH NMR spectroscopy) and w ith quantitative yields (based on mass 
recovery, except for 60a; Scheme 6.18 and Table 6.3). A ll reactions using aromatic 
isothiocyanates 60d-h  finished within 20 h at room  temperature. The reactions w ith  
aliphatic isothiocyanates 60a-c w ere slower46 and required 40 h at 40 °C, whereas the 
reaction w ith 60a did not go to completion.
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Table 6.2 S o lu tio n -P h a se  S y n th e s is  o f  H y d a n to in  S u b -L ib ra r y  ( ± ) - 5 6 ( a - i ) - ( ± ) - 5 9 ( a - i ) a'h
N
O ' 
MeN
OMe
(±)-56a 87%
S
N 
O ' 
MeN'
OMe
(±)-56f 95%
N
O; 
MeN
(±)-57a 89%
S
N 
O ' 
MeN
O^
(±)-57f 97%
Ph
\ _
N 
O ' 
MeN
/P
_
N
O' 
MeN’
P h
N
O!
MeN
OMe
(±)-56b 78%
EtO
O ?
MeN
OMe
(±)-56c 87%
OMe
(±)-56d 95%
M
N
O ' 
MeN
OMe
(±)-56g 88%
OMe
(±)-56h 88%
Ph
N
O ' 
MeN
u2^ _
N
O' 
MeN'
/O Ph
N 
O ' 
MeN
(±)-57b 82%
EtO
(±)-57c 87% (±)-57d 98%
N
O
MeN'
M
N
O ' 
MeN
(±)-57g 95%
O
O—I
(±)-57h 90%
O ^ ^ - N  
MeN
OMe
(±)-56e 94%
N
N 
O: 
MeN
OMe
(±)-56i 99%
F3C
MeN sJ X J L
(±)-57e 96%
N
N
O ' 
MeN’
(±)-57i >99%
N '  
O" 
MeN,
(±)-58a 80%
a ^ O 
(±)-58f 92%
N "
MeN
v y
(±)-59a 81%
O7
MeN
\ j  
(±)-59f 97%
Ph
„O
N—
OA 
MeN
/O
° 2Cv^_
N "
O/  
MeN
Ph> 
N "
MeN,
(±)-58b 57%
EtO
0  
N~
O" 
MeN
O
(±)-58g 92%
N "
MeN
(±)-58h 81%
N"f
MeN.
%- /O  
Oy 
MeN,
v y
(±)-59c 83% (±)-59d 97%
(±)-59h 88%
S o
O
MeN
H OJ
(±)-58c 76% (±)-58d 91% (±)-58e 94%
N ^
N
O ^ ^ N  
MeN’
(±)-58i >99%
FsC,
(±)-59e 98%
N-v
N "  
O ^ V / N , ,  
MeN,
v j
(±)-59i 95%
1 % = Purity determined by LC-MS at 215 nm. b Quantitative yields based on mass recovery.
F3C
OO
O
O
OOO
O OO
O
O
O O
O
O
EtO2C
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Table 6.3 S o lu tio n -P h a se  S y n th e s is  o f  T h io h y d a n to in  S u b -L ib ra r y  ( ± ) - 6 1 ( a - h ) - ( ± ) - 6 4 ( a - h ) a'h'c
N 
O ' 
MeN’
(±)-61a 80%d
O ^ ^ N . . .  
MeN,
OMe
(±)-61e 93%
Ph
N  
O ' 
MeN
yS
OMe
(±)-61b 95%
N
O; 
MeN
/,S
(±)-61f 95%
- *2 ^_
N
O: 
MeN'
/S
OMe
(±)-61c 94%
N—f  
O ­
MeN
,S
(±)-61g 88%
Ph
N 
O 
MeN
OMe
(±)-61d 93%
Q
nV*
Of
MeN
OMe
(±)-61h 87%
N 
O ' 
MeN
„S
O^
(±)-62a 94% e
F3C,
V
N 
O: 
MeN
(±)-62e 96%
Ph
N
O ' 
MeN
.S
(±)-62b 99%
EtO
V
N 
O 
MeN
(±)-62f 98%
° 2CV^_
N
O; 
MeN'
O—1
(±)-62c 87%
VJ' 
N - ^ "
O :
MeN
S
H L  1
O >
(±)-62g 95%
Ph,
N 
O= 
MeN'
(±)-62d 96%
N  //
N
O' 
MeN’
O^
(±)-62h >99%
N "
O /  
MeN
(±)-63a 73%f
f3c
0  S 
N~
O /
MeN,
(±)-63e 93%b
N "
MeN,
(±)-64a 90% g
F3C
0 ,
Of 
MeN
V /
(±)-64e 97%
Ph
N "
OA 
MeN
(±)-63b 95%b
.Svv {  
N~
MeN,
(±)-63f 98%b
(±)-64b 96%
EtO
(±)-64f 98%
O2C,^_
N ~ 
O" 
MeN
(±)-63c 89%
„SM
N "  
O" 
MeN
(±)-63g 92%b
EtO2C
N~
MeN,
(±)-64c 98%
v y
(±)-64g 99%
p h,
N ~
O /  
MeN
(±)-63d 98%b
N
N~'ß 
O"
MeN
(±)-63h 93%
N "
MeN,
\ j  
(±)-64d 98%
N " T
O '
MeN
(±)-64h 99%
a % = Purity determined by LC-MS at 215 nm. b Purity percentage calculated excluding residual DMF peak 
(1-12%) when present. c Quantitative yields based on mass recovery, except for 60a. d Plus (±)-21 (10%). 
e Plus (±)-22 (6%). f Plus (±)-23 (14%). g Plus (±)-24 (8%).
S
F3C
S
OO
OO
S
OO
O O
S
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S chem e 6.18 Thiohydantoin Annulation Sub-Library from  Substrates (±)-21-(±)-24.
R s
MeO2C H RNCS
60a-h, DMF O ­
MeNMeN 21-40 °C, 20-40 h
(±)-21-(±)-24 (±)-61 (a-h)-(±)-64(a-h)
R = Et a, PhCH2CH2 b, EtO2CCH2CH2 c, Ph d, 4-CF3C6H4 e, 
4-EtOC6H4 f, 3-NCC6H4 g, 3-Py h
6.3 C onclusion
A reliable m ethod for synthesizing an array of the pharmaceutically important 
scaffolds pyrrolo[3,4-c]isoquinolines (±)-20 and (±)-21, [1,3]dioxolo[4,5-g]pyrrolo[3,4-
c]isoquinoline (±)-22, furo[2,3-d]pyrrolo[3,4-b]pyridine (±)-23, and pyrrolo[3',4':5,6]- 
pyrido[3,4-b]indole (±)-24 has been presented. Parallel derivatization of these  
com pounds in solution phase has been described resulting in the synthesis of two  
libraries: acylation and annulation of a (thio)hydantoin ring. These libraries combine 
two or three of the follow ing privileged structures: 2-arylethyl amine, tetrahydro- 
(hetero)areno[c]pyridine (e.g., tetrahydroisoquinoline or tetrahydro-ß-carboline), and 
(2-thio)hydantoin. The two libraries gave good yields and high purities.
Cyclization reactions, Pictet-Spengler and Bischler-Napieralski, of substrates (±)-25 
and (±)-26 to form a benzazepine skeleton were troublesom e and resulted in low  
yields. These cyclizations are lim ited to com pounds w ith very electron-rich aryl groups 
(e.g., 3,4,5-trimethoxyphenyl).
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6.5 Experimental Section
For general experimental details, see Sections 2.5 (p 33) and 4.5 (p 104).
G e n e ra l P ro ced ure  fo r  P ic te t-S p e n g le r  R e ac tio n . Formaldehyde (1-3 equiv, from a 37 wt% 
in H2O solution) was added to a solution of a-amino ester/a-aminomethyl ester in CH2Cl2 (0.1 
M). Trifluoroacetic acid (2 equiv) was slowly added and the resulting reaction mixture was 
stirred at room temperature for the time indicated in each case. Saturated aqueous NaHCO3 (2 
mL per mmol) was added and the organic phase was separated. The aqueous phase was 
extracted with CH2Cl2 (2 x 12 mL per mmol) and the organic extracts were combined, washed
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with brine (6 mL per mmol), and dried over MgSO4. Removal of the solvent under reduced 
pressure left a residue, which was purified by column chromatography on silica gel 
(CH2Cl2/MeOH, 19:1—>9:1). An alternative work-up, generally giving better yields, involved the 
immediate filtration of the reaction mixture through an ISOLUTE® SCX-2 column before 
purification.
(±)-Methyl
MeO2C H
MeN
(±)
(3aR,9bR)-2-methyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]isoquinoline-3a- 
carboxylate 2 0 .
According to the general procedure, the reaction of a-amino ester (±)-15 (234 
mg, 1.00 mmol) with formaldehyde (30 mg, 1.00 mmol) over 48 h afforded 
(±)-20 (69 mg, 28%) as a colorless oil. 1H NMR [400 MHz, 5 (ppm), CDCls]: 
7.22-7.05 (m, 4 !H, 6-CH + 7-CH + 8-CH + 9-CH), 3.91 (d, J = 15.8 Hz, 1 !H, 5-CHH), 3.86 (d, J =
15.8 Hz, 1 !H, 5-CHH), 3.81 (dd(3), J = 8.2 Hz, 1 !H, 9b-CH), 3.76 (s, 3 !H, OCH3), 3.34 (d, J = 10.1 
Hz, 1 !H, 3-CHH), 3.28 (dd(3), J = 8.4 Hz, 1 !H, 1-CHH), 2.58 (d, J = 10.1 Hz, 1 !H, 3-CHH), 2.54 
(dd(3), J = 8.9 Hz, 1 !H, 1-CHH), 2.38 (s, 3 !H, NCH3), 2.23 (bs, 1 !H, NH). 13C NMR [75 MHz, 5 
(ppm), CDCla]: 175.0 (CO2), 135.4 (5a-C), 134.5 (9a-C), 129.0 (9-C), 126.9 (6-C)*, 126.4 (7-C)*, 126.1 
(8-C)*, 67.3 (3-C), 67.2 (3a-C), 63.7 (1-C), 52.8 (OCH3), 44.9 (5-C), 43.7 (9b-C), 42.2 (NCH3). FTIR 
[V (cm-1), neat]: 3334, 2949, 2840, 2789, 1727, 1452, 1240, 760. MS [ESI (m/z)] calcd for 
(C14H18N2O2 + H)+ = 247, found 247. Rf: 0.41 (CH2Cl2/MeOH, 8:1). Purity: 97.2% (GC).
(±)-Methyl (3aR,9bR)-6,8-dimethoxy-2-methyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]iso-
MeO2C H quinoline-3a-carboxylate 21.
MeN 3a I According to the general procedure, the reaction of a-amino ester (±)-16
,,OMe
16 (1.30 g, 4.41 mmol) with formaldehyde (132 mg, 4.41 mmol) over 45 min
J 7
8 1 afforded (±)-21 (1.21 g, 90%) as a colorless oil. 1H NMR [400 MHz, 5
/x\ OMe
(±) (ppm), CDCl3]: 6.29 (d, J = 2.2 Hz, 1 !H, 7-CH), 6.26 (d, J = 2.2 Hz, 1 !H, 9-
CH), 3.89 (d, J = 16.1 Hz, 1 !H, 5-CHH), 3.78 (s, 3 !H, 6 -OCH3)*, 3.77 (s, 3 !H, 8-OCH3)*, 3.74 (s, 3 
!H, CO2CH3)*, 3.76-3.70 (m, 2 !H, 5-CHH + 9b-CH), 3.31 (d, J = 10.2 Hz, 1 !H, 3-CHH), 3.26 
(dd(3), J = 8.4 Hz, 1 !H, 1-CHH), 2.60 (dd(3), J = 8.9 Hz, 1 !H, 1-CHH), 2.57 (d, J = 10.2 Hz, 1 !H,
3-CHH), 2.38 (s, 3 !H, NCH3), 2.28 (bs, 1 !H, NH). 13C NMR [75 MHz, 5 (ppm), CDO3]: 175.2 
(CO2), 159.1 (6-C), 156.6 (8-C), 136.4 (9a-C), 116.8 (5a-C), 104.4 (9-C), 96.3 (7-C), 67.7 (3-C), 66.8 
(3a-C), 63.3 (1-C), 55.4 (6-OCH3)*, 55.3 (8-OCH3)*, 52.6 (CO2CH3), 43.8 (9b-C), 42.1 (NCH3), 39.0 
(5-C). FTIR [ V (cm-1), neat]: 3330, 2941, 2836, 2784, 1725, 1606, 1454, 1236, 1151, 830. HRMS [EI 
(m/z)] calcd for Ci6H22N2O4 = 306.1580, found for [M+^ ] = 306.1566 (|A| = 4.4 ppm), peaks at 
(relative intensity): 306 (7), 248 (81), 204 (17), 188 (43), 84 (23), 57 (100), 42 (56). Rf: 0.45 
(CH2Cl2/MeOH, 8:1). Purity: 98.7% (GC).
(±)-Methyl (3aR,10bR)-2-methyl-2,3,3a,4,5,10b-hexahydro-1H,8H-[1,3]dioxolo[4,5-g]pyrrolo- 
[3,4-c]isoquinoline-3a-carboxylate 22.
According to the general procedure, the reaction of a-amino ester (±)-17 
(1.06 g, 3.81 mmol) with formaldehyde (114 mg, 3.81 mmol) over 2.5 h 
afforded (±)-22 (1.01 g, 91%) as a yellow oil. 1H NMR [400 MHz, 5 (ppm), 
CDO3]: 6.59 (s, 1 1H, 10-CH), 6.54 (s, 1 1H, 6-CH), 5.89 (d, J = 1.2 Hz, 1 1H, 8-
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CHH), 5.88 (d, J = 1.2 Hz, 1 1H, 8-CHH), 3.80 (d, J = 15.6 Hz, 1 1H, 5-CHH), 3.76 (s, 3 1H, OCH3), 
3.74 (d, J = 15.6 Hz, 1 1H, 5-CHH), 3.68 (dd(3), J = 8.3 Hz, 1 1H, 10b-CH), 3.32 (d, J = 10.2 Hz, 1 
1H, 3-CHH), 3.22 (dd(3), J = 8.4 Hz, 1 1H, 1-CHH), 2.56 (d, J = 10.2 Hz, 1 1H, 3-CHH), 2.48 (dd(3), 
J = 8.8 Hz, 1 1H, 1-CHH), 2.37 (s, 3 1H, NCH3), 2.32 (bs, 1 1H, NH). 13C NMR [75 MHz, 5 (ppm), 
CDCl3]: 175.3 (CO2), 146.5 (9a-C), 146.0 (6a-C), 129.0 (5a-C), 127.9 (10a-C), 108.8 (10-C), 106.2 (6- 
C), 100.8 (8-C), 67.4 (3-C), 67.1 (3a-C), 63.9 (1-C), 52.8 (OCH3), 44.9 (5-C), 43.8 (10b-C), 42.0 
(NCH3). FTIR [V (cm-1), neat]: 3323, 2948, 2839, 2785, 1728, 1486, 1240, 1038, 935, 862. HRMS 
[ESI (m/z)] calcd for (C15H18N2O4 + H)+ = 291.13393, found 291.13458 (| A | = 0.4 ppm). Rf: 0.43 
(CH2Cl2/MeOH, 8:1). Purity: 99.2% (GC).
(±)-Methyl (5aR,8aR)-7-methyl-5,5a,6,7,8,8a-hexahydro-4H-furo[2,3-d]pyrrolo[3,4-b]pyridine- 
MeO2C N 5a-carboxylate 23.
MelN^ E "13a According to the general procedure, the reaction of a-amino ester (±)-18 (1.04
H T  ] i3 g, 4.64 mmol) with formaldehyde (181 mg, 6.03 mmol) over 3.5 h afforded (±)- 
(±) 2 23 (717 mg, 65%) as a yellow oil. 1H NMR [400 MHz, 5 (ppm), CDQ3]: 7.26 (d, 
J = 2.0 Hz, 1 1H, 2-CH), 6.19 (d, J = 2.0 Hz, 1 1H, 3-CH), 3.80 (d, J = 15.6 Hz, 1 1H, 4-CHH), 3.76 (d, 
J = 15.6 Hz, 1 1H, 4-CHH), 3.75 (s, 3 1H, OCH3), 3.72 (dd(3), J = 6 .6  Hz, 1 1H, 8a-CH), 2.99 (d, J =
9.8 Hz, 1 1H, 6-CHH), 2.95 (dd(3), J = 8.5 Hz, 1 1H, 8-CHH), 2.85 (dd; J = 9.0, 6.1 Hz; 1 1H, 8- 
CHH), 2.72 (d, J = 9.8 Hz, 1 1H, 6-CHH), 2.36 (s, 3 1H, NCH3), 2.32 (bs, 1 1H, NH). 13C NMR [75 
MHz, 5 (ppm), CDCl3]: 174.0 (CO2), 149.2 (8b-C), 141.2 (2-C), 116.5 (3a-C), 108.0 (3-C), 6 8 .6  (5a-C),
66 .8  (6-C), 59.8 (8-C), 52.7 (OCH3), 41.7 (NCH3), 40.1 (4-C + 8a-C). FTIR [ V (cm-1), neat]: 3329, 
2947, 2838, 2785, 1727, 1233, 728. HRMS [EI (m/z)] calcd for C12H16N2O3 = 236.1161, found for 
[M+^ ] = 236.1156 (|A| = 1.3 ppm), peaks at (relative intensity): 236 (15), 178 (25), 57 (100), 42 
(16). Rf: 0.36 (CHCk/MeOH, 8:1). Purity: 97.9% (GC).
(±)-Methyl (3aR,10cR)-2,6-dimethyl-1,2,3,3a,4,5,6,10c-octahydropyrrolo[3',4':5,6]pyrido[3,4-b]- 
indole-3a-carboxylate 24.
According to the general procedure, the reaction of a-amino ester (±)-19 
(1.10 g, 3.83 mmol) with formaldehyde (115 mg, 3.83 mmol) over 25 min 
afforded (±)-24 (985 mg, 8 6 %) as a light yellow solid. 1H NMR [400 MHz, 5 
(ppm), CDCl3]: 7.46 (d, J = 7.8 Hz, 1 1H, 10-CH), 7.26 (d, J = 8.3 Hz, 1 1H, 7- 
CH), 7.18-7.15 (m, 1 1H, 8-CH), 7.11-7.06 (m, 1 1H, 9-CH), 4.14 (dd; J = 15.9, 1.7 Hz; 1 1H, 5- 
CHH), 3.99 (d, J = 15.9 Hz, 1 1H, 5-CHH), 3.98 (ddd(6); J = 8.0, 8.0, 1.7 Hz; 1 1H, 10c-CH), 3.72 (s, 
3 1H, OCH3), 3.58 (s, 3 1H, 6-NCH3), 3.30 (dd(3), J = 8.3 Hz, 1 1H, 1-CHH), 3.24 (d, J = 10.0 Hz, 1 
1H, 3-CHH), 2.75 (dd(3), J = 8.2 Hz, 1 1H, 1-CHH), 2.64 (d, J = 10.0 Hz, 1 1H, 3-CHH), 2.41 (s, 3
1H, 2 -NCH3), 2.17 (bs, 1 1H, NH). 13C NMR [75 MHz, 5 (ppm), CDQ3]: 174.9 (CO2), 137.1 (6a-C),
133.9 (5a-C), 126.9 (10a-C), 121.2 (8-C), 119.2 (9-C), 118.1 (10-C), 108.9 (7-C), 107.5 (10b-C), 67.5 (3- 
C), 67.2 (3a-C), 61.9 (1-C), 52.6 (OCH3), 42.1 (2 -NCH3), 39.9 (10c-C), 39.2 (5-C), 29.4 (6-NCH3). 
FTIR [ V (cm-1), neat]: 3325, 2935, 2835, 2783, 1731, 1470, 1231, 739. HRMS [EI (m/z)] calcd for 
C17H21N3O2 = 299.1634, found for [M+^ ] = 299.1633 (| A | = 0.3 ppm), peaks at (relative intensity): 
299 (65), 241 (100), 209 (59), 181 (42), 58 (54), 57 (26), 42 (11). Rf: 0.32 (CHCk/MeOH, 8:1). Mp:
150.7 °C. Purity: >99.5% (GC).
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Compounds (±)-27 and (±)-33. According to the general procedure, the reaction of a- 
aminomethyl ester (±)-25 (38 mg, 123 |j,mol) with formaldehyde (11 mg, 369 jamol) over 48 h 
afforded (±)-27 (8 mg, 20%) as a yellow oil and (±)-33 (7 mg, 18%) as a yellow oil.
(±)-Methyl (3aR,10bS)-7,9-dimethoxy-2-methyl-1,2,3,3a,4,5,6,10b-octahydropyrrolo[3,4-d][2]- 
benzazepine-3a-carboxylate 27.
!H NMR [400 MHz, 5 (ppm), CDCls]: 6.40 (s, 2 XH, 8-CH + 10-CH), 4.38
OMe (dd(3), J = 7.4 Hz, 1 XH, 10b-CH), 4.18 (d, J = 13.6 Hz, 1 XH, 6-CHH), 3.82 (s,
6 !H, CO2CH3* + 7 -OCH3*), 3.79 (s, 3 !H, 9-OCH3*), 3.73 (d, J = 13.6 Hz, 1 
!H, 6-CHH), 3.22 (dd; J = 9.3, 7.8 Hz; 1 XH, 1-CHH), 3.07 (d, J = 13.0 Hz, 1 
!H, 4-CHH), 3.04 (d, J = 9.5 Hz, 1 XH, 3-CHH), 2.83 (dd; J = 9.3, 7.1 Hz; 1 XH, 1-CHH), 2.70 (d, J =
13.0 Hz, 1 !H, 4-CHH), 2.52 (bs, 1 XH, NH), 2.36 (s, 3 XH, NCH3), 2.35 (d, J = 9.5 Hz, 1 XH, 3-CHH). 
13C NMR [75 MHz, 5 (ppm), CDCla]: 176.4 (CO2), 159.8 (9-C), 158.0 (7-C), 142.2 (10a-C), 115.8 
(6a-C), 104.7 (10-C), 96.5 (8-C), 65.5 (3-C), 61.3 (1-C), 57.0 (3a-C), 55.8 (7 -OCH3)*, 55.4 (9-OCH3)*,
52.9 (CO2CH3), 49.0 (4-C), 46.6 (10b-C), 42.3 (NCH3), 39.9 (6-C). FTIR [ V (cm-1), neat]: 3334, 2941, 
2835, 2780, 1727, 1603, 1200, 1147, 829, 729. HRMS [EI (m/z)] calcd for C17H24N2O4 = 320.1736, 
found for [M+^ ] = 320.1730 (| A | = 1.9 ppm), peaks at (relative intensity): 320 (100), 244 (67), 176 
(36), 84 (41), 57 (72). Rf: 0.22 (CH2O 2/MeOH, 8:1).
(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-2,3,5,6,8,12b-hexahydro-1H,4H-3a,7-methanopyrrolo 
[3,4-f] [2,4]benzodiazonin-4-one 33.
!H NMR [400 MHz, 5 (ppm), CDCb]: 6.55 (d, J = 2.2 Hz, 1 XH, 12-CH), 6.41 
(d, J = 2.2 Hz, 1 !H, 10-CH), 5.69 (bs, 1 XH, NH), 4.65 (d, J = 11.2 Hz, 1 XH, 6- 
CHH), 4.41 (d, J = 11.6 Hz, 1 XH, 8-CHH), 4.18 (ddd(6); J = 11.2, 2.6, 2.6 Hz; 
1 !H, 6-CHH), 3.84 (s, 3 XH, 9-OCH3)*, 3.82 (s, 3 XH, H-OCH3)*, 3.64 (d, J =
11.6 Hz, 1 1H, 8-CHH), 3.45 (dd; J = 6.1, 2.3 Hz; 1 1H, 12b-CH), 3.26 (dd; J =
9.8, 2.3 Hz; 1 XH, 1-CHH), 3.09 (dd; J = 9.8, 6.1 Hz; 1 XH, 1-CHH), 3.06 (d, J = 9.3 Hz, 1 XH, 3- 
CHH), 2.82 (dd; J = 14.4, 2.0 Hz; 1 XH, 13-CHH), 2.71 (d, J = 14.4 Hz, 1 XH, 13-CHH), 2.43 (s, 3 XH, 
NCH3), 2.39 (d, J = 9.3 Hz, 1 XH, 3-CHH). FTIR [V (cm-1), neat]: 3225, 2935, 2835, 2782, 1655, 
1603, 1202, 1148. Rf: 0.15 (CHCk/MeOH, 8:1).
Compounds (±)-28 and (±)-34. According to the general procedure, the reaction of a- 
aminomethyl ester (±)-26 (38 mg, 126 |j,mol) with formaldehyde (8 mg, 267 |j,mol) over 48 h 
afforded (±)-28 (7 mg, 18%) as a yellow oil and (±)-34 (6 mg, 17%) as a yellow oil.
(±)-Methyl (3aR,11cS)-2,7-dimethyl-2,3,3a,4,5,6,7,11c-octahydro-1H-pyrrolo[3',4':5,6]azepmo- 
[3,4-b]indole-3a-carboxylate 28.
!H NMR [400 MHz, 5 (ppm), CDO3]: 7.57 (d, J = 7.8 Hz, 1 1H, 11-CH), 7.22 
(d, J = 8.0 Hz, 1 1H, 8-CH), 7.17 (dd(3), J = 7.4 Hz, 1 1H, 9-CH), 7.09 (dd(3), J =
7.3 Hz, 1 1H, 10-CH), 4.38 (dd(3), J = 8.8  Hz, 1 1H, 11c-CH), 4.23 (2d(3), J =
16.5 Hz, 2 1H, 6-CH2), 3.65 (s, 3 1H, OCH3), 3.59 (s, 3 1H, 7 -NCH3), 3.40 (d, J =
9.8 Hz, 1 1H, 3-CHH), 3.23 (d, J = 14.2 Hz, 1 1H, 4-CHH), 3.22 (dd(3), J = 8.5 Hz, 1 1H, 1-CHH), 
3.19 (d, J = 14.2 Hz, 1 1H, 4-CHH), 2.81 (d, J = 9.8 Hz, 1 1H, 3-CHH), 2.61 (dd(3), J = 9.2 Hz, 1 1H,
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1-CHH), 2.41 (s, 3 1H, 2 -NCH3), 2.37 (bs, 1 1H, NH). 13C NMR [75 MHz, 5 (ppm), CDCb]: 176.2 
(CO2), 136.6 (7a-C), 135.2 (6a-C), 128.8 (11a-C), 121.3 (9-C), 119.2 (10-C), 117.9 (11-C), 109.8 (11b- 
C), 108.5 (8-C), 65.6 (1-C), 65.4 (3-C), 58.6 (3a-C), 54.1 (4-C), 52.4 (OCH3), 48.1 (6-C), 42.1 (2- 
NCH3), 41.0 (11c-C), 29.7 (7 -NCH3). FTIR [V (cm-1), neat]: 3358, 2937, 2835, 2780, 1721, 1464, 
1240, 737. HRMS [EI (m/z)] calcd for C18H23N3O2 = 313.1790, found for [M+-] = 313.1805 (| A | =
4.7 ppm), peaks at (relative intensity): 313 (66), 268 (26), 183 (22), 84 (25), 57 (100). RF: 0.20 
(CH2Cl2/MeOH, 8 :1 ).
(±)-(3aR,13cR)-2,9-Dimethyl-1,2,3,5,6,8,9,13c-octahydro-4H-3a,7-methanopyrrolo[3',4':7,8][1,3]- 
diazonino[5,6-b]indol-4-one 34.
!H NMR [300 MHz, 5 (ppm), CDO3]: 7.49 (d, J = 7.8 Hz, 1 1H, 13-CH), 7.23 (d, 
J = 8.1 Hz, 1 1H, 10-CH), 7.18 (ddd(7); J = 8.1, 6 .6, 1.2 Hz; 1 1H, 11-CH), 7.08 
(ddd(7); J = 7.8, 6 .6, 1.5 Hz; 1 1H, 12-CH), 5.87 (bs, 1 1H, NH), 4.83 (d, J = 12.0 
Hz, 1 1H, 6-CHH), 4.51 (d, J = 17.4 Hz, 1 1H, 8-CHH), 4.28 (d, J = 17.4 Hz, 1 1H, 
8-CHH), 4.19 (ddd(6); J = 12.0, 2.3, 2.3 Hz; 1 1H, 6-CHH), 4.13 (t, J = 9.6 Hz, 1 
1H, 13c-CH), 3.69 (d, J = 9.6 Hz, 2 1H, 1 -CH2), 3.63 (s, 3 1H, 9-NCH3), 3.60 (d, J = 9.6 Hz, 1 1H, 3- 
CHH), 3.44 (d, J = 9.6 Hz, 1 1H, 3-CHH), 3.43 (d, J = 15.4 Hz, 1 1H, 14-CHH), 3.29 (d, J = 15.4 Hz,
1 1H, 14-CHH), 2.54 (s, 3 1H, 2 -NCH3). 13C NMR [75 MHz, 5 (ppm), CDO3]: 136.9 (9a-C), 134.7 
(8a-C), 128.2 (13a-C), 121.9 (11-C), 119.7 (12-C), 118.6 (13-C), 109.0 (10-C), 65.2 (6-C), 63.0, 60.2,
53.0, 52.9, 51.2, 45.1, 43.4 (2 -NCH3), 29.9 (9-NCH3). Rf: 0.14 (CH2O 2/MeOH, 8:1).
11
(±)-Methyl (3R,4S)-3-(acetamidomethyl)-4-(3,5-dimethoxyphenyl)-1-methylpyrrolidine-3-car-
2 CO2Me boxylate 42.
3 f 2
MeN Acetic anhydride (0.5 mL) was added to a solution of a-aminomethyl
V-'J",,iix 2L^OMe
ester (±)-25 (302 mg, 979 |j,mol) in pyridine (2 mL). The resulting reaction
OMe
mixture was stirred at room temperature for 2 h. The solvent was 
evaporated under vacuum. A saturated solution of NaHCO3 (2 mL) was 
then added to the residue and extrated with CH2Cl2 (2 x 5 mL). The combined organic extracts 
were dried (MgSO4) and the solvent was evaporated under vacuum to afford (±)-42 (337 mg, 
98%) as a yellow oil, of sufficient purity for the next step. *H NMR [400 MHz, 5 (ppm), CDO3]: 
6.41 (d, J = 2.2 Hz, 2 1H, 2'-CH + 6 '-CH), 6.36 (t, J = 2.2 Hz, 1 1H, 4'-CH), 5.78 (dd; J = 8.4, 3.8 Hz; 1 
1H, NH), 3.98 (dd; J = 9.8, 7.3 Hz; 1 1H, 4-CH), 3.80 (s, 3 1H, CO2CH3), 3.78 (s, 6 1H, 2 x OCH3),
3.62 (dd; J = 13.9, 8.4 Hz; 1 1H, CHHNH), 3.42 (d, J = 10.6 Hz, 1 1H, 2-CHH), 3.26 (dd; J = 9.8, 7.3 
Hz; 1 1H, 5-CHH), 3.00 (t, J = 9.8 Hz, 1 1H, 5-CHH), 2.86 (dd; J = 13.9, 3.8 Hz; 1 1H, CHHNH),
2.57 (d, J = 10.6 Hz, 1 1H, 2-CHH), 2.50 (s, 3 1H, NCH3), 1.83 (s, 3 1H, CH3CO). 13C NMR [75 
MHz, 5 (ppm), CDCl3]: 175.7 (CO2), 170.4 (CON), 160.9 (3'-C + 5'-C), 139.0 (1'-C), 106.9 (2'-C + 6 '- 
C), 99.1 (4'-C), 62.4 (2-C), 59.4 (5-C), 56.3 (3-C), 55.4 (2 x OCH3), 52.8 (CO2CH3), 50.1 (4-C), 42.5 
(CH2NH), 41.9 (NCH3), 23.3 (CH3CO). FTIR [V (cm-1), neat]: 3285, 2948, 2836, 2781, 1728, 1658, 
1594, 1203, 1155, 1064, 841. Rf: 0.37 (CH2O 2/MeOH, 8:1).
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(±)-Methyl (3R,4S)-3-(acetamidomethyl)-1-methyl-4-(3,4,5-trimethoxyphenyl)pyrrolidine-3-
CO2Me carboxylate 48.
MeN T,'"''NHAC Acetic anhydride (0.5 mL) was added to a solution of a-aminomethyl\.— i '  3'  .OMe
ester (±)-47 (266 mg, 786 ^mol) in pyridine (2 mL). The resulting reaction
6'
OMe mixture was stirred at room temperature for 2 h. The solvent was 
(±) OMe(±) evaporated under vacuum and the residue was filtered through an
ISOLUTE® SCX-2 column; washing: MeOH (12 mL), eluting: 1 M NH3/MeOH (12 mL); to afford 
(±)-48 (285 mg, 95%) as a yellow oil. *H NMR [400 MHz, 5 (ppm), CDO3]: 6.54 (s, 2 1H, 2'-CH + 
6 '-CH), 5.62 (dd; J = 8.4, 3.4 Hz; 1 1H, NH), 3.91 (dd(3), J = 8.0 Hz, 1 1H, 4-CH), 3.86 (s, 6 1H, 3'- 
OCH3 + 5 '-OCH3), 3.83 (s, 3 1H, 4 '-OCH3), 3.80 (s, 3 1H, CO2CH3), 3.63 (dd; J = 13.8, 8.4 Hz; 1 1H, 
CHHNH), 3.23 (d, J = 10.0 Hz, 1 1H, 2-CHH), 3.08 (dd; J = 9.2, 7.4 Hz; 1 1H, 5-CHH), 2.87 (dd(3), J 
= 8.9 Hz, 1 1H, 5-CHH), 2.85 (dd; J = 13.8, 3.4 Hz; 1 1H, CHHNH), 2.57 (d, J = 10.0 Hz, 1 1H, 2- 
CHH), 2.42 (s, 3 1H, NCH3), 1.81 (s, 3 1H, CH3CO). 13C NMR [75 MHz, 5 (ppm), CDQ3]: 175.9 
(CO2), 169.6 (CON), 152.8 (3'-C + 5'-C), 137.0 (4'-C), 133.4 (1'-C), 105.7 (2'-C + 6 '-C), 63.6 (2-C), 60.9 
(4 '-OCH3), 60.8 (5-C), 56.5 (3-C), 56.2 (3 '-OCH3 + 5 '-OCH3), 52.7 (CO2CH3), 50.6 (4-C), 43.1 
(CH2NH), 42.2 (NCH3), 23.4 (CH3CO). Rf: 0.43 (CH2Cl2/MeOH, 8:1). Purity: >99.5% (GC).
(±)-Methyl (3aR,10bR)-7,8,9-trimethoxy-2,6-dimethyl-1,2,3,3a,4,10b-hexahydropyrrolo[3,4- 
MeO2C 4 d][2]benzazepine-3a-carboxylate 49.
MeN 10iï 'V^ Me Compound (±)-48 (220 mg, 578 |j,mol) and POCl3 (122 mg, 795 mmol) in
5
" x > ^ 4 ' 
5'
H \^OMe MeCN (25 mL) were heated at reflux for 5 h. The mixture was cooled and
i°^ //7(±) concentrated to an oily residue. The residue was dissolved in CHCl3 (20
M O 8 OMe J
MeO mL) and 1 M NaOH (20 mL). The layers were separated and the organic
phase was washed with half-strength brine (10 mL). The organic phase was dried (MgSO4), 
concentrated in vacuo and the residue was purified by column chromatrography 
(CH2Cl2/MeOH, 14:1) to afford (±)-49 (148 mg, 71%) as a white solid. *H NMR [400 MHz, 5 
(ppm), CDCl3]: 6.57 (s, 1 1H, 10-CH), 3.90 (s, 3 1H, 9-OCH3), 3.88 (s, 3 1H, 7-OCH3)*, 3.87 (d, J =
10.7 Hz, 1 1H, 4-CHH), 3.85 (s, 3 1H, 8-OCH3)*, 3.80 (dd; J = 11.6, 7.4 Hz; 1 1H, 10b-CH), 3.72 (s, 3 
1H, CO2CH3), 3.43 (d, J = 10.0 Hz, 1 1H, 3-CHH), 3.27 (dd; J = 10.7, 1.0 Hz; 1 1H, 4-CHH), 3.10 (d, J 
= 10.0 Hz, 1 1H, 3-CHH), 3.03 (dd(3), J = 8.0 Hz, 1 1H, 1-CHH), 2.42 (s, 3 1H, CCH3), 2.36 (s, 3 1H, 
NCH3), 2.24 (dd; J = 11.6, 8.7 Hz; 1 1H, 1-CHH). 13C NMR [75 MHz, 5 (ppm), CDQ3]: 175.2 
(CO2), 170.9 (6-C), 154.0 (9-C), 151.8 (7-C), 141.3 (8-C), 133.4 (10a-C), 121.9 (6a-C), 110.0 (10-C),
64.4 (3-C), 62.8 (1-C), 61.5 (7 -OCH3)*, 61.0 (8-OCH3)*, 60.6 (3a-C), 56.2 (9-OCH3), 54.1 (4-C), 52.9 
(10b-C), 52.6 (CO2CH3), 41.7 (NCH3), 27.8 (CCH3). FTIR [V (cm-1), neat]: 2939, 2836, 2782, 1729, 
1634, 1592, 1245, 1167. MS [ESI (m/z)] calcd for (C19H26N2O5 + H)+ = 363, found 363. Rf: 0.45 
(CH2Cl2/MeOH, 8 :1 ).
General Procedure for Acylation Reaction Using Parallel Synthesis. A solution of acyl 
chloride 50a-h (0.10 mmol) from a 0.3 M stock solution in CH2Cl2 was added to a solution of 
polyhydropyrrolopyridine (0.10 mmol) in CH2Cl2 (1.5 mL). The resulting reaction mixture was 
stirred at room temperature for 17 h. After that time, a saturated solution of NaHCO3 (1.5 mL) 
was added and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2 x 1.5 
mL) and the combined organic layers were evaporated to dryness under vacuum.
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(±)-Methyl (3aR,9bR)-4-acetyl-6,8-dimethoxy-2-methyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo- 
[3,4-c]isoquinoline-3a-carboxylate 51a.
(From (±)-21) iH NMR [300 MHz, 5 (ppm), CDCla]: 6.37 (d, J = 2.4 Hz, 1 
!H, 7-CH), 6.29 (d, J = 2.4 Hz, 1 XH, 9-CH), 4.94 (d, J = 15.3 Hz, 1 XH, 5- 
CHH), 4.20 (d, J = 10.8 Hz, 1 XH, 3-CHH), 4.17 (d, J = 15.3 Hz, 1 XH, 5- 
CHH), 3.84 (s, 3 XH, 6-OCH3), 3.79 (s, 3 XH, 8-OCH3), 3.66 (s, 3 XH, 
CO2CH3), 3.46 (dd; J = 9.6, 7.5 Hz; 1 XH, 9b-CH), 3.15 (dd; J = 9.0, 7.5 Hz; 1 
!H, 1-CHH), 2.47 (d, J = 10.8 Hz, 1 XH, 3-CHH), 2.36 (s, 3 XH, NCH3), 2.31 (dd(3), J = 9.3 Hz, 1 XH,
1-CHH), 2.23 (s, 3 XH, COCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 173.2 (CO2), 171.0 (CON),
160.0 (8-C), 156.2 (6-C), 135.1 (9a-C), 113.5 (5a-C), 104.2 (9-C), 97.1 (7-C), 67.8 (3a-C), 66.8 (3-C),
63.2 (1-C), 55.6 (6-OCH3), 55.5 (8-OCH3), 52.7 (CO2CH3), 48.4 (9b-C), 41.8 (NCH3), 40.1 (5-C), 22.8 
(COCH3). FTIR [ V (cm-1), neat]: 2940, 2838, 2781, 1737, 1643, 1605, 1242, 1149, 728. MS [APCI 
(m/z)] calcd for (Ci8H24N2O5 + H)+ = 349, found 349. Crude yield: 80%. Purity: >99% (LC).
O.
MeO2C
3^ t ^
MeN
(±)-Methyl (3aR,9bR)-6,8-dimethoxy-2-methyl-4-(2-phenylacetyl)-2,3,3a,4,5,9b-hexahydro-1H- 
pyrrolo[3,4-c]isoquinoline-3a-carboxylate 51b.
(From (±)-21) ^  NMR [300 MHz, 5 (ppm), CDCI3]: 7.40-7.18 (m, 5 1H, 
Ph), 6.31 (d, J = 2.1 Hz, 1 1H, 7-CH)*, 6.27 (d, J = 2.1 Hz, 1 1H, 9-CH)*, 5.02 
(d, J = 15.3 Hz, 1 1H, 5-CHH), 4.21 (d, J = 10.8 Hz, 1 1H, 3-CHH), 4.03 (d, J 
= 15.3 Hz, 1 1H, 5-CHH), 3.86 (s, 2 1H, 7 -CH2), 3.77 (s, 3 1H, 8-OCH3), 3.72 
(s, 3 1H, 6-OCH3), 3.65 (s, 3 1H, CO2CH3), 3.45 (dd; J = 9.6, 7.8 Hz; 1 1H, 9b- 
CH), 3.12 (dd; J = 8.7, 7.8 Hz; 1 1H, 1-CHH), 2.45 (d, J = 10.8 Hz, 1 1H, 3-CHH), 2.35 (s, 3 1H, 
NCH3), 2.29 (dd(3), J = 9.3 Hz, 1 1H, 1-CHH). MS [APCI (m/z)] calcd for (C24H28N2O5 + H)+ = 
425, found 425. Crude yield: 98%. Purity: 8 8 % (LC).
(±) OMe
(±)-Methyl (3aR,9bR)-4-[3-(ethoxycarbonyl)propanoyl]-6,8-dimethoxy-2-methyl-2,3,3a,4,5,9b-
(From (±)-21) MS [APCI (m/z)] calcd for (C22H30N2O7 + H)+ = 435, 
found 435. Crude yield: 99%. Purity: 97% (LC).
(±)-Methyl (3aR,9bR)-4-benzoyl-6,8-dimethoxy-2-methyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo- 
[3,4-c]isoquinoline-3a-carboxylate 51d.
(From (±)-21) ^  NMR [300 MHz, 5 (ppm), CDCI3]: 7.54-7.35 (m, 5 1H, 
Ph), 6.39 (d, J = 2.1 Hz, 1 1H, 9-CH), 6.37 (d, J = 2.1 Hz, 1 1H, 7-CH), 4.97 
(d, J = 15.6 Hz, 1 1H, 5-CHH), 4.39 (d, J = 11.4 Hz, 1 1H, 3-CHH), 4.17 (d, J 
= 15.6 Hz, 1 1H, 5-CHH), 3.79 (s, 3 1H, 8-OCH3), 3.72 (s, 3 1H, 6-OCH3), 3.68 
(s, 3 1H, CO2CH3), 3.71-3.64 (m, 1 1H, 9b-CH), 3.38 (dd; J = 9.9, 7.8 Hz; 1 
1H, 1-CHH), 2.98 (d, J = 11.4 Hz, 1 1H, 3-CHH), 2.76 (dd(3), J = 9.9 Hz, 1 
1H, 1-CHH), 2.57 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 172.6 (CO2), 171.8 (CON),
160.2 (8-C), 156.0 (6-C), 135.3 (1'-C), 135.1 (9a-C), 130.5 (4'-C), 128.4 (2'-C + 6 '-C), 127.8 (3'-C + 5'- 
C), 114.4 (5a-C), 104.5 (9-C), 97.6 (7-C), 68.3 (3a-C), 64.8 (3-C), 61.5 (1-C), 55.5 (6-OCH3 + 8-OCH3),
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52.9 (CO2CH3), 48.1 (9b-C), 41.9 (NCH3), 41.3 (5-C). FTIR [ V (cm-1), neat]: 2949, 2839, 2783, 1738, 
1628, 1601, 1211, 1150, 726, 703. MS [APCI (m/z)] calcd for (C23H26N2O5 + H)+ = 411, found 411. 
Crude yield: 92%. Purity: 96% (LC).
MeOoC 3,J i^N
MeN
4'_CF
OMe
(±)-Methyl (3aR,9bR)-6,8-dimethoxy-2-methyl-4-[4-(trifluoromethyl)benzoyl]-2,3,3a,4,5,9b- 
hexahydro-1H-pyrrolo[3,4-c]isoquinolme-3a-carboxylate 51e.
(From (±)-21) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.78-7.65 (m, 2 1H, 
3'-CH + 5'-CH), 7.64-7.53 (m, 2 1H, 2'-CH + 6 '-CH), 6.39 (d, J = 2.1 Hz, 1 
1H, 7-CH)*, 6.37 (d, J = 2.1 Hz, 1 1H, 9-CH)*, 4.89 (d, J = 15.6 Hz, 1 1H, 5- 
CHH), 4.27 (d, J = 10.8 Hz, 1 1H, 3-CHH), 4.07 (d, J = 15.6 Hz, 1 1H, 5- 
CHH), 3.82 (s, 3 1H, 8-OCH3), 3.75 (s, 3 1H, 6-OCH3), 3.69 (s, 3 1H, 
CO2CH3), 3.58 (dd; J = 9.6, 7.8 Hz; 1 1H, 9b-CH), 3.21 (dd; J = 8.7, 7.8 Hz; 
1 1H, 1-CHH), 2.69 (d, J = 10.8 Hz, 1 1H, 3-CHH), 2.43 (s, 3 1H, NCH3), 2.40 (dd(3), J = 9.3 Hz, 1 
1H, 1-CHH). MS [APCI (m/z)] calcd for (C24H25F3N2O5 + H)+ = 479, found 479. Crude yield: 
quantitative. Purity: 98% (LC).
(±)
9 ^
8
OMe
(±)-Methyl (3aR,9bR)-4-(4-ethoxybenzoyl)-6,8-dimethoxy-2-methyl-2,3,3a,4,5,9b-hexahydro-
(From (±)-21) MS [APCI (m/z)] calcd for (C25H30N2O6 + H)+ = 455, 
found 455. Crude yield: 94%. Purity: 95% (LC).
(±)-Methyl (3aR,9bR)-4-(3-cyanobenzoyl)-6,8-dimethoxy-2-methyl-2,3,3a,4,5,9b-hexahydro- 
1H-pyrrolo[3,4-c]isoquinoline-3a-carboxylate 51g.
(From (±)-21) MS [APCI (m/z)] calcd for (C24H2sN3Os + H)+ = 436, found 
436. Crude yield: 90%. Purity: 98% (LC).
(±)-Methyl (3aR,9bR)-4-(4-chlorobenzoyl)-6,8-dimethoxy-2-methyl-2,3,3a,4,5,9b-hexahydro- 
1H-pyrrolo[3,4-c]isoquinoline-3a-carb oxylate 51h.
(From (±)-21) *H NMR [300 MHz, 5 (ppm), CDQ3]: 7.45-7.35 (m, 4 1H, 
C6H4), 6.39 (d, J = 2.1 Hz, 1 1H, 7-CH), 6.35 (d, J = 2.1 Hz, 1 1H, 9-CH), 4.95 
(d, J = 15.6 Hz, 1 1H, 5-CHH), 4.28 (d, J = 10.8 Hz, 1 1H, 3-CHH), 4.06 (d, J 
= 15.6 Hz, 1 1H, 5-CHH), 3.81 (s, 3 1H, 8-OCH3), 3.77 (s, 3 1H, 6-OCH3), 3.68 
(s, 3 1H, CO2CH3), 3.56 (dd; J = 9.6, 7.8 Hz; 1 1H, 9b-CH), 3.21 (dd; J = 9.0,
7.8 Hz; 1 1H, 1-CHH), 2.65 (d, J = 10.8 Hz, 1 1H, 3-CHH), 2.42 (s, 3 1H, 
NCH3), 2.38 (dd(3), J = 9.6 Hz, 1 1H, 1-CHH). 13C NMR [75 MHz, 5 (ppm), CDCb]: 172.8 (CO2),
170.5 (CON), 160.3 (8-C), 156.0 (6-C), 136.6 (4'-C), 136.3 (9a-C), 133.9 (1'-C), 129.5 (3'-C + 5'-C),
128.7 (2'-C + 6 '-C), 114.3 (5a-C), 104.8 (9-C), 97.3 (7-C), 68.3 (3a-C), 65.4 (3-C), 62.9 (1-C), 55.62 (6-
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OCH3), 55.57 (8-OCHa), 52.9 (CO2CH3), 48.8 (9b-C), 41.9 (NCH3), 41.2 (5-C). FTIR [ V (cm-1), 
neat]: 2950, 2839, 2783, 1739, 1633, 1603, 1213, 1151, 835, 613. MS [APCI (m/z)] calcd for 
(C23H25CIN2O5 + H)+ = 445, found 445. Crude yield: 96%. Purity: 91% (LC).
(±)-Methyl (3aR,10bR)-4-acetyl-2-methyl-2,3,3a,4,5,10b-hexahydro-1H,8H-[1,3]dioxolo[4,5-g]- 
pyrrolo[3,4-c]isoquinoline-3a-carboxylate 52a.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3]: 6.70 (s, 1 1H, 10-CH)*, 
6.65 (s, 1 1H, 6-CH)*, 5.94 (s, 2 1H, 8-CH2), 4.54 (d, J = 14.7 Hz, 1 1H, 5-CHH), 
4.44 (d, J = 14.7 Hz, 1 1H, 5-CHH), 4.13 (d, J = 10.8 Hz, 1 1H, 3-CHH), 3.65 (s, 
3 1H, OCH3), 3.43 (dd; J = 9.3, 7.8 Hz; 1 1H, 10b-CH), 3.10 (dd; J = 8.7, 7.8 Hz; 
1 1H, 1-CHH), 2.51 (d, J = 10.8 Hz, 1 1H, 3-CHH), 2.37 (s, 3 1H, NCH3), 2.34 
(dd(3), J = 9.3 Hz, 1 1H, 1-CHH), 2.20 (s, 3 1H, COCH3). MS [APCI (m/z)] calcd for (C17H20N2O5 
+ H)+ = 333, found 333. Crude yield: 67%. Purity: >99% (LC).
(±)-Methyl (3aR,10bR)-2-methyl-4-(2-phenylacetyl)-2,3,3a,4,5,10b-hexahydro-1H,8H-[1,3]diox- 
olo[4,5-g]pyrrolo[3,4-c]isoqumolme-3a-carboxylate 52b.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.41-7.20 (m, 5 1H, Ph),
6.62 (s, 1 1H, 10-CH), 6.39 (s, 1 1H, 6-CH), 5.91 (d, J = 1.5 Hz, 1 1H, 8-CHH), 
5.89 (d, J = 1.5 Hz, 1 1H, 8-CHH), 4.53 (d, J = 15.0 Hz, 1 1H, 5-CHH), 4.28 (d, 
J = 15.0 Hz, 1 1H, 5-CHH), 4.14 (d, J = 10.8 Hz, 1 1H, 3-CHH), 3.84 (s, 2 1H,
2 -CH2), 3.66 (s, 3 1H, OCH3), 3.42 (dd; J = 9.0, 7.8 Hz; 1 1H, 10b-CH), 3.07 
(dd; J = 9.3, 7.8 Hz; 1 1H, 1-CHH), 2.52 (d, J = 10.8 Hz, 1 1H, 3-CHH), 2.36 (s, 3 1H, NCH3), 2.32 
(dd(3), J = 9.3 Hz, 1 1H, 1-CHH). MS [APCI (m/z)] calcd for (C23H24N2O5 + H)+ = 409, found 409. 
Crude yield: 92%. Purity: 96% (LC).
(±)-Methyl (3aR,10bR)-4-[3-(ethoxycarbonyl)propanoyl]-2-methyl-2,3,3a,4,5,10b-hexahydro-
(From (±)-22) MS [APCI (m/z)] calcd for (C21H26N2O7 + H)+ = 419, 
found 419. Crude yield: 95%. Purity: 97% (LC).
(±)-Methyl (3aR,10bR)-4-benzoyl-2-methyl-2,3,3a,4,5,10b-hexahydro-1H,8H-[1,3]dioxolo[4,5-g] 
pyrrol o [3,4-c]isoquinoline-3a-carb oxylate 52d.
(From (±)-22) MS [APCI (m/z)] calcd for (C22H22N2O5 + H)+ = 395, found 
395. Crude yield: 8 6 %. Purity: 8 8 % (LC).
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(±)-Methyl (3aR,10bR)-2-methyl-4-[4-(trifluoromethyl)benzoyl]-2,3,3a,4,5,10b-hexahydro-1H, 
8H-[1,3]dioxolo[4,5-g]pyrrolo[3,4-c]isoqumolme-3a-carboxylate 52e.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDO3]: 7.78-7.68 (m, 2 1H, 
3'-CH + 5'-CH), 7.62-7.53 (m, 2 1H, 2'-CH + 6 '-CH), 6.71 (s, 1 1H, 10-CH), 
6.54 (s, 1 1H, 6-CH), 5.97 (d, J = 1.5 Hz, 1 1H, 8-CHH), 5.95 (d, J = 1.5 Hz, 
1 1H, 8-CHH), 4.42 (d, J = 15.3 Hz, 1 1H, 5-CHH), 4.34 (d, J = 15.3 Hz, 1 
1H, 5-CHH), 4.21 (d, J = 10.8 Hz, 1 1H, 3-CHH), 3.70 (s, 3 1H, OCH3), 3.55 
(dd; J = 9.0, 7.8 Hz; 1 1H, 10b-CH), 3.17 (dd; J = 9.3, 7.8 Hz; 1 1H, 1-CHH),
2.73 (d, J = 10.8 Hz, 1 1H, 3-CHH), 2.43 (s, 3 1H, NCH3), 2.42 (dd(3), J = 9.3 Hz, 1 1H, 1-CHH). MS 
[APCI (m/z)] calcd for (C23H21F3N2Os + H)+ = 463, found 463. Crude yield: 94%. Purity: 96% 
(LC).
(±)-Methyl (3aR,10bR)-4-(4-ethoxybenzoyl)-2-methyl-2,3,3a,4,5,10b-hexahydro-1H,8H-[1,3]di- 
J \ 4' OEt oxolo[4,5-g]pyrrolo[3,4-c]isoquinoline-3a-carboxylate 52f.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDO3]: 7.44-7.38 (m, 2 1H, 
2'-CH + 6 '-CH), 6.94-6.88 (m, 2 1H, 3'-CH + 5'-CH), 6.71 (s, 1 1H, 10-CH),
6.58 (s, 1 1H, 6-CH), 5.97 (d, J = 1.5 Hz, 1 1H, 8-CHH), 5.95 (d, J = 1.5 Hz, 
1 1H, 8-CHH), 4.58 (d, J = 15.3 Hz, 1 1H, 5-CHH), 4.31 (d, J = 15.3 Hz, 1 
1H, 5-CHH), 4.25 (d, J = 10.8 Hz, 1 1H, 3-CHH), 4.10 (q, J = 6.9 Hz, 2 1H, 
CH2CH3), 3.68 (s, 3 1H, OCH3), 3.52 (dd; J = 9.3, 7.5 Hz; 1 1H, 10b-CH), 
3.18 (dd; J = 9.0, 7.5 Hz; 1 1H, 1-CHH), 2.63 (d, J = 10.8 Hz, 1 1H, 3-CHH), 2.41 (s, 3 1H, NCH3), 
2.35 (dd(3), J = 9.3 Hz, 1 1H, 1-CHH), 1.44 (t, J = 6.9 Hz, 3 1H, CH2CH3). 13C NMR [75 MHz, 5 
(ppm), CDCl3]: 173.0 (CO2), 171.2 (CON), 160.9 (4'-C), 147.4 (9a-C), 146.7 (6a-C), 129.7 (2'-C + 6 '- 
C), 128.0 (10a-C), 127.4 (1'-C), 127.2 (5a-C), 114.4 (3'-C + 5'-C), 109.1 (10-C), 106.5 (6-C), 101.2 (8- 
C), 68.1 (3a-C), 65.3 (3-C), 63.7 (CH2CH3), 62.8 (1-C), 52.9 (OCH3), 48.6 (10b-C), 47.9 (5-C), 41.9 
(NCH3), 14.8 (CH2CH3). FTIR [ V (cm-1), neat]: 2938, 2842, 2781, 1737, 1628, 1606, 1243, 1037, 932, 
845. MS [APCI (m/z)] calcd for (C24H26N2O6 + H)+ = 439, found 439. Crude yield: 94%. Purity: 
96% (LC).
O
2
5
(±)-Methyl (3aR,10bR)-4-(3-cyanobenzoyl)-2-methyl-2,3,3a,4,5,10b-hexahydro-1H,8H-[1,3]di- 
oxolo[4,5-g]pyrrolo[3,4-c]isoquinoline-3a-carboxylate 52g.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDO3]: 7.79-7.75 (m, 2 1H, 2'- 
CH + 4'-CH), 7.68 (dt; J = 7.8, 1.3 Hz; 1 1H, 6 '-CH), 7.58 (dd(3), J = 8.1 Hz, 
1 1H, 5'-CH), 6.71 (s, 1 1H, 10-CH), 6.53 (s, 1 1H, 6-CH), 5.97 (d, J = 1.2 Hz, 
1 1H, 8-CHH), 5.95 (d, J = 1.2 Hz, 1 1H, 8-CHH), 4.43-4.33 (m, 2 1H, 5- 
CH2), 4.17 (d, J = 10.8 Hz, 1 1H, 3-CHH), 3.70 (s, 3 1H, OCH3), 3.56 (dd; J =
9.0, 7.8 Hz; 1 1H, 10b-CH), 3.17 (dd; J = 9.3, 7.8 Hz; 1 1H, 1-CHH), 2.77 (d, 
J = 10.8 Hz, 1 1H, 3-CHH), 2.46 (dd(3), J = 9.3 Hz, 1 1H, 1-CHH), 2.44 (s, 3 1H, NCH3). 13C NMR 
[75 MHz, 5 (ppm), CDCl3]: 172.3 (CO2), 168.8 (CON), 147.7 (9a-C), 147.0 (6a-C), 137.0 (1'-C), 133.9 
(4'-C), 131.6 (6 '-C), 131.1 (2'-C), 129.7 (5'-C), 127.5 (10a-C), 126.0 (5a-C), 118.0 (CN), 113.3 (3'-C),
109.1 (10-C), 106.4 (6-C), 101.4 (8-C), 68.4 (3a-C), 65.4 (3-C), 62.5 (1-C), 53.0 (OCH3), 48.5 (10b-C),
48.1 (5-C), 41.8 (NCH3). FTIR [ V (cm-1), neat]: 2948, 2842, 2782, 2230, 1737, 1634, 1246, 1037, 933,
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735. MS [APCI (m/z)] calcd for (C23H2iN3Os + H)+ = 420, found 420. Crude yield: 96%. Purity: 
98% (LC).
(±)-Methyl (3aR,10bR)-4-(4-chlorobenzoyl)-2-methyl-2,3,3a,4,5,10b-hexahydro-1H,8H-[1,3]di- 
C| oxolo[4,5-g]pyrrolo[3,4-c]isoqumolme-3a-carboxylate 52h.
(From (±)-22) MS [APCI (m/z)] calcd for (C22H21CIN2O5 + H)+ = 429, 
found 429. Crude yield: 90%. Purity: 81% (LC).
(±)-Methyl (5aR,8aR)-5-acetyl-7-methyl-5,5a,6,7,8,8a-hexahydro-4H-furo[2,3-d]pyrrolo[3,4-b]- 
/  pyridine-5a-carboxylate 53a.
(From (±)-23) MS [APCI (m/z)] calcd for (C14H18N2O4 + H)+ = 279, found 279. 
Crude yield: 62%. Purity: 8 8 % (LC).
MeO2C’r
(±)
O.
MeO2C
6_ ^
2'
^,3'
MeN
O
(±)
(±)-Methyl (5aR,8aR)-7-methyl-5-(2-phenylacetyl)-5,5a,6,7,8,8a-hexahydro-4H-furo[2,3-d]pyr- 
rolo[3,4-b] pyridine-5a-carb oxylate 53b.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.38-7.20 (m, 6 1H, 2- 
CH + Ph), 6.22 (d, J = 1.8 Hz, 1 1H, 3-CH), 4.64-4.52 (m, 2 1H, 4 -CH2), 4.04 
(d, J = 11.1 Hz, 1 1H, 6-CHH), 3.86 (d, J = 15.6 Hz, 1 1H, 2'-CHH), 3.82 (d, J 
= 15.6 Hz, 1 !H, 2'-CHH), 3.70 (s, 3 !H, OCH3), 3.46 (dd(3), J = 6.8  Hz, 1 !H, 
8a-CH), 3.12 (dd; J = 8.7, 6.6  Hz; 1 !H, 8-CHH), 2.59 (d, J = 11.1 Hz, 1 !H, 6-CHH), 2.51 (dd; J = 
8.7, 7.5 Hz; 1 !H, 8-CHH), 2.35 (s, 3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 173.7 
(CON), 173.6 (CO2), 146.1 (8b-C), 142.6 (2-C), 134.2 (1''-C), 129.1 (2''-C + 6 ''-C), 128.8 (3''-C + 5''-C),
127.1 (4''-C), 112.4 (3a-C), 108.0 (3-C), 69.9 (5a-C), 68.2 (6-C), 60.8 (8-C), 52.9 (OCH3), 43.8 (4-C),
42.4 (8a-C), 42.3 (2'-C), 41.7 (NCH3). FTIR [V (cm-1), neat]: 2946, 2839, 2783, 1736, 1648, 1247, 
757, 728, 699. MS [APCI (m/z)] calcd for (C20H22N2O4 + H)+ = 355, found 355. Crude yield: 89%. 
Purity: 96% (LC).
MeÜ2C
6_
MeN
(±)-Methyl (5aR,8aR)-5-[3-(ethoxycarbonyl)propanoyl]-7-methyl-5,5a,6,7,8,8a-hexahydro-4H- 
,^CO2Et furo[2,3-d]pyrrolo[3,4-b]pyridine-5a-carboxylate 53c.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDO3]: 7.35 (d, J = 1.8 Hz, 1 
!H, 2-CH), 6.28 (d, J = 1.8 Hz, 1 !H, 3-CH), 4.64 (dd; J = 14.1, 0.9 Hz; 1 !H, 
4-CHH), 4.58 (dd; J = 14.1, 1.8 Hz; 1 !H, 4-CHH), 4.14 (q, J = 7.2 Hz, 2 !H,
, , 2
(±) CH2CH3), 4.02 (d, J = 11.1 Hz, 1 !H, 6-CHH), 3.70 (s, 3 !H, OCH3), 3.48
(dd(3), J = 7.2 Hz, 1 !H, 8a-CH), 3.15 (dd; J = 8.7, 6.6  Hz; 1 !H, 8-CHH), 2.82-2.73 (m, 2 !H, 2'- 
CH2), 2.68 (t, J = 6.1 Hz, 2 !H, 3 '-CH2), 2.56 (d, J = 11.1 Hz, 1 !H, 6-CHH), 2.51 (dd; J = 8.7, 7.8 Hz; 
1 !H, 8-CHH), 2.35 (s, 3 !H, NCH3), 1.26 (t, J = 7.2 Hz, 3 !H, CH2CH3). 13C NMR [75 MHz, 5 
(ppm), CDCl3]: 174.2 (CON), 173.7 (5 a-CO2), 172.9 (3 '-CO2), 146.0 (8b-C), 142.7 (2-C), 112.3 (3a-C),
108.0 (3-C), 69.8 (5a-C), 68.2 (6-C), 60.7 (8-C + CH2CH3), 53.0 (OCH3), 43.4 (4-C), 42.3 (8a-C), 41.6 
(NCH3), 29.9 (2'-C), 29.2 (3'-C), 14.3 (CH2CH3). FTIR [V (cm-1), neat]: 2949, 2840, 2783, 1731,
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1655, 1248, 746. MS [APCI (m/z)] calcd for (C18H24N2O6 + H)+ = 365, found 365. Crude yield: 
8 8 %. Purity: 97% (LC).
(±)-Methyl (5aR,8aR)-5-benzoyl-7-methyl-5,5a,6,7,8,8a-hexahydro-4H-furo[2,3-d]pyrrolo[3,4-b] 
pyridine-5a-carboxylate 53d.
(From (±)-23) MS [APCI (m/z)] calcd for (C19H20N2O4 + H)+ = 341, found 
341. Crude yield: 95%. Purity: 70% (LC).
MeO?C
MeN
H u  
(±)
(±)-Methyl (5aR,8aR)-7-methyl-5-[4-(trifluoromethyl)benzoyl]-5,5a,6,7,8,8a-hexahydro-4H- 
” 4^„CF3 furo[2,3-d]pyrrolo[3,4-b]pyridine-5a-carboxylate 53e.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.78-7.69 (m, 2 1H, 
3'-CH + 5'-CH), 7.62-7.55 (m, 2 1H, 2'-CH + 6 '-CH), 7.32 (d, J = 1.8 Hz, 1 
1H, 2-CH), 6.15 (d, J = 1.8 Hz, 1 1H, 3-CH), 4.43 (dd; J = 15.0, 1.2 Hz; 1 1H,
4-CHH), 4.37 (dd; J = 15.0, 1.8 Hz; 1 !H, 4-CHH), 4.12 (d, J = 11.1 Hz, 1 
!H, 6-CHH), 3.80 (s, 3 !H, OCH3), 3.62 (dd(3), J = 7.0 Hz, 1 !H, 8a-CH), 
3.28 (dd; J = 8.7, 6.6  Hz; 1 !H, 8-CHH), 2.72 (d, J = 11.1 Hz, 1 !H, 6-CHH), 2.57 (dd(3), J = 8.2 Hz, 
1 !H, 8-CHH), 2.42 (s, 3 !H, NCH3). MS [APCI (m/z)] calcd for (C20H19F3N2O4 + H)+ = 409, found 
409. Crude yield: 98%. Purity: 8 8 % (LC).
MeN
MeO?C 6,J i^N
(±) O 2
(±)-Methyl (5aR,8aR)-5-(4-ethoxybenzoyl)-7-methyl-5,5a,6,7,8,8a-hexahydro-4H-furo[2,3-d]- 
pyrrolo[3,4-b]pyridine-5a-carboxylate 53f.
(From (±)-23) iH NMR [300 MHz, 5 (ppm), CDCI3]: 7.54-7.42 (m, 2 !H, 
2'-CH + 6 '-CH), 7.31 (d, J = 1.8 Hz, 1 !H, 2-CH), 6.97-6.89 (m, 2 !H, 3'-CH 
+ 5'-CH), 6.15 (d, J = 1.8 Hz, 1 !H, 3-CH), 4.57 (d, J = 15.3 Hz, 1 !H, 4- 
CHH), 4.46 (dd; J = 15.3, 1.5 Hz; 1 !H, 4-CHH), 4.14 (d, J = 11.1 Hz, 1 !H, 
6-CHH), 4.08 (q, J = 6.9 Hz, 2 !H, CH2CH3), 3.78 (s, 3 !H, OCH3), 3.61 
(dd(3), J = 6.9 Hz, 1 !H, 8a-CH), 3.29 (dd; J = 8.7, 6.6  Hz; 1 !H, 8-CHH), 2.65 (d, J = 11.1 Hz, 1 !H, 
6-CHH), 2.55 (dd(3), J = 8.2 Hz, 1 !H, 8-CHH), 2.40 (s, 3 !H, NCH3), 1.44 (t, J = 6.9 Hz, 3 !H, 
CH2CH3). MS [APCI (m/z)] calcd for (C21H24N2O5 + H)+ = 385, found 385. Crude yield: 92%. 
Purity: 92% (LC).
(±)-Methyl (5aR,8aR)-5-(3-cyanobenzoyl)-7-methyl-5,5a,6,7,8,8a-hexahydro-4H-furo[2,3-d]pyr- 
rolo[3,4- b] pyridine-5a-carb oxylate 53g.
(From (±)-23) ^  NMR [300 MHz, 5 (ppm), CDCb]: 7.86-7.69 (m, 3 !H, 2'- 
CH + 4'-CH + 6 '-CH), 7.59 (t, J = 8.1 Hz, 1 !H, 5'-CH), 7.33 (d, J = 1.8 Hz, 1 
!H, 2-CH), 6.15 (d, J = 1.8 Hz, 1 !H, 3-CH), 4.40 (s, 2 !H, 4 -CH2), 4.12 (d, J 
= 11.1 Hz, 1 !H, 6-CHH), 3.80 (s, 3 !H, OCH3), 3.65 (dd(3), J = 6.9 Hz, 1 
!H, 8a-CH), 3.30 (dd; J = 8.7, 6.9 Hz; 1 !H, 8-CHH), 2.80 (d, J = 11.1 Hz, 1 
!H, 6-CHH), 2.67 (dd; J = 8.7, 7.8 Hz; 1 !H, 8-CHH), 2.46 (s, 3 !H, NCH3). MS [APCI (m/z)] calcd 
for (C20H19N3O4 + H)+ = 366, found 366. Crude yield: 91%. Purity: 89% (LC).
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(±)-Methyl (5aR,8aR)-5-(4-chlorobenzoyl)-7-methyl-5,5a,6,7,8,8a-hexahydro-4H-furo[2,3-d]pyr- 
Cl rolo[3,4-b]pyridine-5a-carboxylate 53h.
(From (±)-23) MS [APCI (m/z)] calcd for (C19H19CIN2O4 + H)+ = 375, 
found 375. Crude yield: 95%. Purity: 63% (LC).
NMe
W 7
( ± ) 9 8
(±)-Methyl (3aR,10cR)-4-acetyl-2,6-dimethyl-1,2,3,3a/4,5,6,10c-octahydropyrrolo[3',4':5,6]pyr- 
ido[3,4-b]indole-3a-carboxylate 54a.
MeO~C N 5 (From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.47 (d, J = 7.8 Hz, 1 1H, 
MeN i3a ■ 15a 10-CH), 7.31 (d, J = 8.1 Hz, 1 1H, 7-CH), 7.24 (dd(3), J = 8.1 Hz, 1 1H, 8-CH), 
7.12 (dd(3), J = 7.4 Hz, 1 XH, 9-CH), 4.78 (s, 2 XH, 5 -CH2), 4.26 (d, J = 11.1 Hz, 
1 !H, 3-CHH), 3.84 (dd; J = 9.7, 6.9 Hz; 1 XH, 10c-CH), 3.70 (s, 3 XH, OCH3),
3.69 (s, 3 !H, 6-NCH3), 3.51 (dd; J = 8.1, 6.9 Hz; 1 XH, 1-CHH), 2.49 (d, J = 11.1 
Hz, 1 !H, 3-CHH), 2.38 (s, 3 XH, 2 -NCH3), 2.32 (s, 3 XH, COCH3), 2.24 (dd(3), J = 9.0 Hz, 1 XH, 1- 
CHH). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 174.4 (CO2), 173.9 (CON), 137.9 (6a-C), 128.8 (5a-C),
125.8 (10a-C), 122.1 (8-C), 119.7 (9-C), 118.5 (10-C), 109.1 (7-C), 105.3 (10b-C), 69.3 (3-C), 68.4 (3a- 
C), 63.2 (1-C), 53.0 (OCH3), 42.8 (5-C), 42.6 (10c-C), 41.9 (2 -NCH3), 29.6 (6-NCH3), 23.7 (COCH3). 
FTIR [V (cm-1), neat]: 2947, 2838, 2780, 1735, 1657, 1246, 742. MS [APCI (m/z)] calcd for 
(C19H23N3O3 + H)+ = 342, found 342. Crude yield: 62%. Purity: >99% (LC).
(±)-Methyl (3aR,10cR)-2,6-dimethyl-4-(2-phenylacetyl)-1,2,3,3a,4,5,6,10c-octahydropyrrolo- 
[3',4':5,6]pyrido[3,4-b]mdole-3a-carboxylate 54b.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.45 (d, J = 7.8 Hz, 1 
!H, 10-CH), 7.39-7.24 (m, 6  XH, 7-CH + Ph), 7.24-7.16 (m, 1 XH, 8-CH), 7.14­
7.07 (m, 1 !H, 9-CH), 4.76 (s, 2 XH, 5 -CH2), 4.27 (d, J = 11.1 Hz, 1 XH, 3- 
CHH), 3.96 (d, J = 15.6 Hz, 1 XH, 2'-CHH), 3.90 (d, J = 15.6 Hz, 1 XH, 2'- 
CHH), 3.83 (dd; J = 9.0, 6.9 Hz; 1 XH, 10c-CH), 3.68 (s, 3 XH, OCH3), 3.53 (s, 3 
!H, 6-NCH3), 3.47 (dd; J = 8.4, 6.9 Hz; 1 XH, 1-CHH), 2.48 (d, J = 11.1 Hz, 1 XH, 3-CHH), 2.37 (s, 3 
!H, 2 -NCH3), 2.24 (dd(3), J = 9.0 Hz, 1 XH, 1-CHH). MS [APCI (m/z)] calcd for (C25H27N3O3 + 
H)+ = 418, found 418. Crude yield: 97%. Purity: >99% (LC).
(±)-Methyl (3aR,10cR)-4-[3-(ethoxycarbonyl)propanoyl]-2,6-dimethyl-1,2,3,3a,4,5,6,10c-octahy- 
dropyrrolo[3',4':5,6]pyrido[3,4-b]mdole-3a-carboxylate 54c.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.47 (d, J = 7.8 Hz, 1 
!H, 10-CH), 7.31 (d, J = 8.1 Hz, 1 XH, 7-CH), 7.23 (ddd(7); J = 8.1, 6.9, 0.9 
Hz; 1 !H, 8-CH), 7.11 (ddd(7); J = 7.8, 6.9, 1.2 Hz; 1 XH, 9-CH), 4.86 (d, J =
14.7 Hz, 1 !H, 5-CHH), 4.80 (d, J = 14.7 Hz, 1 XH, 5-CHH), 4.25 (d, J = 11.1 
Hz, 1 !H, 3-CHH), 4.16 (q, J = 7.2 Hz, 2 XH, CH2CH3), 3.84 (dd; J = 9.3, 6.6 
Hz; 1 !H, 10c-CH), 3.68 (s, 3 XH, OCH3)*, 3.67 (s, 3 XH, 6-NCH3)*, 3.50 (dd; J = 8.7, 6.6  Hz; 1 XH, 1- 
CHH), 2.93-2.83 (m, 2 XH, 2 '-CH2), 2.77-2.70 (m, 2 XH, 3 '-CH2), 2.46 (d, J = 11.1 Hz, 1 XH, 3-CHH),
2.38 (s, 3 !H, 2 -NCH3), 2.25 (dd(3), J = 9.0 Hz, 1 XH, 1-CHH), 1.27 (t, J = 7.2 Hz, 3 XH, CH2CH3). 
MS [APCI (m/z)] calcd for (C23H29N3O5 + H)+ = 428, found 428. Crude yield: 94%. Purity: 96% 
(LC).
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(±)-Methyl (3aR,10cR)-4-benzoyl-2,6-dimethyl-1,2,3,3a,4,5,6,10c-octahydropyrrolo[3',4':5,6]pyr- 
ido[3,4-b]indole-3a-carboxylate 54d.
(From (±)-24) MS [APCI (m/z)] calcd for (C24H25N3O3 + H)+ = 404, found 
404. Crude yield: 81%. Purity: 95% (LC).
MeOpC 
■
MeN
W 7
(±) 9 8
(±)-Methyl (3aR,10cR)-2,6-dimethyl-4-[4-(trifluoromethyl)benzoyl]-1,2,3,3a,4,5,6,10c-octahy- 
3' 4^'^CF3 dropyrrolo[3',4':5,6]pyrido[3,4-b]indole-3a-carboxylate 54e.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCls]: 7.79-7.73 (m, 2 XH, 
3'-CH + 5'-CH), 7.70-7.63 (m, 2 XH, 2'-CH + 6 '-CH), 7.49 (d, J = 7.8 Hz, 1 
!H, 10-CH), 7.32-7.19 (m, 2 XH, 7-CH + 8-CH), 7.17-7.09 (m, 1 XH, 9-CH), 
4.70 (d, J = 15.3 Hz, 1 XH, 5-CHH), 4.62 (dd; J = 15.3, 1.2 Hz; 1 XH, 5- 
CHH), 4.33 (d, J = 11.1 Hz, 1 XH, 3-CHH), 3.96 (dd; J = 9.6, 6.6  Hz; 1 XH, 
10c-CH), 3.78 (s, 3 XH, OCH3), 3.61 (dd; J = 8.7, 6.6  Hz; 1 XH, 1-CHH), 3.48 
(s, 3 !H, 6-NCH3), 2.61 (d, J = 11.1 Hz, 1 XH, 3-CHH), 2.45 (s, 3 XH, 2 -NCH3), 2.35 (dd(3), J = 9.2 
Hz, 1 !H, 1-CHH). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 173.9 (CON), 173.7 (CO2), 140.1 (1'-C),
137.7 (6a-C), 131.9 (q, J = 31.9 Hz, 4'-C), 129.3 (5a-C), 127.7 (2'-C + 6 '-C), 126.1 (q, J = 3.7 Hz, 3'-C + 
5'-C), 125.9 (10a-C), 123.7 (q, J = 280.6 Hz, CF3), 122.2 (8-C), 119.9 (9-C), 118.5 (10-C), 109.2 (7-C),
105.6 (10b-C), 68.9 (3a-C), 68.7 (3-C), 63.1 (1-C), 53.1 (OCH3), 44.2 (5-C), 43.0 (10c-C), 42.0 (2- 
NCH3), 29.6 (6-NCH3). FTIR [ V (cm-1), neat]: 2948, 2840, 2782, 1735, 1651, 1321, 1241, 854, 741. 
MS [APCI (m/z)] calcd for (C25H24F3N3O3 + H)+ = 472, found 472. Crude yield: 95%. Purity: 
>99% (LC).
(±)-Methyl (3aR,10cR)-4-(4-ethoxybenzoyl)-2,6-dimethyl-1,2,3,3a,4,5,6,10c-octahydropyrrolo-
(From (±)-24) MS [APCI (m/z)] calcd for (C26H29N3O4 + H)+ = 448, 
found 448. Crude yield: 95%. Purity: 90% (LC).
MeO2C
3' CN
MeN
(±)-Methyl (3aR,10cR)-4-(3-cyanobenzoyl)-2,6-dimethyl-1,2,3,3a,4,5,6,10c-octahydropyrrolo- 
[3',4' :5,6] pyrido[3,4- b] indole-3a-carb oxylate 54g.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.84 (t, J = 1.5 Hz, 1 
!H, 2'-CH), 7.81-7.75 (m, 2 XH, 4'-CH + 6 '-CH), 7.62 (dd(3), J = 7.6 Hz, 1 
!H, 5'-CH), 7.49 (d, J = 7.5 Hz, 1 !H, 10-CH), 7.33-7.19 (m, 2 !H, 7-CH + 8- 
CH), 7.18-7.09 (m, 1 !H, 9-CH), 4.68 (d, J = 15.6 Hz, 1 !H, 5-CHH), 4.62 
(dd; J = 15.6, 0.9 Hz; 1 !H, 5-CHH), 4.31 (d, J = 11.1 Hz, 1 !H, 3-CHH), 
3.96 (dd; J = 9.3, 6.9 Hz; 1 !H, 10c-CH), 3.78 (s, 3 !H, OCH3), 3.62 (dd; J =
8.4, 6.9 Hz; 1 !H, 1-CHH), 3.48 (s, 3 !H, 6-NCH3), 2.59 (d, J = 11.1 Hz, 1 !H, 3-CHH), 2.45 (s, 3 !H,
2 -NCH3), 2.35 (dd(3), J = 9.3 Hz, 1 !H, 1-CHH). MS [APCI (m/z)] calcd for (C25H24N4O3 + H)+ = 
429, found 429. Crude yield: 92%. Purity: >99% (LC).
(±)
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(±)-Methyl (3aR,10cR)-4-(4-chlorobenzoyl)-2,6-dimethyl-1,2,3,3a,4,5,6,10c-octahydropyrrolo- 
Cl [3',4':5,6]pyrido[3,4-b]indole-3a-carboxylate 54h.
(From (±)-24) MS [APCI (m/z)] calcd for (C24H24CIN3O3 + H)+ = 438, 
found 438. Crude yield: 99%. Purity: 8 8 % (LC).
General Procedure for Hydantoin Annulation Using Parallel Synthesis. A solution of 
isocyanate 55 (0.12 mmol for a, 0.10 mmol for b-i) from a 0.3 M stock solution in CH2Cl2 (except 
for 55h,i which are insoluble and were used as a solid) was added to a solution of 
polyhydropyrrolopyridine (0.10 mmol) in CH2Cl2 (1.5 mL). The resulting reaction mixture was 
stirred at 40 °C for 55a-c and at room temperature for 55d-i for 40 h. After that time, the solvent 
was evaporated and the samples were analyzed.
(±)-(3aR,12bR)-5-Ethyl-9,11-dimethoxy-2-methyl-2,3,8,12b-tetrahydro-1H,4H-imidazo[1,5-b]- 
pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 56a.
(From (±)-21) MS [APCI (m/z)] calcd for (Ci8H23N3O4 + H)+ = 346, found 
346. Crude yield: quantitative. Purity: 87% (LC).
(±) OMe
(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-5-phenethyl-2,3,8,12b-tetrahydro-1H,4H-imidazo[1,5
-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 56b.
(From (±)-21) MS [APCI (m/z)] calcd for (C24H27N3O4 + H)+ = 422, 
found 422. Crude yield: quantitative. Purity: 78% (LC).
(±) OMe
(±)-Ethyl 3-{(3aR,12bR)-9,11-dimethoxy-2-methyl-4,6-dioxo-2,3,5,6,8,12b-hexahydro-1H,4H- 
imidazo[1,5-b]pyrrolo[3,4-c]isoquinolin-5-yl}propanoate 56c.
(From (±)-21) *H NMR [300 MHz, 5 (ppm), CDCl3]: 6.31 (d, J = 2.4 Hz, 
1 1H, 10'-CH), 6.23 (d, J = 2.4 Hz, 1 1H, 12'-CH), 5.23 (d, J = 16.5 Hz, 1 
1H, 8 -CHH), 4.08 (q, J = 7.2 Hz, 2 1H, CH2CH), 3.90 (d, J = 16.5 Hz, 1 
1H, 8 '-CHH), 3.80 (s, 3 1H, 9'-OCH3), 3.81-3.74 (m, 2 1H, 3 -CH2), 3.77 (s, 
3 1H, 11'-OCH3), 3.60 (dd; J = 7.5, 5.1 Hz; 1 1H, 12'b-CH), 3.15 (dd; J =
9.0, 7.5 Hz; 1 1H, 1'-CHH), 3.02 (bs, 2 1H, 3'-CH2), 2.76-2.66 (m, 1 1H, 1'- 
CHH), 2.62 (t, J = 7.2 Hz, 2 1H, 2 -CH2), 2.36 (bs, 3 1H, NCH3), 1.20 (t, J = 7.2 Hz, 3 1H, CH2CH5). 
13C NMR [75 MHz, 5 (ppm), CDCl3]: 176.0 (4'-C), 170.8 (CO2), 160.0 (11'-C), 156.8 (9'-C), 155.1 (6'- 
C), 136.8 (12'a-C), 114.9 (8'a-C), 104.3 (12'-C), 96.9 (10'-C), 67.6 (3'a-C), 65.4 (1'-C), 63.5 (3'-C), 60.9 
(CH2CH3), 55.6 (9'-OCH3), 55.5 (11'-OCH3), 45.1 (12'b-C), 41.8 (NCH3), 35.0 (3-C), 34.8 (8'-C), 32.6
(±) OMe
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(2-C), 14.2 (CH2CH3). FTIR [ V (cm-1), neat]: 2928, 2849, 2785, 1769, 1710, 1607, 1149, 832. MS 
[APCI (m/z)] calcd for (C2iH27N3O6 + H)+ = 418, found 418. Crude yield: quantitative. Purity: 
87% (LC).
(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-5-phenyl-2,3,8,12b-tetrahydro-1H,4H-imidazo[1,5-b]- 
pyrrolo[3,4-c]isoqumolme-4,6(5H)-dione 56d.
(From (±)-21) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.46-7.28 (m, 5 1H, 
Ph), 6.33 (d, J = 2.4 Hz, 1 1H, 10-CH), 6.27 (d, J = 2.4 Hz, 1 1H, 12-CH), 5.33 
(d, J = 16.2 Hz, 1 1H, 8-CHH), 3.99 (d, J = 16.2 Hz, 1 1H, 8-CHH), 3.81 (s, 3 
1H, 9-OCH3), 3.78 (s, 3 1H, 1 1 -OCH3), 3.71 (dd; J = 7.2, 4.5 Hz; 1 1H, 12b- 
CH), 3.14 (dd; J = 9.0, 7.2 Hz; 1 1H, 1-CHH), 3.10 (s, 2 1H, 3-CH2), 2.73 (dd; 
J = 9.0, 4.5 Hz; 1 1H, 1-CHH), 2.35 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 
(ppm), CDCI3]: 175.3 (4-C), 160.1 (11-C), 156.9 (9-C), 154.3 (6-C), 137.3 (12a-C), 132.0 (1'-C), 129.0 
(3'-C + 5'-C), 128.1 (4'-C), 126.0 (2'-C + 6 '-C), 115.0 (8a-C), 104.4 (12-C), 96.9 (10-C), 67.6 (3a-C),
65.8 (1-C), 64.3 (3-C), 55.6 (9-OCH3), 55.5 (H-OCH3), 45.6 (12b-C), 41.8 (NCH3), 35.0 (8-C). FTIR 
[ V (cm-1), neat]: 2942, 2839, 2787, 1772, 1716, 1607, 1152, 834, 763, 690. MS [APCI (m/z)] calcd 
for (C22H23N3O4 + H)+ = 394, found 394. Crude yield: quantitative. Purity: 95% (LC).
(±) OMe
(±)-3aR,12bR)-9,l1-Dimethoxy-2-methyl-5-[4-(trifluoromethyl)phenyl]-2,3,8,12b-tetrahydro- 
1H,4H-imidazo[1,5-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 56e.
(From (±)-21) MS [APCI (m/z)] calcd for (C23H22F3N3O4 + H)+ = 462, 
found 462. Crude yield: quantitative. Purity: 94% (LC).
(±) OMe
(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-5-(2-thienyl)-2,3,8,12b-tetrahydro-1H,4H-imidazo[1,5 
-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 56f.
(From (±)-21) MS [APCI (m/z)] calcd for (C2üH21N3 0 4S + H)+ = 400, found 
400. Crude yield: quantitative. Purity: 95% (LC).
(±) OMe
(±)-(3aR,12bR)-5-(4-Ethoxyphenyl)-9,11-dimethoxy-2-methyl-2,3,8,12b-tetrahydro-1H,4H-imi- 
EtO dazo[1,5-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 56g.
(From (±)-21) MS [APCI (m/z)] calcd for (C24H27N3Os + H)+ = 438, 
found 438. Crude yield: quantitative. Purity: 8 8 % (LC).
(±) OMe
207
C hapter 6
(±)-3-{(3aR,12bR)-9,11-Dimethoxy-2-methyl-4,6-dioxo-2,3,5,6,8,12b-hexahydro-1H,4H-imidazo-
[1,5-b]pyrrolo[3,4-c]isoquinolm-5-yl}benzomtrile 56h.
(From (±)-21) MS [APCI (m/z)] calcd for (C23H22N4O4 + H)+ = 419, 
found 419. Crude yield: quantitative. Purity: 8 8 % (LC).
(±) OMe
(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-5-(3-pyridyl)-2,3,8,12b-tetrahydro-1H,4H-imidazo- 
[1,5-b]pyrrolo[3,4-c]isoqumolme-4,6(5H)-dione 56i.
(From (±)-21) MS [APCI (m/z)] calcd for (C21H22N4O4 + H)+ = 395, found 
395. Crude yield: quantitative. Purity: 99% (LC).
(±) OMe
MeN 3i3br a
(±)-(3aR,13bR)-5-Ethyl-2-methyl-2,3,8,13b-tetrahydro-1H,4H,11H-[1,3]dioxolo[4,5-g]imidazo- 
[1,5-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 57a.
O N (From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3]: 6.65 (s, 1 1H, 9-CH), 6.57
^ ^ 8 (s, 1 1H, 13-CH), 5.92 (s, 2 1H, H-CH2), 4.83 (d, J = 15.9 Hz, 1 1H, 8-CHH), 4.17 
(d, J = 15.9 Hz, 1 1H, 8-CHH), 3.63-3.45 (m, 3 1H, 13b-CH + CH2CH3), 3.14­
3.01 (m, 2 1H, 1-CHH + 3-CHH), 2.92 (d, J = 10.2 Hz, 1 1H, 3-CHH), 2.56 (dd; J 
= 7.5, 6.0 Hz; 1 1H, 1-CHH), 2.34 (s, 3 1H, NCH3), 1.17 (t, J = 7.2 Hz, 3 1H, 
CH2CH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 175.9 (4-C), 156.1 (6-C), 147.4 (12a-C), 146.6 (9a- 
C), 128.4 (13a-C), 127.0 (8a-C), 109.1 (13-C), 106.9 (9-C), 101.3 (11-C), 67.9 (3a-C), 65.7 (1-C), 64.2 
(3-C), 45.5 (13b-C), 41.7 (NCH3), 40.6 (8-C), 34.3 (CH2CH3), 13.6 (CH2CH3). FTIR [ V (cm-1), neat]: 
2928, 2850, 2783, 1768, 1708, 1035, 933. MS [APCI (m/z)] calcd for (C17H19N3O4 + H)+ = 330, 
found 330. Crude yield: quantitative. Purity: 89% (LC).
12a \  O  
( ± )  O ^ 1
(±)-(3aR,13bR)-2-Methyl-5-phenethyl-2,3,8,13b-tetrahydro-1H,4H,11H-[1,3]dioxolo[4,5-g]imi- 
dazo[1,5-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 57b.
(From (±)-22) MS [APCI (m/z)] calcd for (C23H23N3O4 + H)+ = 406, found 
406. Crude yield: quantitative. Purity: 82% (LC).
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Syn th esis  o f  (H etero)areno[d]pyrrolo[3,4-b]pyridines and (Hetero)areno[c]pyrrolo[3,4-e]azepines and Their D eriva tiza tion
(±)-Ethyl
EtO2C
O
MeN
3-{(3aR,13bR)-2-methyl-4,6-dioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3]dioxolo- 
[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoqumolm-5-yl}propanoate 57c.
(From (±)-22) MS [APCI (m/z)] calcd for (C2ÜH23N3O6 + H)+ = 402, found
402. Crude yield: quantitative. Purity: 87% (LC).
O
(±) O—I
(±)-(3aR,13bR)-2-Methyl-5-phenyl-2,3,8,13b-tetrahydro-1H,4H,11H-[1,3]dioxolo[4,5-g]imidazo- 
[1,5-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 57d.
(From (±)-22) MS [APCI (m/z)] calcd for (C21H 19N3O4 + H)+ = 378, found
378. Crude yield: quantitative. Purity: 98% (LC).
(±)-(3aR,13bR)-2-Methyl-5-[4-(trifluoromethyl)phenyl]-2,3,8,13b-tetrahydro-1H,4H,11H-[1,3]- 
dioxolo[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 57e.
(From (±)-22) MS [APCI (m/z)] calcd for (C22H18F3N3O4 + H)+ = 446, found
446. Crude yield: quantitative. Purity: 96% (LC).
(±)-(3aR,13bR)-2-Methyl-5-(2-thienyl)-2,3,8,13b-tetrahydro-1H,4H,11H-[1,3]dioxolo[4,5-g]imi- 
dazo[1,5-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 57f.
(From (±)-22) MS [APCI (m/z)] calcd for (C19H17N3O4S + H)+ = 384, found 
384. Crude yield: quantitative. Purity: 97% (LC).
(±)-(3aR,13bR)-5-(4-Ethoxyphenyl)-2-methyl-2,3,8,13b-tetrahydro-1H,4H,11H-[1,3]dioxolo[4,5- 
EtO g]imidazo[1,5-b]pyrrolo[3,4-c]isoquinoline-4,6(5H)-dione 57g.
(From (±)-22) MS [APCI (m/z)] calcd for (Q3H23N3O5 + H)+ = 422, found 
422. Crude yield: quantitative. Purity: 95% (LC).
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C hapter 6
(±)-3-{(3aR,13bR)-2-Methyl-4,6-dioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3]dioxolo[4,5-g]- 
imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-5-yl}benzomtrile 57h.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.83 (dd(3), J = 1.6 
Hz, 1 !H, 2-CH), 7.75 (ddd(6); J = 7.8, 1.6, 1.6 Hz; 1 !H, 4-CH), 7.61 
(ddd(6); J = 7.8, 1.3, 1.3 Hz; 1 ^ ,  6-CH), 7.54 (t, J = 7.8 Hz, 1 ^ ,  5-CH),
6.69 (s, 1 !H, 9-CH), 6.62 (s, 1 ^ ,  13'-CH), 5.94 (s, 2 ^ ,  11'-CH2), 4.92 (d, J 
= 15.6 Hz, 1 !H, 8 '-CHH), 4.31 (d, J = 15.6 Hz, 1 !H, 8 '-CHH), 3.72 (dd; J =
7.5, 5.1 Hz; 1 ^ ,  13'b-CH), 3.15 (d, J = 10.5 Hz, 1 ^ ,  3'-CHH), 3.12 (dd; J 
= 9.0, 7.5 Hz; 1 ^ ,  1'-CHH), 3.05 (d, J = 10.5 Hz, 1 ^ ,  3'-CHH), 2.65 (dd; J = 9.0, 5.1 Hz; 1 !H, 1'- 
CHH), 2.37 (s, 3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 174.5 (4'-C), 153.9 (6 '-C), 147.7 
(12'a-C), 146.9 (9'a-C), 133.0 (3-C), 131.4 (6-C), 130.0 (5-C), 129.8 (4-C), 129.0 (2-C), 128.4 (13'a-C),
126.7 (8 'a-C), 118.0 (CN), 113.3 (1-C), 109.1 (13'-C), 106.9 (9'-C), 101.4 (11'-C), 68.1 (3'a-C), 65.8 (1'- 
C), 64.8 (3'-C), 46.0 (13'b-C), 41.6 (NCH3), 40.9 (8 '-C). FTIR [V (cm-1), neat]: 2943, 2842, 2786, 
2230, 1776, 1718, 1037, 932. MS [APCI (m/z)] calcd for (C22H18N4O4 + H)+ = 403, found 403. 
Crude yield: quantitative. Purity: 90% (LC).
(±)
9'a
12'a \  O
O — !
(±)-(3aR,13bR)-2-Methyl-5-(3-pyridyl)-2,3,8,13b-tetrahydro-1H,4H,11H-[1,3]dioxolo[4,5-g]imi- 
dazo[1,5-b]pyrrolo[3,4-c]isoquinolme-4,6(5.H)-dione 57i.
(From (±)-22) MS [APCI (m/z)] calcd for (C20H18N4O4 + H)+ = 379, found
379. Crude yield: quantitative. Purity: >99% (LC).
O
(±)-(3aR,11bR)-5-Ethyl-2-methyl-2,3,8,11b-tetrahydro-1H,4H-furo[2,3-d]imidazo[1,5-a]pyrrolo- 
[3,4-b]pyridine-4,6(5H)-dione 58a.
(From (±)-23) MS [APCI (m/z)] calcd for (C14H17N3O3 + H)+ = 276, found 276. 
Crude yield: quantitative. Purity: 80% (LC).O^ y N-,MeN
(±)
(±)-(3aR,11bR)-2-Methyl-5-phenethyl-2,3,8,11b-tetrahydro-1H,4H-furo[2,3-d]imidazo[1,5-a]- 
pyrrolo[3,4-b]pyridine-4,6(5H)-dione 58b.
(From (±)-23) MS [APCI (m/z)] calcd for (C2oH2iN3O3 + H)+ = 352, found 
352. Crude yield: quantitative. Purity: 57% (LC).
(±)
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Syn th esis  o f  (H etero)areno[d]pyrrolo[3,4-b]pyridines and (Hetero)areno[c]pyrrolo[3,4-e]azepines and Their D eriva tiza tion
(±)-Ethyl 3-{(3aR ,11bR)-2-methyl-4,6-dioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-d]imidazo- 
[1,5-a]pyrrolo[3,4-b]pyridin-5-yl}propanoate 58c.
(From (±)-23) MS [APCI (m/z)] calcd for (C17H21N3O5 + H)+ = 348, found
348. Crude yield: quantitative. Purity: 76% (LC).
(±)
(±)-(3aR,11bR)-2-Methyl-5-phenyl-2,3,8,11b-tetrahydro-1H,4H-furo[2,3-d]imidazo[1,5-a]pyr- 
rolo[3,4-b]pyridine-4,6(5H)-dione 58d.
O (From (±)-23) MS [APCI (m/z)] calcd for (C18H17N3O3 + H)+ = 324, found 324.
N~N^ Crude yield: quantitative. Purity: 91% (LC).
MeH ¿
(±)
(±)-(3aR,11bR)-2-Methyl-5-[4-(trifluoromethyl)phenyl]-2,3,8,11b-tetrahydro-1H,4H-furo[2,3-d] 
imidazo[1,5-a]pyrrolo[3,4-b]pyridine-4,6(5.H)-dione 58e.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.77-7.69 (m, 2 1H, 3'-CH 
+ 5'-CH), 7.68-7.60 (m, 2 1H, 2'-CH + 6 '-CH), 7.37 (d, J = 1.8 Hz, 1 1H, 10-CH),
6.31 (d, J = 1.8 Hz, 1 1H, 9-CH), 5.07 (dd; J = 15.9, 1.5 Hz; 1 1H, 8-CHH), 4.19 
(dd; J = 15.9, 1.8 Hz; 1 ^ ,  8-CHH), 3.63 (bd, J = 5.4 Hz, 1 ^ ,  11b-CH), 3.30 (d, 
J = 10.5 Hz, 1 !H, 3-CHH), 3.26 (d, J = 9.3 Hz, 1 !H, 1-CHH), 2.90 (dd; J = 9.3,
5.4 Hz; 1 !H, 1-CHH), 2.89 (d, J = 10.5 Hz, 1 !H, 3-CHH), 2.37 (s, 3 !H, NCH3). 
13C NMR [75 MHz, 5 (ppm), CDCI3]: 174.2 (4-C), 153.3 (6-C), 147.5 (11a-C), 142.6 (10-C), 134.9 (q, 
J = 1.4 Hz, 1'-C), 130.0 (q, J = 32.7 Hz, 4'-C), 126.3 (q, J = 3.7 Hz, 3'-C + 5'-C), 125.9 (2'-C + 6 '-C),
123.9 (q, J = 270.5 Hz, CF3), 115.7 (8a-C), 108.2 (9-C), 68.4 (3a-C), 62.2 (3-C), 60.0 (1-C), 42.2 (11b- 
C), 41.8 (NCH3), 36.2 (8-C). FTIR [V (cm-1), neat]: 2945, 2843, 2794, 1777, 1721, 1324, 842, 739. 
MS [APCI (m/z)] calcd for (Ci9Hi6F3N3O3 + H)+ = 392, found 392. Crude yield: quantitative. 
Purity: 94% (LC).
(±)-(3aR,11bR)-2-Methyl-5-(2-thienyl)-2,3,8,11b-tetrahydro-1H,4H-furo[2,3-d]imidazo[1,5-a]- 
pyrrolo[3,4-b]pyridine-4,6(5H)-dione 58f.
,O (From (±)-23) MS [APCI (m/z)] calcd for (C16H15N3O3S + H)+ = 330, found 330. 
Crude yield: quantitative. Purity: 92% (LC).
S­
N-
MeN
^ ÍJ  
(±)
(±)-(3aR,11bR)-5-(4-Ethoxyphenyl)-2-methyl-2,3,8,11b-tetrahydro-1H,4H-furo[2,3-d]imidazo- 
EtO [1,5-a]pyrrolo[3,4-b]pyridine-4,6(5H)-dione 58g.
(From (±)-23) MS [APCI (m/z)] calcd for (C20H21N3O4 + H)+ = 368, found 368.
N_ O^ Crude yield: quantitative. Purity: 92% (LC).
O= .N.
MeN
H O - / /  
(±)
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C hapter 6
(±)-3-{(3aR,11bR)-2-Methyl-4,6-dioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-d]imidazo[1,5-a] 
pyrrolo[3,4-b]pyridin-5-yl}benzomtrile 58h.
(From (±)-23) MS [APCI (m/z)] calcd for (C19H16N4O3 + H)+ = 349, found
349. Crude yield: quantitative. Purity: 81% (LC).
MeN 311b -V11a ,
H O - / /
(±)
(±)-(3aR ,11bR)-2-Methyl-5-(3-pyridyl)-2,3,8,11b-tetrahydro-1H,4H-furo[2,3-d]imidazo[1,5-a]- 
pyrrolo[3,4-b]pyridine-4,6(5H)-dione 58i.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDCls]: 8.78 (d, J = 2.4 Hz, 1 1H, 2'- 
CH), 8.60 (dd; J = 4.8, 1.5 Hz; 1 1H, 6 '-CH), 7.83 (ddd; J = 8.1, 2.4, 1.5 Hz; 1 1H, 4'- 
CH), 7.41 (ddd; J = 8.1, 4.8, 0.6 Hz; 1 1H, 5'-CH), 7.36 (d, J = 1.8 Hz, 1 1H, 10-CH),
6.31 (d, J = 1.8 Hz, 1 1H, 9-CH), 5.07 (dd; J = 15.9, 1.5 Hz; 1 1H, 8-CHH), 4.19 (dd; 
(±) - J = 15.9, 1.8 Hz; 1 1H, 8-CHH), 3.64 (bd, J = 5.4 Hz, 1 1H, 11b-CH), 3.29 (d, J =
10.8 Hz, 1 1H, 3-CHH), 3.24 (d, J = 9.3 Hz, 1 1H, 1-CHH), 2.90 (d, J = 10.8 Hz, 1 1H, 3-CHH), 2.89 
(dd; J = 9.3, 5.4 Hz; 1 1H, 1-CHH), 2.37 (s, 3 1H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCls]:
174.2 (4-C), 153.3 (6-C), 148.9 (6 '-C), 147.6 (11a-C), 146.8 (2'-C), 142.6 (10-C), 133.1 (4'-C), 128.9 (3'- 
C), 123.7 (5'-C), 115.6 (8a-C), 108.2 (9-C), 6 8 .6  (3a-C), 62.3 (3-C), 60.1 (1-C), 42.2 (11b-C), 41.8 
(NCH3), 36.2 (8-C). FTIR [V (cm-1), neat]: 2946, 2840, 2791, 1775, 1717, 732, 705. MS [APCI 
(m/z)] calcd for (C17H1 6N4O3 + H)+ = 325, found 325. Crude yield: quantitative. Purity: >99% 
(LC).
(±)-(3aR,13cR)-5-Ethyl-2,9-dimethyl-1,2,3,8,9,13c-hexahydro-4H-imidazo[1,,5,:1,6]pyrrolo[3,,4':
5,6]pyrido[3,4-b]indole-4,6(5H)-dione 59a.
(From (±)-24) MS [APCI (m/z)] calcd for (C19H22N4O2 + H)+ = 339, found 
339. Crude yield: quantitative. Purity: 81% (LC).
(±)-(3aR,13cR)-2,9-Dimethyl-5-phenethyl-1,2,3,8,9,13c-hexahydro-4H-imidazo[1',5':1,6]pyrrolo- 
[3',4' :5,6] pyrido[3,4- b] indole-4,6(5H)-dione 59b.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCl3]: 7.42 (d, J = 7.8 Hz, 1 
1H, 13-CH), 7.29 (d, J = 8.1 Hz, 1 1H, 10-CH), 7.25-7.08 (m, 7 1H, 11-CH +
12-CH + Ph), 5.21 (dd; J = 16.2, 0.6 Hz; 1 1H, 8-CHH), 4.37 (d, J = 16.2 Hz, 
1 1H, 8-CHH), 3.78 (t, J = 7.2 Hz, 2 1H, NCH2CH2), 3.68 (s, 3 1H, 9-NCH3), 
3.64 (d, J = 5.7 Hz, 1 1H, 13c-CH), 3.22 (d, J = 10.5 Hz, 1 1H, 3-CHH), 3.18 
(d, J = 9.3 Hz, 1 1H, 1-CHH), 2.98-2.89 (m, 3 1H, 1-CHH + NCH2CH2),
2.73 (d, J = 10.5 Hz, 1 1H, 3-CHH), 2.32 (s, 3 1H, 2 -NCH3). 13C NMR [75 
MHz, 5 (ppm), CDO3]: 175.9 (4-C), 155.5 (6-C), 137.8 (1'-C), 137.6 (9a-C), 131.7 (8a-C), 129.1 (2'-C 
+ 6 '-C), 128.6 (3'-C + 5'-C), 126.8 (4'-C), 125.5 (13a-C), 122.1 (11-C), 119.7 (12-C), 118.0 (13-C), 109.4 
(10-C), 108.0 (13b-C), 68.1 (3a-C), 62.35 (1-C), 62.28 (3-C), 41.9 (2-NCHs), 40.8 (13c-C), 40.3 
(NCH2CH2), 34.9 (8-C), 34.0 (NCH2CH2), 29.8 (9-NCHs). FTIR [V (cm-1), neat]: 2946, 2851, 2789, 
1768, 1709, 742, 699. MS [APCI (m/z)] calcd for (C25H26N4O2 + H)+ = 415, found 415. Crude 
yield: quantitative. Purity: 83% (LC).
212
Syn th esis  o f  (H etero)areno[d]pyrrolo[3,4-b]pyridines and (Hetero)areno[c]pyrrolo[3,4-e]azepines and Their D eriva tiza tion
(±)-Ethyl 3-{(3aR,13cR)-2,9-dimethyl-4,6-dioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imidazo[1',5':1,6] 
pyrrolo[3',4':5,6]pyrido[3,4-b]mdol-5-yl}propanoate 59c.
(From (±)-24) MS [APCI (m/z)] calcd for (C22H26N4O4 + H)+ = 411, found
411. Crude yield: quantitative. Purity: 83% (LC).
(±)-(3aR,13cR)-2,9-Dimethyl-5-phenyl-1,2,3,8,9,13c-hexahydro-4H-imidazo[1',5':1,6]pyrrolo- 
[3',4':5,6]pyrido[3,4-b]mdole-4,6(5.H)-dione 59d.
(From (±)-24) MS [APCI (m/z)] calcd for (C23H22N4O2 + H)+ = 387, found
387. Crude yield: quantitative. Purity: 97% (LC).
(±)-(3aR,13cR)-2,9-Dimethyl-5-[4-(trifluoromethyl)phenyl]-1,2,3,8,9,13c-hexahydro-4H-imida- 
zo[1',5,:1,6]pyrrolo[3,,4':5,6]pyrido[3,4-b]indole-4,6(5H)-dione 59e.
(From (±)-24) MS [APCI (m/z)] calcd for (C24H2iF3N4O2 + H)+ = 455, found 
455. Crude yield: quantitative. Purity: 98% (LC).
(±)-(3aR,13cR)-2,9-Dimethyl-5-(2-thienyl)-1,2,3,8,9,13c-hexahydro-4H-imidazo[1,,5':1,6]pyrrolo 
[3',4':5,6]pyrido[3,4-b]indole-4,6(5H)-dione 59f.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.53 (dd; J = 3.9, 1.2 Hz; 1 
1H, 3'-CH), 7.45 (d, J = 7.8 Hz, 1 1H, 13-CH), 7.30 (d, J = 8.1 Hz, 1 1H, 10-CH), 
7.26-7.20 (m, 1 1H, 11-CH), 7.15 (dd; J = 5.4, 1.2 Hz; 1 1H, 5'-CH), 7.14-7.08 
(m, 1 1H, 12-CH), 6.99 (dd; J = 5.4, 3.9 Hz; 1 1H, 4'-CH), 5.33 (d, J = 15.9 Hz, 1 
1H, 8-CHH), 4.44 (d, J = 15.9 Hz, 1 1H, 8-CHH), 3.95 (d, J = 6.0 Hz, 1 1H, 13c- 
CH), 3.70 (s, 3 1H, 9-NCH3), 3.28 (d, J = 10.5 Hz, 1 1H, 3-CHH), 3.18 (d, J = 9.0 
Hz, 1 1H, 1-CHH), 3.03 (dd; J = 9.0, 6.0 Hz; 1 1H, 1-CHH), 2.95 (d, J = 10.5 Hz, 
1 1H, 3-CHH), 2.34 (s, 3 1H, 2 -NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 173.6 (4-C), 153.4 (6- 
C), 137.5 (9a-C), 132.5 (2'-C), 131.1 (8a-C), 125.4 (13a-C), 125.2 (4'-C), 122.2 (11-C), 121.7 (5'-C),
119.9 (3'-C), 119.8 (12-C), 118.1 (13-C), 109.4 (10-C), 108.6 (13b-C), 68.1 (3a-C), 63.2 (3-C), 62.7 (1­
C), 41.9 (2 -NCH3), 41.3 (13c-C), 35.3 (8-C), 29.9 (9-NCH3). FTIR [ V (cm-1), neat]: 2937, 2841, 2790, 
1773, 1716, 733, 698. MS [APCI (m/z)] calcd for (C21H2üN4 0 2S + H)+ = 393, found 393. Crude 
yield: quantitative. Purity: 97% (LC).
213
C hapter 6
(±)-(3aR ,13cR)-5-(4-Ethoxyphenyl)-2,9-dimethyl-1,2,3,8,9,13c-hexahydro-4H-imidazo[1',5':1,6]- 
pyrrolo[3',4':5,6]pyrido[3,4-b]indole-4,6(5.H)-dione 59g.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCla]: 7.48 (d, J = 7.8 Hz, 1 XH,
13-CH), 7.34-7.20 (m, 4 XH, 10-CH + 11-CH + 2'-CH + 6 '-CH), 7.12 (ddd(7); J 
= 7.8, 6.9, 0.9 Hz; 1 XH, 12-CH), 6.98-6.90 (m, 2 XH, 3'-CH + 5'-CH), 5.33 (dd; 
J = 16.2, 0.9 Hz; 1 XH, 8-CHH), 4.43 (dd; J = 16.2, 0.9 Hz; 1 XH, 8-CHH), 4.04 
(q, J = 6.9 Hz, 2 XH, CH2CH3), 3.95 (dd; J = 6.0, 0.9 Hz; 1 XH, 13c-CH), 3.70 (s,
3 !H, 9-NCH3), 3.31 (d, J = 10.5 Hz, 1 XH, 3-CHH), 3.20 (d, J = 9.0 Hz, 1 XH, 
1-CHH), 3.01 (dd; J = 9.0, 6.0 Hz; 1 XH, 1-CHH), 2.95 (d, J = 10.5 Hz, 1 XH, 3- 
CHH), 2.34 (s, 3 XH, 2-NCHs), 1.41 (t, J = 6.9 Hz, 3 XH, CH2CH3). 13C NMR [75 MHz, 5 (ppm), 
CDCI3]: 175.5 (4-C), 158.8 (4'-C), 154.9 (6-C), 137.5 (9a-C), 131.5 (8a-C), 127.6 (2'-C + 6 '-C), 125.5 
(13a-C), 124.3 (1'-C), 122.1 (11-C), 119.8 (12-C), 118.1 (13-C), 115.0 (3'-C + 5'-C), 109.4 (10-C), 108.6 
(13b-C), 68.3 (3a-C), 63.8 (CH2CH3), 63.2 (3-C), 62.7 (1-C), 42.0 (2 -NCH3), 41.2 (13c-C), 35.1 (8-C),
29.9 (9-NCH3), 14.9 (CH2CH3). FTIR [ V (cm-1), neat]: 2936, 2841, 2788, 1772, 1714, 1247, 735. MS 
[APCI (m/z)] calcd for (C25H26N4O3 + H)+ = 431, found 431. Crude yield: quantitative. Purity: 
95% (LC).
EtO
(±)-3-{(3aR,13cR)-2,9-Dimethyl-4,6-dioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imidazo[1',5':1,6]pyr- 
rolo[3',4':5,6]pyrido[3,4-b]mdol-5-yl}benzomtrile 59h.
(From (±)-24) MS [APCI (m/z)] calcd for (C24H21N5O2 + H)+ = 412, found
412. Crude yield: quantitative. Purity: 8 8 % (LC).
(±)-(3aR,13cR)-2,9-Dimethyl-5-(3-pyridyl)-1,2,3,8,9,13c-hexahydro-4H-imidazo[1',5':1,6]pyrrolo 
[3',4':5,6]pyrido[3,4-b]indole-4,6(5.H)-dione 59i.
(From (±)-24) MS [APCI (m/z)] calcd for (C22H21N5O2 + H)+ = 388, found
388. Crude yield: quantitative. Purity: 95% (LC).
General Procedure for Thiohydantoin Annulation Using Parallel Synthesis. A solution of 
isothiocyanate 60 (0.12 mmol for a, 0.10 mmol for b-h) from a 0.3 M stock solution in DMF was 
added to a solution of polyhydropyrrolopyridine (0.10 mmol) in DMF (1.5 mL). The resulting 
reaction mixture was stirred at 40 °C for 40 h for 60a-c and at room temperature for 20 h for 
60d-h. After that time, the solvent was evaporated and the samples were analyzed.
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(±)-(3aR ,12bR)-5-Ethyl-9,11-dimethoxy-2-methyl-6-thioxo-2,3,5,6,8,12b-hexahydro-1H,4H-imi- 
S dazo[1,5-b]pyrrolo[3,4-c]isoquinolm-4-one 61a.
(From (±)-21) MS [APCI (m/z)] calcd for (C18H23N3O3S + H)+ = 362, found 
OM 362. Crude yield: quantitative. Purity: 80% (LC).
O
MeN
(±) OMe
(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-5-phenethyl-6-thioxo-2,3,5,6,8,12b-hexahydro-1H,4H
-imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-4-one 61b.
(From (±)-21) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.26-7.14 (m, 5 
!H, Ph), 6.33 (d, J = 2.4 Hz, 1 !H, 10-CH), 6.20 (d, J = 2.4 Hz, 1 !H, 12- 
CH), 5.90 (d, J = 16.2 Hz, 1 !H, 8-CHH), 4.17 (d, J = 16.2 Hz, 1 !H, 8- 
CHH), 4.09-4.00 (m, 2 !H, NCH2CH2), 3.83 (s, 3 !H, 9-OCHs), 3.78 (s, 3 
!H, 1 1 -OCH3), 3.43 (dd; J = 6 .6, 3.3 Hz; 1 !H, 12b-CH), 3.04-2.96 (m, 4 
1H, 1-CHH + 3-CHH + NCH2CH2), 2.77 (dd; J = 9.3, 3.3 Hz; 1 1H, 1- 
CHH), 2.68 (d, J = 10.5 Hz, 1 !H, 3-CHH), 2.28 (s, 3 !H, NCH3). i3C 
NMR [75 MHz, 5 (ppm), CDCI3]: 180.4 (6-C), 176.5 (4-C), 160.1 (11-C), 156.9 (9-C), 138.0 (1'-C),
137.4 (12a-C), 129.2 (2'-C + 6 '-C), 128.5 (3'-C + 5'-C), 126.6 (4'-C), 114.5 (8a-C), 104.1 (12-C), 96.9 
(10-C), 69.5 (3a-C), 65.6 (1-C), 63.6 (3-C), 55.7 (9-OCH3), 55.5 (H-OCH3), 46.6 (12b-C), 42.9 
(NCH2CH2), 41.6 (NCH3), 38.8 (8-C), 33.6 (NCH2CH2). FTIR [V (cm-1), neat]: 2938, 2837, 2786, 
1741, 1673, 1603, 1149, 834, 747, 699. MS [APCI (m/z)] calcd for (C24H27N3O3S + H)+ = 438, 
found 438. Crude yield: quantitative. Purity: 95% (LC).
(±) OMe
(±)-Ethyl 3-{(3aR,12bR)-9,11-dimethoxy-2-methyl-4-oxo-6-thioxo-2,3,5,6,8,12b-hexahydro-1H,
4H-imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-5-yl}propanoate 61c.
(From (±)-21) MS [APCI (m/z)] calcd for (C21H27N3O5S + H)+ = 434, 
found 434. Crude yield: quantitative. Purity: 94% (LC).
(±) OMe
(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-5-phenyl-6-thioxo-2,3,5,6,8,12b-hexahydro-1H,4H- 
imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-4-one 61d.
(From (±)-21) *H NMR [400 MHz, 5 (ppm), CDCI3]: 7.48-7.40 (m, 3 !H, 3'- 
CH + 4'-CH + 5'-CH), 7.40-7.28 (m, 2 !H, 2'-CH + 6 '-CH), 6.35 (d, J = 2.2 
Hz, 1 !H, 10-CH), 6.28 (d, J = 2.2 Hz, 1 !H, 12-CH), 6.00 (d, J = 16.1 Hz, 1 
!H, 8-CHH), 4.29 (d, J = 16.1 Hz, 1 !H, 8-CHH), 3.83 (s, 3 !H, 9-OCH3), 3.79 
(s, 3 !H, 1 1 -OCH3), 3.75 (dd; J = 6 .8, 3.4 Hz; 1 !H, 12b-CH), 3.26 (d, J = 10.5 
Hz, 1 !H, 3-CHH), 3.12 (dd; J = 9.0, 6.8  Hz; 1 !H, 1-CHH), 2.99 (d, J = 10.5 
Hz, 1 !H, 3-CHH), 2.90 (dd; J = 9.0, 3.4 Hz; 1 !H, 1-CHH), 2.35 (s, 3 !H, NCH3). 13C NMR [75 
MHz, 5 (ppm), CDCI3]: 180.4 (6-C), 176.2 (4-C), 160.2 (11-C), 157.0 (9-C), 137.4 (12a-C), 133.5 (1'- 
C), 129.2 (4'-C), 129.1 (3'-C + 5'-C), 128.5 (2'-C + 6 '-C), 114.5 (8a-C), 104.0 (12-C), 97.0 (10-C), 70.0 
(3a-C), 65.7 (1-C), 64.1 (3-C), 55.8 (9-OCH3), 55.6 (H-OCH3), 46.9 (12b-C), 41.7 (NCH3), 39.2 (8-C).
(±) OMe
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HRMS [EI (m/z)] calcd for C22H23N3O3S = 409.1460, found for [M+-] = 409.1460 (|A| = 0.0 
ppm), peaks at (relative intensity): 409 (22), 57 (100), 42 (11). MS [APCI (m/z)] calcd for 
(C22H23N3O3S + H)+ = 410, found 410. Mp: 135.1 (dec.). Crude yield: quantitative. Purity: 93% 
(LC).
(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-6-thioxo-5-[4-(trifluoromethyl)phenyl]-2,3,5,6,8,12b- 
hexahydro-1H,4H-imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-4-one 61e.
(From (±)-21) *H NMR [300 MHz, 5 (ppm), CDCfe]: 7.77-7.69 (m, 2 XH, 
3'-CH + 5'-CH), 7.52-7.44 (m, 2 XH, 2'-CH + 6 '-CH), 6.36 (d, J = 2.4 Hz, 1 
!H, 10-CH), 6.29 (d, J = 2.4 Hz, 1 XH, 12-CH), 5.99 (d, J = 16.5 Hz, 1 XH, 8- 
CHH), 4.29 (d, J = 16.5 Hz, 1 XH, 8-CHH), 3.84 (s, 3 XH, 9-OCH3), 3.79 (s, 3 
!H, 1 1 -OCH3), 3.77 (dd; J = 6.9, 3.4 Hz; 1 XH, 12b-CH), 3.26 (d, J = 10.5 Hz, 
1 !H, 3-CHH), 3.13 (dd; J = 9.0, 6.9 Hz; 1 XH, 1-CHH), 3.00 (d, J = 10.5 Hz, 
1 !H, 3-CHH), 2.89 (dd; J = 9.0, 3.4 Hz; 1 XH, 1-CHH), 2.35 (s, 3 XH, 
NCH3). 13C NMR [75 MHz, 5 (ppm), CDCb]: 179.4 (6-C), 175.8 (4-C), 160.3 (11-C), 157.0 (9-C),
137.2 (12a-C), 136.4 (q, J = 1.4 Hz, 1'-C), 131.0 (q, J = 32.7 Hz, 4'-C), 129.0 (2'-C + 6 '-C), 126.2 (q, J =
3.7 Hz, 3'-C + 5'-C), 123.8 (q, J = 270.8 Hz, CF3), 114.3 (8a-C), 104.1 (12-C), 97.0 (10-C), 70.1 (3a-C),
65.7 (1-C), 64.1 (3-C), 55.8 (9-OCH3), 55.5 (H-OCH3), 46.9 (12b-C), 41.6 (NCH3), 39.2 (8-C). FTIR 
[ V (cm-1), neat]: 2939, 2841, 2788, 1751, 1672, 1608, 1320, 1151, 840. MS [APCI (m/z)] calcd for 
(C23H22F3N3O3S + H)+ = 478, found 478. Crude yield: quantitative. Purity: 93% (LC).
(±) OMe
(±)-(3aR,12bR)-5-(4-Ethoxyphenyl)-9,11-dimethoxy-2-methyl-6-thioxo-2,3,5,6,8,12b-hexahydro- 
EtO 1H,4H-imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-4-one 61f.
(From (±)-21) MS [APCI (m/z)] calcd for (C24H27N3O4S + H)+ = 454, 
found 454. Crude yield: quantitative. Purity: 95% (LC).
(±) OMe
(±)-3-{(3aR,12bR)-9,11-Dimethoxy-2-methyl-4-oxo-6-thioxo-2,3,5,6,8,12b-hexahydro-1H,4H-
imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-5-yl}benzomtrile 61g.
(From (±)-21) MS [APCI (m/z)] calcd for (C23H22N4O3S + H)+ = 435, 
found 435. Crude yield: quantitative. Purity: 8 8 % (LC).
(±) OMe
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(±)-(3aR,12bR)-9,11-Dimethoxy-2-methyl-5-(3-pyridyl)-6-thioxo-2,3,5,6,8,12b-hexahydro-1.H, 
4H-imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-4-one 61h.
(From (±)-21) MS [APCI (m/z)] calcd for (C21H22N4O3S + H)+ = 411, found 
411. Crude yield: quantitative. Purity: 87% (LC).
OMe 
OMe
(±)-(3aR,13bR)-5-Ethyl-2-methyl-6-thioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3]dioxolo[4,5- 
g]imidazo[1,5-b]pyrrolo[3,4-c]isoquinolm-4-one 62a.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3]: 6.67 (s, 1 1H, 9-CH), 6.57 
(s, 1 1H, 13-CH), 5.92 (s, 2 1H, 11-CH2), 5.54 (d, J = 15.3 Hz, 1 1H, 8 -CHH), 4.47 
(d, J = 15.3 Hz, 1 !H, 8-CHH), 3.86 (q, J = 7.2 Hz, 2 !H, CH2CH3), 3.61 (dd; J =
6.9, 3.9 Hz; 1 !H, 13b-CH), 3.04 (dd; J = 9.0, 6.9 Hz; 1 !H, 1-CHH), 3.03 (d, J =
10.2 Hz, 1 !H, 3-CHH), 2.92 (d, J = 10.2 Hz, 1 !H, 3-CHH), 2.72 (dd; J = 9.0, 3.9 
Hz; 1 !H, 1-CHH), 2.33 (s, 3 !H, NCH3), 1.21 (t, J = 7.2 Hz, 3 !H, CH2CHs). 13C NMR [75 MHz, 5 
(ppm), CDCls]: 181.2 (6-C), 176.3 (4-C), 147.6 (12a-C), 146.7 (9a-C), 128.8 (13a-C), 126.5 (8a-C),
108.7 (13-C), 107.0 (9-C), 101.3 (11-C), 69.8 (3a-C), 65.9 (1-C), 64.2 (3-C), 46.8 (13b-C), 44.2 (8-C),
41.6 (NCH3), 37.3 (CH2CH3), 13.1 (CH2CH3). FTIR [V (cm-1), neat]: 2938, 2843, 2785, 1738, 1673, 
1035, 932. MS [APCI (m/z)] calcd for (C17H19N3O3S + H)+ = 346, found 346. Crude yield: 
quantitative. Purity: 94% (LC).
(±)-(3aR,13bR)-2-Methyl-5-phenethyl-6-thioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3]dioxo- 
lo[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoqumolm-4-one 62b.
(From (±)-22) MS [APCI (m/z)] calcd for (C23H23N3O3S + H)+ = 422, found 
422. Crude yield: quantitative. Purity: 99% (LC).
(±)-Ethyl 3-{(3aR,13bR)-2-methyl-4-oxo-6-thioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3]diox- 
olo[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoqumolm-5-yl}propanoate 62c.
(From (±)-22) MS [APCI (m/z)] calcd for (C2üH23N3 0 5 S + H)+ = 418, 
found 418. Crude yield: quantitative. Purity: 87% (LC).
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(±)-(3aR,13bR)-2-Methyl-5-phenyl-6-thioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3]dioxolo- 
[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoqumolm-4-one 62d.
(From (±)-22) MS [APCI (m/z)] calcd for (C21H19N3O3S + H)+ = 394, found
394. Crude yield: quantitative. Purity: 96% (LC).
(±)-(3aR,13bR)-2-Methyl-6-thioxo-5-[4-(trifluoromethyl)phenyl]-2,3,5,6,8,13b-hexahydro-1H, 
4H,11H-[1,3]dioxolo[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoqumolm-4-one 
62e.
(From (±)-22) MS [APCI (m/z)] calcd for (C22H18F3N3O3S + H)+ = 462, 
found 462. Crude yield: quantitative. Purity: 96% (LC).
(±)-(3aR,13bR)-5-(4-Ethoxyphenyl)-2-methyl-6-thioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3] 
EtO dioxolo[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoqumolm-4-one 62f.
(From (±)-22) MS [APCI (m/z)] calcd for (C23H23N3O4S + H)+ = 438, found 
438. Crude yield: quantitative. Purity: 98% (LC).
(±)-3-{(3aR,13bR)-2-Methyl-4-oxo-6-thioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3]dioxolo- 
[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoqumolm-5-yl}benzomtrile 62g.
(From (±)-22) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.73-7.65 (m, 2 1H, 2- 
CH + 6-CH), 7.63-7.54 (m, 2 1H, 4-CH + 5-CH), 6.70 (s, 1 1H, 9'-CH), 6.63 
(s, 1 1H, 13-CH), 5.94 (s, 2 1H, 1 1 '-CH2), 5.60 (d, J = 15.3 Hz, 1 1H, 8 '-CHH),
4.59 (d, J = 15.3 Hz, 1 1H, 8 '-CHH), 3.77 (dd; J = 6.9, 3.9 Hz; 1 1H, 13'b-CH), 
3.21 (d, J = 10.2 Hz, 1 1H, 3'-CHH), 3.08 (dd; J = 9.3, 6.9 Hz; 1 !H, 1'-CHH),
3.04 (d, J = 10.2 Hz, 1 1H, 3'-CHH), 2.80 (dd; J = 9.3, 3.9 Hz; 1 !H, 1'-CHH), 
2.37 (s, 3 !H, NCH3). 13C NMR [75 MHz, 5 (ppm), CDCI3]: 179.6 (6 '-C), 175.3 (4'-C), 147.8 (12'a-C),
146.9 (9'a-C), 134.1 (3-C), 133.0 (4-C), 132.5 (6-C), 132.1 (2-C), 129.9 (5-C), 128.6 (13'a-C), 126.1 (8 'a- 
C), 117.8 (CN), 113.3 (1-C), 108.8 (13'-C), 107.1 (9'-C), 101.4 (11'-C), 70.5 (3'a-C), 65.9 (1'-C), 64.7 
(3'-C), 47.2 (13'b-C), 44.6 (8 '-C), 41.4 (NCH3). FTIR [V (cm-1), neat]: 2939, 2844, 2788, 2230, 1752,
1670, 1036, 932. MS [APCI (m/z)] calcd for (C22H18N4O3S + H)+ = 419, found 419. Crude yield: 
quantitative. Purity: 95% (LC).
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(±)-(3aR ,13bR)-2-Methyl-5-(3-pyridyl)-6-thioxo-2,3,5,6,8,13b-hexahydro-1H,4H,11H-[1,3]diox- 
olo[4,5-g]imidazo[1,5-b]pyrrolo[3,4-c]isoqumolm-4-one 62h.
(From (±)-22) MS [APCI (m/z)] calcd for (C20H18N4O3S + H)+ = 395, found
395. Crude yield: quantitative. Purity: >99% (LC).
(±)-(3aR,11bR)-5-Ethyl-2-methyl-6-thioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-d|imidazo- 
\ l  [1,5-a]pyrrolo[3,4-b]pyridin-4-one 63a.
O ^T N  (From (±)-23) MS [APCI (m/z)] calcd for (C14H17N3O2S + H)+ = 292, found 292. 
MeN^ A  Crude yield: quantitative. Purity: 73% (LC).
(±)
(±)-(3aR,11bR)-2-Methyl-5-phenethyl-6-thioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-d]imi- 
dazo [1,5-a] pyrr olo[3,4-b] pyridin-4-one 63b.
(From (±)-23) MS [APCI (m/z)] calcd for (C20H21N3O2S + H)+ = 368, found 
368. Crude yield: quantitative. Purity: 95% (LC).
(±)
(±)-Ethyl 3-{(3aR,11bR)-2-methyl-4-oxo-6-thioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-d]- 
imidazo [1,5-a] pyrrolo[3,4-b] pyridin-5-yl}propanoate 63c.
(From (±)-23) MS [APCI (m/z)] calcd for (C17H21N3O4S + H)+ = 364, found
(±)
(±)-(3aR,11bR)-2-Methyl-5-phenyl-6-thioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-d]imidazo 
[1,5-a]pyrrolo[3,4-b]pyridin-4-one 63d.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDCls]: 7.54-7.43 (m, 3 1H, 3'-CH + 
4'-CH + 5'-CH), 7.38 (d, J = 1.8 Hz, 1 1H, 10-CH), 7.35-7.28 (m, 2 1H, 2'-CH + 6 '- 
CH), 6.33 (d, J = 1.8 Hz, 1 1H, 9-CH), 5.78 (dd; J = 15.9, 1.5 Hz; 1 1H, 8-CHH),
4.39 (dd; J = 15.9, 2.1 Hz; 1 !H, 8-CHH), 3.68 (d, J = 5.1 Hz, 1 !H, 11b-CH), 3.36 
(d, J = 10.5 Hz, 1 !H, 3-CHH), 3.29 (d, J = 9.0 Hz, 1 !H, 1-CHH), 2.91 (dd; J = 9.0,
5.1 Hz; 1 !H, 1-CHH), 2.86 (d, J = 10.5 Hz, 1 !H, 3-CHH), 2.38 (s, 3 !H, NCH3). 
13C NMR [75 MHz, 5 (ppm), CDCla]: 180.9 (6-C), 175.5 (4-C), 147.2 (11a-C), 142.8 (10-C), 133.2 (1'- 
C), 129.4 (4'-C), 129.2 (3'-C + 5'-C), 128.5 (2'-C + 6 '-C), 115.6 (8a-C), 108.4 (9-C), 70.6 (3a-C), 62.0 (3- 
C), 59.5 (1-C), 43.1 (11b-C), 41.8 (NCH3), 40.3 (8-C). FTIR [ V (cm-1), neat]: 2939, 2845, 2791, 1749,
1671, 742, 732, 692. MS [APCI (m/z)] calcd for (C18H17N3O2S + H)+ = 340, found 340. Crude 
yield: quantitative. Purity: 98% (LC).
H O - / /
(±)
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(±)-(3aR,11bR)-2-Methyl-6-thioxo-5-[4-(trifluoromethyl)phenyl]-2,3,5,6,8,11b-hexahydro-1H,
f3c
s
4H-furo[2,3-d]imidazo[1,5-a]pyrrolo[3,4-b]pyridin-4-one 63e.
(From (±)-23) MS [APCI (m/z)] calcd for (C19H16F3N3O2S + H)+ = 408, found 
408. Crude yield: quantitative. Purity: 93% (LC).
(±)
EtO
4'
3' {  6'
(±)
(±)-(3aR,11bR)-5-(4-Ethoxyphenyl)-2-methyl-6-thioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-
d] imidazo [1,5-a] pyrrolo[3,4-b] pyridin-4-one 63f.
(From (±)-23) *H NMR [300 MHz, 5 (ppm), CDCI3]: 7.37 (d, J = 1.8 Hz, 1 1H, 
10-CH), 7.24-7.17 (m, 2 1H, 2'-CH + 6 '-CH), 7.02-6.93 (m, 2 1H, 3'-CH + 5'-CH),
6.32 (d, J = 1.8 Hz, 1 1H, 9-CH), 5.77 (dd; J = 15.9, 1.5 Hz; 1 1H, 8-CHH), 4.38 
(dd; J = 15.9, 1.8 Hz; 1 1H, 8-CHH), 4.06 (q, J = 6.9 Hz, 2 1H, CH2CH3), 3.66 (d, 
J = 5.4 Hz, 1 1H, 11b-CH), 3.34 (d, J = 10.5 Hz, 1 1H, 3-CHH), 3.29 (d, J = 9.3 
Hz, 1 1H, 1-CHH), 2.92 (dd; J = 9.3, 5.4 Hz; 1 1H, 1-CHH), 2.85 (d, J = 10.5 Hz, 
1 1H, 3-CHH), 2.37 (s, 3 1H, NCH3), 1.42 (t, J = 6.9 Hz, 3 1H, CH2CH3). 13C NMR [75 MHz, 5 
(ppm), CDCI3]: 181.4 (6-C), 175.7 (4-C), 159.5 (4'-C), 147.2 (11a-C), 142.8 (10-C), 129.6 (2'-C + 6 '-C),
125.6 (1'-C), 115.6 (8a-C), 115.0 (3'-C + 5'-C), 108.4 (9-C), 70.5 (3a-C), (33.8 (CH2CH3), 62.0 (3-C),
59.5 (1-C), 43.0 (11b-C), 41.8 (NCH3), 40.4 (8-C), 14.9 (CH2CH3). FTIR [ V (cm-1), neat]: 2936, 2840, 
2791, 1747, 1671, 1246, 733. MS [APCI (m/z)] calcd for (C20H21N3O3S + H)+ = 384, found 384. 
Crude yield: quantitative. Purity: 98% (LC).
(±)-3-{(3aR,11bR)-2-Methyl-4-oxo-6-thioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-d]imidazo- 
[1,5-a]pyrrolo[3,4-b]pyridin-5-yl}benzomtrile 63g.
(From (±)-23) MS [APCI (m/z)] calcd for (C19H16N4O2S + H)+ = 365, found
(±)
(±)-(3aR,11bR)-2-Methyl-5-(3-pyridyl)-6-thioxo-2,3,5,6,8,11b-hexahydro-1H,4H-furo[2,3-d]imi- 
dazo[1,5-a]pyrrolo[3,4-b]pyridin-4-one 63h.
S (From (±)-23) MS [APCI (m/z)] calcd for (C17H16N4O2S + H)+ = 341, found 341. 
___7 ' Crude yield: quantitative. Purity: 93% (LC).
MeH ¿
(±)
(±)-(3aR,13cR)-5-Ethyl-2,9-dimethyl-6-thioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imidazo[1,,5,:1,6]- 
pyrrolo[3',4' :5,6] pyrido [3,4- b] indol-4-one 64a.
(From (±)-24) MS [APCI (m/z)] calcd for (C19H22N4OS + H)+ = 355, found 
355. Crude yield: quantitative. Purity: 90% (LC).
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(±)-(3aR,13cR)-2,9-Dimethyl-5-phenethyl-6-thioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imidazo[1',5':
1,6]pyrrolo[3',4':5,6]pyrido[3,4-b]mdol-4-one 64b.
(From (±)-24) MS [APCI (m/z)] calcd for (C25H26N4OS + H)+ = 431, found 
431. Crude yield: quantitative. Purity: 96% (LC).
NMe
(±)
(±)-Ethyl 3-{(3aR,13cR)-2,9-dimethyl-4-oxo-6-thioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imidazo- 
[1,,5':1,6]pyrrolo[3,,4':5,6]pyrido[3,4-b]indol-5-yl}propanoate 64c.
(From (±)-24) iH NMR [300 MHz, 5 (ppm), CDCI3]: 7.44 (d, J = 7.8 Hz, 1 
!H, 13'-CH), 7.30 (d, J = 8.1 Hz, 1 !H, 10'-CH), 7.31-7.19 (m, 1 !H, 11'-CH), 
7.14-7.08 (m, 1 !H, 12'-CH), 5.99 (dd; J = 16.2, 0.9 Hz; 1 !H, 8 '-CHH), 4.57 
(dd; J = 16.2, 1.2 Hz; 1 !H, 8 '-CHH), 4.16 (t, J = 7.2 Hz, 2 !H, 3 -CH2), 4.12 
(q, J = 7.2 Hz, 2 !H, CH2CH3), 3.87 (dd; J = 6.0, 0.9 Hz; 1 !H, 13'c-CH), 3.71 
(s, 3 !H, 9'-NCHs), 3.25 (d, J = 10.5 Hz, 1 !H, 3'-CHH), 3.20 (d, J = 9.0 Hz, 1 
!H, 1-CHH), 3.00 (dd; J = 9.0, 6.0 Hz; 1 !H, 1'-CHH), 2.80 (d, J = 10.5 Hz, 1 !H, 3'-CHH), 2.81-2.64 
(m, 2 !H, 2 -CH2), 2.32 (s, 3 !H, 2'-NCHs), 1.23 (t, J = 7.2 Hz, 1 !H, CH2CH3). 13C NMR [75 MHz, 5 
(ppm), CDCls]: 180.8 (6 -C), 176.4 (4'-C), 170.9 (CO2), 137.8 (9'a-C), 131.0 (8 'a-C), 125.2 (13'a-C),
122.2 (11'-C), 119.8 (12'-C), 118.1 (13'-C), 109.5 (10'-C), 108.6 (13'b-C), 70.5 (3'a-C), 62.6 (3'-C), 62.2 
(1'-C), 61.0 (CH2CH3), 41.91 (2 '-NCH3), 41.89 (13'c-C), 39.1 (8 '-C), 37.9 (3-C), 32.3 (2-C), 29.9 (9'- 
NCH3), 14.3 (CH2CH3). FTIR [V (cm-1), neat]: 2938, 2840, 2789, 1736, 1674, 739. MS [APCI 
(m/z)] calcd for (C22H26N4O3S + H)+ = 427, found 427. Crude yield: quantitative. Purity: 98% 
(LC).
(±)-(3aR,13cR)-2,9-Dimethyl-5-phenyl-6-thioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imidazo[1',5':
1,6] pyrrolo[3',4' :5,6] pyrido [3,4- b] indol-4-one 64d.
(From (±)-24) MS [APCI (m/z)] calcd for (C23H22N4OS + H)+ = 403, found
403. Crude yield: quantitative. Purity: 98% (LC).
(±)-(3aR,13cR)-2,9-Dimethyl-6-thioxo-5-[4-(trifluoromethyl)phenyl]-1,2,3,5,6,8,9,13c-octahydro 
-4H-imidazo[1,,5':1,6]pyrrolo[3,,4':5,6]pyrido[3,4-b]indol-4-one 64e.
(From (±)-24) MS [APCI (m/z)] calcd for (C24H21F3N3OS + H)+ = 471, found 
471. Crude yield: quantitative. Purity: 97% (LC).
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(±)-(3aR ,13cR)-5-(4-Ethoxyphenyl)-2,9-dimethyl-6-thioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imida- 
EtO zo[1',5':1,6]pyrrolo[3',4':5,6]pyrido[3,4-b]mdol-4-one 64f.
(From (±)-24) MS [APCI (m/z)] calcd for (C25H26N4O2S + H)+ = 447, found
447. Crude yield: quantitative. Purity: 98% (LC).
(±)-3-{(3aR,13cR)-2,9-Dimethyl-4-oxo-6-thioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imidazo[1',5,:1,6]- 
pyrrolo[3',4':5,6]pyrido[3,4-b]mdol-5-yl}benzomtrile 64g.
(From (±)-24) MS [APCI (m/z)] calcd for (C24H21N5OS + H)+ = 428, found 
428. Crude yield: quantitative. Purity: 99% (LC).
(±)-(3aR,13cR)-2,9-Dimethyl-5-(3-pyridyl)-6-thioxo-1,2,3,5,6,8,9,13c-octahydro-4H-imidazo- 
[1,,5':1,6]pyrrolo[3,,4,:5,6]pyrido[3,4-b]mdol-4-one 64h.
(From (±)-24) *H NMR [300 MHz, 5 (ppm), CDCI3]: 8.66  (dd; J = 4.8, 1.5 Hz; 1 
1H, 6 ’-CH), 8.63 (d, J = 2.4 Hz, 1 1H, 2'-CH), 7.71 (ddd; J = 8.1, 2.4, 1.5 Hz; 1 
1H, 4'-CH), 7.49 (d, J = 7.8 Hz, 1 !H, 13-CH), 7.43 (ddd; J = 8.1, 4.8, 0.6 Hz; 1 
!H, 5-CH), 7.33 (d, J = 8.1 Hz, 1 !H, 10-CH), 7.28-7.22 (m, 1 !H, 11-CH), 7.17­
7.11 (m, 1 !H, 12-CH), 6.10 (dd; J = 16.2, 0.9 Hz; 1 !H, 8-CHH), 4.68 (dd; J = 
16.2, 1.2 Hz; 1 !H, 8-CHH), 4.05 (dd; J = 5.7, 0.9 Hz; 1 !H, 13c-CH), 3.74 (s, 3 
!H, 9-NCH3), 3.41 (d, J = 10.5 Hz, 1 !H, 3-CHH), 3.25 (d, J = 9.0 Hz, 1 !H, 1-CHH), 3.04 (dd; J =
9.0, 5.7 Hz; 1 !H, 1-CHH), 2.94 (d, J = 10.5 Hz, 1 !H, 3-CHH), 2.36 (s, 3 !H, 2 -NCH3). 13C NMR [75 
MHz, 5 (ppm), CDCI3]: 180.4 (6-C), 175.8 (4-C), 150.0 (6 '-C), 149.4 (2'-C), 137.8 (9a-C), 136.0 (4'-C),
130.9 (8a-C), 130.3 (3'-C), 125.2 (13a-C), 123.7 (5'-C), 122.3 (11-C), 120.0 (12-C), 118.1 (13-C), 109.6 
(10-C), 108.6 (13b-C), 71.1 (3a-C), 63.1 (3-C), 62.3 (1-C), 42.4 (13c-C), 41.8 (2 -NCH3), 39.5 (8-C),
30.0 (9-NCH3). FTIR [ V (cm-1), neat]: 2937, 2841, 2790, 1749, 1670, 733, 703. MS [APCI (m/z)] 
calcd for (C22H21N5OS + H)+ = 404, found 404. Crude yield: quantitative. Purity: 99% (LC).
6.6  References and Notes
1 (a) O'Dell, D. K.; Rimmerman, N.; Pickens, S. R.; Walker, J. M. Bioorg. Med. Chem. 2007, 15, 
6164-6169. (b) Gudmundsson, K. Carboline Derivatives and Their Use as Inhibitors of 
Flaviviridae Infections. WO 2007002051, January 4, 2007; Chem. Abstr. 2007, 146, 100663. (c) 
Collins, M. A. Neurotoxicology 2004, 25, 117-120. (d) Rolf, S.; Bruns, H.-J.; Wichter, T.; Kirchhof, 
P.; Ribbing, M.; Wasmer, K.; Paul, M.; Breithardt, G.; Haverkamp, W.; Eckardt, L. Eur. Heart J.
2003, 24, 1104-1112. (e) Nagatsu, T. Neurosci. Res. 1997, 29, 99-111. (f) Rohloff, J. C.; Dyson, N. 
H.; Gardner, J. O.; Alfredson, T. V.; Sparacino, M. L.; Robinson, J., III. J. Org. Chem. 1993, 58, 
1935-1938. (g) Charifson, P. S. Drugs Fut. 1989, 14, 1179-1185. (h) Rinehart, K. L., Jr.; Kobayasi, 
J.; Harbour, G. C.; Hughes, R. G., Jr.; Mizak, S. A.; Scahill, T. A. J. Am . Chem. Soc. 1984, 106, 1524­
1526. (i) Collins, M. A.; Nijm, W. P.; Borge, G. F.; Teas, G.; Goldfarb, C. Science 1979, 206, 1184­
1186.
222
Syn th esis  o f  (H etero)areno[d]pyrrolo[3,4-b]pyridines and (Hetero)areno[c]pyrrolo[3,4-e]azepines and Their D eriva tiza tion
2 Kim, H.-J.; Soh, Y.; Jang, J.-H.; Lee, J.-S.; Oh, Y. J.; Surh, Y.-J. Mol. Pharmacol. 2001, 60, 440-449.
3 Peng, J.; Hu, J.-F.; Kazi, A. B.; Li, Z.; Avery, M.; Peraud, O.; Hill, R. T.; Franzblau, S. G.; Zhang, 
F.; Schinazi, R. F.; Wirtz, S. S.; Tharnish, P.; Kelly, M.; Wahyuono, S.; Hammann, M. T. J. Am. 
Chem. Soc. 2003, 125, 13382-13386.
4 (a) Cao, R.; Chen, Q.; Hou, X.; Chen, H.; Guan, H.; Ma, Y.; Peng, W.; Xu, A. Bioorg. Med. Chem.
2004, 12, 4613-4623. (b) Couture, A.; Deniau, E.; Grandclaudon, P.; Lebrun, S. Tetrahedron: 
A sym m etry  2003, 14, 1309-1316. (c) Leonard, J.; Hague, A. B.; Jones, M. F. Tetrahedron Lett. 1997, 
38, 3071-3074.
5 (a) Pictet, A.; Spengler, T. Ber. Dtsch. Chem. Ges. 1911, 44, 2030-2036. For reviews, see: (b) 
Tinsley, J. M. Pictet-Spengler Isoquinoline Synthesis. In Name Reactions in Heterocyclic Chemistry; 
Li, J. J.; Corey, E. J., Eds.; Wiley & Sons: Hoboken, NJ, USA, 2005; pp 469-479. (c) Cox, E. D.; 
Cook, J. M. Chem. Rev. 1995, 95, 1797-1842. (d) Whaley, W. M.; Govindachari, T. R. Org. React. 
1951, 6, 151-190.
6 (a) For an example, see: Wee, A. G. H.; Yu, Q. J. Org. Chem. 2001, 66, 8935-8943. (b) For a 
review about cyclizations using N-acyl-iminium ions, see: Maryanoff, B. E.; Zhang, H.-C.; 
Cohen, J. H.; Turchi, I. J.; Maryanoff, C. A. Chem. Rev. 2004, 104, 1431-1628.
7 Kinderman, S. S.; Wekking, M. M. T.; van Maarseveen, J. H.; Schoemaker, H. E.; Hiemstra, H.; 
Rutjes, F. P. J. T. J. Org. Chem. 2005, 70, 5519-5527.
8 Gremmen, C.; Willemse, B.; Wanner, M. J.; Koomen, G.-J. Org. Lett. 2000, 2, 1955-1958.
9 Wanner, M. J.; van der Haas, R. N. S.; de Cuba, K. R.; van Maarseveen, J. H.; Hiemstra, H. 
Angew. Chem. Int. Ed. 2007, 46, 7485-7487.
10 Zhang, L.; Meier, W.; Wats, E.; Costello, T. D.; Ma, P.; Ensinger, C. L.; Rodgers, J. M.; 
Jacobson, I. C.; Rajagopalan, P. Tetrahedron Lett. 1995, 36, 8387-8390.
11 Cho, S.-D.; Song, S.-Y.; Hur, E.-J.; Chen, M.; Joo, W.-H.; Falck, J. R.; Yoon, Y.-J.; Shin, D.-S. 
Tetrahedron Lett. 2001, 42, 6251-6253.
12 Myers, A. G.; Kung, D. W. Org. Lett. 2000, 2, 3019-3022.
13 Padwa, A.; Brodney, M. A.; Marino, J. P., Jr.; Osterhout, M. H.; Price, A. T. J. Org. Chem. 1997, 
62, 67-77.
14 Enders, D.; Shilvock, J. P. Chem. Soc. Rev. 2000, 29, 359-373.
15 (a) Martin, S. F.; Humphrey, J. M.; Ali, A.; Hillier, M. C. J. Am . Chem. Soc. 1999, 121, 866-867. 
(b) Winkler, J. D.; Axten, J. M. J. Am . Chem. Soc. 1998, 120, 6425-6426.
16 Yu, J.; Wearing, X. Z.; Cook, J. M. Tetrahedron Lett. 2003, 44, 543-547.
17 Corey, E. J.; Gin, D. Y.; Kania, R. S. J. Am . Chem. Soc. 1996, 118, 9202-9203.
18 Niles, S. Med Ad News 200 -  World's Best-Selling Medicines. M ed A d News, Jul, 2008.
19 (a) Li, J. J.; Johnson, D. S.; Sliskovic, D. R.; Roth, B. D. Contemporary Drug Synthesis; Wiley- 
Interscience: New York, NY, USA, 2004. (b) Descamps, M.; Radisson, J. Process for Preparation 
of N-Phenylacetyl Derivative of Tetrahydrothieno[3,2-c]pyridine and Intermediate of Synthesis. 
EP 0466569, January 15, 1992; Chem. Abstr. 1992, 117, 90266.
20 Iitaka, Y.; Ishizaki, M.; Hoshino, O. J. Org. Chem. 1992, 57, 7285-7295.
21 Marco-Contelles, J.; Carreiras, M. C.; Rodríguez, C.; Villaroya, M.; García, A. G. Chem. Rev. 
2006, 106, 116-133.
223
C hapter 6
22 Ollero, L.; Castedo, L.; Domínguez, D. Tetrahedron 1999, 55, 4445-4456.
23 (a) Sidduri, A.; Lou, J. P.; Campbell, R.; Rowan, K.; Tilley, J. W. Tetrahedron Lett. 2001, 42, 
8757-8760. (b) Miller, W. H.; Alberts, D. P.; Bhatnagar, P. K.; Bondinell, W. E.; Callahan, J. F.; 
Calvo, R. R.; Cousins, R. D.; Erhard, K. F.; Heerding, D. A.; Keenan, R. M.; Kwon, C.; Manley, P. 
J.; Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Uzinskas, I. N.; Venslavsky, J. W.; Yuan, C. C.- 
K.; Haltiwanger, R. C.; Gowen, M.; Hwang, S.-M.; James, I. E.; Lark, M. W.; Rieman, D. J.; 
Stroup, G. B.; Azzarano, L. M.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; 
Huffman, W. F. J. Med. Chem. 2000, 43, 22-26. (c) Warshawasky, A. M.; Flynn, G. A.; Koehl, J. R.; 
Mehdi, S.; Vaz, R. J. Bioorg. Med. Chem. Lett. 1996, 6, 957-962. (d) Coffen, D. L.; Schaer, B.; 
Bizzaro, F. T.; Cheung, J. B. J. Org. Chem. 1984, 49, 296-300. (e) Benjamin, L. E., Sr.; Fryer, R. I.; 
Gilman, N. W.; Trybulski, E. J. J. Med. Chem. 1983, 26, 100-103.
24 Fevig, J. M.; Feng, J.; Ahmad, S. Pyrrolo(oxo)isoquinolines as 5HT Ligands. U.S. Patent 
2006014777, January 19, 2006; Chem. Abstr. 2006, 144, 150353.
25 (a) Unver, N. Phytochem. Rev. 2007, 6, 125-135. (b) Baxendale, I. R.; Ley, S. V. Ind. Eng. Chem. 
Res. 2005, 44 , 8588-8592.
26 Teller, S.; Eluwa, S.; Koller, M.; Uecker, A.; Beckers, T.; Baasner, S.; Böhmer, F.-D.; Mahboobi, 
S. Eur. J. Med. Chem. 2000, 35, 413-427.
27 Carey, J. S.; Laffan, D.; Thomson, C.; Williams, M. T. Org. Biomol. Chem. 2006, 4, 2337-2347.
28 (a) Jiang, W.; Guan, J.; Macielag, M. J.; Zhang, S.; Qiu, Y.; Kraft, P.; Bhattacharjee, S.; John, T. 
M.; Haynes-Johnson, D.; Lundeen, S.; Sui, Z. J. Med. Chem. 2005, 48, 2126-2133. (b) Daugan, A.; 
Grondin, P.; Ruault, C.; Le Monnier de Gouville, A.-C.; Coste, H.; Linget, J. M.; Kirilovsky, J.; 
Hyafil, F.; Labaudinière, R. J. Med. Chem. 2003, 46, 4533-4542. (c) Plate, R.; van Hout, R. H. M.; 
Behm, H.; Ottenheijm, H. C. J. J. Org. Chem. 1987, 52, 555-560.
29 (a) Biotage Home Page. http://www.biotage.com/DynPage.aspx?id=23908#SCX2 (accessed 
May 5, 2009). (b) These types of columns are used for the isolation of a wide range of basic 
compounds. ISOLUTE® SCX-2 columns are silica-based sorbents with a chemically bonded 
propylsulfonic acid.
30 For reactions in the 3-position of furans with N -acyl-iminium ions, see: (a) Rose, M. D.; 
Cassidy, M. P.; Rashatasakhon, P.; Padwa, A. J. Org. Chem. 2007, 72, 538-549. (b) Nielsen, T. E.; 
Meldal, M. J. Org. Chem. 2004, 69, 3765-3773.
31 For an example in the 3-position of a benzo[b]furan, see: Van der Mey, M.; Windhorst, A. D.; 
Klok, R. P.; Herscheid, J. D. M.; Kennis, L. E.; Bischoff, F.; Bakker, M.; Langlois, X.; Heylen, L.; 
Jurzak, M.; Leysen, J. E. Bioorg. Med. Chem. 2006, 14, 4526-4534.
32 Marino, G. Adv. Heterocycl. Chem. 1971, 13, 235-315.
33 For examples of cyclization in the 4-position of an indole, see: (a) Somei, M.; Teranishi, S.; 
Yamada, K.; Yamada, F. Chem. Pharm. Bull. 2001, 49, 1159-1165. (b) Nakatsuka, S.; Miyazaki, H.; 
Goto, T. Chem. Lett. 1981, 407-410.
34 For examples of cyclization in the 2-position, see: (a) Kametani, T.; Fukumoto, K.; Kigasawa, 
K.; Hiiragi, M.; Ishimaru, H.; Wakisaka, K. J. Chem. Soc. (C) 1971, 1805-1808. (b) Ref. 5(d).
35 This cyclization was also tried with compounds (±)-3b and (±)-3e from Chapter 3, but in both 
cases there was no trace of cyclized product after 48 h. We foresaw a similar result with the least 
reactive substrates (±)-3a, (±)-3c, and (±)-3d.
36 Shamma, M.; Hillman, M. J. Tetrahedron 1971, 27, 1363-1374.
37 Nyerges, M.; Rudas, M.; Bitter, I.; Töke, L.; Szántay, C., Jr. Tetrahedron 1997, 53, 3269-3280.
224
Syn th esis  o f  (H etero)areno[d]pyrrolo[3,4-b]pyridines and (Hetero)areno[c]pyrrolo[3,4-e]azepines and Their D eriva tiza tion
38 (a) Bischler, A.; Napieralski, B. Ber. Dtsch. Chem. Ges. 1893, 26, 1903-1908. (b) For a review, see: 
Whaley, W. M.; Govindachari, T. R. Org. React. 1951, 6, 74-150.
39 Clark, M. T.; Chang, J.; Navran, S. S.; Huzoor-Akbar; Mukhopadhyay, A.; Amin, H.; Feller, D. 
R.; Miller, D. D. J. Med. Chem. 1986, 29, 181-185.
40 (a) Kim, S.; Ko, H.; Kim, S.; Lee, T. J. Comb. Chem. 2002, 4, 549-551. (b) An, H.; Cook, P. D. 
Chem. Rev. 2000, 100, 3311-3340. (c) Nikam, S. S.; Kornberg, B. E.; Ault-Justus, S. E.; Rafferty, M. 
F. Tetrahedron Lett. 1998, 39, 1121-1124.
41 Charton, J.; Delaure, S.; Vendeville, S.; Debreu-Fontaine, M.-A.; Girault-Mizzi, S.; Sergheraert, 
C. Tetrahedron Lett. 2001, 42, 7559-7561.
42 Ozaki, S. Chem. Rev. 1972, 72, 457-496.
43 The impurities were analyzed by LC-MS, but no substrate or urea was found. It was a mixture 
of small peaks (usually with no mass associated with them).
44 Blanco-Ania, D.; Hermkens, P. H. H.; Sliedregt, L. A. J. M.; Scheeren, H. W.; Rutjes, F. P. J. T. J. 
Comb. Chem. 2009, 11, 527-538.
45 Fuentes, J.; Salameh, B. A. B.; Pradera, M. A.; Fernández de Cordoba, F. J.; Gasch, C. 
Tetrahedron 2006, 62, 97-111.
46 Mukerjee, A. K., Ashare, R. Chem. Rev. 1991, 91, 1-24.
225
There should be a bit of Gabriela Andersen-Schiess in every scientist.
226
SUMMARY
This thesis deals with the design and synthesis of skeleton-diversified libraries of 
compounds with a core structure based on the 2 -arylethyl amine moiety: the common 
feature of the monoamine neurotransmitters (e.g., serotonin, dopamine, and 
noradrenaline). Appetite, mood, attention, pleasure, and movement are some of the 
functions controlled by the monoamine-neurotransmitter systems. Dysfunction in 
these systems causes diseases and disorders (e.g., obesity and depression), some of 
which are treated using drugs active in the same systems owing to the presence of the 
2-arylethyl amine core structure. Thus, synthesis of new potential drugs with the 
mentioned scaffold is of interest from a pharmaceutical point of view.
The presented research is divided in two parts: (1) the methodology to synthesize the 
main scaffolds (Chapters 2, 3, and 6) and (2) the solution-phase parallel synthesis of the 
target compounds using these scaffolds (Chapters 4, 5, and 6 ).
The structure of the main scaffolds (±)-1-(±)-3 is based on a ß-arylpyrrolidine, which 
contains an a-aminomethyl (1) or a-amino ester (2 and 3) for further functionalization 
(Scheme 1). These structures contain a conformationally constrained 2-arylethyl amine 
moiety, which facilitates the study of their interactions with the receptors and permits 
the rational design of more potent and selective drugs in the future. Pyrrolidines (±)-1- 
(±)-3 were synthesized by three successive reactions: (1) a Knoevenagel condensation 
reaction to form acrylates substituted with a masked amino function (a cyano or a nitro
S chem e 1 Synthesis o f the M ain Scaffolds (±)-1-(±)-3.
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group), (2) a 1,3-dipolar cycloaddition reaction to form the pyrrolidine ring, and (3) a 
reduction to form an aminomethyl or amino group (Scheme 1). The aryl groups 
selected for the scaffolds were phenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 1,3- 
benzodioxol-5-yl, 1-methylpyrrol-2-yl or 2-furyl, and 1-methylindol-3-yl.
In Chapter 6 , pyrrolidines (±)-2 were transformed into the more rigid tri- and 
tetracyclic scaffolds (±)-4, by combining the 2-arylethyl amine moiety with a 
tetrahydro-(hetero)areno[c]pyridine, another privileged structure with a wide range of 
biological and pharmacological properties. These scaffolds were obtained using the 
Pictet-Spengler reaction (Scheme 2).
S chem e 2 Synthesis o f the Tri- and Tetracyclic Scaffolds (±)-4.
All the scaffolds synthesized on gram scale for the library syntheses are depicted in 
Figure 1.
OMe
(±) Me
MeOMe
OMe Me
F ig u re  1 A ll the Scaffolds Used for Library Syntheses.
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In Chapters 4, 5, and 6 these scaffolds were further derivatized in a parallel fashion 
to generate several libraries. These libraries combine the 2-arylethyl amine moiety with 
other privileged structures, such as (thio)hydantoins and dihydrouracils. Although the 
combination of privileged structures does not necessarily exhibit any of the properties 
of the constituents, it fulfils the increasing need for new chemical entities and 
structural diversity. This combination also increases the rigidity of the 2-arylethyl 
amine moiety. In Chapter 4, the synthesis of a 152-compound library of hydantoins and
2-thiohydantoins spiro-fused to pyrrolidines (±)-2 and (±)-3 is described (Scheme 3a). 
In Chapter 5, a library of dihydrouracils spiro-fused to pyrrolidines (±)-1 is presented 
(Scheme 3b).
GO2Me 
NH2d "  
''Ar
S chem e 3 Libraries Synthesized from  Scaffolds (±)-1-(±)-4. 
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Under the same conditions, a library of a-ureidomethyl acids was synthesized by the 
hydrolysis of the corresponding spiro dihydrouracils (Scheme 3b). Finally, two further 
libraries were synthesized from scaffolds (±)-4 and are presented in Chapter 6 : one 
library was formed by the acylation of the secondary amine and the second by the 
annulation of a (thio)hydantoin ring (Scheme 3c). The reagents utilized for the library 
syntheses were isocyanates, isothiocyanates, and acyl chlorides substituted with 
groups of differing electronic and steric effects; that is, alkyl (methyl, ethyl), 
hydrocarbyl (PhCH2, PhCH2CH2), organyl (CH2CH2CO2Et), phenyl, electron-rich aryl 
(4 -EtOCéH4), electron-poor aryl (4 -CF3C6H4, 3 -NCC6H4), and heteroaryl (2-thienyl, 3- 
pyridyl) groups.
Chapter 5 presents some of the exploration results obtained from this research 
towards the feasibility of other possible structures that could be suitable for library 
syntheses. Briefly described are the syntheses of two spiro dihydrothiouracils (Scheme 
4a), two spiro ß-lactams (Scheme 4a), and one tetrahydromethanobenzazepine (Scheme 
4b).
S chem e 4 Exploration Reactions for Possible Scaffolds for Library Synthesis.
a) R
oY^y s
M e N H " - NH
'''Ar
(±)
O
C02Me
M . N ^ - NH2
'''Ar
MeN
NH
'Ar
(±)-1 (±)
b) NC^ „ C 0 2Me
MeO MeO
C02Me 
'  CN
OMe OMe
(±)
All the main scaffolds and all target compounds prepared in this work were 
transferred to Solvay Pharmaceuticals and N.V. Organon for biological testing.
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In dit proefschrift wordt het ontwerp en de synthese behandeld van skelet- 
gediversificeerde bibliotheken van verbindingen. Het basisskelet van deze 
verbindingen is de 2-arylethylaminogroep: het gemeenschappelijke kenmerk van de 
monoamine neurotransmitters (bijv. serotonine, dopamine en noradrenaline). Eetlust, 
stemming, aandacht, genot en beweging zijn enkele van de functies welke door de 
monoamine neurotransmittersystemen worden gestuurd. Afwijkingen in deze 
systemen veroorzaken ziektes en stoornissen (bijv. overgewicht en depressiviteit), 
waarvan sommige worden behandeld met medicijnen welke hun activiteit op deze 
systemen danken aan de aanwezigheid van het 2-arylethylamine basisskelet. Dit maakt 
de synthese van nieuwe potentiële medicijnen op basis van dit skelet interessant vanuit 
farmaceutisch oogpunt.
Het beschreven onderzoek omvat twee delen: (1) de methodologie om de basis­
skeletten te bereiden (Hoofdstukken 2, 3 en 6) en (2) de parallele synthese in oplossing 
van de doelverbindingen uitgaande van de basisskeletten (Hoofdstukken 4, 5 en 6).
De structuur van de basisskeletten (±)-1-(±)-3 is gebaseeerd op een ß-arylpyrrolidine, 
met daaraan een a-aminomethyl (1) of een a-amino ester (2 en 3) voor verdere functio- 
nalisering (Schema 1). Deze structuren bevatten een conformationeel vastgelegde 2- 
arylethylaminogroep, welke het bestuderen van de interacties met de receptoren 
vergemakkelijkt en het mogelijk maakt om in de toekomst een rationeel ontwerp te 
maken van potentere en selectievere medicijnen. Pyrrolidines (±)-1-(±)-3 werden
S ch em a 1 Synthese van de Basisskeletten (±)-1-(±)-3.
ÇO2M©
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bereid met drie opeenvolgende reacties: (1) een Knoevenagel condensatiereactie om 
acrylaten te verkrijgen, gesubstitueerd met een gemaskeerde aminofunctie (een cyano- 
of een nitrogroep), (2) een 1,3-dipolaire cycloadditiereactie om de pyrrolidinering te 
maken en (3) een reductie leidend tot een aminomethyl- of een aminogroep (Schema 1). 
De geselecteerde arylgroepen voor de basisskeletten waren fenyl, 4-methoxyfenyl, 3,5- 
di-methoxyfenyl, 1,3-benzodioxol-5-yl, 1-methylpyrrol-2-yl, 2-furyl en 1-methylindol-
In Hoofdstuk 6 is beschreven hoe de pyrrolidines (±)-2 werden omgezet in de meer 
starre tri- en tetracyclische skeletten (±)-4. Hierbij wordt de 2-arylethylaminogroep 
gecombineerd met een tetrahydro-(hetero)areno[c]pyridine, eveneens een structuur­
eenheid met een breed scala aan biologische en farmacologische eigenschappen. Deze 
skeletten werden verkregen door middel van een Pictet-Spenglerreactie (Schema 2).
S ch em a 2 Synthese van de Tri- en Tetracyclische Skeletten (±)-4.
Alle skeletten welke op gramschaal werden bereid ten behoeve van de 
bibliotheeksyntheses zijn weergegeven in Figuur 1.
3-yl.
(±) Me
F ig u u r 1 Skeletten Gebruikt voor Bibliotheeksynthese.
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In de Hoofdstukken 4, 5 en 6 is beschreven hoe de skeletten verder gederivatiseerd 
werden door middel van parallele synthese, leidend tot verschillende bibliotheken. 
Deze bibliotheken combineren de 2-arylethylaminogroep met andere "bevoorrechte" 
structuureenheden, zoals (thio)hydantoïnes en dihydrouracillen. Alhoewel een 
combinatie van zulke "bevoorrechte" structuureenheden niet noodzakelijkerwijs enige 
eigenschap hoeft de bezitten van de afzonderlijke componenten, voldoet het maken 
ervan wel aan de behoefte aan nieuwe chemische entiteiten en chemische diversiteit. 
Daarnaast vergroot deze combinatie ook de starheid van de 2-arylethylaminogroep. In
S ch em a 3 Bibliotheken Gemaakt uit Skeletten (±)-1-(±)-4.
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Hoofdstuk 4 wordt de synthese beschreven van een bibliotheek van 152 hydantoïnes 
en 2-thiohydantoïnes welke spiro-gefuseerd zijn met de pyrrolidines (±)-2 en (±)-3 
(Schema 3a). In Hoofdstuk 5 wordt een bibliotheek beschreven van dihydrouracillen, 
spiro-gefuseerd met pyrrolidine (±)-1 (Schema 3b).
Onder dezelfde condities werd een een bibliotheek van a-ureïdomethylzuren 
gesynthetiseerd, door hydrolyse van de overeenkomstige dihydrouracillen (Schema 
3b). Tenslotte werden nog twee verdere bibliotheken gesynthetiseerd vanuit skelet 
(±)-4, zoals beschreven in Hoofdstuk 6: één door acylering van het secundaire amine en 
één door annulering van een (thio)hydantoïne ring (Schema 3c). De reagentia welke 
gebruikt werden voor de bibliotheeksynthese waren iso(thio)cyanaten en 
acylchlorides, gesubstitueerd met groepen met verschillende electronische en sterische 
eigenschappen, te weten, alkyl (bijv. methyl, ethyl), hydrocarbyl (bijv. PhCH, 
PhCH2CH2), organyl (bijv. CH2CH2CO2Et), fenyl, electronenrijke aryl (4-EtOCéH4), 
electronenarme aryl (4-CF3C6H4, 3-NCC6H4) en heteroaryl (2-thienyl, 3-pyridyl) 
groepen.
Daarnaast worden in Hoofdstuk 5 enkele andere gedurende het onderzoek 
verkregen structuren beschreven welke gebruikt zouden kunnen worden voor 
bibliotheeksynthese. Hierbij wordt kort ingegaan op de synthese van twee spiro 
dihydrothiouracillen (Schema 4a), twee spiro ß-lactamen (Schema 4a) en één 
tetrahydromethanobenzazepine (Schema 4b).
S ch em a 4 Mogelijke Andere Skeletten voor Bibliotheeksynthese.
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Alle basisskeletten en alle doelverbindingen zijn overgedragen aan Solvay 
Pharmaceuticals en N.V. Organon voor het doen van biologische testen.
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